1<!doctype html> 2<html dir="ltr" lang="en-GB" prefix="og: https://ogp.me/ns#"> 3<head> 4 <meta charset="UTF-8"> 5 <meta name="viewport" content="width=device-width, initial-scale=1"> 6 <link rel="profile" href="https://gmpg.org/xfn/11"> 7 8 <title>Clinical publications - Oncotherm Kft.</title> 9 10 <!-- All in One SEO 5.0.1.1 - aioseo.com --> 11 <meta name="robots" content="max-image-preview:large" /> 12 <link rel="canonical" href="https://oncotherm.com/clinical-publications/" /> 13 <meta name="generator" content="All in One SEO (AIOSEO) 5.0.1.1" /> 14 <meta property="og:locale" content="en_GB" /> 15 <meta property="og:site_name" content="Oncotherm Kft. -" /> 16 <meta property="og:type" content="website" /> 17 <meta property="og:title" content="Clinical publications - Oncotherm Kft." /> 18 <meta property="og:url" content="https://oncotherm.com/clinical-publications/" /> 19 <meta property="og:image" content="https://oncotherm.com/wp-content/uploads/2022/11/logo_ar-01.svg" /> 20 <meta property="og:image:secure_url" content="https://oncotherm.com/wp-content/uploads/2022/11/logo_ar-01.svg" /> 21 <meta property="og:image:width" content="220" /> 22 <meta property="og:image:height" content="50" /> 23 <meta name="twitter:card" content="summary_large_image" /> 24 <meta name="twitter:title" content="Clinical publications - Oncotherm Kft." /> 25 <meta name="twitter:image" content="https://oncotherm.com/wp-content/uploads/2022/11/logo_ar-01.svg" /> 26
26<script type="application/ld+json" class="aioseo-schema"> 27 {"@context":"https:\/\/schema.org","@graph":[{"@type":"BreadcrumbList","@id":"https:\/\/oncotherm.com\/clinical-publications\/#breadcrumblist","itemListElement":[{"@type":"ListItem","@id":"https:\/\/oncotherm.com#listItem","position":1,"name":"Home","item":"https:\/\/oncotherm.com","nextItem":{"@type":"ListItem","@id":"https:\/\/oncotherm.com\/clinical-publications\/#listItem","name":"Archives for "}},{"@type":"ListItem","@id":"https:\/\/oncotherm.com\/clinical-publications\/#listItem","position":2,"name":"Archives for ","previousItem":{"@type":"ListItem","@id":"https:\/\/oncotherm.com#listItem","name":"Home"}}]},{"@type":"CollectionPage","@id":"https:\/\/oncotherm.com\/clinical-publications\/#collectionpage","url":"https:\/\/oncotherm.com\/clinical-publications\/","name":"Clinical publications - Oncotherm Kft.","inLanguage":"en-GB","isPartOf":{"@id":"https:\/\/oncotherm.com\/#website"},"breadcrumb":{"@id":"https:\/\/oncotherm.com\/clinical-publications\/#breadcrumblist"}},{"@type":"Organization","@id":"https:\/\/oncotherm.com\/#organization","name":"Oncotherm Kft.","url":"https:\/\/oncotherm.com\/","logo":{"@type":"ImageObject","url":"https:\/\/oncotherm.com\/wp-content\/uploads\/2022\/11\/logo_ar-01.svg","@id":"https:\/\/oncotherm.com\/clinical-publications\/#organizationLogo","width":220,"height":50},"image":{"@id":"https:\/\/oncotherm.com\/clinical-publications\/#organizationLogo"}},{"@type":"WebSite","@id":"https:\/\/oncotherm.com\/#website","url":"https:\/\/oncotherm.com\/","name":"Oncotherm Kft.","inLanguage":"en-GB","publisher":{"@id":"https:\/\/oncotherm.com\/#organization"}}]} 28 </script>
28 29 <!-- All in One SEO --> 30 31<link rel="alternate" href="https://oncotherm.com/hu/klinikai-publikaciok/" hreflang="hu" /> 32<link rel="alternate" href="https://oncotherm.com/clinical-publications/" hreflang="en" /> 33<link rel="alternate" href="https://oncotherm.com/de/klinische-publikationen/" hreflang="de" /> 34<link rel='dns-prefetch' href='//maps.googleapis.com' /> 35<link rel='dns-prefetch' href='//www.googletagmanager.com' /> 36<style id="wp-img-auto-sizes-contain-inline-css"> 37img:is([sizes=auto i],[sizes^="auto," i]){contain-intrinsic-size:3000px 1500px} 38/*# sourceURL=wp-img-auto-sizes-contain-inline-css */ 39</style> 40 41<link rel='stylesheet' id='cf7apps-honeypot-frontend-css' href='https://oncotherm.com/wp-content/plugins/contact-form-7-honeypot/legacy-honeypot/includes/css/honeypot-frontend.css?ver=3.7.1' media='all' /> 42<link rel='stylesheet' id='contact-form-7-css' href='https://oncotherm.com/wp-content/plugins/contact-form-7/includes/css/styles.css?ver=6.1.7' media='all' /> 43<link rel='stylesheet' id='cookie-notice-front-css' href='https://oncotherm.com/wp-content/plugins/cookie-notice/css/front.min.css?ver=3.1.9' media='all' /> 44<link rel='stylesheet' id='lbwps-styles-photoswipe5-main-css' href='https://oncotherm.com/wp-content/plugins/lightbox-photoswipe/assets/ps5/styles/main.css?ver=5.13.0' media='all' /> 45<link rel='stylesheet' id='dashicons-css' href='https://oncotherm.com/wp-includes/css/dashicons.min.css?ver=9b4fda4fc00966c4c30efe23c40953c0' media='all' /> 46<link rel='stylesheet' id='rmp-menu-styles-css' href='https://oncotherm.com/wp-content/uploads/rmp-menu/css/rmp-menu.css?ver=12.22.42' media='all' /> 47<link rel='stylesheet' id='sow-icon-default-77a6afac270e-css' href='https://oncotherm.com/wp-content/uploads/siteorigin-widgets/sow-icon-default-77a6afac270e.css?ver=9b4fda4fc00966c4c30efe23c40953c0' media='all' /> 48<link rel='stylesheet' id='sow-image-default-4e6925654b7a-css' href='https://oncotherm.com/wp-content/uploads/siteorigin-widgets/sow-image-default-4e6925654b7a.css?ver=9b4fda4fc00966c4c30efe23c40953c0' media='all' /> 49<link rel='stylesheet' id='sow-image-default-8b5b6f678277-css' href='https://oncotherm.com/wp-content/uploads/siteorigin-widgets/sow-image-default-8b5b6f678277.css?ver=9b4fda4fc00966c4c30efe23c40953c0' media='all' /> 50<link rel='stylesheet' id='sow-image-default-e4c2d9f6c920-css' href='https://oncotherm.com/wp-content/uploads/siteorigin-widgets/sow-image-default-e4c2d9f6c920.css?ver=9b4fda4fc00966c4c30efe23c40953c0' media='all' /> 51<link rel='stylesheet' id='pojo-a11y-css' href='https://oncotherm.com/wp-content/plugins/pojo-accessibility/modules/legacy/assets/css/style.min.css?ver=1.0.0' media='all' /> 52<link rel='stylesheet' id='oncotherm-style-css' href='https://oncotherm.com/wp-content/themes/oncotherm/style.css?ver=1.0.0' media='all' /> 53<link rel='stylesheet' id='slick-css-css' href='https://oncotherm.com/wp-content/themes/oncotherm/css/slick.css?ver=9b4fda4fc00966c4c30efe23c40953c0' media='all' /> 54<link rel='stylesheet' id='slick-theme-css-css' href='https://oncotherm.com/wp-content/themes/oncotherm/css/slick-theme.css?ver=9b4fda4fc00966c4c30efe23c40953c0' media='all' /> 55<link rel='stylesheet' id='dflip-style-css' href='https://oncotherm.com/wp-content/plugins/3d-flipbook-dflip-lite/assets/css/dflip.min.css?ver=2.4.37' media='all' /> 56<link rel='stylesheet' id='wpc-filter-everything-css' href='https://oncotherm.com/wp-content/plugins/filter-everything/assets/css/filter-everything.min.css?ver=1.9.6' media='all' /> 57<link rel='stylesheet' id='wpc-filter-everything-custom-css' href='https://oncotherm.com/wp-content/uploads/cache/filter-everything/201e335fb0207fa2b238a2a4c4ed80c8.css?ver=9b4fda4fc00966c4c30efe23c40953c0' media='all' />
58<script id="jquery-core-js" src="https://oncotherm.com/wp-content/plugins/jquery-manager/assets/js/jquery-3.5.1.min.js"></script>
vendor: 1 bytes, line 58
58
59<script id="jquery-migrate-js" src="https://oncotherm.com/wp-content/plugins/jquery-manager/assets/js/jquery-migrate-3.3.0.min.js"></script>
vendor: 1 bytes, line 59
59
60<script id="cookie-notice-front-js-before"> 61var cnArgs = {"ajaxUrl":"https:\/\/oncotherm.com\/wp-admin\/admin-ajax.php","nonce":"4735d4a978","hideEffect":"fade","position":"bottom","onScroll":false,"onScrollOffset":100,"onClick":false,"cookieName":"cookie_notice_accepted","cookieTime":2592000,"cookieTimeRejected":2592000,"globalCookie":false,"redirection":false,"cache":false,"revokeCookies":false,"revokeCookiesOpt":"automatic"}; 62 63//# sourceURL=cookie-notice-front-js-before 64</script>
vendor: 1 bytes, line 64
64
65<script id="cookie-notice-front-js" src="https://oncotherm.com/wp-content/plugins/cookie-notice/js/front.min.js?ver=3.1.9"></script>
vendor: 1 bytes, line 65
65
66<script id="lbwps-options-js-extra"> 67var lbwpsOptions = {"label_facebook":"Share on Facebook","label_twitter":"Tweet","label_pinterest":"Pin it","label_download":"Download image","label_copyurl":"Copy image URL","label_ui_close":"Close [Esc]","label_ui_zoom":"Zoom","label_ui_prev":"Previous [\u2190]","label_ui_next":"Next [\u2192]","label_ui_error":"The image cannot be loaded","label_ui_fullscreen":"Toggle fullscreen [F]","label_ui_download":"Download image","share_facebook":"1","share_twitter":"1","share_pinterest":"1","share_download":"1","share_direct":"0","share_copyurl":"0","close_on_drag":"1","history":"1","show_counter":"1","show_fullscreen":"1","show_download":"0","show_zoom":"1","show_caption":"1","loop":"1","pinchtoclose":"1","taptotoggle":"1","close_on_click":"1","fulldesktop":"0","use_alt":"0","usecaption":"1","desktop_slider":"1","share_custom_label":"","share_custom_link":"","wheelmode":"zoom","spacing":"12","idletime":"4000","hide_scrollbars":"1","caption_type":"overlay","bg_opacity":"100","padding_left":"0","padding_top":"0","padding_right":"0","padding_bottom":"0"}; 68//# sourceURL=lbwps-options-js-extra 69</script>
vendor: 1 bytes, line 69
69
70<script id="slick-min-js-js" src="https://oncotherm.com/wp-content/themes/oncotherm/js/slick.min.js?ver=9b4fda4fc00966c4c30efe23c40953c0"></script>
vendor: 1 bytes, line 70
70
71<script id="custom-js-js" src="https://oncotherm.com/wp-content/themes/oncotherm/js/custom-js.js?ver=1.0.0"></script>
71 72 73<!-- Google tag (gtag.js) snippet added by Site Kit --> 74<!-- Google Analytics snippet added by Site Kit -->
vendor: 80 bytes, lines 74-75
74 75<script id="google_gtagjs-js" src="https://www.googletagmanager.com/gtag/js?id=
75GT-WVJGXK7
vendor: 18 bytes, line 75
75" async></script>
76<script id="google_gtagjs-js-after"> 77window.dataLayer = window.dataLayer || [];function gtag(){dataLayer.push(arguments);} 78gtag("set","linker",{"domains":["oncotherm.com"]}); 79gtag("js", new Date()); 80gtag("set", "developer_id.dZTNiMT", true); 81gtag("config", "GT-WVJGXK7"); 82//# sourceURL=google_gtagjs-js-after 83</script>
83 84<link rel="https://api.w.org/" href="https://oncotherm.com/wp-json/" /><meta name="generator" content="Site Kit by Google 1.186.0" /><style type="text/css"> 85#pojo-a11y-toolbar .pojo-a11y-toolbar-toggle a{ background-color: #4054b2; color: #ffffff;} 86#pojo-a11y-toolbar .pojo-a11y-toolbar-overlay, #pojo-a11y-toolbar .pojo-a11y-toolbar-overlay ul.pojo-a11y-toolbar-items.pojo-a11y-links{ border-color: #4054b2;} 87body.pojo-a11y-focusable a:focus{ outline-style: solid !important; outline-width: 1px !important; outline-color: #FF0000 !important;} 88#pojo-a11y-toolbar{ top: 90px !important;} 89#pojo-a11y-toolbar .pojo-a11y-toolbar-overlay{ background-color: #162c4d;} 90#pojo-a11y-toolbar .pojo-a11y-toolbar-overlay ul.pojo-a11y-toolbar-items li.pojo-a11y-toolbar-item a, #pojo-a11y-toolbar .pojo-a11y-toolbar-overlay p.pojo-a11y-toolbar-title{ color: #9e8053;} 91#pojo-a11y-toolbar .pojo-a11y-toolbar-overlay ul.pojo-a11y-toolbar-items li.pojo-a11y-toolbar-item a.active{ background-color: #162c4d; color: #9e8053;} 92@media (max-width: 767px) { #pojo-a11y-toolbar { top: 80px !important; } }</style><style type="text/css" id="filter-everything-inline-css">.wpc-orderby-select{width:100%}.wpc-filters-open-button-container{display:none}.wpc-debug-message{padding:16px;font-size:14px;border:1px dashed #ccc;margin-bottom:20px}.wpc-debug-title{visibility:hidden}.wpc-button-inner,.wpc-chip-content{display:flex;align-items:center}.wpc-icon-html-wrapper{position:relative;margin-right:10px;top:2px}
92.wpc-icon-html-wrapper span{display:block;height:1px;width:18px;border-radius:3px;background:#2c2d33;margin-bottom:4px;position:relative}span.wpc-icon-line-1:after,span.wpc-icon-line-2:after,span.wpc-icon-line-3:after{content:"";display:block;width:3px;height:3px;border:1px solid #2c2d33;background-color:#fff;position:absolute;top:-2px;box-sizing:content-box}span.wpc-icon-line-3:after{border-radius:50%;left:2px}span.wpc-icon-line-1:after{border-radius:50%;left:5px}span.wpc-icon-line-2:after{border-radius:50%;left:12px}body .wpc-filters-open-button-container a.wpc-filters-open-widget,body .wpc-filters-open-button-container a.wpc-open-close-filters-button{display:inline-block;text-align:left;border:1px solid #2c2d33;border-radius:2px;line-height:1.5;padding:7px 12px;background-color:transparent;color:#2c2d33;box-sizing:border-box;text-decoration:none!important;font-weight:400;transition:none;position:relative}@media screen and (max-width:768px){.wpc_show_bottom_widget .wpc-filters-open-button-container,.wpc_show_open_close_button .wpc-filters-open-button-container{display:block}.wpc_show_bottom_widget .wpc-filters-open-button-container{margin-top:1em;margin-bottom:1em}}</style> 93<link rel="icon" href="https://oncotherm.com/wp-content/uploads/2022/11/cropped-favi-32x32.png" sizes="32x32" /> 94<link rel="icon" href="https://oncotherm.com/wp-content/uploads/2022/11/cropped-favi-192x192.png" sizes="192x192" /> 95<link rel="apple-touch-icon" href="https://oncotherm.com/wp-content/uploads/2022/11/cropped-favi-180x180.png" /> 96<meta name="msapplication-TileImage" content="https://oncotherm.com/wp-content/uploads/2022/11/cropped-favi-270x270.png" /> 97<link rel='stylesheet' id='sow-icon-default-543ad11e08c1-css' href='https://oncotherm.com/wp-content/uploads/siteorigin-widgets/sow-icon-default-543ad11e08c1.css?ver=9b4fda4fc00966c4c30efe23c40953c0' media='all' /> 98<link rel='stylesheet' id='siteorigin-widget-icon-font-ionicons-css' href='https://oncotherm.com/wp-content/plugins/so-widgets-bundle/icons/ionicons/style.css?ver=9b4fda4fc00966c4c30efe23c40953c0' media='all' /> 99<link rel='stylesheet' id='siteorigin-panels-front-css' href='https://oncotherm.com/wp-content/plugins/siteorigin-panels/css/front-flex.min.css?ver=2.36.0' media='all' /> 100<link rel='stylesheet' id='siteorigin-widget-icon-font-materialicons-css' href='https://oncotherm.com/wp-content/plugins/so-widgets-bundle/icons/materialicons/style.css?ver=9b4fda4fc00966c4c30efe23c40953c0' media='all' /> 101<link rel='stylesheet' id='sow-image-default-c67d20f9f743-css' href='https://oncotherm.com/wp-content/uploads/siteorigin-widgets/sow-image-default-c67d20f9f743.css?ver=9b4fda4fc00966c4c30efe23c40953c0' media='all' /> 102<link rel='stylesheet' id='sow-social-media-buttons-flat-8f436be6ec16-css' href='https://oncotherm.com/wp-content/uploads/siteorigin-widgets/sow-social-media-buttons-flat-8f436be6ec16.css?ver=9b4fda4fc00966c4c30efe23c40953c0' media='all' /> 103<link rel='stylesheet' id='siteorigin-widget-icon-font-fontawesome-css' href='https://oncotherm.com/wp-content/plugins/so-widgets-bundle/icons/fontawesome/style.css?ver=9b4fda4fc00966c4c30efe23c40953c0' media='all' /> 104 105</head> 106 107<body class="archive post-type-archive post-type-archive-klinikai-publikaciok wp-custom-logo wp-theme-oncotherm cookies-not-set ally-default hfeed no-sidebar klinikai-publikaciok modulated-electrohyperthermia-in-locally-advanced-cervical-cancer-results-of-an-observational-study-of-95-patients language-en"> 108 <button type="button" aria-controls="rmp-container-2025" aria-label="Menu Trigger" id="rmp_menu_trigger-2025" class="rmp_menu_trigger rmp-menu-trigger-boring"> 109 <span class="rmp-trigger-box"> 110 <span class="responsive-menu-pro-inner"></span> 111 </span> 112 </button> 113 <div id="rmp-container-2025" class="rmp-container rmp-container rmp-slide-left"> 114 <div id="rmp-menu-additional-content-2025" class="rmp-menu-additional-content"> 115 Add more content here... </div> 116 <div id="rmp-menu-wrap-2025" class="rmp-menu-wrap"><ul id="rmp-menu-2025" class="rmp-menu" role="menubar" aria-label="Mobil main menu"><li id="rmp-menu-item-3233" class=" menu-item menu-item-type-post_type menu-item-object-page current-menu-ancestor current-menu-parent current_page_parent current_page_ancestor menu-item-has-children rmp-menu-item rmp-menu-item-current-ancestor rmp-menu-item-current-parent rmp-menu-item-has-children rmp-menu-top-level-item" role="none"><a href="https://oncotherm.com/oncothermia/" class="rmp-menu-item-link" role="menuitem" >Oncothermia<div class="rmp-menu-subarrow">+</div></a><ul aria-label="Oncothermia" 117 role="menu" data-depth="2" 118 class="rmp-submenu rmp-submenu-depth-1"><li id="rmp-menu-item-6147" class=" menu-item menu-item-type-post_type menu-item-object-page rmp-menu-item rmp-menu-sub-level-item" role="none"><a href="https://oncotherm.com/oncothermia/" class="rmp-menu-item-link" role="menuitem" >Oncothermia</a></li><li id="rmp-menu-item-3396" class=" menu-item menu-item-type-custom menu-item-object-custom current-menu-item rmp-menu-item rmp-menu-current-item rmp-menu-sub-level-item" role="none"><a href="https://oncotherm.com/clinical-publications/" class="rmp-menu-item-link" role="menuitem" >Clinical Publications</a></li><li id="rmp-menu-item-3240" class=" menu-item menu-item-type-post_type menu-item-object-page rmp-menu-item rmp-menu-sub-level-item" role="none"><a href="https://oncotherm.com/collection-of-experimental-publications/" class="rmp-menu-item-link" role="menuitem" >Experimental publications</a></li><li id="rmp-menu-item-3457" class=" menu-item menu-item-type-custom menu-item-object-custom rmp-menu-item rmp-menu-sub-level-item" role="none"><a href="https://oncotherm.com/oncothermia-journal/" class="rmp-menu-item-link" role="menuitem" >Oncothermia Journal</a></li></ul></li><li id="rmp-menu-item-3229" class=" menu-item menu-item-type-custom menu-item-object-custom menu-item-has-children rmp-menu-item rmp-menu-item-has-children rmp-menu-top-level-item" role="none"><a href="##" class="rmp-menu-item-link" role="menuitem" >Partners<div class="rmp-menu-subarrow">+</div></a><ul aria-label="Partners" 119 role="menu" data-depth="2" 120 class="rmp-submenu rmp-submenu-depth-1"><li id="rmp-menu-item-4028" class=" menu-item menu-item-type-custom menu-item-object-custom rmp-menu-item rmp-menu-sub-level-item" role="none"><a href="https://oncotherm.com/map/distributor-partnerships/" class="rmp-menu-item-link" role="menuitem" >Distributors</a></li><li id="rmp-menu-item-4029" class=" menu-item menu-item-type-custom menu-item-object-custom rmp-menu-item rmp-menu-sub-level-item" role="none"><a href="https://oncotherm.com/map/research-partnerships" class="rmp-menu-item-link" role="menuitem" >Research Partnerships</a></li><li id="rmp-menu-item-4030" class=" menu-item menu-item-type-custom menu-item-object-custom rmp-menu-item rmp-menu-sub-level-item" role="none"><a href="https://oncotherm.com/map/oncothermia-clinics/" class="rmp-menu-item-link" role="menuitem" >Oncothermia Clinics</a></li><li id="rmp-menu-item-3245" class=" menu-item menu-item-type-post_type menu-item-object-page rmp-menu-item rmp-menu-sub-level-item" role="none"><a href="https://oncotherm.com/faq-professional/" class="rmp-menu-item-link" role="menuitem" >FAQ Professional</a></li><li id="rmp-menu-item-3246" class=" menu-item menu-item-type-post_type menu-item-object-page rmp-menu-item rmp-menu-sub-level-item" role="none"><a href="https://oncotherm.com/faq-patient/" class="rmp-menu-item-link" role="menuitem" >FAQ Patient</a></li><li id="rmp-menu-item-3247" class=" menu-item menu-item-type-post_type menu-item-object-page rmp-menu-item rmp-menu-sub-level-item" role="none"><a href="https://oncotherm.com/faq-distributor/" class="rmp-menu-item-link" role="menuitem" >FAQ Distributor</a></li></ul></li><li id="rmp-menu-item-3230" class=" menu-item menu-item-type-custom menu-item-object-custom menu-item-has-children rmp-menu-item rmp-menu-item-has-children rmp-menu-top-level-item" role="none"><a href="##" class="rmp-menu-item-link" role="menuitem" >Products<div class="rmp-menu-subarrow">+</div></a><ul aria-label="Products" 121 role="menu" data-depth="2" 122 class="rmp-submenu rmp-submenu-depth-1"><li id="rmp-menu-item-4532" class=" menu-item menu-item-type-post_type menu-item-object-page rmp-menu-item rmp-menu-sub-level-item" role="none"><a href="https://oncotherm.com/ehy-2030/" class="rmp-menu-item-link" role="menuitem" >EHY-2030</a></li><li id="rmp-menu-item-4533" class=" menu-item menu-item-type-post_type menu-item-object-page rmp-menu-item rmp-menu-sub-level-item" role="none"><a href="https://oncotherm.com/labehy/" class="rmp-menu-item-link" role="menuitem" >LabEHY</a></li></ul></li><li id="rmp-menu-item-3458" class=" menu-item menu-item-type-custom menu-item-object-custom menu-item-has-children rmp-menu-item rmp-menu-item-has-children rmp-menu-top-level-item" role="none"><a href="##" class="rmp-menu-item-link" role="menuitem" >News<div class="rmp-menu-subarrow">+</div></a><ul aria-label="News" 123 role="menu" data-depth="2" 124 class="rmp-submenu rmp-submenu-depth-1"><li id="rmp-menu-item-3459" class=" menu-item menu-item-type-taxonomy menu-item-object-category rmp-menu-item rmp-menu-sub-level-item" role="none"><a href="https://oncotherm.com/news/" class="rmp-menu-item-link" role="menuitem" >Latest news</a></li><li id="rmp-menu-item-3460" class=" menu-item menu-item-type-taxonomy menu-item-object-category rmp-menu-item rmp-menu-sub-level-item" role="none"><a href="https://oncotherm.com/events/" class="rmp-menu-item-link" role="menuitem" >Events</a></li><li id="rmp-menu-item-3461" class=" menu-item menu-item-type-taxonomy menu-item-object-category rmp-menu-item rmp-menu-sub-level-item" role="none"><a href="https://oncotherm.com/corporate-social-responsibility/" class="rmp-menu-item-link" role="menuitem" >Corporate Social Responsibility</a></li></ul></li><li id="rmp-menu-item-3272" class=" menu-item menu-item-type-post_type menu-item-object-page menu-item-has-children rmp-menu-item rmp-menu-item-has-children rmp-menu-top-level-item" role="none"><a href="https://oncotherm.com/about-us/" class="rmp-menu-item-link" role="menuitem" >About Us<div class="rmp-menu-subarrow">+</div></a><ul aria-label="About Us" 125 role="menu" data-depth="2" 126 class="rmp-submenu rmp-submenu-depth-1"><li id="rmp-menu-item-4130" class=" menu-item menu-item-type-custom menu-item-object-custom rmp-menu-item rmp-menu-sub-level-item" role="none"><a href="https://oncotherm.com/about-us/#oncothermteam" class="rmp-menu-item-link" role="menuitem" >Oncotherm Team</a></li><li id="rmp-menu-item-4129" class=" menu-item menu-item-type-custom menu-item-object-custom rmp-menu-item rmp-menu-sub-level-item" role="none"><a href="https://oncotherm.com/about-us/#timeline" class="rmp-menu-item-link" role="menuitem" >Timeline of Oncotherm</a></li><li id="rmp-menu-item-4128" class=" menu-item menu-item-type-custom menu-item-object-custom rmp-menu-item rmp-menu-sub-level-item" role="none"><a href="https://oncotherm.com/about-us/#tenders" class="rmp-menu-item-link" role="menuitem" >Tenders</a></li><li id="rmp-menu-item-4126" class=" menu-item menu-item-type-post_type menu-item-object-page rmp-menu-item rmp-menu-sub-level-item" role="none"><a href="https://oncotherm.com/certificates/" class="rmp-menu-item-link" role="menuitem" >Certificates</a></li><li id="rmp-menu-item-4127" class=" menu-item menu-item-type-custom menu-item-object-custom rmp-menu-item rmp-menu-sub-level-item" role="none"><a href="https://oncotherm.com/about-us/#contact" class="rmp-menu-item-link" role="menuitem" >Contact</a></li></ul></li><li id="rmp-menu-item-3277" class=" menu-item menu-item-type-post_type menu-item-object-page rmp-menu-item rmp-menu-top-level-item" role="none"><a href="https://oncotherm.com/career/" class="rmp-menu-item-link" role="menuitem" >Career</a></li><li id="rmp-menu-item-3278" class="pll-parent-menu-item menu-item menu-item-type-custom menu-item-object-custom menu-item-has-children rmp-menu-item rmp-menu-item-has-children rmp-menu-top-level-item" role="none"><a href="#pll_switcher" class="rmp-menu-item-link" role="menuitem" >EN<div class="rmp-menu-subarrow">+</div></a><ul aria-label="EN" 127 role="menu" data-depth="2" 128 class="rmp-submenu rmp-submenu-depth-1"><li id="rmp-menu-item-3278-hu" class="lang-item lang-item-3 lang-item-hu lang-item-first menu-item menu-item-type-custom menu-item-object-custom rmp-menu-item rmp-menu-sub-level-item" role="none"><a href="https://oncotherm.com/hu/klinikai-publikaciok/" class="rmp-menu-item-link" role="menuitem" lang="hu-HU" hreflang="hu-HU" >HU</a></li><li id="rmp-menu-item-3278-de" class="lang-item lang-item-617 lang-item-de menu-item menu-item-type-custom menu-item-object-custom rmp-menu-item rmp-menu-sub-level-item" role="none"><a href="https://oncotherm.com/de/klinische-publikationen/" class="rmp-menu-item-link" role="menuitem" lang="de-DE" hreflang="de-DE" >DE</a></li></ul></li></ul></div> <div id="rmp-search-box-2025" class="rmp-search-box"> 129 <form action="https://oncotherm.com/" class="rmp-search-form" role="search"> 130 <input type="search" name="s" title="Search" placeholder="Search" class="rmp-search-box"> 131 </form>
132 </div> 133 </div> 134 <div id="page" class="site"> 135 <a class="skip-link screen-reader-text" href="#primary">Skip to content</a> 136 <div id="hirlevel-badge"> 137 <section id="sow-image-5" class="widget widget_sow-image"><div 138 139 class="so-widget-sow-image so-widget-sow-image-default-e4c2d9f6c920" 140 141 > 142<div class="sow-image-container"> 143 <a href="https://oncotherm.com/sign-up-for-newsletter/" 144 > 145 <img 146 src="https://oncotherm.com/wp-content/uploads/2023/05/hirlevel-badge_en-01.svg" width="30" height="70" alt="" decoding="async" class="so-widget-image"/> 147 </a></div> 148 149</div></section> </div> 150 <header id="masthead" class="site-header"> 151 <div class="container flex space-between"> 152 <div class="site-branding"> 153 <a href="https://oncotherm.com/" class="custom-logo-link" rel="home"><img width="220" height="50" src="https://oncotherm.com/wp-content/uploads/2022/11/logo_ar-01.svg" class="custom-logo" alt="Oncotherm Kft." decoding="async" /></a> 154 </div><!-- .site-branding --> 155 <div class="right-header flex "> 156 <nav id="site-navigation" class="main-navigation"> 157 158 <div class="menu-main-nav-en-container"><ul id="primary-menu" class="menu"><li id="menu-item-3233" class="menu-item menu-item-type-post_type menu-item-object-page current-menu-ancestor current-menu-parent current_page_parent current_page_ancestor menu-item-has-children menu-item-3233"><a href="https://oncotherm.com/oncothermia/">Oncothermia</a> 159<ul class="sub-menu"> 160 <li id="menu-item-6147" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-6147"><a href="https://oncotherm.com/oncothermia/">Oncothermia</a></li> 161 <li id="menu-item-3396" class="menu-item menu-item-type-custom menu-item-object-custom current-menu-item menu-item-3396"><a href="https://oncotherm.com/clinical-publications/" aria-current="page">Clinical Publications</a></li> 162 <li id="menu-item-3240" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-3240"><a href="https://oncotherm.com/collection-of-experimental-publications/">Experimental publications</a></li> 163 <li id="menu-item-3457" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-3457"><a href="https://oncotherm.com/oncothermia-journal/">Oncothermia Journal</a></li> 164</ul> 165</li> 166<li id="menu-item-3229" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-has-children menu-item-3229"><a href="##">Partners</a> 167<ul class="sub-menu"> 168 <li id="menu-item-4028" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-4028"><a href="https://oncotherm.com/map/distributor-partnerships/">Distributors</a></li> 169 <li id="menu-item-4029" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-4029"><a href="https://oncotherm.com/map/research-partnerships">Research Partnerships</a></li> 170 <li id="menu-item-4030" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-4030"><a href="https://oncotherm.com/map/oncothermia-clinics/">Oncothermia Clinics</a></li> 171 <li id="menu-item-3245" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-3245"><a href="https://oncotherm.com/faq-professional/">FAQ Professional</a></li> 172 <li id="menu-item-3246" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-3246"><a href="https://oncotherm.com/faq-patient/">FAQ Patient</a></li> 173 <li id="menu-item-3247" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-3247"><a href="https://oncotherm.com/faq-distributor/">FAQ Distributor</a></li> 174</ul> 175</li> 176<li id="menu-item-3230" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-has-children menu-item-3230"><a href="##">Products</a> 177<ul class="sub-menu"> 178 <li id="menu-item-4532" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-4532"><a href="https://oncotherm.com/ehy-2030/">EHY-2030</a></li> 179 <li id="menu-item-4533" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-4533"><a href="https://oncotherm.com/labehy/">LabEHY</a></li> 180</ul> 181</li> 182<li id="menu-item-3458" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-has-children menu-item-3458"><a href="##">News</a> 183<ul class="sub-menu"> 184 <li id="menu-item-3459" class="menu-item menu-item-type-taxonomy menu-item-object-category menu-item-3459"><a href="https://oncotherm.com/news/">Latest news</a></li> 185 <li id="menu-item-3460" class="menu-item menu-item-type-taxonomy menu-item-object-category menu-item-3460"><a href="https://oncotherm.com/events/">Events</a></li> 186 <li id="menu-item-3461" class="menu-item menu-item-type-taxonomy menu-item-object-category menu-item-3461"><a href="https://oncotherm.com/corporate-social-responsibility/">Corporate Social Responsibility</a></li> 187</ul> 188</li> 189<li id="menu-item-3272" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-has-children menu-item-3272"><a href="https://oncotherm.com/about-us/">About Us</a> 190<ul class="sub-menu"> 191 <li id="menu-item-4130" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-4130"><a href="https://oncotherm.com/about-us/#oncothermteam">Oncotherm Team</a></li> 192 <li id="menu-item-4129" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-4129"><a href="https://oncotherm.com/about-us/#timeline">Timeline of Oncotherm</a></li> 193 <li id="menu-item-4128" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-4128"><a href="https://oncotherm.com/about-us/#tenders">Tenders</a></li> 194 <li id="menu-item-4126" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-4126"><a href="https://oncotherm.com/certificates/">Certificates</a></li> 195 <li id="menu-item-4127" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-4127"><a href="https://oncotherm.com/about-us/#contact">Contact</a></li> 196</ul> 197</li> 198<li id="menu-item-3277" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-3277"><a href="https://oncotherm.com/career/">Career</a></li> 199<li id="menu-item-3278" class="pll-parent-menu-item menu-item menu-item-type-custom menu-item-object-custom menu-item-has-children menu-item-3278"><a href="#pll_switcher">EN</a> 200<ul class="sub-menu"> 201 <li id="menu-item-3278-hu" class="lang-item lang-item-3 lang-item-hu lang-item-first menu-item menu-item-type-custom menu-item-object-custom menu-item-3278-hu"><a href="https://oncotherm.com/hu/klinikai-publikaciok/" lang="hu-HU" hreflang="hu-HU">HU</a></li> 202 <li id="menu-item-3278-de" class="lang-item lang-item-617 lang-item-de menu-item menu-item-type-custom menu-item-object-custom menu-item-3278-de"><a href="https://oncotherm.com/de/klinische-publikationen/" lang="de-DE" hreflang="de-DE">DE</a></li> 203</ul> 204</li> 205</ul></div> </nav><!-- #site-navigation --> 206 <section id="siteorigin-panels-builder-3" class="widget widget_siteorigin-panels-builder"><div id="pl-w6489d1a75c44d" class="panel-layout" ><div id="pg-w6489d1a75c44d-0" class="panel-grid panel-no-style" ><div id="pgc-w6489d1a75c44d-0-0" class="panel-grid-cell" ><div id="panel-w6489d1a75c44d-0-0-0" class="so-panel widget widget_sow-icon panel-first-child panel-last-child" data-index="0" ><div id="keres-ikon" class="panel-widget-style panel-widget-style-for-w6489d1a75c44d-0-0-0" ><div 207 208 class="so-widget-sow-icon so-widget-sow-icon-default-543ad11e08c1" 209 210 > 211<div class="sow-icon-container sow-icon"> 212 <span class="sow-icon-ionicons" data-sow-icon="" 213 214 aria-hidden="true"></span> </div> 215</div></div></div></div></div><div id="pg-w6489d1a75c44d-1" class="panel-grid panel-has-style" ><div id="kereso" class="panel-row-style panel-row-style-for-w6489d1a75c44d-1" ><div id="pgc-w6489d1a75c44d-1-0" class="panel-grid-cell" ><div id="panel-w6489d1a75c44d-1-0-0" class="so-panel widget widget_search panel-first-child panel-last-child" data-index="1" ><form role="search" method="get" class="search-form" action="https://oncotherm.com/"> 216 <label> 217 <span class="screen-reader-text">Search for:</span> 218 <input type="search" class="search-field" placeholder="Search …" value="" name="s" /> 219 </label> 220 <input type="submit" class="search-submit" value="Search" /> 221 </form></div></div></div></div></div></section><section id="sow-icon-2" class="widget widget_sow-icon"><div 222 223 class="so-widget-sow-icon so-widget-sow-icon-default-77a6afac270e" 224 225 > 226<div class="sow-icon-container sow-icon"> 227 <span class="sow-icon-materialicons sowm-regular" data-sow-icon="" 228 229 aria-hidden="true"></span> </div> 230</div></section> </div> 231 </div> 232 233 </header><!-- #masthead --> 234 <div id="palyazat"> 235 <section id="sow-image-6" class="widget widget_sow-image"><div 236 237 class="so-widget-sow-image so-widget-sow-image-default-4e6925654b7a" 238 239 > 240<div class="sow-image-container"> 241 <a href="https://oncotherm.com/projects-financed-by-the-hungarian-ministry-of-finance/" 242 > 243 <img 244 src="https://oncotherm.com/wp-content/uploads/2024/01/kedvezmenyezetti_infoblokk_fekvo_angol_rgb.jpg" width="300" height="88" sizes="(max-width: 300px) 100v
244w, 300px" alt="" decoding="async" class="so-widget-image"/> 245 </a></div> 246 247</div></section><section id="sow-image-12" class="widget widget_sow-image"><div 248 249 class="so-widget-sow-image so-widget-sow-image-default-8b5b6f678277" 250 251 > 252<div class="sow-image-container"> 253 <a href="https://oncotherm.com/our-projects-implemented-with-co-financing-from-the-european-union/" 254 > 255 <img 256 src="https://oncotherm.com/wp-content/uploads/2026/03/kedvezmenyezetti_infoblokk_fekvo_angol_rgb-300x88.png" width="230" height="67" srcset="https://oncotherm.com/wp-content/uploads/2026/03/kedvezmenyezetti_infoblokk_fekvo_angol_rgb-300x88.png 300w, https://oncotherm.com/wp-content/uploads/2026/03/kedvezmenyezetti_infoblokk_fekvo_angol_rgb.png 600w" sizes="(max-width: 230px) 100vw, 230px" alt="" decoding="async" class="so-widget-image"/> 257 </a></div> 258 259</div></section> </div> 260 <!-- home-slider --> 261 <!-- home-slider --> 262 <main id="primary" class="site-main ot-events"> 263<div class="container kp-top"> 264 265 <section id="sow-editor-3" class="widget widget_sow-editor"><div 266 267 class="so-widget-sow-editor so-widget-sow-editor-base" 268 269 > 270<div class="siteorigin-widget-tinymce textwidget"> 271 <h1 class="page-title" style="text-align: left; margin-bottom: 10px;">CLINICAL PUBLICATIONS</h1> 272<p>If you would like to read about experimental publications <span style="color: #9e8053;"><a style="color: #9e8053;" href="https://oncotherm.com/collection-of-experimental-publications/" target="_blank" rel="noopener">please click here</a></span></p> 273</div> 274</div></section><section id="wpc_filters_widget-9" class="widget widget_wpc_filters_widget"><div class="wpc-filters-main-wrap wpc-filter-set-3389 wpc-horizontal-layout wpc-horizontal-cols-3" data-wpc-hide-empty="no" data-wpc-use-apply-button="" data-set="3389"> 275<div class="wpc-filters-open-button-container wpc-open-button-3389 "> 276 <a class="wpc-open-close-filters-button wpc-show-counts-no" href="javascript:void(0);" data-wid="3389"><span class="wpc-button-inner"> <span class="wpc-icon-html-wrapper"> 277 <span class="wpc-icon-line-1"></span> 278 <span class="wpc-icon-line-2"></span> 279 <span class="wpc-icon-line-3"></span> 280</span> 281 <span class="wpc-filters-button-text">Filters</span></span></a> 282</div><div class="wpc-spinner"></div><div class="wpc-filters-widget-content wpc-show-counts-no wpc-query-on-the-page"><div class="wpc-widget-close-container"> 283 <a class="wpc-widget-close-icon"> 284 <span class="wpc-icon-html-wrapper"> 285 <span class="wpc-icon-line-1"></span><span class="wpc-icon-line-2"></span><span class="wpc-icon-line-3"></span> 286 </span> 287 </a><span class="wpc-widget-popup-title">Filters</span></div><div class="wpc-filters-widget-containers-wrapper"> 288<div class="wpc-filters-widget-top-container"><div class="wpc-widget-top-inside"><div class="wpc-inner-widget-chips-wrapper"><ul class="wpc-filter-chips-list wpc-filter-chips-3389-1 wpc-filter-chips-3389 wpc-empty-chips-container" data-set="3389" data-setcount="3389-1"> 289 </ul></div></div></div><div class="wpc-filters-scroll-container"><div class="wpc-filters-widget-wrapper"> 290<div class="wpc-posts-found wpc-posts-found-hidden" data-found=""> 291</div><div class="wpc-filters-section wpc-filters-section-3389s wpc-filter-layout-search-field" data-fid="3389s"> 292 <div class="wpc-filter-header"> 293 <div class="widget-title wpc-filter-title">SEARCH</div></div><form action="https://oncotherm.com/clinical-publications/" role="search" method="GET" class="wpc-filter-search-form"><div class="wpc-search-field-wrapper wpc-search-field-wrapper-3389s"><span class="wpc-search-icon"></span><label for="srch" class="screen-reader-text">Search</label><input type="text" class="wpc-search-field" placeholder="Author" value="" name="srch"><span class="wpc-search-clear-icon-wrapper"><a class="wpc-search-clear-icon" href="https://oncotherm.com/clinical-publications/" title="Clear search">×</a></span> 294 </div></form></div><div class="wpc-filters-section wpc-filters-section-3394 wpc-filter-bizonyitas wpc-filter-post_meta wpc-filter-layout-dropdown wpc-counter-length-2 wpc-filter-terms-count-10 wpc-filter-visible-term-names" data-fid="3394" data-filter-e-name="bizonyitas"> 295 <div class="wpc-filter-header"> 296 <div class="widget-title wpc-filter-title">Evidence</div></div> <div class="wpc-filter-content wpc-filter-bizonyitas"> 297 <select id="wpc-post_meta-bizonyitas-3394" 298 aria-label="wpc-post_meta-bizonyitas-3394" 299 class="wpc-filters-widget-select" style="width: 100%"> 300 301 <option class="wpc-dropdown-default wpc-dropdown-default-bizonyitas" value="
3010" data-wpc-link="https://oncotherm.com/clinical-publications/" id="wpc-option-post_meta-bizonyitas-0" data-wpc-select-parent-text="" data-wpc-default-option-text="Evidence">Evidence</option> 302 <option data-wpc-chip="Case report" class="wpc-term-item wpc-term-count-12 wpc-term-id-11" value="11" data-wpc-link="https://oncotherm.com/clinical-publications/?_bizonyitas=case-report" id="wpc-option-post_meta-bizonyitas-11" data-wpc-e-name="bizonyitas" data-wpc-slug="case-report" data-term-id="11"> 303 Case report</option> 304 <option data-wpc-chip="Clinical study" class="wpc-term-item wpc-term-count-4 wpc-term-id-60" value="60" data-wpc-link="https://oncotherm.com/clinical-publications/?_bizonyitas=clinical-study" id="wpc-option-post_meta-bizonyitas-60" data-wpc-e-name="bizonyitas" data-wpc-slug="clinical-study" data-term-id="60"> 305 Clinical study</option> 306 <option data-wpc-chip="Comparative study" class="wpc-term-item wpc-term-count-1 wpc-term-id-36" value="36" data-wpc-link="https://oncotherm.com/clinical-publications/?_bizonyitas=comparative-study" id="wpc-option-post_meta-bizonyitas-36" data-wpc-e-name="bizonyitas" data-wpc-slug="comparative-study" data-term-id="36"> 307 Comparative study</option> 308 <option data-wpc-chip="Open-label study" class="wpc-term-item wpc-term-count-3 wpc-term-id-53" value="53" data-wpc-link="https://oncotherm.com/clinical-publications/?_bizonyitas=open-label-study" id="wpc-option-post_meta-bizonyitas-53" data-wpc-e-name="bizonyitas" data-wpc-slug="open-label-study" data-term-id="53"> 309 Open-label study</option> 310 <option data-wpc-chip="Phase I" class="wpc-term-item wpc-term-count-6 wpc-term-id-15" value="15" data-wpc-link="https://oncotherm.com/clinical-publications/?_bizonyitas=phase-i" id="wpc-option-post_meta-bizonyitas-15" data-wpc-e-name="bizonyitas" data-wpc-slug="phase-i" data-term-id="15"> 311 Phase I</option> 312 <option data-wpc-chip="Phase I/II" class="wpc-term-item wpc-term-count-2 wpc-term-id-27" value="27" data-wpc-link="https://oncotherm.com/clinical-publications/?_bizonyitas=phase-i-ii" id="wpc-option-post_meta-bizonyitas-27" data-wpc-e-name="bizonyitas" data-wpc-slug="phase-i-ii" data-term-id="27"> 313 Phase I/II</option> 314 <option data-wpc-chip="Phase II" class="wpc-term-item wpc-term-count-6 wpc-term-id-38" value="38" data-wpc-link="https://oncotherm.com/clinical-publications/?_bizonyitas=phase-ii" id="wpc-option-post_meta-bizonyitas-38" data-wpc-e-name="bizonyitas" data-wpc-slug="phase-ii" data-term-id="38"> 315 Phase II</option> 316 <option data-wpc-chip="Phase III" class="wpc-term-item wpc-term-count-6 wpc-term-id-17" value="17" data-wpc-link="https://oncotherm.com/clinical-publications/?_bizonyitas=phase-iii" id="wpc-option-post_meta-bizonyitas-17" data-wpc-e-name="bizonyitas" data-wpc-slug="phase-iii" data-term-id="17"> 317 Phase III</option> 318 <option data-wpc-chip="Retrospective study" class="wpc-term-item wpc-term-count-7 wpc-term-id-33" value="33" data-wpc-link="https://oncotherm.com/clinical-publications/?_bizonyitas=retrospective-study" id="wpc-option-post_meta-bizonyitas-33" data-wpc-e-name="bizonyitas" data-wpc-slug="retrospective-study" data-term-id="33"> 319 Retrospective study</option> 320 <option data-wpc-chip="Review" class="wpc-term-item wpc-term-count-8 wpc-term-id-6" value="6" data-wpc-link="https://oncotherm.com/clinical-publications/?_bizonyitas=review" id="wpc-option-post_meta-bizonyitas-6" data-wpc-e-name="bizonyitas" data-wpc-slug="review" data-term-id="6"> 321 Review</option> 322 <!-- end foreach --> 323 324 </select> 325 </div> 326</div><div class="wpc-filters-section wpc-filters-section-3391 wpc-filter-terapia wpc-filter-post_meta wpc-filter-layout-dropdown wpc-counter-length-2 wpc-filter-terms-count-23 wpc-filter-visible-term-names" data-fid="3391" data-filter-e-name="terapia"> 327 <div class="wpc-filter-header"> 328 <div class="widget-title wpc-filter-title">Therapy</div></div> <div class="wpc-filter-content wpc-filter-terapia"> 329 <select id="wpc-post_meta-terapia-3391" 330 aria-label="wpc-post_meta-terapia-3391" 331 class="wpc-filters-widget-select" style="width: 100%"> 332 333 <option class="wpc-dropdown-default wpc-dropdown-default-terapia" value="
3330" data-wpc-link="https://oncotherm.com/clinical-publications/" id="wpc-option-post_meta-terapia-0" data-wpc-select-parent-text="" data-wpc-default-option-text="Therapy">Therapy</option> 334 <option data-wpc-chip="Autophagy Inhibitor+mEHT" class="wpc-term-item wpc-term-count-1 wpc-term-id-31" value="31" data-wpc-link="https://oncotherm.com/clinical-publications/?_terapia=autophagy-inhibitormeht" id="wpc-option-post_meta-terapia-31" data-wpc-e-name="terapia" data-wpc-slug="autophagy-inhibitormeht" data-term-id="31"> 335 Autophagy Inhibitor+mEHT</option> 336 <option data-wpc-chip="CCRT + mEHT" class="wpc-term-item wpc-term-count-1 wpc-term-id-221" value="221" data-wpc-link="https://oncotherm.com/clinical-publications/?_terapia=ccrt-meht" id="wpc-option-post_meta-terapia-221" data-wpc-e-name="terapia" data-wpc-slug="ccrt-meht" data-term-id="221"> 337 CCRT + mEHT</option> 338 <option data-wpc-chip="Chemotherapy, Hyperthermia, Phytotherapy" class="wpc-term-item wpc-term-count-1 wpc-term-id-41" value="41" data-wpc-link="https://oncotherm.com/clinical-publications/?_terapia=chemotherapy-hyperthermia-phytotherapy" id="wpc-option-post_meta-terapia-41" data-wpc-e-name="terapia" data-wpc-slug="chemotherapy-hyperthermia-phytotherapy" data-term-id="41"> 339 Chemotherapy, Hyperthermia, Phytotherapy</option> 340 <option data-wpc-chip="Chemotherapy, Ketogenic Diet, Hyperthermia, Hyperbaric Oxygen Therapy" class="wpc-term-item wpc-term-count-1 wpc-term-id-16" value="16" data-wpc-link="https://oncotherm.com/clinical-publications/?_terapia=chemotherapy-ketogenic-diet-hyperthermia-hyperbaric-oxygen-therapy" id="wpc-option-post_meta-terapia-16" data-wpc-e-name="terapia" data-wpc-slug="chemotherapy-ketogenic-diet-hyperthermia-hyperbaric-oxygen-therapy" data-term-id="16"> 341 Chemotherapy, Ketogenic Diet, Hyperthermia, Hyperbaric Oxygen Therapy</option> 342 <option data-wpc-chip="Conventional treatment, Hyperthermia" class="wpc-term-item wpc-term-count-1 wpc-term-id-59" value="59" data-wpc-link="https://oncotherm.com/clinical-publications/?_terapia=conventional-treatment-hyperthermia" id="wpc-option-post_meta-terapia-59" data-wpc-e-name="terapia" data-wpc-slug="conventional-treatment-hyperthermia" data-term-id="59"> 343 Conventional treatment, Hyperthermia</option> 344 <option data-wpc-chip="CRT+mEHT" class="wpc-term-item wpc-term-count-2 wpc-term-id-4" value="4" data-wpc-link="https://oncotherm.com/clinical-publications/?_terapia=crtmeht" id="wpc-option-post_meta-terapia-4" data-wpc-e-name="terapia" data-wpc-slug="crtmeht" data-term-id="4"> 345 CRT+mEHT</option> 346 <option data-wpc-chip="CT+mEHT" class="wpc-term-item wpc-term-count-22 wpc-term-id-29" value="29" data-wpc-link="https://oncotherm.com/clinical-publications/?_terapia=ctmeht" id="wpc-option-post_meta-terapia-29" data-wpc-e-name="terapia" data-wpc-slug="ctmeht" data-term-id="29"> 347 CT+mEHT</option> 348 <option data-wpc-chip="CT+RT+mEHT" class="wpc-term-item wpc-term-count-11 wpc-term-id-11" value="11" data-wpc-link="https://oncotherm.com/clinical-publications/?_terapia=ctrtmeht" id="wpc-option-post_meta-terapia-11" data-wpc-e-name="terapia" data-wpc-slug="ctrtmeht" data-term-id="11"> 349 CT+RT+mEHT</option> 350 <option data-wpc-chip="CT+WBH" class="wpc-term-item wpc-term-count-2 wpc-term-id-97" value="97" data-wpc-link="https://oncotherm.com/clinical-publications/?_terapia=ctwbh" id="wpc-option-post_meta-terapia-97" data-wpc-e-name="terapia" data-wpc-slug="ctwbh" data-term-id="97"> 351 CT+WBH</option> 352 <option data-wpc-chip="ECT" class="wpc-term-item wpc-term-count-1 wpc-term-id-67" value="67" data-wpc-link="https://oncotherm.com/clinical-publications/?_terapia=ect" id="wpc-option-post_meta-terapia-67" data-wpc-e-name="terapia" data-wpc-slug="ect" data-term-id="67"> 353 ECT</option> 354 <option data-wpc-chip="IMT+mEHT" class="wpc-term-item wpc-term-count-3 wpc-term-id-33" value="33" data-wpc-link="https://oncotherm.com/clinical-publications/?_terapia=imtmeht" id="wpc-option-post_meta-terapia-33" data-wpc-e-name="terapia" data-wpc-slug="imtmeht" data-term-id="33"> 355 IMT+mEHT</option> 356 <option data-wpc-chip="Integrative Therapeutic Options" class="wpc-term-item wpc-term-count-1 wpc-term-id-28" value="28" data-wpc-link="https://oncotherm.com/clinical-publications/?_terapia=integrative-therapeutic-options" id="wpc-option-post_meta-terapia-28" data-wpc-e-name="terapia" data-wpc-slug="integrative-therapeutic-options" data-term-id="28"> 357 Integrative Therapeutic Options</option> 358 <option data-wpc-chip="IVC + mEHT + BSC" class="wpc-term-item wpc-term-count-1 wpc-term-id-18" value="18" data-wpc-link="https://oncotherm.com/clinical-publications/?_terapia=ivc-meht-bsc" id="wpc-option-post_meta-terapia-18" data-wpc-e-name="terapia" data-wpc-slug="ivc-meht-bsc" data-term-id="18"> 359 IVC + mEHT + BSC</option> 360 <option data-wpc-chip="MEHT" class="wpc-term-item wpc-term-count-25 wpc-term-id-5" value="5" data-wpc-link="https://oncotherm.com/clinical-publications/?_terapia=meht" id="wpc-option-post_meta-terapia-5" data-wpc-e-name="terapia" data-wpc-slug="meht" data-term-id="5"> 361 MEHT</option> 362 <option data-wpc-chip="MEHT + TTF" class="wpc-term-item wpc-term-count-1 wpc-term-id-3" value="3" data-wpc-link="https://oncotherm.com/clinical-publications/?_terapia=meht-ttf" id="wpc-option-post_meta-terapia-3" data-wpc-e-name="terapia" data-wpc-slug="meht-ttf" data-term-id="3"> 363 MEHT + TTF</option> 364 <option data-wpc-chip="MEHT+OV therapy+DC" class="wpc-term-item wpc-term-count-1 wpc-term-id-66" value="66" data-wpc-link="https://oncotherm.com/clinical-publications/?_terapia=mehtov-therapydc" id="wpc-option-post_meta-terapia-66" data-wpc-e-name="terapia" data-wpc-slug="mehtov-therapydc" data-term-id="66"> 365 MEHT+OV therapy+DC</option> 366 <option data-wpc-chip="MEHT+TCM" class="wpc-term-item wpc-term-count-2 wpc-term-id-37" value="37" data-wpc-link="https://oncotherm.com/clinical-publications/?_terapia=mehttcm" id="wpc-option-post_meta-terapia-37" data-wpc-e-name="terapia" data-wpc-slug="mehttcm" data-term-id="37"> 367 MEHT+TCM</option> 368 <option data-wpc-chip="MEHT+Vitamins" class="wpc-term-item wpc-term-count-1 wpc-term-id-72" value="72" data-wpc-link="https://oncotherm.com/clinical-publications/?_terapia=mehtvitamins" id="wpc-option-post_meta-terapia-72" data-wpc-e-name="terapia" data-wpc-slug="mehtvitamins" data-term-id="72"> 369 MEHT+Vitamins</option> 370 <option data-wpc-chip="PT + mEHT" class="wpc-term-item wpc-term-count-1 wpc-term-id-35" value="35" data-wpc-link="https://oncotherm.com/clinical-publications/?_terapia=pt-meht" id="wpc-option-post_meta-terapia-35" data-wpc-e-name="terapia" data-wpc-slug="pt-meht" data-term-id="35"> 371 PT + mEHT</option> 372 <option data-wpc-chip="RT+mEHT" class="wpc-term-item wpc-term-count-4 wpc-term-id-9" value="9" data-wpc-link="https://oncotherm.com/clinical-publications/?_terapia=rtmeht" id="wpc-option-post_meta-terapia-9" data-wpc-e-name="terapia" data-wpc-slug="rtmeht" data-term-id="9"> 373 RT+mEHT</option> 374 <option data-wpc-chip="SRG+CT+mEHT" class="wpc-term-item wpc-term-count-3 wpc-term-id-57" value="5
3747" data-wpc-link="https://oncotherm.com/clinical-publications/?_terapia=srgctmeht" id="wpc-option-post_meta-terapia-57" data-wpc-e-name="terapia" data-wpc-slug="srgctmeht" data-term-id="57"> 375 SRG+CT+mEHT</option> 376 <option data-wpc-chip="SRG+CT+RT+mEHT" class="wpc-term-item wpc-term-count-1 wpc-term-id-95" value="95" data-wpc-link="https://oncotherm.com/clinical-publications/?_terapia=srgctrtmeht" id="wpc-option-post_meta-terapia-95" data-wpc-e-name="terapia" data-wpc-slug="srgctrtmeht" data-term-id="95"> 377 SRG+CT+RT+mEHT</option> 378 <option data-wpc-chip="TSL+mEHT" class="wpc-term-item wpc-term-count-1 wpc-term-id-30" value="30" data-wpc-link="https://oncotherm.com/clinical-publications/?_terapia=tslmeht" id="wpc-option-post_meta-terapia-30" data-wpc-e-name="terapia" data-wpc-slug="tslmeht" data-term-id="30"> 379 TSL+mEHT</option> 380 <!-- end foreach --> 381 382 </select> 383 </div> 384</div><div class="wpc-filters-section wpc-filters-section-3395 wpc-filter-indikacio wpc-filter-post_meta wpc-filter-layout-dropdown wpc-counter-length-2 wpc-filter-terms-count-24 wpc-filter-visible-term-names" data-fid="3395" data-filter-e-name="indikacio"> 385 <div class="wpc-filter-header"> 386 <div class="widget-title wpc-filter-title">Indication</div></div> <div class="wpc-filter-content wpc-filter-indikacio"> 387 <select id="wpc-post_meta-indikacio-3395" 388 aria-label="wpc-post_meta-indikacio-3395" 389 class="wpc-filters-widget-select" style="width: 100%"> 390 391 <option class="wpc-dropdown-default wpc-dropdown-default-indikacio" value="0" data-wpc-link="https://oncotherm.com/clinical-publications/" id="wpc-option-post_meta-indikacio-0" data-wpc-select-parent-text="" data-wpc-default-option-text="Indication">Indication</option> 392 <option data-wpc-chip="Bone" class="wpc-term-item wpc-term-count-2 wpc-term-id-79" value="79" data-wpc-link="https://oncotherm.com/clinical-publications/?_indikacio=bone" id="wpc-option-post_meta-indikacio-79" data-wpc-e-name="indikacio" data-wpc-slug="bone" data-term-id="79"> 393 Bone</option> 394 <option data-wpc-chip="Breast Cancer" class="wpc-term-item wpc-term-count-3 wpc-term-id-5" value="5" data-wpc-link="https://oncotherm.com/clinical-publications/?_indikacio=breast-cancer" id="wpc-option-post_meta-indikacio-5" data-wpc-e-name="indikacio" data-wpc-slug="breast-cancer" data-term-id="5"> 395 Breast Cancer</option> 396 <option data-wpc-chip="Cervical cancer" class="wpc-term-item wpc-term-count-4 wpc-term-id-17" value="17" data-wpc-link="https://oncotherm.com/clinical-publications/?_indikacio=cervical-cancer" id="wpc-option-post_meta-indikacio-17" data-wpc-e-name="indikacio" data-wpc-slug="cervical-cancer" data-term-id="17"> 397 Cervical cancer</option> 398 <option data-wpc-chip="Gastric Cancer" class="wpc-term-item wpc-term-count-1 wpc-term-id-16" value="16" data-wpc-link="https://oncotherm.com/clinical-publications/?_indikacio=gastric-cancer" id="wpc-option-post_meta-indikacio-16" data-wpc-e-name="indikacio" data-wpc-slug="gastric-cancer" data-term-id="16"> 399 Gastric Cancer</option> 400 <option data-wpc-chip="Gastrointestinal" class="wpc-term-item wpc-term-count-4 wpc-term-id-4" value="4" data-wpc-link="https://oncotherm.com/clinical-publications/?_indikacio=gastrointestinal" id="wpc-option-post_meta-indikacio-4" data-wpc-e-name="indikacio" data-wpc-slug="gastrointestinal" data-term-id="4"> 401 Gastrointestinal</option> 402 <option data-wpc-chip="Glioblastoma" class="wpc-term-item wpc-term-count-2 wpc-term-id-3" value="3" data-wpc-link="https://oncotherm.com/clinical-publications/?_indikacio=glioblastoma" id="wpc-option-post_meta-indikacio-3" data-wpc-e-name="indikacio" data-wpc-slug="glioblastoma" data-term-id="3"> 403 Glioblastoma</option> 404 <option data-wpc-chip="Gliomas" class="wpc-term-item wpc-term-count-1 wpc-term-id-39" value="39" data-wpc-link="https://oncotherm.com/clinical-publications/?_indikacio=gliomas" id="wpc-option-post_meta-indikacio-39" data-wpc-e-name="indikacio" data-wpc-slug="gliomas" data-term-id="39"> 405 Gliomas</option> 406 <option data-wpc-chip="Gliomas (advanced)" class="wpc-term-item wpc-term-count-11 wpc-term-id-9" value="9" data-wpc-link="https://oncotherm.com/clinical-publications/?_indikacio=gliomas-advanced" id="wpc-option-post_meta-indikacio-9" data-wpc-e-name="indikacio" data-wpc-slug="gliomas-advanced" data-term-id="9"> 407 Gliomas (advanced)</option> 408 <option data-wpc-chip="Gynecology" class="wpc-term-item wpc-term-count-13 wpc-term-id-7" value="7" data-wpc-link="https://oncotherm.com/clinical-publications/?_indikacio=gynecology" id="wpc-option-post_meta-indikacio-7" data-wpc-e-name="indikacio" data-wpc-slug="gynecology" data-term-id="7"> 409 Gynecology</option> 410 <option data-wpc-chip="Hemangioma" class="wpc-term-item wpc-term-count-1 wpc-term-id-67" value="67" data-wpc-link="https://oncotherm.com/clinical-publications/?_indikacio=hemangioma" id="wpc-option-post_meta-indikacio-67" data-wpc-e-name="indikacio" data-wpc-slug="hemangioma" data-term-id="67"> 411 Hemangioma</option> 412 <option data-wpc-chip="Immuno-oncology" class="wpc-term-item wpc-term-count-6 wpc-term-id-24" value="24" data-wpc-link="https://oncotherm.com/clinical-publications/?_indikacio=immuno-oncology" id="wpc-option-post_meta-indikacio-24" data-wpc-e-name="indikacio" data-wpc-slug="immuno-oncology" data-term-id="24"> 413 Immuno-oncology</option> 414 <option data-wpc-chip="Liver" class="wpc-term-item wpc-term-count-2 wpc-term-id-88" value="88" data-wpc-link="https://oncotherm.com/clinical-publications/?_indikacio=liver" id="wpc-option-post_meta-indikacio-88" data-wpc-e-name="indikacio" data-wpc-slug="liver" data-term-id="88">
415 Liver</option> 416 <option data-wpc-chip="Lung" class="wpc-term-item wpc-term-count-7 wpc-term-id-20" value="20" data-wpc-link="https://oncotherm.com/clinical-publications/?_indikacio=lung" id="wpc-option-post_meta-indikacio-20" data-wpc-e-name="indikacio" data-wpc-slug="lung" data-term-id="20"> 417 Lung</option> 418 <option data-wpc-chip="Lung cancer" class="wpc-term-item wpc-term-count-3 wpc-term-id-14" value="14" data-wpc-link="https://oncotherm.com/clinical-publications/?_indikacio=lung-cancer" id="wpc-option-post_meta-indikacio-14" data-wpc-e-name="indikacio" data-wpc-slug="lung-cancer" data-term-id="14"> 419 Lung cancer</option> 420 <option data-wpc-chip="Lyme-disease" class="wpc-term-item wpc-term-count-1 wpc-term-id-72" value="72" data-wpc-link="https://oncotherm.com/clinical-publications/?_indikacio=lyme-disease" id="wpc-option-post_meta-indikacio-72" data-wpc-e-name="indikacio" data-wpc-slug="lyme-disease" data-term-id="72"> 421 Lyme-disease</option> 422 <option data-wpc-chip="Melanoma" class="wpc-term-item wpc-term-count-1 wpc-term-id-94" value="94" data-wpc-link="https://oncotherm.com/clinical-publications/?_indikacio=melanoma" id="wpc-option-post_meta-indikacio-94" data-wpc-e-name="indikacio" data-wpc-slug="melanoma" data-term-id="94"> 423 Melanoma</option> 424 <option data-wpc-chip="Multiple" class="wpc-term-item wpc-term-count-4 wpc-term-id-13" value="13" data-wpc-link="https://oncotherm.com/clinical-publications/?_indikacio=multiple" id="wpc-option-post_meta-indikacio-13" data-wpc-e-name="indikacio" data-wpc-slug="multiple" data-term-id="13"> 425 Multiple</option> 426 <option data-wpc-chip="Non-oncology" class="wpc-term-item wpc-term-count-7 wpc-term-id-22" value="22" data-wpc-link="https://oncotherm.com/clinical-publications/?_indikacio=non-oncology" id="wpc-option-post_meta-indikacio-22" data-wpc-e-name="indikacio" data-wpc-slug="non-oncology" data-term-id="22"> 427 Non-oncology</option> 428 <option data-wpc-chip="Pancreas" class="wpc-term-item wpc-term-count-8 wpc-term-id-25" value="25" data-wpc-link="https://oncotherm.com/clinical-publications/?_indikacio=pancreas" id="wpc-option-post_meta-indikacio-25" data-wpc-e-name="indikacio" data-wpc-slug="pancreas" data-term-id="25"> 429 Pancreas</option> 430 <option data-wpc-chip="Prostate" class="wpc-term-item wpc-term-count-14 wpc-term-id-61" value="61" data-wpc-link="https://oncotherm.com/clinical-publications/?_indikacio=prostate" id="wpc-option-post_meta-indikacio-61" data-wpc-e-name="indikacio" data-wpc-slug="prostate" data-term-id="61"> 431 Prostate</option> 432 <option data-wpc-chip="Rectal Cancer" class="wpc-term-item wpc-term-count-3 wpc-term-id-12" value="12" data-wpc-link="https://oncotherm.com/clinical-publications/?_indikacio=rectal-cancer" id="wpc-option-post_meta-indikacio-12" data-wpc-e-name="indikacio" data-wpc-slug="rectal-cancer" data-term-id="12"> 433 Rectal Cancer</option> 434 <option data-wpc-chip="Sarcoma" class="wpc-term-item wpc-term-count-2 wpc-term-id-57" value="57" data-wpc-link="https://oncotherm.com/clinical-publications/?_indikacio=sarcoma" id="wpc-option-post_meta-indikacio-57" data-wpc-e-name="indikacio" data-wpc-slug="sarcoma" data-term-id="57"> 435 Sarcoma</option> 436 <option data-wpc-chip="Temperature" class="wpc-term-item wpc-term-count-3 wpc-term-id-32" value="32" data-wpc-link="https://oncotherm.com/clinical-publications/?_indikacio=temperature" id="wpc-option-post_meta-indikacio-32" data-wpc-e-name="indikacio" data-wpc-slug="temperature" data-term-id="32"> 437 Temperature</option> 438 <option data-wpc-chip="Toxicity" class="wpc-term-item wpc-term-count-1 wpc-term-id-104" value="104" data-wpc-link="https://oncotherm.com/clinical-publications/?_indikacio=toxicity" id="wpc-option-post_meta-indikacio-104" data-wpc-e-name="indikacio" data-wpc-slug="toxicity" data-term-id="104"> 439 Toxicity</option> 440 <!-- end foreach --> 441 442 </select> 443 </div> 444</div><div class="wpc-filters-section wpc-filters-section-3389 wpc-filter-layout-submit-button wpc-pc-sticky-buttons"> 445 <div class="wpc-sticky-buttons"> 446 <a class="wpc-filters-submit-button" href="https://oncotherm.com/clinical-publications/" data-wpc-apply-url="https://oncotherm.com/clinical-publications/" data-wpc-apply-base-url="" data-apply-button-page=""> 447 Filter<span class='wpc-pc-apply-button wpc-hidden-term-count'>(110)</span></a> 448 <a class="wpc-filters-reset-button wpc-filters-reset-button-3389" href="https://oncotherm.com/clinical-publications/" data-wpc-apply-reset-url="https://oncotherm.com/clinical-publications/">Reset</a> 449 </div> 450</div> 451</div> 452</div>
453<div class="wpc-filters-widget-controls-container"> 454 <div class="wpc-filters-widget-controls-wrapper"><div class="wpc-filters-widget-controls-item wpc-filters-widget-controls-one"> 455 <a class="wpc-filters-apply-button wpc-posts-loaded" href="https://oncotherm.com/clinical-publications/">Show <span class="wpc-filters-found-posts-wrapper">(<span class="wpc-filters-found-posts" data-wpc-total-found-posts="110">110</span>)</span></a> 456</div> 457<div class="wpc-filters-widget-controls-item wpc-filters-widget-controls-two"> 458 <a class="wpc-filters-close-button" href="https://oncotherm.com/clinical-publications/">Cancel </a> 459</div> 460 </div><div class="wpc-filters-section wpc-filters-section-3389 wpc-filter-layout-submit-button wpc-pc-sticky-buttons"> 461 <div class="wpc-sticky-buttons"> 462 <a class="wpc-filters-submit-button" href="https://oncotherm.com/clinical-publications/" data-wpc-apply-url="https://oncotherm.com/clinical-publications/" data-wpc-apply-base-url="" data-apply-button-page=""> 463 Filter<span class='wpc-pc-apply-button wpc-hidden-term-count'>(110)</span></a> 464 <a class="wpc-filters-reset-button wpc-filters-reset-button-3389" href="https://oncotherm.com/clinical-publications/" data-wpc-apply-reset-url="https://oncotherm.com/clinical-publications/">Reset</a> 465 </div> 466</div> 467</div></div> 468</div> 469</div> 470</section></div> 471 472 <div class="accordion-list"> 473 474<article id="post-3393" class="post-3393 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry"> 475 476 <header class="pub-entry-header"> 477 <div class="container"> 478 <h2>Modulated electrohyperthermia in locally advanced cervical cancer Results of an observational study of 95 patients</h2> 479 </div> 480 </header><!-- .entry-header --> 481 482 483<div class="entry-content kl-pub-content"> 484 <div class="container"> 485 <div class="acf-fields"> 486 <div class="acf-row"><span class="publ-label">Indication:</span> Gynecology <hr/> <span class="publ-label">Evidence:</span> </div> 487 <div class="publ-acf acf-row acf-flex"> 488 <span class="publ-label">Author: </span> 489 <div class="szerzok"> 490 491 492 493 <span class="sz-nev">Sun Young Lee</span> 494 495 496 497 <span class="sz-nev">Dong Hyun Lee</span> 498 499 500 501 <span class="sz-nev">Dong-Hyu Cho</span> 502 503 </div> 504 505 </div> 506 <div class="acf-row"><span class="publ-label">No. of patients:</span> 95 <hr/> <span class="publ-label">Therapy:</span> CCRT + mEHT<hr/> <span class="publ-label">Year:</span> 2023</div> 507 </div><!-- .acf-fields --> 508 <p><strong>Abstract</strong><br /> 509Abstract Most federation of gynecology and obstetrics stage II or higher locally advanced cervical cancer (LACC) patients are treated with concurrent chemoradiotherapy (CCRT); however, recurrence is high, and the prognosis is poor. In this observational retrospective study, data from LACC patients treated with CCRT alone or combined with modulated electrohyperthermia (mEHT) were collected from 2011 to 2018. Ninety-five LACC patients, including 53 (%) treated with CCRT alone and 42 (%) treated with CCRT + mEHT, were enrolled. The complete remission rate significantly increased with CCRT + mEHT compared with CCRT alone among LACC cases with lymph node metastasis (45% vs 71%, P = .0377). Additionally, at the last follow-up point, the no-evidence-of-disease rate significantly improved with CCRT + mEHT compared with CCRT (58% vs 82%, P = .0315). Disease-free survival increased in the CCRT + mEHT group with lymph node metastasis (P = .04). The addition of mEHT to CCRT led to a better therapeutic response in LACC with regional lymph node metastasis without severe complications.</p> 510<p><strong>Abbreviations</strong><br /> 511AEs = adverse events, CCRT = concurrent chemoradiotherapy, CR = complete remission, DFS = disease-free survival, HIF-1a = hypoxia-inducible factor-1a, LACC = locally advanced cervical cancer, mEHT = modulated electrohyperthermia, NED = no-evidence-of-disease, OS = overall survival, RF = radio frequency, VEGF = vascular endothelial growth factor.</p> 512 513 <div id="teljes-cikk" class="btn"> 514 <a href="https://journals.lww.com/md-journal/Fulltext/2023/01200/Modulated_electrohyperthermia_in_locally_advanced.1.aspx" target="_blank">
514 View abstract</a> 515 </div> 516 517 </div> <!-- .container --> 518</div><!-- .entry-content --> 519 520 521 522</article><!-- #post-3393 --> 523 524 525<article id="post-3279" class="post-3279 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry"> 526 527 <header class="pub-entry-header"> 528 <div class="container"> 529 <h2>Meta-Analysis of Modulated Electro-Hyperthermia and Tumor Treating Fields in the Treatment of Glioblastomas</h2> 530 </div> 531 </header><!-- .entry-header --> 532 533 534<div class="entry-content kl-pub-content"> 535 <div class="container"> 536 <div class="acf-fields"> 537 <div class="acf-row"><span class="publ-label">Indication:</span> Glioblastoma <hr/> <span class="publ-label">Evidence:</span> </div> 538 <div class="publ-acf acf-row acf-flex"> 539 <span class="publ-label">Author: </span> 540 <div class="szerzok"> 541 542 543 544 <span class="sz-nev">Attila Marcell Szasz</span> 545 546 547 548 <span class="sz-nev">Elisabeth EstefanÃa</span> 549 550 551 552 <span class="sz-nev">Arrojo Alvarez</span> 553 554 555 556 <span class="sz-nev">Giammaria Fiorentini</span> 557 558 559 560 <span class="sz-nev">Magdolna Herold</span> 561 562 563 564 <span class="sz-nev">Zoltan Herold</span> 565 566 567 568 <span class="sz-nev">Donatella Sarti</span> 569 570 571 572 <span class="sz-nev">Magdolna Dank</span> 573 574 </div> 575 576 </div> 577 <div class="acf-row"><span class="publ-label">No. of patients:</span> 450 <hr/> <span class="publ-label">Therapy:</span> mEHT + TTF<hr/> <span class="publ-label">Year:</span> 2022</div> 578 </div><!-- .acf-fields --> 579 <p class="text-align-justify"><span style="color: #9e8053;"><strong>Simple Summary</strong></span><br /> 580Glioblastoma is a highly aggressive brain tumor, which has a very poor 5-year survival rate (<5%). In the last decades, the concomitant use of two non-invasive, electromagnetic devices, modulated electro-hyperthermia (mEHT) and Tumor Treating Fields (TTF) has been introduced. Both mEHT and TTF have specific anti-tumor effects, which can help to achieve a more efficient<br /> 581treatment of patients and a higher rate of therapeutic response. In this meta-analysis we investigated how patient survival rates change if either device is used. The significant difference in the 1-year survival rates between the treated (>60%) and untreated groups (historical data: <40%) confirms the observation that the use of both mEHT and TTF in the treatment of glioblastomas benefits patients. In addition, it is important to emphasize that most studies have proven that the mEHT or TTF-treated patientsâ quality of life is much better than that of the untreated patients.</p> 582<p class="text-align-justify"><span style="color: #9e8053;"><strong>Abstract</strong></span><br /> 583Background: Glioblastoma is one of the most difficult to treat and most aggressive brain tumors, having a poor survival rate. The use of non-invasive modulated electro-hyperthermia (mEHT) and Tumor Treating Fields (TTF) devices has been introduced in the last few decades, both of which having proven anti-tumor effects. Methods: A meta-analysis of randomized and observational studies about mEHT and TTF was conducted. Results: A total of seven and fourteen studies about mEHT and TTF were included, with a total number of 450 and 1309 cases, respectively. A 42% [95% confidence interval (95% CI): 25â59%] 1-year survival rate was found for mEHT, which was raised to 61% (95% CI: 32â89%) if only the studies conducted after 2008 were investigated. In the case of TTF, 1-year survival was 67% (95% CI: 53â81%). Subgroup analyses revealed that newly diagnosed patients might get extra benefits from the early introduction of the devices (mEHT all studies: 73% vs. 37%, p = 0.0021; mEHT studies after 2008: 73% vs. 54%, p = 0.4214; TTF studies: 83% vs. 52%, p = 0.0083), compared with recurrent glioblastoma. Conclusions: Our meta-analysis showed that both mEHT and TTF can improve glioblastoma survival, and the most benefit may be achieved in newly diagnosed cases.</p> 584<p class="text-align-justify"><span style="color: #9e8053;"><strong>Keywords:</strong>Â </span>astrocytoma; glioblastoma; modulated electro-hyperthermia; tumor treating fields</p> 585 586 <div id="teljes-cikk" class="btn"> 587 <a href="https://doi.org/10.3390/cancers15030880" target="_blank">
587 View abstract</a> 588 </div> 589 590 </div> <!-- .container --> 591</div><!-- .entry-content --> 592 593 594 595</article><!-- #post-3279 --> 596 597 598<article id="post-3280" class="post-3280 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry"> 599 600 <header class="pub-entry-header"> 601 <div class="container"> 602 <h2>The first experience of application of remote radiotherapy in combination with hyperthermia (oncothermia) in the treatment of patients with primary gliomas of the brain of a high degree of malignancy</h2> 603 </div> 604 </header><!-- .entry-header --> 605 606 607<div class="entry-content kl-pub-content"> 608 <div class="container"> 609 <div class="acf-fields"> 610 <div class="acf-row"><span class="publ-label">Indication:</span> Gliomas (advanced) <hr/> <span class="publ-label">Evidence:</span> </div> 611 <div class="publ-acf acf-row acf-flex"> 612 <span class="publ-label">Author: </span> 613 <div class="szerzok"> 614 615 616 617 <span class="sz-nev">Solodkiy VA.</span> 618 619 620 621 <span class="sz-nev">Panshin GA.</span> 622 623 624 625 <span class="sz-nev">Izmailov TR.</span> 626 627 628 629 <span class="sz-nev">Shevchenko TA.</span> 630 631 </div> 632 633 </div> 634 <div class="acf-row"><span class="publ-label">No. of patients:</span> 20 <hr/> <span class="publ-label">Therapy:</span> RT+mEHT<hr/> <span class="publ-label">Year:</span> 2021</div> 635 </div><!-- .acf-fields --> 636 <div class="c-rich-text"> 637<h2>Abstract</h2> 638<p>High-grade brain gliomas are characterized by a rapid clinical course and a 2-year survival rate of 8-12%. Despite the improvement of methods of surgery, radiotherapy (RT), and systemic drug therapy, it is still not possible to significantly increase the overall and relapse-free survival in patients withth is neuro-oncological pathology, and the combination of RT and CT with hyperthermic electrotherapy (oncothermy) (OT) looks like a promising method that helps to increase the effectiveness of special treatment. At the same time, oncothermia does not cause brain edema and does not worsen the quality of life of neuro-oncological patients. At the same time, a possible alternative to further progress in improving the results of treatment of primary brain gliomas (WHO Grade III-IV) is not only to optimize the radiotherapy program, but also to combine standard methods of radical treatment with hyperthermic electrotherapy. This article presents preliminary immediate results of treatment of 20 patients who received special treatment in the RSCRR with an assessment of the toxicity and safety of its implementation and with an assessment of the likely resumption of continued tumor growth 1.5 and 3 months after the end of treatment. In General, the data obtained indicate the safety of the developed method of special treatment of this category of neuro-oncological patients, which confirms the results obtained in 28.09.2019 patent for an invention. However, for final conclusions, further clinical studies are required on a larger group of patients with longer follow-up periods, followed by a thorough analysis of the results.</p> 639</div> 640<div class="field field--name-field-url field--type-link field--label-hidden field__item"><a href="https://voprosyonkologii.ru/index.php/journal/issue/view/45" target="_blank" rel="noopener">https://voprosyonkologii.ru/index.php/journal/issue/view/45</a></div> 641 642 <div id="teljes-cikk" class="btn"> 643 <a href="https://voprosyonkologii.ru/index.php/journal/issue/view/45" target="_blank"> View abstract</a> 644 </div> 645 646 </div> <!-- .container --> 647</div><!-- .entry-content --> 648 649 650 651</article><!-- #post-3280 --> 652 653 654<article id="post-3281" class="post-3281 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry"> 655 656 <header class="pub-entry-header"> 657 <div class="container"> 658 <h2>Modulated Electro-Hyperthermic (mEHT) Treatment in the Therapy of Inoperable Pancreatic Cancer PatientsâA Single-Center Case-Control Study</h2> 659 </div> 660 </header><!-- .entry-header --> 661 662 663<div class="entry-content kl-pub-content"> 664 <div class="container"> 665 <div class="acf-fields"> 666 <div class="acf-row"><span class="publ-label">Indication:</span> Gastrointestinal <hr/> <span class="publ-label">Evidence:</span> </div> 667 <div class="publ-acf acf-row acf-flex"> 668 <span class="publ-label">Author: </span> 669 <div class="szerzok"> 670 671 672 673 <span class="sz-nev">Flora Greta Petenyi</span> 674 675 676 677 <span class="sz-nev">Tamas Garay</span> 678 679 680 681 <span class="sz-nev">Dorottya Muhl</span> 682 683 684 685 <span class="sz-nev">Blanka Izso</span> 686 687 688 689 <span class="sz-nev">Adam Karaszi</span> 690 691 692 693 <span class="sz-nev">Erika Borbenyi</span> 694 695 696 697 <span class="sz-nev">Magdolna Herold</span> 698 699 700 701 <span class="sz-nev">Zoltan Herold</span> 702 703 704 705 <span class="sz-nev">Attila Marcell Szasz</span> 706 707 708 709 <span class="sz-nev">Magdolna Dan</span> 710 711 </div> 712 713 </div> 714 <div class="acf-row"><span class="publ-label">No. of patients:</span> 78 <hr/> <span class="publ-label">Therapy:</span> mEHT<hr/> <span class="publ-label">Year:</span> 2021</div> 715 </div><!-- .acf-fields --> 716 <p>Abstract: Our present oncological treatment arsenal has limited treatment options for pancreatic ductal adenocarcinoma (PDAC). Extended reviews have shown the benefits of hyperthermia for PDAC, supporting the perspectives with the improvements of the treatment possibilities. METHODS: A retrospective single-center case-control study was conducted with the inclusion of 78 inoperable PDAC patients. Age-, sex-, chemotherapy-, stage-, and ascites formation-matched patients were assigned to two equal groups based on the application of modulated electro-hyperthermia (mEHT). The EHY2030 mEHT device was used. RESULTS: A trend in favor of mEHT was found in overall survival (p = 0.1420). To further evaluate the potential beneficial effects of mEHT, the presence of distant metastasis or ascites in the patientsâ oncological history was investigated. Of note, mEHT treatment had a favorable effect on patientsâ overall survival in metastatic disease (p = 0.0154), while less abdominal fluid responded to the mEHT treatment in a more efficient way (p 0.0138). CONCLUSION: mEHT treatment was associated with improved overall survival in PDAC in our single-center retrospective case-control study. The outcome measures encourage us to design a randomized prospective clinical study to further confirm the efficiency of mEHT in this patien cohort.</p> 717 718 <div id="teljes-cikk" class="btn"> 719 <a href="https://doi.org/10.3390/%20diseases9040081" target="_blank">
719 View abstract</a> 720 </div> 721 722 </div> <!-- .container --> 723</div><!-- .entry-content --> 724 725 726 727</article><!-- #post-3281 --> 728 729 730<article id="post-3282" class="post-3282 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry"> 731 732 <header class="pub-entry-header"> 733 <div class="container"> 734 <h2>Modulated electro-hyperthermia in stage III and IV pancreatic cancer: Results of an observational study on 158 patients</h2> 735 </div> 736 </header><!-- .entry-header --> 737 738 739<div class="entry-content kl-pub-content"> 740 <div class="container"> 741 <div class="acf-fields"> 742 <div class="acf-row"><span class="publ-label">Indication:</span> Gastrointestinal <hr/> <span class="publ-label">Evidence:</span> </div> 743 <div class="publ-acf acf-row acf-flex"> 744 <span class="publ-label">Author: </span> 745 <div class="szerzok"> 746 747 748 749 <span class="sz-nev">Giammaria Fiorentini</span> 750 751 752 753 <span class="sz-nev">Donatella Sarti</span> 754 755 756 757 <span class="sz-nev">Girolamo Ranieri</span> 758 759 760 761 <span class="sz-nev">Cosmo Damiano Gadaleta</span> 762 763 764 765 <span class="sz-nev">Caterina Fiorentini</span> 766 767 768 769 <span class="sz-nev">Carlo Milandri</span> 770 771 772 773 <span class="sz-nev">Andrea Mambrini</span> 774 775 776 777 <span class="sz-nev">Stefano Guadagni</span> 778 779 </div> 780 781 </div> 782 <div class="acf-row"><span class="publ-label">No. of patients:</span> 158 <hr/> <span class="publ-label">Therapy:</span> CRT+mEHT<hr/> <span class="publ-label">Year:</span> 2021</div> 783 </div><!-- .acf-fields --> 784 <p class="text-align-justify"><span style="color: #9e8053;">Abstract</span><br /> 785BACKGROUND<br /> 786An increasing number of studies report the beneficial effects of regional hyperthermia in association with chemotherapy (CHT) and radiotherapy for the treatment of pancreatic cancer; in particular, the use of modulated electrohyperthermia (mEHT) results in increased survival and tumor response.</p> 787<p class="text-align-justify"><span style="color: #9e8053;">AIM</span><br /> 788To compare outcomes of CHT alone or in association with mEHT for the treatment of stage III and IV pancreatic cancer. METHODS<br /> 789This was an observational retrospective study; data were collected for patients with stage III-IV pancreatic cancer that were treated with CHT alone or in combination with mEHT from 2003 to 2019. A total of 158 patients were included in the study out 270 patients screened in four Italian hospitals; 58 (37%) of these received CHT + mEHT and 100 (63%) CHT. CHT was mainly gemcitabine-based<br /> 790regimens in both groups.</p> 791<p class="text-align-justify"> 792<span style="color: #9e8053;">RESULTS</span><br /> 793Overall (19.5 mo vs 11.02 mo, P < 0.001) and progression-free (12 mo vs 3 mo, P < 0.001) survival were better for the CHT + mEHT group compared to the CHT group. The association of mEHT resulted also in an improvement of tumor response with disease control rate 95% vs 58% (P < 0.001) at 3 mo. Toxicity was comparable in the two study groups, and mEHT related adverse events were<br /> 794limited in 8 patients presenting G1-2 skin burns.</p> 795<p class="text-align-justify"><span style="color: #9e8053;">CONCLUSION</span><br /> 796The addition of mEHT to systemic CHT improved overall and progression-freesurvival and local tumor control with comparable toxicity.</p> 797 798 799 </div> <!-- .container --> 800</div><!-- .entry-content --> 801 802 803 804</article><!-- #post-3282 --> 805 806 807<article id="post-3283" class="post-3283 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry"> 808 809 <header class="pub-entry-header"> 810 <div class="container"> 811 <h2>Clinical study of modulated electroâhyperthermia for advanced metastatic breast cancer</h2> 812 </div> 813 </header><!-- .entry-header --> 814 815 816<div class="entry-content kl-pub-content"> 817 <div class="container"> 818 <div class="acf-fields"> 819 <div class="acf-row"><span class="publ-label">Indication:</span> Breast Cancer <hr/> <span class="publ-label">Evidence:</span> </div> 820 <div class="publ-acf acf-row acf-flex"> 821 <span class="publ-label">Author: </span> 822 <div class="szerzok"> 823 824 825 826 <span class="sz-nev">Takuya Nagata</span> 827 828 829 830 <span class="sz-nev">Masahiko Kanamori</span> 831 832 833 834 <span class="sz-nev">Shinichi Sekine</span> 835 836 837 838 <span class="sz-nev">Mie Arai</span> 839 840 841 842 <span class="sz-nev">Makoto Moriyama</span> 843 844 845 846 <span class="sz-nev">Tsutomu Fujii</span> 847 848 </div> 849 850 </div> 851 <div class="acf-row"><span class="publ-label">No. of patients:</span> 10 <hr/> <span class="publ-label">Therapy:</span> mEHT<hr/> <span class="publ-label">Year:</span> 2021</div> 852 </div><!-- .acf-fields --> 853 <p><span style="color: #9e8053;"><strong>Abstract.</strong></span> Modulated electroâhyperthermia (mEHT) is a new treatment modality developed to overcome the problems associated with traditional hyperthermia; mEHT uses a precise impedanceâmatched system and modulated radiofrequency current flow to malignant tumors. It selects the malignant cells based on their biophysical differences, due to their high metabolic rate, individual (autonomic) behavior and membrane status. The aim of the present study was to report the outcomes of mEHT in the treatment of advanced breast cancer. mEHT was examined in 10 patients with advanced metastatic breast cancer and recurrent disease, who were considered incurable by standard therapy protocols. Of the 10 patients, partial response was achieved in 3, disease stability in 3, and progressive disease in 4; however, their quality of life was improved based on their subjective reports. No adverse effects were observed in any of the 10 patients. The present study demonstrated the feasibility of mEHT as a possible therapy for advanced breast cancer cases when standard therapies fail. Moreover, mEHT had no side effects and may be combined with various treatments for longâterm therapy.</p> 854 855 856 </div> <!-- .container --> 857</div><!-- .entry-content --> 858 859 860 861</article><!-- #post-3283 --> 862 863 864<article id="post-3284" class="post-3284 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry"> 865 866 <header class="pub-entry-header"> 867 <div class="container"> 868 <h2>âOncothermiaâ (Modulated electro-hyperthermia) â Present status and future development</h2> 869 </div> 870 </header><!-- .entry-header --> 871 872 873<div class="entry-content kl-pub-content"> 874 <div class="container"> 875 <div class="acf-fields"> 876 <div class="acf-row"><span class="publ-label">Indication:</span> <hr/> <span class="publ-label">Evidence:</span> Review</div> 877 <div class="publ-acf acf-row acf-flex"> 878 <span class="publ-label">Author: </span> 879 <div class="szerzok"> 880 881 882 883 <span class="sz-nev">Masahiko Kanamori</span> 884 885 886 887 <span class="sz-nev">Tsutomu Sato</span> 888 889 890 891 <span class="sz-nev">Tomoko Shima</span> 892 893 894 895 <span class="sz-nev">Jun-Ichi Saitoh</span> 896 897 898 899 <span class="sz-nev">
899 Gabor Andocs</span> 900 901 902 903 <span class="sz-nev">Takashi Kondo</span> 904 905 </div> 906 907 </div> 908 <div class="acf-row"><span class="publ-label">No. of patients:</span> <hr/> <span class="publ-label">Therapy:</span> mEHT<hr/> <span class="publ-label">Year:</span> 2021</div> 909 </div><!-- .acf-fields --> 910 <p>Modulated electro-hyperthermia (mEHT) â trade name: Oncothermia â is an emerging curative treatment method in oncological hyperthermia. Although mEHT is similar to other classic hyperthermia methods to utilize temperature rise in tumor, there are several features; i.e. use precise impedance-matched, capacitive-coupled 13.56 MHz radiofrequency (RF) with amplitude modulation, in order to keep the tumor temperature below the cytotoxic range (ï¼42 °C) but induce continuous temperature gradient on the tumor cell membrane. This in homogenous, non-equilibrium heating on the cell membrane induces programmed cancer cell death (apoptosis). mEHT effectiveness has been also proven in clinical studies, and has fewer side effects due to low RF output. Therefore, not only thermal effects but also non-thermal (temperature independent) effects of mEHT are important for considering the biological and clinical significance. Basic, preclinical and clinical reports have been published after âOncothermia: Principles and Practicesâ by Szasz A. et al. In this review article these outcomes will be summarized and discuss on the further possibilities and problems of mEHT.</p> 911 912 913 </div> <!-- .container --> 914</div><!-- .entry-content --> 915 916 917 918</article><!-- #post-3284 --> 919 920 921<article id="post-3285" class="post-3285 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry"> 922 923 <header class="pub-entry-header"> 924 <div class="container"> 925 <h2>Modulated electroâhyperthermia with weekly paclitaxel or cisplatin in patients with recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: The KGOG 3030 trial</h2> 926 </div> 927 </header><!-- .entry-header --> 928 929 930<div class="entry-content kl-pub-content"> 931 <div class="container"> 932 <div class="acf-fields"> 933 <div class="acf-row"><span class="publ-label">Indication:</span> Gynecology <hr/> <span class="publ-label">Evidence:</span> </div> 934 <div class="publ-acf acf-row acf-flex"> 935 <span class="publ-label">Author: </span> 936 <div class="szerzok"> 937 938 939 940 <span class="sz-nev">Kidong Kim</span> 941 942 943 944 <span class="sz-nev">JaeâHoon Kim</span> 945 946 947 948 <span class="sz-nev">Seung Cheol Kim</span> 949 950 951 952 <span class="sz-nev">Yong Beom Kim</span> 953 954 955 956 <span class="sz-nev">ByungâHo Nam</span> 957 958 959 960 <span class="sz-nev">Jae Hong No</span> 961 962 963 964 <span class="sz-nev">Hanbyoul Cho</span> 965 966 967 968 <span class="sz-nev">Woong Ju</span> 969 970 971 972 <span class="sz-nev">Dong Hoon Suh</span> 973 974 975 976 <span class="sz-nev">Yun Hwan Kim</span> 977 978 </div> 979 980 </div> 981 <div class="acf-row"><span class="publ-label">No. of patients:</span> 12 <hr/> <span class="publ-label">Therapy:</span> mEHT<hr/> <span class="publ-label">Year:</span> 2021</div> 982 </div><!-- .acf-fields --> 983 <p>The study (KGOG 3030) aimed to evaluate the safety of modulated electroâhyperthermia (mEHT) therapy with weekly administration of paclitaxel or cisplatin in female patients with recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal carcinoma. A total of 12 patients were randomized into the paclitaxel or cisplatin arm at a 1:1 ratio. Patients received weekly administration of paclitaxel (70 mg/m2) or cisplatin (40 mg/m2) intravenously on days 1, 8 and 15, and underwent mEHT therapy for 1 h on days 1, 4, 8, 11, 15, 18, 21 and 24 for each 4âweek cycle. The primary endpoint was the occurrence of doseâlimiting toxicity (DLT). The secondary endpoints were treatmentâemergent adverse events (TEAEs), objective response rate, carbohydrate antigen 125 (CA125) response rate, progressionâfree survival (PFS) and overall survival (OS). In total, 16 patients were recruited, but four patients dropped out. None of the 12 remaining patients (6 each in the two arms) experienced DLT. Overall, 0 and 4 grade 3 TEAEs (anemia, nausea, neutrophil count decreased and platelet
983count decreased) occurred in the paclitaxel and cisplatin arm, respectively. Furthermore, one confirmed partial response and two CA125 responses were observed in the cisplatin arm. The median PFS time in the paclitaxel and cisplatin arms was 3.0 months (range, 1.7â4.6 months) and 6.8 months (range, 3.9â11.8 months), respectively, while the median OS time was 11.5 months (range, 8.4â28.8+ months) and not reached (range, 3.9â38.5+ months), respectively. In conclusion, mEHT therapy with weekly paclitaxel or cisplatin appeared safe and warrants further investigation. The present trial was registered with www.clinicaltrials.gov on January 22, 2015 (trial registration no. NCT02344095).</p> 984 985 986 </div> <!-- .container --> 987</div><!-- .entry-content --> 988 989 990 991</article><!-- #post-3285 --> 992 993 994<article id="post-3286" class="post-3286 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry"> 995 996 <header class="pub-entry-header"> 997 <div class="container"> 998 <h2>Marked local and distant response of heavily treated breast cancer with cardiac metastases treated by combined low dose radiotherapy, low dose immunotherapy and hyperthermia: a case report</h2> 999 </div> 1000 </header><!-- .entry-header --> 1001 1002 1003<div class="entry-content kl-pub-content"> 1004 <div class="container"> 1005 <div class="acf-fields"> 1006 <div class="acf-row"><span class="publ-label">Indication:</span> Breast Cancer <hr/> <span class="publ-label">Evidence:</span> Case report</div> 1007 <div class="publ-acf acf-row acf-flex"> 1008 <span class="publ-label">Author: </span> 1009 <div class="szerzok"> 1010 1011 1012 1013 <span class="sz-nev">Mau-Shin Chi</span> 1014 1015 1016 1017 <span class="sz-nev">Jen-Hong Wu</span> 1018 1019 1020 1021 <span class="sz-nev">Suzun Shaw</span> 1022 1023 1024 1025 <span class="sz-nev">Ching-Jung Wu</span> 1026 1027 1028 1029 <span class="sz-nev">Liang-Kuang Chen</span> 1030 1031 1032 1033 <span class="sz-nev">Ho-Chi Hsu</span> 1034 1035 1036 1037 <span class="sz-nev">Kwan-Hwa Chi</span> 1038 1039 </div> 1040 1041 </div> 1042 <div class="acf-row"><span class="publ-label">No. of patients:</span> 1 <hr/> <span class="publ-label">Therapy:</span> CT+RT+mEHT<hr/> <span class="publ-label">Year:</span> 2021</div> 1043 </div><!-- .acf-fields --> 1044 <p>Abstract: Breast cancer (BC) with cardiac metastases (CMs) is often associated with poor prognosis due to late stage of diagnosis. Palliative radiotherapy (RT) for CMs is generally used for symptomatic treatment and to maintain normal cardiac function. Palliative RT with hyperthermia (HT) or immunotherapy have been reported to be effective in prolonging the overall survival and progression-free survival in metastatic patients. In this case report, we present a heavily pretreated 51-year-old lady of metastatic BC presented with recurrent right breast mass with progressive exertional dyspnea caused by symptomatic CM. She received combined palliative low-dose palliative RT [20 Gray (Gy) in 12 fractions], combined with low-dose chemotherapy, biweekly HT treatment course, and low-dose âdouble blockadeâ immunotherapy by ipilimumab (0.3 mg/kg) and nivolumab (0.5 mg/kg). The irradiated right chest tumors responded rapidly to treatment. Interestingly, unirradiated metastatic lesions outside the RT and HT treatment field also demonstrated a sustained abscopal response. She continued monthly low-dose immunotherapy in conjunction with HT after RT. The posttreatment cardiac echography disclosed considerably reduced pericardial effusions without cardiac wall motion abnormalities. She remained stable for more than 6 months with no notable treatment-related toxicities. The combination of low-dose RT, low-dose immunotherapy, and HT protocol appears to be a safe method with promising efficacy in metastatic BC patients.</p> 1045 1046 <div id="teljes-cikk" class="btn"> 1047 <a href="https://dx.doi.org/10.21037/tro-21-16" target="_blank"> View abstract</a> 1048 </div> 1049 1050 </div> <!-- .container --> 1051</div><!-- .entry-content --> 1052 1053 1054 1055</article><!-- #post-3286 --> 1056 1057 1058<article id="post-3287" class="post-3287 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry"> 1059 1060 <header class="pub-entry-header"> 1061 <div class="container"> 1062 <h2>Beneficial effects of modulated electro-hyperthermia during neoadjuvant treatment for locally advanced rectal cancer</h2> 1063 </div> 1064 </header><!-- .entry-header --> 1065 1066 1067<div class="entry-content kl-pub-content"> 1068 <div class="container"> 1069 <div class="acf-fields"> 1070 <div class="acf-row"><span class="publ-label">Indication:</span> Rectal Cancer <hr/> <span class="publ-label">Evidence:</span> </div> 1071 <div class="publ-acf acf-row acf-flex"> 1072 <span class="publ-label">Author: </span> 1073 <div class="szerzok"> 1074 </div> 1075 1076 </div> 1077 <div class="acf-row"><span class="publ-label">No. of patients:</span> 120 <hr/> <span class="publ-label">Therapy:</span> mEHT<hr/> <span class="publ-label">Year:</span> 2021</div> 1078 </div><!-- .acf-fields --> 1079 <p>Purpose: Modulated electro-hyperthermia (mEHT) may enhance the tumor response, although the effectiveness of combined neoadjuvant therapy remains unclear. Therefore, we investigated the role of mEHT with neoadjuvant therapy for locally advanced rectal cancer. Materials and methods: Clinical data were analyzed for 120 patients who received neoadjuvant treatment for locally advanced rectal cancer (T3/4 or Nþ, M0) from May 2012 to December 2017. Capecitabine or 5-fluorouracil was administered along with radiotherapy. Patients were categorized
1079into mEHT group (62 patients) and non-mEHT group (58 patients) depending on whether mEHT was added. Surgery was performed 6â8 weeks after the end of radiotherapy. Results: The median age was 59 years (range, 33â83). The median radiation dose was significantly less for mEHT group (40 Gy) than for non-mEHT group (50.4 Gy). In mEHT group, 80.7% showed down-staging compared with 67.2% in non-mEHT group. For large tumors of more than 65 cm3 (mean), improved tumor regression was observed in 31.6% of mEHT group compared with 0% of non-mEHT group (p¼.024). The gastrointestinal toxicity rate of mEHT group was 64.5%, which was found to be statistically significantly less than 87.9% of non-mEHT group (p¼.010). The 2-year disease-free survival was 96% for mEHT group and 79% for non-mEHT group (p¼.054). Conclusion: The overall mEHT group had a comparable response and survival using less radiation dosing compared with standard care; the subgroup with large tumors showed improved efficacy for tumor regression after mEHT.</p> 1080 1081 1082 </div> <!-- .container --> 1083</div><!-- .entry-content --> 1084 1085 1086 1087</article><!-- #post-3287 --> 1088 1089 1090<article id="post-3288" class="post-3288 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry"> 1091 1092 <header class="pub-entry-header"> 1093 <div class="container"> 1094 <h2>Evidence based tools to improve efficiency of currently administered oncotherapies for tumors of the hepatopancreatobiliary system</h2> 1095 </div> 1096 </header><!-- .entry-header --> 1097 1098 1099<div class="entry-content kl-pub-content"> 1100 <div class="container"> 1101 <div class="acf-fields"> 1102 <div class="acf-row"><span class="publ-label">Indication:</span> <hr/> <span class="publ-label">Evidence:</span> </div> 1103 <div class="publ-acf acf-row acf-flex"> 1104 <span class="publ-label">Author: </span> 1105 <div class="szerzok"> 1106 1107 1108 1109 <span class="sz-nev">Herold Z.</span> 1110 1111 1112 1113 <span class="sz-nev">Szasz A.</span> 1114 1115 1116 1117 <span class="sz-nev">Dank M.</span> 1118 1119 </div> 1120 1121 </div> 1122 <div class="acf-row"><span class="publ-label">No. of patients:</span> <hr/> <span class="publ-label">Therapy:</span> <hr/> <span class="publ-label">Year:</span> 2021</div> 1123 </div><!-- .acf-fields --> 1124 <p>Hepatopancreatobiliary tumors are challenging to treat, and the advanced or metastatic forms have a very low 5-year survival rate. Several drug combinations have been tested, and new therapeutic approaches have been introduced in the last decades, including radiofrequency and heat based methods. Hyperthermia is the artificial heating of tumors by various biophysical methods that may possess immunostimulant, tumoricidal, and chemoradiotherapy sensitizer effects. Both whole-body and regional hyperthermia studies have been conducted since the 1980s after the introduction of deep-seated tumor hyperthermia techniques. Results of the effects of hyperthermia in hepatocellular and pancreatic cancer are known from several studies. Hyperthermia in biliary cancers is a less investigated area. High local and overall responses to treatment, increased progression-free and overall survival, and improved laboratory and quality-of-life results are associated with hyperthermia in all three tumor types. With the evolution of chemotherapeutic agents and the introduction of newer techniques, the combination of adjuvant hyperthermia with those therapies is advantageous and has not been associated with an increase in alarming adverse effects. However, despite the many positive effects of hyperthermia, its use is still only known at the experimental level, and its concomitant utilization in routine cancer treatment is not certain because of the lack of thorough clinical studies.</p> 1125<p>Herold Z., Szasz A.M., Dank M., Evidence based tools to improve efficiency of currently administered oncotherapies for tumors of the hepatopancreatobiliary system. <em>World J Gastrointest Oncol</em> 2021; 13(9): 1109-1120 [DOI: <a href="https://dx.doi.org/10.4251/wjgo.v13.i9.1109" target="_blank" rel="noopener">10.4251/wjgo.v13.i9.1109</a>]</p> 1126<p><a href="https://www.wjgnet.com/1948-5204/full/v13/i9/1109.htm" target="_blank" rel="noopener">Evidence based tools to improve efficiency of currently administered oncotherapâ¦</a></p> 1127 1128 <div id="teljes-cikk" class="btn"> 1129 <a href="https://www.wjgnet.com/1948-5204/full/v13/i9/1109.htm" target="_blank">
1129 View abstract</a> 1130 </div> 1131 1132 </div> <!-- .container --> 1133</div><!-- .entry-content --> 1134 1135 1136 1137</article><!-- #post-3288 --> 1138 1139 1140<article id="post-3289" class="post-3289 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry"> 1141 1142 <header class="pub-entry-header"> 1143 <div class="container"> 1144 <h2>Suppression of Metastatic Melanoma Growth in Lung by Modulated Electro-Hyperthermia Monitored by a Minimally Invasive Heat Stress Testing Approach in Mice</h2> 1145 </div> 1146 </header><!-- .entry-header --> 1147 1148 1149<div class="entry-content kl-pub-content"> 1150 <div class="container"> 1151 <div class="acf-fields"> 1152 <div class="acf-row"><span class="publ-label">Indication:</span> Lung cancer <hr/> <span class="publ-label">Evidence:</span> </div> 1153 <div class="publ-acf acf-row acf-flex"> 1154 <span class="publ-label">Author: </span> 1155 <div class="szerzok"> 1156 1157 1158 1159 <span class="sz-nev">Mbuotidem Jeremiah Thomas</span> 1160 1161 1162 1163 <span class="sz-nev">Eniko Major</span> 1164 1165 1166 1167 <span class="sz-nev">Anett Benedek</span> 1168 1169 1170 1171 <span class="sz-nev">ldikó Horváth</span> 1172 1173 1174 1175 <span class="sz-nev">Domokos Máthé</span> 1176 1177 1178 1179 <span class="sz-nev">Ralf Bergmann</span> 1180 1181 1182 1183 <span class="sz-nev">Attila Marcell Szász</span> 1184 1185 1186 1187 <span class="sz-nev">Tibor Krenács</span> 1188 1189 1190 1191 <span class="sz-nev">Zoltán Benyó</span> 1192 1193 </div> 1194 1195 </div> 1196 <div class="acf-row"><span class="publ-label">No. of patients:</span> <hr/> <span class="publ-label">Therapy:</span> mEHT<hr/> <span class="publ-label">Year:</span> 2020</div> 1197 </div><!-- .acf-fields --> 1198 <p><strong>Simple Summary</strong><br /> 1199The lung is the most frequent site of distant melanoma metastases. Metastases of melanoma in the lungs oï¬er a very poor prognosis, with a 5-year survival rate of below 10%. Hyperthermic therapies including modulated electro-hyperthermia (mEHT) in clinical settings have been used to improve the eï¬cacy of radiotherapy, chemotherapy, and immunotherapy of tumors. In this study, we focused primarily on the optimization of mEHT for targeted lung treatment of mice lungsburdenedwithB16F10melanomapulmonarymetastases,withaparticularfocusonelucidating the mechanism of action of mEHT on treated melanoma cells while investigating any potential treatment-relatedsideeï¬ectsonnormallungtissue. mEHTshowedevidenceofsigniï¬cantanti-tumor eï¬ects as demonstrated by the reduced number of pulmonary metastatic nodules, DNA damage response, downregulation of Ki67 expression, higher immune cell inï¬ltration, and upregulation of p21waf1 expression in mEHT-treated tumors.</p> 1200<p><strong>Abstract</strong><br /> 1201Modulated electro-hyperthermia (mEHT) is a novel complementary therapy in oncology which is based on the higher conductivity and permittivity of cancerous tissues due to their enhanced glycolytic activity and ionic content compared to healthy normal tissues. We aimed to evaluate the potential of mEHT, inducing local hyperthermia, in the treatment of pulmonary metastatic melanoma. Our primary objective was the optimization of mEHT for targeted lung treatment as well as to identify the mechanism of its potential anti-tumor eï¬ect in the B16F10 mouse melanoma pulmonarymetastasesmodelwhileinvestigatingthepotentialtreatment-relatedsideeï¬ectsofmEHT on normal lung tissue. Repeated treatment of tumor-bearing lungs with mEHT induced signiï¬cant anti-tumor eï¬ects as demonstrated by the lower number of tumor nodules and the downregulation of Ki67 expression in treated tumor cells. mEHT treatment provoked signiï¬cant DNA double-strand breaks indicated by the increased expression of phosphorylated H2AX protein in treated tumors, although treatment-induced elevation of cleaved/activated casp
1201ase-3 expression was insigniï¬cant, suggesting the minimal role of apoptosis in this process. The mEHT-related signiï¬cant increase in p21waf1 positive tumor cells suggested that p21waf1-mediated cell cycle arrest plays an important role in the anti-tumor eï¬ect of mEHT on melanoma metastases. Signiï¬cantly increased CD3+, CD8+ T-lymphocytes, and F4/80+CD11b+ macrophage density in the whole lung and tumor of treated animals emphasizes the mobilizing capability of mEHT on immune cells. In conclusion, mEHT can reduce the growth potential of melanoma, thus oï¬ering itself as a complementary therapeutic option to chemo- and/or radiotherapy.</p> 1202 1203 <div id="teljes-cikk" class="btn"> 1204 <a href="https://www.scirp.org/journal/PaperInformation.aspx?PaperID=106089" target="_blank"> View abstract</a> 1205 </div> 1206 1207 </div> <!-- .container --> 1208</div><!-- .entry-content --> 1209 1210 1211 1212</article><!-- #post-3289 --> 1213 1214 1215<article id="post-3290" class="post-3290 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry"> 1216 1217 <header class="pub-entry-header"> 1218 <div class="container"> 1219 <h2>A randomized phase II trial of best supportive care with or without hyperthermia and vitamin C for heavily pretreated, advanced, refractory non-small-cell lung cancer</h2> 1220 </div> 1221 </header><!-- .entry-header --> 1222 1223 1224<div class="entry-content kl-pub-content"> 1225 <div class="container"> 1226 <div class="acf-fields"> 1227 <div class="acf-row"><span class="publ-label">Indication:</span> Lung cancer <hr/> <span class="publ-label">Evidence:</span> Phase I.</div> 1228 <div class="publ-acf acf-row acf-flex"> 1229 <span class="publ-label">Author: </span> 1230 <div class="szerzok"> 1231 1232 1233 1234 <span class="sz-nev">Junwen Ou</span> 1235 1236 1237 1238 <span class="sz-nev">Xinyu Zhu</span> 1239 1240 1241 1242 <span class="sz-nev">Pengfei Chen</span> 1243 1244 1245 1246 <span class="sz-nev">Yanping Du</span> 1247 1248 1249 1250 <span class="sz-nev">Yimin Lu</span> 1251 1252 1253 1254 <span class="sz-nev">Xiufan Peng</span> 1255 1256 1257 1258 <span class="sz-nev">Shuang Bao</span> 1259 1260 1261 1262 <span class="sz-nev">Junhua Wang</span> 1263 1264 1265 1266 <span class="sz-nev">Xinting Zhang</span> 1267 1268 1269 1270 <span class="sz-nev">Tao Zhang</span> 1271 1272 1273 1274 <span class="sz-nev">Clifford L.K. Pang</span> 1275 1276 </div> 1277 1278 </div> 1279 <div class="acf-row"><span class="publ-label">No. of patients:</span> 97 <hr/> <span class="publ-label">Therapy:</span> IVC + mEHT + BSC<hr/> <span class="publ-label">Year:</span> 2020</div> 1280 </div><!-- .acf-fields --> 1281 <p><strong>Abstract</strong></p> 1282<p id="sp0010">Our previous study indicated that intravenous vitamin C (IVC) treatment concurrent with modulated electrohyperthermia (mEHT) was safe and improved the quality of life (QoL) of non-small-cell lung cancer (NSCLC) patients. The aim of this trial was to further verify the efficacy of the above combination therapy in previously treated patients with refractory advanced (stage IIIb or IV) NSCLC. A total of 97 patients were randomized to receive IVC and mEHT plus best supportive care (BSC) (n = 49 in the active arm, receiving 1 g/kg * d IVC concurrently with mEHT, three times a week for 25 treatments in total) or BSC alone (n = 48 in the control arm). After a median follow-up of 24 months, progression-free survival (PFS) and overall survival (OS) were significantly prolonged by combination therapy compared to BSC alone (PFS: 3 months vs 1.85 months, P < 0.05; OS: 9.4 months vs 5.6 months, P < 0.05). QoL was significantly increased in the active arm despite the advanced stage of disease. The 3-month disease control rate after treatment was 42.9
1282% in the active arm and 16.7% in the control arm (PÂ <Â 0.05). Overall, IVCÂ and mEHT may have the ability to improve the prognosis of patients with advanced NSCLC.</p> 1283 1284 <div id="teljes-cikk" class="btn"> 1285 <a href="https://www.sciencedirect.com/science/article/pii/S2090123220300539?via%3Dihub=" target="_blank"> View abstract</a> 1286 </div> 1287 1288 </div> <!-- .container --> 1289</div><!-- .entry-content --> 1290 1291 1292 1293</article><!-- #post-3290 --> 1294 1295 1296<article id="post-3291" class="post-3291 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry"> 1297 1298 <header class="pub-entry-header"> 1299 <div class="container"> 1300 <h2>Analysis of the effects of mEHT on the treatmentrelated toxicity and quality of life of HIV-positive cervical cancer patients</h2> 1301 </div> 1302 </header><!-- .entry-header --> 1303 1304 1305<div class="entry-content kl-pub-content"> 1306 <div class="container"> 1307 <div class="acf-fields"> 1308 <div class="acf-row"><span class="publ-label">Indication:</span> Cervical cancer <hr/> <span class="publ-label">Evidence:</span> Phase III</div> 1309 <div class="publ-acf acf-row acf-flex"> 1310 <span class="publ-label">Author: </span> 1311 <div class="szerzok"> 1312 1313 1314 1315 <span class="sz-nev">Carrie Anne Minnaar</span> 1316 1317 1318 1319 <span class="sz-nev">Jeffrey Allan Kotzen</span> 1320 1321 1322 1323 <span class="sz-nev">Thanushree Naidoo</span> 1324 1325 1326 1327 <span class="sz-nev">Mariza Tunmer</span> 1328 1329 1330 1331 <span class="sz-nev">Vinay Sharma</span> 1332 1333 1334 1335 <span class="sz-nev">Mboyo-Di-Tamba Vangu</span> 1336 1337 1338 1339 <span class="sz-nev">Ans Baeyens</span> 1340 1341 </div> 1342 1343 </div> 1344 <div class="acf-row"><span class="publ-label">No. of patients:</span> <hr/> <span class="publ-label">Therapy:</span> CRT+mEHT<hr/> <span class="publ-label">Year:</span> 2020</div> 1345 </div><!-- .acf-fields --> 1346 <div class="c-rich-text"> 1347<p><strong>ABSTRACT</strong><br /> 1348<strong>Introduction:Â </strong>HIV infection is associated with increased treatment-related toxicity and worse outcomes in locally advanced cervical cancer patients (LACC), especially in resource-constrained settings. Local control (LC) in a phase III randomized, controlled trial investigating modulated electro-hyperthermia (mEHT) on LACC patients in South Africa (ethics registration: M120477/M190295), was significantly higher in participants randomized to receive chemoradiotherapy (CRT) with mEHT compared to CRT alone (stratum: HIV status, accounting for age and stage). This analysis investigates whether mEHT adds to the toxicity profile of CRT in HIV-positive LACC participants.<br /> 1349<strong>Methods:Â </strong>Inclusion criteria: signed informed consent; International Federation of Gynecology and Obstetrics stages IIB to IIIB squamous cell carcinoma of the cervix; HIV-positive patients: CD4 count >200 cell/mL/on antiretroviral treatment for >6 months; eligible for CRT with radical intent. Recruitment: January 2014 to November 2017 (ClinicalTrials.gov: NCT03332069). Acute toxicity (evaluated using CTCAE v4 criteria) and quality of life (according to EORTC forms) in 206 participants randomized for treatment were evaluated alongside the LC results to determine safety and efficacy in HIV-positive participants.<br /> 1350<strong>Results:Â </strong>Compliance to mEHT treatment was high (97% completed 8 treatments) with no significant differences in CRT-related toxicity between treatment groups or between HIV-positive and -negative participants. Adverse events attributed to mEHT were minor, even in obese patients, and did not affect CRT compliance. Participants treated with mEHT reported improved fatigue, pain, emotional and cognitive functioning.<br /> 1351<strong>Conclusion:</strong> mEHT did not cause unexpected CRT-related toxicities and is a safe treatment modality for HIV-positive patients, with minor limitations regarding body weight, even in a low-resource setting.</p> 1352</div> 1353 1354 <div id="teljes-cikk" class="btn"> 1355 <a href="https://www.tandfonline.com/doi/full/10.1080/02656736.2020.1737253" target="_blank"> View abstract</a> 1356 </div> 1357 1358 </div> <!-- .container --> 1359</div><!-- .entry-content --> 1360 1361 1362 1363</article><!-- #post-3291 --> 1364 1365 1366<article id="post-3292" class="post-3292 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry"> 1367 1368 <header class="pub-entry-header"> 1369 <div class="container"> 1370 <h2>Feasibility of Modulated Electro-Hyperthermia in Preoperative Treatment for Locally Advanced Rectal Cancer: Early Phase 2 Clinical Results</h2> 1371 </div> 1372 </header><!-- .entry-header --> 1373 1374 1375<div class="entry-content kl-pub-content"> 1376 <div class="container"> 1377 <div class="acf-fields"> 1378 <div class="acf-row"><span class="publ-label">Indication:</span> Rectal Cancer <hr/> <span class="publ-label">Evidence:</span> Phase I</div> 1379 <div class="publ-acf acf-row acf-flex"> 1380 <span class="publ-label">Author: </span> 1381 <div class="szerzok"> 1382 1383 1384 1385 <span class="sz-nev">S H You</span> 1386 1387 1388 1389 <span class="sz-nev"> S Kim</span> 1390 1391 </div> 1392 1393 </div> 1394 <div class="acf-row"><span class="publ-label">No. of patients:</span> 60 <hr/> <span class="publ-label">Therapy:</span> mEHT<hr/> <span class="publ-label">Year:</span> 2020</div> 1395 </div><!-- .acf-fields --> 1396 <div id="region-content-top" class="c-region c-region--content-top"> 1397<div class="c-region__inner"> 1398<header class="c-page-title"> 1399<div class="c-container"> 1400<div class="c-container__content"> 1401<div class="row column"> 1402<div class="row"> 1403<div class="column">
1404<div id="region-content" class="c-region c-region--content"> 1405<div class="c-region__inner"> 1406<div id="block-oncotherm-content" data-block-plugin-id="system_main_block"> 1407<article class="c-publication c-publication-full" role="article" data-id="1851"> 1408<div class="c-rich-text"> 1409<p><span style="color: #9e8053;"><strong>Abstract:</strong></span> Despite advances in the multimodal approach for rectal cancer, treatment-related side effects remain an important issue. From this perspective, a prospective trial was performed to investigate the feasibility of modulated electro-hyperthermia (mEHT) as a concomitant boost to preoperative chemoradiation in locally advanced rectal cancer. Seventy-six patients with cT3-4 or cT2N+ rectal cancer were enrolled consecutively. Whole pelvic radiotherapy of 40 Gy was delivered with a 2-Gy daily fraction. mEHT with 13.56 MHz frequency was boosted on a twice-weekly schedule concurrently with intravenous 5-fluorouracil or oral capecitabine. Surgical resection was planned 6-8 weeks after radiotherapy. The primary endpoint was the non-inferior treatment response rate assessed by pathologic downstaging and tumor regression. The secondary endpoint was acceptable toxicity during the preoperative treatment period. Sixty patients completed the planned treatment schedule. T- and N-downstaging was demonstrated in 40 patients (66.7%) and 53 patients (88.3%), respectively. Pathologic complete response was noted in 15.0% (9 patients) and 76.7% (46 patients) for T-stage and N-stage, respectively. Total or near total tumor regression was observed in 20 patients (33.3%). Grade â¥3 toxicity occurred only in hematologic assessment; one case (1.7%) of leukopenia and one case (1.7%) of anemia. Sixteen patients (26.7%) developed thermal toxicity, which was mostly Grade 1 (15 patients, 93.8%). The relatively low dose of 40 Gy radiation showed comparable pathologic treatment outcomes and tolerable toxicity profiles with the addition of mEHT, which may potentially replace part of the radiation dose in neoadjuvant treatment for rectal cancer.</p> 1410</div> 1411</article> 1412</div> 1413</div> 1414</div> 1415</div> 1416</div> 1417</div> 1418</div> 1419</div> 1420</header> 1421</div> 1422</div> 1423 1424 <div id="teljes-cikk" class="btn"> 1425 <a href="https://pubmed.ncbi.nlm.nih.gov/32039629/" target="_blank"> View abstract</a> 1426 </div> 1427 1428 </div> <!-- .container --> 1429</div><!-- .entry-content --> 1430 1431 1432 1433</article><!-- #post-3292 --> 1434 1435 1436<article id="post-3293" class="post-3293 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry"> 1437 1438 <header class="pub-entry-header"> 1439 <div class="container"> 1440 <h2>Survival Outcomes of Metabolically Supported Chemotherapy Combined with Ketogenic Diet, Hyperthermia, and Hyperbaric Oxygen Therapy in Advanced Gastric Cancer</h2> 1441 </div> 1442 </header><!-- .entry-header --> 1443 1444 1445<div class="entry-content kl-pub-content"> 1446 <div class="container"> 1447 <div class="acf-fields"> 1448 <div class="acf-row"><span class="publ-label">Indication:</span> Gastric Cancer <hr/> <span class="publ-label">Evidence:</span> </div> 1449 <div class="publ-acf acf-row acf-flex"> 1450 <span class="publ-label">Author: </span> 1451 <div class="szerzok"> 1452 1453 1454 1455 <span class="sz-nev">MS Iyikesici</span> 1456 1457 </div> 1458 1459 </div> 1460 <div class="acf-row"><span class="publ-label">No. of patients:</span> 22 <hr/> <span class="publ-label">Therapy:</span> Chemotherapy, Ketogenic Diet, Hyperthermia, Hyperbaric Oxygen Therapy<hr/> <span class="publ-label">Year:</span> 2020</div> 1461 </div><!-- .acf-fields --> 1462 <p><strong><span style="color: #9e8053;">Abstract:</span></strong></p> 1463<p>Background: Survival outcomes are still far from being satisfactory in patients with advanced gastric cancer, despite availability of novel chemotherapeutic regimens. Aim: This study evaluated the outcomes of patients with advanced gastric cancer who received chemotherapy along with additional treatment modalities targeting multiple tumor cell vulnerabilities. Materials and Methods: A total of 24 patients diagnosed with stage IIIâIV locally advanced or metastatic gastric aden
1463ocarcinoma that received metabolically supported chemotherapy (MSCT) combined with ketogenic diet, local hyperthermia, and hyperbaric oxygen therapy (HBOT) between April 2014 and October 2017 were included in this retrospective study. Survival outcomes were evaluated. Results: In 22 patients (88.0%), complete response was achieved. Mean duration of followâup was 23.9 ± 12.7 months. Mean overall survival was 39.5 months (95% confidence interval [CI]: 28.1â51.0) and mean progression free survival was 36.5 months (95% CI: 25.7â47.2). No problems were encountered due to fasting, hypoglycemia, ketogenic diet, hyperthermia or HBOT. Conclusions: The combination treatment used in this study (MSCT together with a ketogenic diet, hyperthermia and HBOT) appears to be promising in the treatment of advanced gastric cancer. Further research and comparative clinical trials are warranted to support and standardize this novel treatment protocol. Keywords: Advanced gastric cancer, hyperbaric oxygen therapy, hyperthermia, ketogenic diet, metabolically supported chemotherapy</p> 1464 1465 1466 </div> <!-- .container --> 1467</div><!-- .entry-content --> 1468 1469 1470 1471</article><!-- #post-3293 --> 1472 1473 1474<article id="post-3294" class="post-3294 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry"> 1475 1476 <header class="pub-entry-header"> 1477 <div class="container"> 1478 <h2>Potentiation of the Abscopal Effect by Modulated Electro-Hyperthermia in Locally Advanced Cervical Cancer Patients</h2> 1479 </div> 1480 </header><!-- .entry-header --> 1481 1482 1483<div class="entry-content kl-pub-content"> 1484 <div class="container"> 1485 <div class="acf-fields"> 1486 <div class="acf-row"><span class="publ-label">Indication:</span> Cervical cancer <hr/> <span class="publ-label">Evidence:</span> Phase III</div> 1487 <div class="publ-acf acf-row acf-flex"> 1488 <span class="publ-label">Author: </span> 1489 <div class="szerzok"> 1490 1491 1492 1493 <span class="sz-nev">Carrie Anne Minnaar</span> 1494 1495 1496 1497 <span class="sz-nev">Jeffrey Allan Kotzen</span> 1498 1499 1500 1501 <span class="sz-nev">Olusegun Akinwale Ayeni</span> 1502 1503 1504 1505 <span class="sz-nev">Mboyo-Di-Tamba Vangu</span> 1506 1507 1508 1509 <span class="sz-nev">Ans Baeyens</span> 1510 1511 </div> 1512 1513 </div> 1514 <div class="acf-row"><span class="publ-label">No. of patients:</span> 108 <hr/> <span class="publ-label">Therapy:</span> mEHT<hr/> <span class="publ-label">Year:</span> 2020</div> 1515 </div><!-- .acf-fields --> 1516 <p><strong><span style="color: #9e8053;">ABSTRACT</span><br /> 1517Background:</strong> A Phase III randomized controlled trial investigating the addition of modulated electro-hyperthermia (mEHT) to chemoradiotherapy for locally advanced cervical cancer patients is being conducted in South Africa (Human Research Ethics Committee approval: M1704133; <a href="https://clincialtrials.gov/" target="_blank" rel="noopener noreferrer">ClincialTrials.gov</a> ID: NCT03332069). Two hundred and ten participants were randomized and 202 participants were eligible for six month local disease control evaluation. Screening <sup>18</sup>F-FDG PET/CT scans were conducted and repeated at six months post-treatment. Significant improvement in local control was reported in the mEHT group and complete metabolic resolution (CMR) of extra-pelvic disease was noted in some participants. We report on an analysis of the participants with CMR of disease inside and outside the radiation field.<br /> 1518<strong>Method:</strong> Participants were included in this analysis if nodes outside the treatment field (FDG-uptake SUV>2.5) were visualized on pre-treatment scans and if participants were evaluated by <sup>18</sup>F-FDG PET/CT scans at six months post-treatment.<br /> 1519<strong>Results:</strong> One hundred and eight participants (mEHT: HIV-positive <i>n</i> = 25, HIV-negative <i>n</i> = 29; Control Group: HIV-positive <i>n</i> = 26, HIV-negative <i>n</i> = 28) were eligible for analysis. There was a higher CMR of all disease inside and outside the radiation field in the mEHT Group: <i>n</i> = 13 [24.1%] than the control group: <i>n</i> = 3 [5.6%] (Chi squared, Fisher’s exact: <i>p</i>
1519 = 0.013) with no significant difference in the extra-pelvic response to treatment between the HIV-positive and -negative participants of each group.<br /> 1520<strong>Conclusion:</strong> The CMR of disease outside the radiation field at six months post-treatment provides evidence of an abscopal effect which was significantly associated with the addition of mEHT to treatment protocols. This finding is important as the combined synergistic use of radiotherapy with mEHT could broaden the scope of radiotherapy to include systemic disease.</p> 1521 1522 <div id="teljes-cikk" class="btn"> 1523 <a href="https://www.frontiersin.org/articles/10.3389/fonc.2020.00376/full" target="_blank"> View abstract</a> 1524 </div> 1525 1526 </div> <!-- .container --> 1527</div><!-- .entry-content --> 1528 1529 1530 1531</article><!-- #post-3294 --> 1532 1533 1534<article id="post-3295" class="post-3295 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry"> 1535 1536 <header class="pub-entry-header"> 1537 <div class="container"> 1538 <h2>Putative Abscopal Effect in Three Patients Treated by Combined Radiotherapy and Modulated Electrohyperthermia</h2> 1539 </div> 1540 </header><!-- .entry-header --> 1541 1542 1543<div class="entry-content kl-pub-content"> 1544 <div class="container"> 1545 <div class="acf-fields"> 1546 <div class="acf-row"><span class="publ-label">Indication:</span> Multiple <hr/> <span class="publ-label">Evidence:</span> </div> 1547 <div class="publ-acf acf-row acf-flex"> 1548 <span class="publ-label">Author: </span> 1549 <div class="szerzok"> 1550 1551 1552 1553 <span class="sz-nev">Mau-Shin Chi</span> 1554 1555 1556 1557 <span class="sz-nev">Minesh P. Mehta</span> 1558 1559 1560 1561 <span class="sz-nev">Kai-Lin Yang</span> 1562 1563 1564 1565 <span class="sz-nev">Hung-Chih Lai</span> 1566 1567 1568 1569 <span class="sz-nev">Ying-Chu Lin</span> 1570 1571 1572 1573 <span class="sz-nev">Hui-Ling Ko</span> 1574 1575 1576 1577 <span class="sz-nev">Yu-Shan Wang</span> 1578 1579 1580 1581 <span class="sz-nev">Kuang-Wen Liao</span> 1582 1583 1584 1585 <span class="sz-nev">Kwan-Hwa Chi</span> 1586 1587 </div> 1588 1589 </div> 1590 <div class="acf-row"><span class="publ-label">No. of patients:</span> 33 <hr/> <span class="publ-label">Therapy:</span> RT+mEHT<hr/> <span class="publ-label">Year:</span> 2020</div> 1591 </div><!-- .acf-fields --> 1592 <p><strong>ABSTRACT<br /> 1593Purpose: </strong>True abscopal responses from radiation therapy are extremely rare; the combination of immune checkpoint inhibitors with radiation therapy has led to more reports of the abscopal effect, but even in this setting, the genuine magnitude remains unknown and is still considered generally uncommon. We report the occurrence of what appears to be putative, durable abscopal tumor responses with associated auto-immune systemic reactions resulting from the combination of local radiotherapy (RT) and modulated electrohyperthermia (mEHT).</p> 1594<p><strong>Materials and Methods: </strong>Data from advanced cancer patients treated palliatively with RT and mEHT between January and December 2017 were collected as part of a post-marketing safety monitoring program of mEHT therapy. We speciï¬ed a minimum RT dose of 30Gy and at least four mEHT treatments for reporting toxicities, which was the primary aim of the larger study.</p> 1595<p><strong>Results:</strong> Thirty-three patients treated with RT and mEHT, both applied to the same lesion, were included. The median RT dose was 45.5Gy in 20 fractions (fxs) and the median number of mEHT treatments was 12 (range, 4â20). Most patients had subsequent systemic therapy after one course of RT and mEHT. Three patients (9.1%) developed autoimmune toxicities. Case number 1 received RT and mEHT only; case number 2 had two cycles of concurrent low dose chemotherapy during RT; and case number 3 received concurrent immune checkpoint inhibitors. None of the three patients received any further systemic treatment due to obvious treatment-related autoimmune reactions which occurred rapidly after RT; one had autoimmune hepatitis, one had dermatitis herpetiformis and the third developed severe myasthenia gravis. Interestingly, what we surmise to be long-lasting abscopal responses outside the irradiated area, were noted in all three patients.</p> 1596<p><strong>Conclusion:</strong> RT combined with mEHT could putatively result in enhancing immune responsiveness. These preliminary observational ï¬ndings lead to the generation of a hypothesis that this combination induces both an in-situ, tumor-speciï¬c immune reaction and an anti-self-autoimmune reaction, in at least a small proportion of patients, and of those who experience the auto-immune response, tumor response is a concomitant ï¬nding. Mechanisms underlying this phenomenon need to be investigated further.</p> 1597 1598 <div id="teljes-cikk" class="btn"> 1599 <a href="https://www.frontiersin.org/articles/10.3389/fonc.2020.00254/full" target="_blank">
1599 View abstract</a> 1600 </div> 1601 1602 </div> <!-- .container --> 1603</div><!-- .entry-content --> 1604 1605 1606 1607</article><!-- #post-3295 --> 1608 1609 1610<article id="post-3296" class="post-3296 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry"> 1611 1612 <header class="pub-entry-header"> 1613 <div class="container"> 1614 <h2>Breaking Therapy Resistance: An Update on Oncolytic Newcastle Disease Virus for Improvements of Cancer Therapy</h2> 1615 </div> 1616 </header><!-- .entry-header --> 1617 1618 1619<div class="entry-content kl-pub-content"> 1620 <div class="container"> 1621 <div class="acf-fields"> 1622 <div class="acf-row"><span class="publ-label">Indication:</span> Immuno-oncology <hr/> <span class="publ-label">Evidence:</span> </div> 1623 <div class="publ-acf acf-row acf-flex"> 1624 <span class="publ-label">Author: </span> 1625 <div class="szerzok"> 1626 1627 1628 1629 <span class="sz-nev">Volker Schirrmacher</span> 1630 1631 1632 1633 <span class="sz-nev">Stefaan van Gool</span> 1634 1635 1636 1637 <span class="sz-nev">Wilfried Stuecker</span> 1638 1639 </div> 1640 1641 </div> 1642 <div class="acf-row"><span class="publ-label">No. of patients:</span> <hr/> <span class="publ-label">Therapy:</span> <hr/> <span class="publ-label">Year:</span> 2019</div> 1643 </div><!-- .acf-fields --> 1644 <p><strong>Abstract</strong><br /> 1645Resistance to therapy is a major obstacle to cancer treatment. It may exist from the beginning, or it may develop during therapy. The review focusses on oncolytic Newcastle disease virus(NDV)asabiologicalagentwithpotentialtobreaktherapyresistance. Thisavianviruscombines, upon inoculation into non-permissive hosts such as human, 12 described anti-neoplastic eï¬ects with 11describedimmunestimulatoryproperties. FiftyyearsofclinicalapplicationofNDVgivewitnessto the high safety proï¬le of this biological agent. In 2015, an important milestone was achieved, namely the successful production of NDV according to Good Manufacturing Practice (GMP). Based on this, IOZK in Cologne, Germany, obtained a GMP certiï¬cate for the production of a dendritic cell vaccine loadedwithtumorantigensfromalysateofpatient-derivedtumorcellstogetherwithimmunological dangersignalsfromNDVforintracutaneousapplication. Thisupdateincludessinglecasereportsand retrospective analyses from patients treated at IOZK. The review also presents future perspectives, including the concept of in situ vaccination and the combination of NDV or other oncolytic viruses with checkpoint inhibitors.<br /> 1646Keywords: NDV; viral oncolysis; immunogenic cell death; type I interferon; dendritic cells; active-speciï¬c immunotherapy; bispeciï¬c antibodies; gene therapy; checkpoint inhibition; T cell costimulation; RIG-I; IFNAR</p> 1647 1648 <div id="teljes-cikk" class="btn"> 1649 <a href="https://www.ncbi.nlm.nih.gov/pubmed/31480379" target="_blank"> View abstract</a> 1650 </div> 1651 1652 </div> <!-- .container --> 1653</div><!-- .entry-content --> 1654 1655 1656 1657</article><!-- #post-3296 --> 1658 1659 1660<article id="post-3297" class="post-3297 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry"> 1661 1662 <header class="pub-entry-header"> 1663 <div class="container"> 1664 <h2>Long-Term Survival Outcomes of Metabolically Supported Chemotherapy with Gemcitabine-Based or FOLFIRINOX Regimen Combined with Ketogenic Diet, Hyperthermia, and Hyperbaric Oxygen Therapy in Metastatic Pancreatic Cancer</h2> 1665 </div> 1666 </header><!-- .entry-header --> 1667 1668 1669<div class="entry-content kl-pub-content"> 1670 <div class="container"> 1671 <div class="acf-fields"> 1672 <div class="acf-row"><span class="publ-label">Indication:</span> Pancreas <hr/> <span class="publ-label">Evidence:</span> </div> 1673 <div class="publ-acf acf-row acf-flex"> 1674 <span class="publ-label">Author: </span> 1675 <div class="szerzok"> 1676 1677 1678 1679 <span class="sz-nev">Mehmet Salih Iyikesici</span> 1680 1681 </div> 1682 1683 </div> 1684 <div class="acf-row"><span class="publ-label">No. of patients:</span> 25 <hr/> <span class="publ-label">Therapy:</span> <hr/> <span class="publ-label">Year:</span> 2019</div> 1685 </div><!-- .acf-fields --> 1686 <p><strong>Abstract</strong></p> 1687<p>Background: Despite introduction of new chemotherapeutic agents, outcomes of patients with metastatic pancreatic cancer are still poor. Metabolically supported chemotherapy (MSCT) is a novel approach targeting dysregulated energy mechanism of the tumor cell.<br /> 1688Objectives: This study aimed to examine the efficacy of metabolically supported administration of chemotherapy combined with ketogenic diet, hyperthermia, and hyperbaric oxygen therapy (HBOT) in patients with metastatic pancreatic cancer.<br /> 1689Method: This retrospective observational study included 25 patients with metastatic pancreatic ductal carcinoma (stage IV) who received MSCT (either gemcitabine-based or FOLFIRINO
1689X regimen administered concomitantly with induced hypoglycemia) plus ketogenic diet, hyperthermia, and HBOT combination. Survival outcomes were evaluated.<br /> 1690Results: During the mean follow-up duration of 25.4 ± 19.3 months, median overall survival and median progression-free survival were 15.8 months (95% CI, 10.5â21.1) and 12.9 months (95% CI, 11.2â14.6), respectively. Age and gender did not have any effect on overall survival (p > 0.05 for all).<br /> 1691Conclusions: MSCT administered together with ketogenic diet, hyperthermia, and HBOT appears to be a viable option with the potential to improve survival outcomes in patients diagnosed with metastatic pancreatic cancer. Further research, particularly with larger comparative clinical trials, is warranted.</p> 1692 1693 <div id="teljes-cikk" class="btn"> 1694 <a href="https://www.ncbi.nlm.nih.gov/pubmed/31527373" target="_blank"> View abstract</a> 1695 </div> 1696 1697 </div> <!-- .container --> 1698</div><!-- .entry-content --> 1699 1700 1701 1702</article><!-- #post-3297 --> 1703 1704 1705<article id="post-3298" class="post-3298 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry"> 1706 1707 <header class="pub-entry-header"> 1708 <div class="container"> 1709 <h2>Modulated Electro-Hyperthermia as Palliative Treatment for Pancreatic Cancer: A Retrospective Observational Study on 106 Patients</h2> 1710 </div> 1711 </header><!-- .entry-header --> 1712 1713 1714<div class="entry-content kl-pub-content"> 1715 <div class="container"> 1716 <div class="acf-fields"> 1717 <div class="acf-row"><span class="publ-label">Indication:</span> Pancreas <hr/> <span class="publ-label">Evidence:</span> Review</div> 1718 <div class="publ-acf acf-row acf-flex"> 1719 <span class="publ-label">Author: </span> 1720 <div class="szerzok"> 1721 1722 1723 1724 <span class="sz-nev">Giammaria Fiorentini</span> 1725 1726 1727 1728 <span class="sz-nev">Donatella Sarti</span> 1729 1730 1731 1732 <span class="sz-nev">Virginia Casadei</span> 1733 1734 1735 1736 <span class="sz-nev">Carlo Milandri</span> 1737 1738 1739 1740 <span class="sz-nev">Patrizia Dentico</span> 1741 1742 1743 1744 <span class="sz-nev">Andrea Mambrini</span> 1745 1746 1747 1748 <span class="sz-nev">Roberto Nani</span> 1749 1750 1751 1752 <span class="sz-nev">Caterina Fiorentini</span> 1753 1754 1755 1756 <span class="sz-nev">Stefano Guadagni</span> 1757 1758 </div> 1759 1760 </div> 1761 <div class="acf-row"><span class="publ-label">No. of patients:</span> 106 <hr/> <span class="publ-label">Therapy:</span> CT+RT+mEHT<hr/> <span class="publ-label">Year:</span> 2019</div> 1762 </div><!-- .acf-fields --> 1763 <h3 class="text-align-justify"><strong>Abstract</strong></h3> 1764<p class="text-align-justify"><strong>Background</strong>: Pancreatic adenocarcinoma has a poor prognosis, resulting in a <10% survival rate at 5 years. Modulated electro-hyperthermia (mEHT) has been increasingly used for pancreatic cancer palliative care and therapy. Objective: To monitor the efficacy and safety of mEHT for the treatment of advanced pancreatic cancer. <strong>Methods</strong>: We collected data retrospectively on 106 patients affected by stage III-IV pancreatic adenocarcinoma. They were divided into 2 groups: patients who did not receive mEHT (no-mEHT) and patients who were treated with mEHT. We performed mEHT applying a power of 60 to 150 W for 40 to 90 minutes. The mEHT treatment was associated with chemotherapy and/
1764or radiotherapy for 33 (84.6%) patients, whereas 6 (15.4%) patients received mEHT alone. The patients of the no-mEHT group received chemotherapy and/or radiotherapy in 55.2% of cases. <strong>Results</strong>: Median age of the sample was 65.3 years (range = 31-80 years). After 3 months of therapy, the mEHT group had partial response in 22/34 patients (64.7%), stable disease in 10/34 patients (29.4%), and progressive disease in 2/34 patients (8.3%). The no-mEHT group had partial response in 3/36 patients (8.3%), stable disease in 10/36 patients (27.8%), and progressive disease in 23/36 patients (34.3%). The median overall survival of the mEHT group was 18.0 months (range = 1.5-68.0 months) and 10.9 months (range = 0.4-55.4 months) for the non-mEHT group. <strong>Conclusions</strong>: mEHT may improve tumor response and survival of pancreatic cancer patients.</p> 1765 1766 <div id="teljes-cikk" class="btn"> 1767 <a href="https://journals.sagepub.com/doi/10.1177/1534735419878505" target="_blank"> View abstract</a> 1768 </div> 1769 1770 </div> <!-- .container --> 1771</div><!-- .entry-content --> 1772 1773 1774 1775</article><!-- #post-3298 --> 1776 1777 1778<article id="post-3299" class="post-3299 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry"> 1779 1780 <header class="pub-entry-header"> 1781 <div class="container"> 1782 <h2>Feasibility study of metabolically supported chemotherapy with weekly carboplatin/paclitaxel combined with ketogenic diet, hyperthermia and hyperbaric oxygen therapy in metastatic nonsmall cell lung cancer</h2> 1783 </div> 1784 </header><!-- .entry-header --> 1785 1786 1787<div class="entry-content kl-pub-content"> 1788 <div class="container"> 1789 <div class="acf-fields"> 1790 <div class="acf-row"><span class="publ-label">Indication:</span> Lung <hr/> <span class="publ-label">Evidence:</span> </div> 1791 <div class="publ-acf acf-row acf-flex"> 1792 <span class="publ-label">Author: </span> 1793 <div class="szerzok"> 1794 1795 1796 1797 <span class="sz-nev">Mehmet Salih Iyikesici</span> 1798 1799 </div> 1800 1801 </div> 1802 <div class="acf-row"><span class="publ-label">No. of patients:</span> 44 <hr/> <span class="publ-label">Therapy:</span> <hr/> <span class="publ-label">Year:</span> 2019</div> 1803 </div><!-- .acf-fields --> 1804 <p><strong>ABSTRACT</strong><br /> 1805Background: Previous evidence suggests that metabolically supported chemotherapy (MSCT), ketogenic diet, hyperthermia and hyperbaric oxygen therapy (HBOT) could all target vulnerabilities of cancer cells. This study aimed to evaluate the efficacy and the tolerability of this combination therapy in the treatment of stage IV non-small cell lung cancer (NSCLC).<br /> 1806Methods: Forty-four NSCLC patients with distant metastasis that received MSCT (administration of chemotherapy regimen following induced hypoglycemia) plus ketogenic diet, hyperthermia and HBOT combination were included in this retrospective study. Survival and treatment response rates as well as toxicities were evaluated.<br /> 1807Results: Overall response rate (ORR, complete response plus partial response) was 61.4%; whereas, 15.9% and 22.7% of patients had stable disease (SD) and progressive disease (PD), respectively. Mean overall survival (OS) and progression-free survival (PFS) was 42.9months (95% CI: 34.0â51.8) and 41.0months (95% CI: 31.1â50.9), respectively. A higher Eastern Cooperative Oncology Group (ECOG) performance status (ECOG 2) was associated with worse OS and PFS. Patients received chemotherapy cycles with acceptable toxicity and adverse events. No problems were encountered due to fasting, hypoglycemia, ketogenic diet, hyperthermia or hyperbaric oxygen therapy.<br /> 1808Conclusions: Findings of this study suggest that MSCT combined with other modalities targeting multiple pathways and cellular vulnerabilities may bring about remarkable improvements in survival outcomes and treatment response rates in metastatic NSCLC, without additional safety concerns. Large comparative studies are warranted to draw robust conclusions.</p> 1809 1810 <div id="teljes-cikk" class="btn"> 1811 <a href="https://www.tandfonline.com/doi/full/10.1080/02656736.2019.1589584" target="_blank"> View abstract</a> 1812 </div> 1813 1814 </div> <!-- .container --> 1815</div><!-- .entry-content --> 1816 1817 1818 1819</article><!-- #post-3299 --> 1820 1821 1822<article id="post-3300" class="post-3300 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry"> 1823 1824 <header class="pub-entry-header"> 1825 <div class="container"> 1826 <h2>Defining Characteristics of Nodal Disease on PET/CT Scans in Patients W
1826ith HIV-Positive and-Negative Locally Advanced Cervical Cancer in South Africa</h2> 1827 </div> 1828 </header><!-- .entry-header --> 1829 1830 1831<div class="entry-content kl-pub-content"> 1832 <div class="container"> 1833 <div class="acf-fields"> 1834 <div class="acf-row"><span class="publ-label">Indication:</span> Cervical cancer <hr/> <span class="publ-label">Evidence:</span> </div> 1835 <div class="publ-acf acf-row acf-flex"> 1836 <span class="publ-label">Author: </span> 1837 <div class="szerzok"> 1838 1839 1840 1841 <span class="sz-nev">Carrie Anne Minaar</span> 1842 1843 1844 1845 <span class="sz-nev">Ans Baeyens</span> 1846 1847 1848 1849 <span class="sz-nev">Olusegun Akinwale Ayeni</span> 1850 1851 1852 1853 <span class="sz-nev">Jeffrey Allan Kotzen</span> 1854 1855 1856 1857 <span class="sz-nev">Mboyo-Di-Tamba Vangu</span> 1858 1859 </div> 1860 1861 </div> 1862 <div class="acf-row"><span class="publ-label">No. of patients:</span> <hr/> <span class="publ-label">Therapy:</span> <hr/> <span class="publ-label">Year:</span> 2019</div> 1863 </div><!-- .acf-fields --> 1864 <p><strong>Abstract </strong><br /> 1865Literature reports increased FDG nodal uptake in HIV-positive patients. Our aim is to identify differences in presentation and characteristics of FDG-avid lymph nodes between HIV-positive and HIV-negative locally advanced cervical cancer (LACC) patients in our clinical setting. We evaluated 250 pre-treatment 18F-FDG PET/CT imaging studies from women screened for a phase III randomised controlled trial investigating modulated electro-hyperthermia as a radiosensitiser (Ethics approval: M120477). The number of nodes; size; maximum standardised uptake value (SUVmax); symmetry; and relationship between nodal size and SUVmax uptake, were assessed by region and by HIV status. In total, 1314 nodes with a SUVmax ⥠2.5 were visualised. Of 128(51%) HIV-positive participants, 82% were on antiretroviral therapy (ART) and 10 had a CD4 count <
1865200 cells/mL. Overall pattern of presentation and nodal characteristics were similar between HIV-positive and -negative groups and the uniformity in presentation of the nodes draining the cervix strongly suggests these nodes may be attributed to malignancy rather than HIV infection. Novel findings: HIV infection is associated with: >four nodes visualised in the neck, symmetrical inguinal lymph nodes, increased rates of supraclavicular node visualisation; FDG-avid axillary nodes were more common, but not exclusive, in HIV-positive participants. 18F-FDG PET/CT is a reliable staging method for LACC in HIV-positive patients who are not in acute stages of HIV infection, have a CD4 count >200 cells/mL, and/or are on ART and there is a potential risk of underestimating metastatic spread by attributing increased nodal metabolic activity to HIV infection in these patients.</p> 1866 1867 <div id="teljes-cikk" class="btn"> 1868 <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6935993/" target="_blank"> View abstract</a> 1869 </div> 1870 1871 </div> <!-- .container --> 1872</div><!-- .entry-content --> 1873 1874 1875 1876</article>
1876<!-- #post-3300 --> 1877 1878 1879<article id="post-3301" class="post-3301 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry"> 1880 1881 <header class="pub-entry-header"> 1882 <div class="container"> 1883 <h2>Fluctuations hypothesize the new explanation of meridians in living systems</h2> 1884 </div> 1885 </header><!-- .entry-header --> 1886 1887 1888<div class="entry-content kl-pub-content"> 1889 <div class="container"> 1890 <div class="acf-fields"> 1891 <div class="acf-row"><span class="publ-label">Indication:</span> Non-oncology <hr/> <span class="publ-label">Evidence:</span> </div> 1892 <div class="publ-acf acf-row acf-flex"> 1893 <span class="publ-label">Author: </span> 1894 <div class="szerzok"> 1895 1896 1897 1898 <span class="sz-nev">Szigeti Gy</span> 1899 1900 1901 1902 <span class="sz-nev">Szasz A</span> 1903 1904 </div> 1905 1906 </div> 1907 <div class="acf-row"><span class="publ-label">No. of patients:</span> <hr/> <span class="publ-label">Therapy:</span> <hr/> <span class="publ-label">Year:</span> 2019</div> 1908 </div><!-- .acf-fields --> 1909 <h3 class="text-align-justify"><strong>Abstract </strong></h3> 1910<p class="text-align-justify">Biosystems are complex. Their physiology is well-controlled with various negative feedback signals and processes, it describes by opposite interfering effects which are characterized in the Eastern philosophy by Yin-Yang (Y-Y) pairs. Y-Y pairs could be described by the promoter-suppressor pairs in a wide range of physiologic signals creating the homeostasis of the complex system. This type of control appears as fluctuations from the average (mean) value of the signal. The mean carries an ineluctable fluctuation (called pink-noise or 1/f noise). All signals in homeostasis have equal entropy (SE = 1.8), which is the character of the complex equilibrium. The various controlling opposite signals (Y-Y) have different time-scales which change by aging. The processes with smaller time-scale are degraded by aging, but the pink-noise ensures that the deviations of the signals of the healthy homeostatic system remain constant. Meridians are connected to the general transport systems that combined the material and the information transport with the considerable transport networks, like blood, lymph, nerve, cell-junctions, mesenchymal âground substanceâ cytoskeletons. The meridians in this meaning only virtual line averaged from multiple realized paths to connect two acupuncture points by the material, energy and information transport processes. The meridian network is designed by various coupling points (acupoints), which could be perturbed by actuating stimulus. Our objective is to describe the meridian system from complexity point of view.</p> 1911 1912 <div id="teljes-cikk" class="btn"> 1913 <a href="https://www.scirp.org/journal/PaperInformation.aspx?PaperID=89697" target="_blank"> View abstract</a> 1914 </div> 1915 1916 </div> <!-- .container --> 1917</div><!-- .entry-content --> 1918 1919 1920 1921</article>
1921<!-- #post-3301 --> 1922 1923 1924<article id="post-3302" class="post-3302 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry"> 1925 1926 <header class="pub-entry-header"> 1927 <div class="container"> 1928 <h2>Thermal and Nonthermal Effects of Radiofrequency on Living State and Applications as an Adjuvant with Radiation Therapy</h2> 1929 </div> 1930 </header><!-- .entry-header --> 1931 1932 1933<div class="entry-content kl-pub-content"> 1934 <div class="container"> 1935 <div class="acf-fields"> 1936 <div class="acf-row"><span class="publ-label">Indication:</span> Non-oncology <hr/> <span class="publ-label">Evidence:</span> Review</div> 1937 <div class="publ-acf acf-row acf-flex"> 1938 <span class="publ-label">Author: </span> 1939 <div class="szerzok"> 1940 1941 1942 1943 <span class="sz-nev">Andras Szasz</span> 1944 1945 </div> 1946 1947 </div> 1948 <div class="acf-row"><span class="publ-label">No. of patients:</span> <hr/> <span class="publ-label">Therapy:</span> <hr/> <span class="publ-label">Year:</span> 2019</div> 1949 </div><!-- .acf-fields --> 1950 <div class="c-rich-text"> 1951<p class="text-align-justify"><strong>Abstract</strong></p> 1952<p class="text-align-justify">One of the most frequently applied bioelectromagnetic effects is the deep heating of living species with electromotive force energy. Despite its long history, hyperthermia is a rarely applied oncotherapy because of controversial results and complicated control. The challenge in clinical studies of oncological hyperthermia is the disharmony of the local response and local control with overall survival. Both wholeâbody (complete isothermia for the body) and local (isothermia for the chosen target) heating show excellent local effects; however, this is not followed with the expected elongation of survival time. A possible solution could be nonisothermal heating to the heterogeneity of the malignancy itself. The distinguishing parameters to select the target are the electromagnetic properties of the malignant tissue together with the physiological differences between malignant cells and their healthy counterparts. Selection could allow for cellular targeting, generating<br /> 1953natural reactions, such as programmed cell death (apoptosis) followed by immunogenic cell death involving extended immune reactions. This complex method is a new kind of hyperthermia, named modulated electrohyperthermia (tradename oncothermia). The selective, nonequilibrium energy absorption is well synergized with modern radiation therapies, presenting a solution of an active and controllable tumorâspecific immune reaction and subsequent abscopal effects.</p> 1954</div> 1955<div class="field field--name-field-url field--type-link field--label-hidden field__item"></div> 1956 1957 <div id="teljes-cikk" class="btn"> 1958 <a href="http://www.journalrcr.org/article.asp?issn=2588-9273%3Byear%3D2019%3Bvolume%3D10%3Bissue%3D1%3Bspage%3D1%3Bepage%3D17%3Baulast%3DSzasz" target="_blank"> View abstract</a> 1959 </div> 1960 1961 </div> <!-- .container --> 1962</div><!-- .entry-content --> 1963 1964 1965 1966</article>
1966<!-- #post-3302 --> 1967 1968 1969<article id="post-3303" class="post-3303 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry"> 1970 1971 <header class="pub-entry-header"> 1972 <div class="container"> 1973 <h2>Phase I/II clinical trial of modulated electro-hyperthermia treatment in patients with relapsed, refractory or progressive heavily treated ovarian cancer</h2> 1974 </div> 1975 </header><!-- .entry-header --> 1976 1977 1978<div class="entry-content kl-pub-content"> 1979 <div class="container"> 1980 <div class="acf-fields"> 1981 <div class="acf-row"><span class="publ-label">Indication:</span> Gynecology <hr/> <span class="publ-label">Evidence:</span> Phase I/II</div> 1982 <div class="publ-acf acf-row acf-flex"> 1983 <span class="publ-label">Author: </span> 1984 <div class="szerzok"> 1985 1986 1987 1988 <span class="sz-nev">Heon Jong Yoo</span> 1989 1990 1991 1992 <span class="sz-nev">Myong Cheol Lim</span> 1993 1994 1995 1996 <span class="sz-nev">Sang-Soo Seo</span> 1997 1998 1999 2000 <span class="sz-nev">Sokbom Kang</span> 2001 2002 2003 2004 <span class="sz-nev">Jungnam Joo</span> 2005 2006 2007 2008 <span class="sz-nev">Sang-Yoon Park</span> 2009 2010 </div> 2011 2012 </div> 2013 <div class="acf-row"><span class="publ-label">No. of patients:</span> 19 <hr/> <span class="publ-label">Therapy:</span> mEHT<hr/> <span class="publ-label">Year:</span> 2019</div> 2014 </div><!-- .acf-fields --> 2015 <h3 class="text-align-justify">Abstract</h3> 2016<p class="text-align-justify"><strong>Objective:</strong> To determine the maximal tolerated dose (MTD) of modulated electro-hyperthermia (mEHT) treatment and to reveal whether mEHT treatment is feasible and effective as second-line therapy in recurrent and progressive ovarian cancer.</p> 2017<p class="text-align-justify"><strong>Methods:</strong> Patients were treated with mEHT with dose escalation during the first cycle (two sessions each week for three weeks) to determine the MTD. Additional cycles were carried out with the determined dose. Dose limiting toxicity (DLT) was defined grade ⥠2: skin burns and inability to endure the hyperthermic state of the study. The Fact-O quality of life scale was used to assess health-related well-being.</p> 2018<p class="text-align-justify"><strong>Results:</strong> Nineteen patients with recurrent and progressive ovarian cancer were enrolled. In the first cycle of mEHT treatment, no patient developed DLT with applied power up to 110 W, 130 W, and 150 W/day; the 150W was the maximal applied power. Stable disease was observed in only one patient (12.5%). With median progression of 4.0 months (range, 2â17 months), 18 patients (95%) demonstrated disease progression. With median overall survival of 8.0 months (range, 2â32 months), 18 patients (95%) had died. Physical well-being scores were significantly decreased over the study period, although social, emotional, and functional well-being scores did not significantly change.</p> 2019<p class="text-align-justify"><strong>Conclusions:</strong> The mEHT treatment was feasible in patients with recurrent or progressive ovarian cancer without any complication and optimal dose of mEHT treatment was up to 150W for 1 hour/ day.</p> 2020 2021 <div id="teljes-cikk" class="btn"> 2022 <a href="https://academic.oup.com/jjco/advance-article-abstract/doi/10.1093/jjco/hyz071/5487439?redirectedFrom=fulltext" target="_blank"> View abstract</a> 2023 </div> 2024 2025 </div> <!-- .container --> 2026</div><!-- .entry-content --> 2027 2028 2029 2030</article>
2030<!-- #post-3303 --> 2031 2032 2033<article id="post-3304" class="post-3304 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry"> 2034 2035 <header class="pub-entry-header"> 2036 <div class="container"> 2037 <h2>Integrative Therapeutic Options for Treating Stage Four Breast Cancer</h2> 2038 </div> 2039 </header><!-- .entry-header --> 2040 2041 2042<div class="entry-content kl-pub-content"> 2043 <div class="container"> 2044 <div class="acf-fields"> 2045 <div class="acf-row"><span class="publ-label">Indication:</span> Breast Cancer <hr/> <span class="publ-label">Evidence:</span> </div> 2046 <div class="publ-acf acf-row acf-flex"> 2047 <span class="publ-label">Author: </span> 2048 <div class="szerzok"> 2049 2050 2051 2052 <span class="sz-nev">Magda Havas</span> 2053 2054 </div> 2055 2056 </div> 2057 <div class="acf-row"><span class="publ-label">No. of patients:</span> <hr/> <span class="publ-label">Therapy:</span> Integrative Therapeutic Options<hr/> <span class="publ-label">Year:</span> 2019</div> 2058 </div><!-- .acf-fields --> 2059 <p><strong>Abstract</strong><br /> 2060Traditional Western medicine treats breast cancer â the most commonly occurring cancer in women with some combination of surgery, chemotherapy and/
2060or radiation therapy. Few doctorsâ council their patients to use complementary modalities and some forbid their use. However, complementary therapies in the form of agents or activities that minimize exposure to toxins, detoxify the body, strengthen the immune system, increase cellular energy, promote circulation, reduce inflammation, alleviate pain and create a hostile internal environment for the growth of cancerous cells without damage to normal healthy cells have been shown to enhance survival and reduce morbidity of cancer patients. Some of these complementary modalities are presented here as options for both oncologists and patients to consider.</p> 2061 2062 <div id="teljes-cikk" class="btn"> 2063 <a href="http://www.clinicsinoncology.com/pdfs_folder/cio-v4-id1607.pdf" target="_blank"> View abstract</a> 2064 </div> 2065 2066 </div> <!-- .container --> 2067</div><!-- .entry-content --> 2068 2069 2070 2071</article><!-- #post-3304 --> 2072 2073 2074<article id="post-3305" class="post-3305 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry"> 2075 2076 <header class="pub-entry-header"> 2077 <div class="container"> 2078 <h2>The effect of modulated electro-hyperthermia on local disease control in HIV-positive and -negative cervical cancer women in South Africa: Early results from a phase III randomised controlled trial</h2> 2079 </div> 2080 </header><!-- .entry-header --> 2081 2082 2083<div class="entry-content kl-pub-content"> 2084 <div class="container"> 2085 <div class="acf-fields"> 2086 <div class="acf-row"><span class="publ-label">Indication:</span> Cervical cancer <hr/> <span class="publ-label">Evidence:</span> Phase III</div> 2087 <div class="publ-acf acf-row acf-flex"> 2088 <span class="publ-label">Author: </span> 2089 <div class="szerzok"> 2090 2091 2092 2093 <span class="sz-nev">Carrie Anne Minnaar</span> 2094 2095 2096 2097 <span class="sz-nev">Jeffrey Allan Kotzen</span> 2098 2099 2100 2101 <span class="sz-nev">Olusegun Akinwale Ayeni</span> 2102 2103 2104 2105 <span class="sz-nev">Thanushree Naidoo</span> 2106 2107 2108 2109 <span class="sz-nev">Mariza Tunmer</span> 2110 2111 2112 2113 <span class="sz-nev">Vinay Sharma</span> 2114 2115 2116 2117 <span class="sz-nev">Mboyo-Di-Tamba Vangu</span> 2118 2119 2120 2121 <span class="sz-nev">Ans Baeyens</span> 2122 2123 </div> 2124 2125 </div> 2126 <div class="acf-row"><span class="publ-label">No. of patients:</span> 271 <hr/> <span class="publ-label">Therapy:</span> CT+mEHT<hr/> <span class="publ-label">Year:</span> 2019</div> 2127 </div><!-- .acf-fields --> 2128 <p class="text-align-justify"><strong>Background</strong><br /> 2129The global burden of cervical cancer remains high with the highest morbidity and mortality rates reported in developing countries. Hyperthermia as a chemo- and radiosensitiser has shown to improve treatment outcomes. This is an analysis of the local control results at six months post-treatment of patients enrolled in an ongoing study investigating the effects of the addition of modulated electro-hyperthermia (mEHT) to chemoradiotherapy for the treatment of HIV-positive and -negative cervical cancer patients in a low-resource setting.</p> 2130<p class="text-align-justify"> 2131<strong>Methods</strong><br /> 2132This ongoing Phase III randomised controlled trial, conducted at a state hospital in Johannesburg, South Africa, was registered with the appropriate ethics committee. After signing an informed consent, participants with FIGO stages IIB to IIIB squamous cell carcinoma of the cervix were randomised to receive chemoradiotherapy with/without mEHT using a secure online random-sampling tool (stratum: HIV status) accounting for age and stage. Reporting physicians were blind to treatment allocation. HIV-positive participants on antiretroviral treatment, or with a CD4 count >200cell/μL were included. mEHT was administered 2/weekly immediately before external beam radiation. The primary end point is local disease control (LDC) and secondary endpoints are toxicity; quality of life analysis; and two year survival. We report on six month LDC, including nodes visualised in the radiation field on 18FFDG PET/CT (censored for six month survival), and six month local disease free survival (LDFS) (based on intention to treat). Trial status: Recruitment closed (ClinicalTr
2132ials.gov: NCT03332069).</p> 2133<p class="text-align-justify"><strong>Results</strong><br /> 2134271 participants were recruited between January 2014 and November 2017, of which 210 were randomised for trial and 202 were available for analysis at six months post-treatment (mEHT: n = 101; Control: n = 101). Six month LDFS was higher in the mEHT Group (n = 39[38.6%]), than in the Control Group (n = 20[19.8%]); p = 0.003). LDC was also higher in the mEHT Group (n = 40[45.5%]) than the Control Group (n = 20[24.1%]); (p = 0.003).</p> 2135<p class="text-align-justify"><strong>Conclusion</strong><br /> 2136Our results show that mEHT is effective as a chemo-radiosensitiser for cervical cancer, even in high risk a patients and resource-constrained settings.</p> 2137 2138 <div id="teljes-cikk" class="btn"> 2139 <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6584021/" target="_blank"> View abstract</a> 2140 </div> 2141 2142 </div> <!-- .container --> 2143</div><!-- .entry-content --> 2144 2145 2146 2147</article><!-- #post-3305 --> 2148 2149 2150<article id="post-3306" class="post-3306 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry"> 2151 2152 <header class="pub-entry-header"> 2153 <div class="container"> 2154 <h2>Nanoparticles and nanothermia for malignant brain tumors, a suggestion of treatment for further investigations</h2> 2155 </div> 2156 </header><!-- .entry-header --> 2157 2158 2159<div class="entry-content kl-pub-content"> 2160 <div class="container"> 2161 <div class="acf-fields"> 2162 <div class="acf-row"><span class="publ-label">Indication:</span> Gliomas (advanced) <hr/> <span class="publ-label">Evidence:</span> </div> 2163 <div class="publ-acf acf-row acf-flex"> 2164 <span class="publ-label">Author: </span> 2165 <div class="szerzok"> 2166 2167 2168 2169 <span class="sz-nev">Prieto C</span> 2170 2171 2172 2173 <span class="sz-nev">Linares I</span> 2174 2175 </div> 2176 2177 </div> 2178 <div class="acf-row"><span class="publ-label">No. of patients:</span> <hr/> <span class="publ-label">Therapy:</span> TSL+mEHT<hr/> <span class="publ-label">Year:</span> 2018</div> 2179 </div><!-- .acf-fields --> 2180 <h3>Abstract</h3> 2181<p>The current treatment for brain tumors, such as glioblastoma multiforme (GBM), has not been developed enough yet in order to fully heal them. The main causes are the lack of specificity of the treatments, the difficulty of passage of drugs through the blood-brain barrier, heterogeneity and tumor aggressiveness, and widespread dissemination in the brain. The application of nanoparticles (Nps) have been a breakthrough for both diagnostic imaging and targeted therapies. There have been numerous studies with different types of Nps in brain tumors, but we have focused on thermosensitive liposomes, which are characterized by releasing the chemotherapeutic agent included within its lipophilic membranes through heat. Furthermore, increasing the temperature in brain tumors through hyperthermia has been proven therapeutically beneficial. Nanothermia or modulated-electro-hyperthermia (MEHT) is an improved technique that allows to create hot spots in nanorange at the membrane rafts, specifically in tumor cells, theoretically increasing the selectivity of the damage. In scie
2181ntific records, experiments that combine both techniques (thermosensitive liposomes and nanothermia) have never been conducted. We propose a hypothesis for further research.</p> 2182<h4>KEYWORDS:</h4> 2183<p>GBM; Liposomes; MEHT; Nanoparticles; Termosensitive</p> 2184 2185 <div id="teljes-cikk" class="btn"> 2186 <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=Nanoparticles%20and%20nanothermia%20for%20malignant%20brain%20tumors%2C%20a%20suggestion%20of%20treatment%20for%20further%20investigations%2C%20Reports%20of%20Practical%20Oncology%20and%20Radiotherapy" target="_blank"> View abstract</a> 2187 </div> 2188 2189 </div> <!-- .container --> 2190</div><!-- .entry-content --> 2191 2192 2193 2194</article><!-- #post-3306 --> 2195 2196 2197<article id="post-3307" class="post-3307 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry"> 2198 2199 <header class="pub-entry-header"> 2200 <div class="container"> 2201 <h2>Combined treatment with modulated electro-hyperthermia and an autophagy inhibitor effectively inhibit ovarian and cervical cancer growth</h2> 2202 </div> 2203 </header><!-- .entry-header --> 2204 2205 2206<div class="entry-content kl-pub-content"> 2207 <div class="container"> 2208 <div class="acf-fields"> 2209 <div class="acf-row"><span class="publ-label">Indication:</span> Gynecology <hr/> <span class="publ-label">Evidence:</span> </div> 2210 <div class="publ-acf acf-row acf-flex"> 2211 <span class="publ-label">Author: </span> 2212 <div class="szerzok"> 2213 2214 2215 2216 <span class="sz-nev">Wookyeom Yang</span> 2217 2218 2219 2220 <span class="sz-nev">Gwan Hee Han</span> 2221 2222 2223 2224 <span class="sz-nev">Ha-Yeon Shin</span> 2225 2226 2227 2228 <span class="sz-nev">Eun-Ju Lee</span> 2229 2230 2231 2232 <span class="sz-nev">Hanbyoul Cho</span> 2233 2234 2235 2236 <span class="sz-nev">Doo Byung Chay & Jae-Hoon Kim</span> 2237 2238 </div> 2239 2240 </div> 2241 <div class="acf-row"><span class="publ-label">No. of patients:</span> <hr/> <span class="publ-label">Therapy:</span> Autophagy Inhibitor+mEHT<hr/> <span class="publ-label">Year:</span> 2018</div> 2242 </div><!-- .acf-fields --> 2243 <h3 id="abstract">Abstract</h3> 2244<p>Purpose: Modulated electro-hyperthermia (mEHT), known as oncothermia, is an anticancer therapy that induces radiofrequency thermal damage to the cancer tissues. This study aimed to evaluate the potential effectiveness of mEHT as a therapeutic tool in ovarian and cervical cancer.</p> 2245<p>Materials and methods: We used both tumor-bearing mice and ovarian and cervical OVCAR-3, SK-OV-3, HeLa and SNU-17 cancer cell lines to investigate the effects of mEHT in vivo and in vitro, respectively, and determine whether it was enhanced by cotreatment with an autophagy inhibitor.</p> 2246<p>Results: We discovered that phosphorylation of p38, a stress-dependent kinase, was induced at the Thr180/Tyr182 residue in cancer cells exposed to mEHT. Apoptotic markers such as cleaved caspase-3 and poly-ADP ribose polymerase (PARP) were increased in OVCAR-3 and SNU-17 cells. Fluorescence-activated cell sorting (FACS) analysis showed a
2246significant increase in the population of sub-G1 mEHT-exposed cells, which are dying and apoptotic cells. mEHT also reduced both weight and volume of xenograft tumors in mice transplanted with ovarian and cervical cancer cells and patient-derived cancer tissues. We determined that mEHT-induced cellular damage recovery was mediated by autophagy and, therefore, expectedly, cotreatment with mEHT and 3-methyladenine (3-MA), an autophagy inhibitor, more effectively inhibited cancer cell growth than individual treatment did.</p> 2247<p>Conclusions: mEHT treatment alone was sufficient to inhibit cancer growth, while a combined treatment with mEHT and an autophagy inhibitor amplified this inhibition effect.</p> 2248<p>Keywords: Modulated electro-hyperthermia, ovarian cancer, cervical cancer, autophagy inhibitor, anti-cancer effects</p> 2249 2250 <div id="teljes-cikk" class="btn"> 2251 <a href="https://doi.org/10.1080/02656736.2018.1528390" target="_blank"> View abstract</a> 2252 </div> 2253 2254 </div> <!-- .container --> 2255</div><!-- .entry-content --> 2256 2257 2258 2259</article>
2259<!-- #post-3307 --> 2260 2261 2262<article id="post-3308" class="post-3308 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry"> 2263 2264 <header class="pub-entry-header"> 2265 <div class="container"> 2266 <h2>The effect of modulated electro-hyperthermia on temperature and blood flow in human cervical carcinoma</h2> 2267 </div> 2268 </header><!-- .entry-header --> 2269 2270 2271<div class="entry-content kl-pub-content"> 2272 <div class="container"> 2273 <div class="acf-fields"> 2274 <div class="acf-row"><span class="publ-label">Indication:</span> Temperature <hr/> <span class="publ-label">Evidence:</span> Phase I</div> 2275 <div class="publ-acf acf-row acf-flex"> 2276 <span class="publ-label">Author: </span> 2277 <div class="szerzok"> 2278 2279 2280 2281 <span class="sz-nev">Lee S-Y</span> 2282 2283 2284 2285 <span class="sz-nev">Kim J-H</span> 2286 2287 2288 2289 <span class="sz-nev">Han Y-H</span> 2290 2291 2292 2293 <span class="sz-nev">Cho D-H</span> 2294 2295 </div> 2296 2297 </div> 2298 <div class="acf-row"><span class="publ-label">No. of patients:</span> 20 <hr/> <span class="publ-label">Therapy:</span> mEHT<hr/> <span class="publ-label">Year:</span> 2018</div> 2299 </div><!-- .acf-fields --> 2300 <div> 2301<h2 id="abstract">Abstract</h2> 2302</div> 2303<div> 2304<p>Introduction: Mild hyperthermia has been known to enhance the response of tumours to radiotherapy or chemotherapy by increasing tumour blood flow, thereby increasing tumour oxygenation or drug delivery. The purpose of this study was to assess the changes in temperature and blood flow in human cervical cancer in response to regional heating with modulated electro-hyperthermia (mEHT).</p> 2305<p>Methods: The pelvic area of 20 patients with cervical carcinoma was heated with mEHT. The peri-tumour temperature was measured using an internal organ temperature probe. The tumour blood flow was measured using 3D colour Doppler ultrasound by determining the peak systolic velocity/end-diastolic velocity ratio (S/D ratio) and the resistance index (RI) within blood vessels.</p> 2306<p>Results: The mean peri-tumour temperature was 36.7 ± 0.2 °C before heating and increased to 38.5 ± 0.8 °C at the end of heating for 60 min. The marked declines in RI and S/D values strongly demonstrated that heating significantly increased tumour blood perfusion.</p> 2307<p>Conclusions: Regional heating of the pelvic area with mEHT significantly increased the peri-tumour temperature and improved the blood flow in cervical cancer. This is the first demonstration that the blood flow in cervical cancer is increased by regional hyperthermia. Such increases in temperature and blood flow may account for the clinical observations that hyperthermia improves the response of cervical cancer to radiotherapy or chemotherapy.</p> 2308</div> 2309 2310 <div id="teljes-cikk" class="btn"> 2311 <a href="https://www.tandfonline.com/doi/full/10.1080/02656736.2018.1423709" target="_blank"> View abstract</a> 2312 </div> 2313 2314 </div> <!-- .container --> 2315</div><!-- .entry-content --> 2316 2317 2318 2319</article>
2319<!-- #post-3308 --> 2320 2321 2322<article id="post-3309" class="post-3309 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry"> 2323 2324 <header class="pub-entry-header"> 2325 <div class="container"> 2326 <h2>The Induction of Immunogenic Cell Death (ICD) During Maintenance Chemotherapy and Subsequent Multimodal Immunotherapy for Glioblastoma (GBM)</h2> 2327 </div> 2328 </header><!-- .entry-header --> 2329 2330 2331<div class="entry-content kl-pub-content"> 2332 <div class="container"> 2333 <div class="acf-fields"> 2334 <div class="acf-row"><span class="publ-label">Indication:</span> Gliomas (advanced) <hr/> <span class="publ-label">Evidence:</span> Retrospective study</div> 2335 <div class="publ-acf acf-row acf-flex"> 2336 <span class="publ-label">Author: </span> 2337 <div class="szerzok"> 2338 2339 2340 2341 <span class="sz-nev">Van Gool SW</span> 2342 2343 2344 2345 <span class="sz-nev">Makalowski J</span> 2346 2347 2348 2349 <span class="sz-nev">Feyen O</span> 2350 2351 2352 2353 <span class="sz-nev">Prix L</span> 2354 2355 2356 2357 <span class="sz-nev">Schirrmacher V</span> 2358 2359 2360 2361 <span class="sz-nev">Stuecker W1</span> 2362 2363 </div> 2364 2365 </div> 2366 <div class="acf-row"><span class="publ-label">No. of patients:</span> 115 <hr/> <span class="publ-label">Therapy:</span> IMT+mEHT<hr/> <span class="publ-label">Year:</span> 2018</div> 2367 </div><!-- .acf-fields --> 2368 <p class="text-align-justify"><strong>Abstract</strong></p> 2369<p class="text-align-justify">The prognosis of Glioblastoma multiforme remains poor. Immunotherapy improved survival in a small fraction of patients. We studied the efficiency of multimodal immunotherapy as part of first line treatment for patients with GBM. Immunogenic Cell Death (ICD) was induced with Newcastle Disease Virus (NDV) and Modulated Electrohyperthermia (mEHT), and Dendritic Cell (DC) vaccinations loaded with autologous tumor proteins were performed. In a retrospective analysis of 60 adults, we detected 15 adults in whom NDV/mEHT were added at days 8/9/10 during Temozolomide Maintenance (TMZm) cycles, multimodal immunotherapy with NDV/mEHT/DC vaccinations were administered after TMZm, and further 3-day NDV/mEHT maintenance immunotherapy treatments were given thereafter. Median age was 60 years. Median Karnofsky was 90. There was no added toxicity due to immunotherapy. Median progression-free survival was 13 months (m). With a median follow up of 17m (ranging 4-30m), median overall survival was not reached, and estimated overall survival at 30m was 58% (95%CI: +27, -42). The detection of Apo10 protein epitope (Apo10) and Transketolase-like 1 (TKTL1) in monocytes, the mRNA expression level for PDL1 on circulating tumor cells, and the Th1/Th2 balance in CD4+ T cells showed a dynamic interaction between tumor cells and immune reactivity. The data suggest that the additional induction of ICD via NDV/mEHT during TMZm is beneficial in improving overall survival. While TMZm only targets dividing tumor cells, ICD targets dividing and non-dividing tumor cells. DC vaccination induces an antitumoral and anti-viral immune response which is maintained by the 3-day NDV/mEHT maintenance immunotherapy treatments.</p> 2370<p class="text-align-justify"><strong>Keywords</strong>: Newcastle disease virus; Modulated electrohyperthermia;<br /> 2371Glioblastoma; Immunogenic cell death; chemotherapy</p> 2372 2373 <div id="teljes-cikk" class="btn"> 2374 <a href="http://www.iozk.de/aktuelles/iozk_glioblastoma_immunotherapy_austin_oncology_report_2018.pdf" target="_blank"> View abstract</a> 2375 </div> 2376 2377 </div> <!-- .container --> 2378</div><!-- .entry-content --> 2379 2380 2381 2382</article>
2382<!-- #post-3309 --> 2383 2384 2385<article id="post-3310" class="post-3310 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry"> 2386 2387 <header class="pub-entry-header"> 2388 <div class="container"> 2389 <h2>Modulated Electrohyperthermia in Integrative Cancer Treatment for Relapsed Malignant Glioblastoma and Astrocytoma: Retrospective Multicenter Controlled Study</h2> 2390 </div> 2391 </header><!-- .entry-header --> 2392 2393 2394<div class="entry-content kl-pub-content"> 2395 <div class="container"> 2396 <div class="acf-fields"> 2397 <div class="acf-row"><span class="publ-label">Indication:</span> Gliomas (advanced) <hr/> <span class="publ-label">Evidence:</span> Retrospective study</div> 2398 <div class="publ-acf acf-row acf-flex"> 2399 <span class="publ-label">Author: </span> 2400 <div class="szerzok"> 2401 2402 2403 2404 <span class="sz-nev">Fiorentini G</span> 2405 2406 2407 2408 <span class="sz-nev">Sarti D</span> 2409 2410 2411 2412 <span class="sz-nev">Milandri C</span> 2413 2414 2415 2416 <span class="sz-nev">Dentico P</span> 2417 2418 2419 2420 <span class="sz-nev">Mambrini A</span> 2421 2422 2423 2424 <span class="sz-nev">Fiorentini C</span> 2425 2426 2427 2428 <span class="sz-nev">Mattioli G</span> 2429 2430 2431 2432 <span class="sz-nev">Casadei</span> 2433 2434 2435 2436 <span class="sz-nev">Guadagni S</span> 2437 2438 </div> 2439 2440 </div> 2441 <div class="acf-row"><span class="publ-label">No. of patients:</span> 149 <hr/> <span class="publ-label">Therapy:</span> mEHT<hr/> <span class="publ-label">Year:</span> 2018</div> 2442 </div><!-- .acf-fields --> 2443 <h3>Abstract</h3> 2444<h6>BACKGROUND:</h6> 2445<p>There are interesting studies on glioma therapy with modulated electrohyperthermia (mEHT), which combines heat therapy with an electric field. Clinical researchers not only found the mEHT method feasible for palliation but also reported evidence of therapeutic response.</p> 2446<h6>PURPOSE:</h6> 2447<p>To study the efficacy and safety of mEHT for the treatment of relapsed malignant glioma and astrocytoma versus best supportive care (BSC).</p> 2448<h6>METHODS:</h6> 2449<p>We collected data retrospectively on 149 patients affected by malignant glioma and astrocytoma. Inclusion criteria were informed consent signed; >18 years old; histological diagnosis of malignant glioma or astrocytoma; relapsed after surgery, adjuvant temozolomide-based chemotherapy, and radiotherapy; and indication for treatment with mEHT in palliative setting. mEHT was performed with capacitive coupling technique keeping the skin surface at 26°C and the tumor temperature at 40°C to 42.5°C for > 90% of treatment duration (20-60 minutes). The applied power was 40 to 150 W using a step-up heating protocol. Results from patients treated with mEHT were compared with those treated with BSC.</p> 2450<h6>RESULTS:</h6> 2451<p>A total of 149 consecutive patients were enrolled in the study, 111 (74%) had glioblastoma multiforme (GBM), and 38 (26%) had astrocytoma (AST). mEHT was performed for 28 (25%) of GBM and 24 (63%) of AST patients. Tumor response at the 3-month follow-up was observed in 29% and 48% of GBM and AST patients after mEHT, and in 4% and 10% of GBM and AST patients after BSC, respectively. The survival rate at first and second year in the mEHT group was 77.3% and 40.9% for AST, and 61% and 29% for GBM, respectively. The 5-year overall survival of AST was 83% after mEHT versus 25% after BSC and 3.5% after mEHT versus 1.2% after BSC for GBM. The median overall survival of mEHT was 14 months (range 2-108 months) for GBM and 16.5 months (range 3-156 months) for the AST group. We observed 4 long-term survivors in the AST and 2 in the GBM group. Two of the long survivors in AST and 1 in GBM group were treated by mEHT.</p> 2452<h6>CONCLUSIONS:</h6> 2453<p>mEHT in integrative therapy may have a promising role in the treatment and palliation of relapsed GBM and AST.</p> 2454<h6>KEYWORDS:</h6> 2455<p>astrocytoma; modulated electrohyperthermia; relapsed malignant glioma; survival; tumor response</p> 2456 2457 <div id="teljes-cikk" class="btn"> 2458 <a href="https://www.ncbi.nlm.nih.gov/pubmed/30580645" target="_blank"> View abstract</a> 2459 </div> 2460 2461 </div> <!-- .container --> 2462</div><!-- .entry-content --> 2463 2464 2465 2466</article><!-- #post-3310 --> 2467 2468 2469<article id="post-3311" class="post-3311 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry"> 2470 2471 <header class="pub-entry-header"> 2472 <div class="container"> 2473 <h2>Comparing the Effectiveness of Pain Therapy (PT) and Modulated Electro-Hyperthermia (mEHT) Versus Pain Therapy Alone in Treating Patients W
2473ith Painful Bony Metastases: an observational trial</h2> 2474 </div> 2475 </header><!-- .entry-header --> 2476 2477 2478<div class="entry-content kl-pub-content"> 2479 <div class="container"> 2480 <div class="acf-fields"> 2481 <div class="acf-row"><span class="publ-label">Indication:</span> Non-oncology <hr/> <span class="publ-label">Evidence:</span> </div> 2482 <div class="publ-acf acf-row acf-flex"> 2483 <span class="publ-label">Author: </span> 2484 <div class="szerzok"> 2485 2486 2487 2488 <span class="sz-nev">Virginia Casade</span> 2489 2490 2491 2492 <span class="sz-nev">Donatella Sarti</span> 2493 2494 2495 2496 <span class="sz-nev">Carlo Milandri</span> 2497 2498 2499 2500 <span class="sz-nev">Patrizia Dentico</span> 2501 2502 2503 2504 <span class="sz-nev">Stefano Guadagni</span> 2505 2506 2507 2508 <span class="sz-nev">Giammaria Fiorentini</span> 2509 2510 </div> 2511 2512 </div> 2513 <div class="acf-row"><span class="publ-label">No. of patients:</span> 19 <hr/> <span class="publ-label">Therapy:</span> PT + mEHT<hr/> <span class="publ-label">Year:</span> 2018</div> 2514 </div><!-- .acf-fields --> 2515 <p><strong>Overview</strong></p> 2516<p>The aim of the trial is to compare the response, duration of pain relief and time to achieve pain relief after pain therapy (PT) with or without hyperthermia (mEHT) in patients with painful bony metastases. Cancer patients with bony metastases and a VAS score of â¥5 on a 0â 10 scale were treated with fentanyl patches (100 μg every three days) and zoledronic acid (4mg every 28 days) combined with mEHT (PT + mEHT) versus PT alone. Hyperthermia was performed using the Oncotherm EHY2000 plus device with the maintenance of the target temperature for 60 minutes twice a week for 2 weeks. The primary endpoint was VAS = 0â2 after treatment and an ECOG performance status reduction of at least one point from baseline evaluation.  The study included 19 patients: 10 in the PT + mEHT group and 9 patients in the PT-alone group. The average age of the patients was 57 years (range 40â86). The median VAS for the PT + mEHT group was 8 at baseline and had decreased to 3, 1 and 2 at 1, 3 and 6 months after the start of mEHT respectively. The median VAS for the PT-alone group was 8 at baseline and was unchanged at the subsequent time points. The median ECOG of the PT + mEHT group was 2 at baseline and had decreased to 1, 1 and 0 at 1, 3 and 6 months after the start of mEHT respectively. The median ECOG for the PT-alone group was 2 at baseline and was unchanged at the subsequent time points. The addition of mEHT to PT significantly increases the pain control rate and ECOG compared to RT alone for painful bony metastases.</p> 2517 2518 2519 </div> <!-- .container --> 2520</div><!-- .entry-content --> 2521 2522 2523 2524</article><!-- #post-3311 --> 2525 2526 2527<article id="post-3312" class="post-3312 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry"> 2528 2529 <header class="pub-entry-header"> 2530 <div class="container"> 2531 <h2>PD-1, PD-L1 and CTLA-4 in pregnancy-related – and in early-onset breast cancer: A comparative study</h2> 2532 </div> 2533 </header><!-- .entry-header --> 2534 2535 2536<div class="entry-content kl-pub-content"> 2537 <div class="container"> 2538 <div class="acf-fields"> 2539 <div class="acf-row"><span class="publ-label">Indication:</span> <hr/> <span class="publ-label">Evidence:</span> Comparative study</div> 2540 <div class="publ-acf acf-row acf-flex"> 2541 <span class="publ-label">Author: </span> 2542 <div class="szerzok"> 2543 2544 2545 2546 <span class="sz-nev">Ãcs B</span> 2547 2548 2549 2550 <span class="sz-nev">Madaras L</span> 2551 2552 2553 2554 <span class="sz-nev">TÅkés AM</span> 2555 2556 2557 2558 <span class="sz-nev">Kovács AK</span> 2559 2560 2561 2562 <span class="sz-nev">Kovács E</span> 2563 2564 </div> 2565 2566 </div> 2567 <div class="acf-row"><span class="publ-label">No. of patients:</span> 42 <hr/> <span class="publ-label">Therapy:</span> mEHT<hr/> <span class="publ-label">Year:</span> 2017</div> 2568 </div><!-- .acf-fields --> 2569 <h3>Abstract</h3> 2570<div> 2571<h4>PURPOSE:</h4> 2572<p>We aimed to compare the immunohistochemical expression of PD-1, PD-L1 and CTLA-4 of pregnancy-related breast cancer (PRBC) and early onset non-PRBC (YWBC), and their prognosis prediction potential was correlated to that of conventional clinicopathological factors.</p> 2573<h4>METHODS:</h4> 2574<p>Twenty-one PRBC cases were paired with 21 YWBC in this matched case-control study. Immune-checkpoint markers (ICM) were evaluated with immunohistochemistry (IHC) on whole slides using the following antibodies: PD-1 (NAT-105), PD-L1 (28-8) and CTLA-4 (F-8). IHC score was defined as the percentage of positive cells, assessed separately among tumor cells, intratumoral lymphocytes and peritumoral lymphocytes.</p> 2575<h4>RESULTS:</h4> 2576<p>The optimal threshold of PD-L1 expression of tumor cells occurred at 10% for overall survival (OS, AUC = 0.847, p = 0.009), and at 1% for disease-free survival (DFS, AUC = 0.795, p = 0.010). For PD-L1 expression on intratumoral lymphocytes, the optimal cut-off was 1% (AUC = 0.763, p = 0.048). Considering PD-1, PD-L1 and CTLA-4 expression, no significant difference occurred between PRBC and YWBC (p >
2576 0.05 for all comparisons). PD-1, PD-L1 expressed on peritumoral lymphocytes and CTLA-4 failed, but PD-L1 expressed on tumor cells and on intratumoral lymphocytes was suitable to distinguish patient cohorts with different OS and DFS (p â¤Â 0.011 for all comparisons). Higher PD-L1 expression was associated with poor prognosis. PD-L1 expressed on tumor cells represented an independent association with OS (p = 0.023) and DFS (p = 0.032).</p> 2577<h4>CONCLUSIONS:</h4> 2578<p>Our results suggest that PRBC and YWBC do not differ in the expression of PD-1, PD-L1 and CTLA-4. However, our findings emphasize the relevance of PD-L1 expression in early-onset breast cancer, as an independent negative predictor of prognosis.</p> 2579</div> 2580 2581 <div id="teljes-cikk" class="btn"> 2582 <a href="https://www.ncbi.nlm.nih.gov/pubmed/28651116" target="_blank"> View abstract</a> 2583 </div> 2584 2585 </div> <!-- .container --> 2586</div><!-- .entry-content --> 2587 2588 2589 2590</article><!-- #post-3312 --> 2591 2592 2593<article id="post-3313" class="post-3313 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry"> 2594 2595 <header class="pub-entry-header"> 2596 <div class="container"> 2597 <h2>Oncothermia-Booster (Targeted Radiofrequency) Treatment â in Some Non-Oncological Diseases as Special Physiotherapy</h2> 2598 </div> 2599 </header><!-- .entry-header --> 2600 2601 2602<div class="entry-content kl-pub-content"> 2603 <div class="container"> 2604 <div class="acf-fields"> 2605 <div class="acf-row"><span class="publ-label">Indication:</span> Non-oncology <hr/> <span class="publ-label">Evidence:</span> Review</div> 2606 <div class="publ-acf acf-row acf-flex"> 2607 <span class="publ-label">Author: </span> 2608 <div class="szerzok"> 2609 2610 2611 2612 <span class="sz-nev">Mate M</span> 2613 2614 2615 2616 <span class="sz-nev">Molnar I</span> 2617 2618 2619 2620 <span class="sz-nev">Petrovits G et al.</span> 2621 2622 </div> 2623 2624 </div> 2625 <div class="acf-row"><span class="publ-label">No. of patients:</span> 155 <hr/> <span class="publ-label">Therapy:</span> mEHT+TCM<hr/> <span class="publ-label">Year:</span> 2017</div> 2626 </div><!-- .acf-fields --> 2627 <p style="font-weight: 500;"><strong style="font-weight: 800;">Abstract<br /> 2628</strong>Introduction: Oncothermia (OTM) is based on electromagnetic interactions with the living organism. Its nano-targeting approach [established a newer paradigm, which could be applied not only in case of malignancies but in any other diseases, when the non-selective conditions are existing. This technique by now is well proven from the simple laboratory level to the several different clinical applications. Oncothermia method ignites the natural processes to rescue them from the system, re-establishing the better communication harmony between the cells of organism. This method will lead us to the treatment of some non-malignant diseases too to try delaying their development or offering earlier recovery. Our aim was to use OTM on the common basis of equilibrium demand; and use the recognition of the deviations from the complex harmony of the organism or its part for selection to act properly.</p> 2629<p style="font-weight: 500;"><strong style="font-weight: 800;">Study</strong><strong style="font-weight: 800;"> protocol and Method</strong>:<br /> 2630Oncothermia was successfully applied for non malignant conditions like Lyme disease, for non-specific low-back pain, for Peyronie disease, and for Dupuytrenâs contracture, too. We made more extended study, proving in details the applicability of the OTM in these diseases, especially in the situations when traditional Chinese Medicine (TCM) is also applicable (acupuncture, permanent needle techniques). Our special permanent acupuncture method was proven previously and well fits to the complementary applications.Results & Discussion: The synergy of the ancient knowledge – application of heat energy – and the high-tech state-of-art of the medical knowledge could be established with our research. Recognition of the distortions in the healthy tissue have some common principles and possibilities in TCM and OTM: the left complexity of the living organization is recognized by both the methods.OTM application is a useful, harmless additional complementary treatment for management of selected diseases. Our topic is giving western trained physicians clinical applications of modern (Oncothermia-Booster) as a physiotherapeutic – equipment to accommodate accelerating interests in modern complex treatment of chronic low back pain and Dupuytrenâs contracture.</p> 2631<p style="font-weight: 500;"><strong style="font-weight: 800;">Conclusion</strong>:<br /> 2632In recent study data verified the relevant end-points of the study: the safety, the quality of life (QoL), the shortened rest time, duration of painless state, cost/benefit ratio.</p> 2633<p><strong style="font-weight: 800;">Keywords:</strong> Physiotherapy; Oncothermia; Dupuytranâs contracture; Non-specific low back pain</p> 2634<p><strong style="font-weight: 800;">Abbreviations:</strong> OTH: Oncothermy; LBP: Low Back Pain; TCM: Traditional Chinese Medicine; VAS: Visual Analog Scale; QoL: Quality of Life</p> 2635 2636 <div id="teljes-cikk" class="btn"> 2637 <a href="https://juniperpublishers.com/jcmah/pdf/JCMAH.MS.ID.555572.pdf" target="_blank">
2637 View abstract</a> 2638 </div> 2639 2640 </div> <!-- .container --> 2641</div><!-- .entry-content --> 2642 2643 2644 2645</article><!-- #post-3313 --> 2646 2647 2648<article id="post-3314" class="post-3314 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry"> 2649 2650 <header class="pub-entry-header"> 2651 <div class="container"> 2652 <h2>Local modulated electro-hyperthermia in combination with traditional Chinese medicine vs. intraperitoneal chemoinfusion for treatment of peritoneal carcinomatosis with malignant ascites: a phase II randomized trial</h2> 2653 </div> 2654 </header><!-- .entry-header --> 2655 2656 2657<div class="entry-content kl-pub-content"> 2658 <div class="container"> 2659 <div class="acf-fields"> 2660 <div class="acf-row"><span class="publ-label">Indication:</span> <hr/> <span class="publ-label">Evidence:</span> Phase II</div> 2661 <div class="publ-acf acf-row acf-flex"> 2662 <span class="publ-label">Author: </span> 2663 <div class="szerzok"> 2664 2665 2666 2667 <span class="sz-nev">Pang CLK</span> 2668 2669 2670 2671 <span class="sz-nev">Xinting Z</span> 2672 2673 2674 2675 <span class="sz-nev">Zhen W</span> 2676 2677 2678 2679 <span class="sz-nev">Junwen O</span> 2680 2681 2682 2683 <span class="sz-nev">Yimin L</span> 2684 2685 2686 2687 <span class="sz-nev">Roussakow R</span> 2688 2689 </div> 2690 2691 </div> 2692 <div class="acf-row"><span class="publ-label">No. of patients:</span> 260 <hr/> <span class="publ-label">Therapy:</span> mEHT<hr/> <span class="publ-label">Year:</span> 2017</div> 2693 </div><!-- .acf-fields --> 2694 <h3>Abstract</h3> 2695<div> 2696<p>The purpose of this study was to develop a safe and non-toxic alternative to the conventional conservative treatment of peritoneal carcinomatosis with malignant ascites (PCMA) by investigating the efficacy and safety of local modulated electro-hyperthermia (mEHT) combined with the traditional Chinese medicine (TCM) ‘Shi Pi’ herbal decoction, compared with standard intraperitoneal chemoinfusion (IPCI). A randomized, controlled, single-center, open-label clinical trial (phase II) with two parallel groups (allocation ratio, 1:1) was conducted to investigate the efficacy and safety of mEHT+TCM (study group, SG) vs. standard IPCI (control group, CG) in patients with PCMA by intention-to-treat analysis. A total of 260 patients with PCMA were randomly allocated into the two groups (130/130); mEHT was applied for 60 min per session every second day for 4 weeks, for a total of 14 sessions. The TCM decoction was administered orally, at 400 ml daily. In CG, occlusive IPCI with cisplatin (30-60 mg) and fluorouracil (500-600 mg/m2) was applied twice, biweekly. The objective response rate (ORR), quality of life (QoL) and adverse event rate (AER) in the two groups were evaluated 1 month after treatment, analyzed and compared. The present study is registered on ClinicalTrials.gov (<a title="See in ClinicalTrials.gov" href="http://clinicaltrials.gov/show/NCT02638051" target="_blank" rel="noopener">NCT02638051</a>). No case was lost or excluded (0/260). The ORR in SG was 77.69% (101/130) vs. 63.85% (73/130) in CG (P<0.05). The QoL in SG was 49.23% vs. 32.3% in CG (P<0.05). The AER in SG was 2.3% (3/130) vs. 12.3% (16/130) in CG (P<0.05). All the adverse events were grade I. In conclusion, the combination of mEHT with TCM achieves better control of PCMA compared with standard IPCI, with less toxicity. Both components of the combination are non-toxic treatments easily tolerated by patients. Thus, this combined treatment may be preferred due to the better benefit-harm balance.</p> 2697</div> 2698 2699 <div id="teljes-cikk" class="btn"> 2700 <a href="https://www.ncbi.nlm.nih.gov/pubmed/28529748" target="_blank"> View abstract</a> 2701 </div> 2702 2703 </div> <!-- .container --> 2704</div><!-- .entry-content --> 2705 2706 2707 2708</article><!-- #post-3314 --> 2709 2710 2711<article id="post-3315" class="post-3315 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry"> 2712 2713 <header class="pub-entry-header"> 2714 <div class="container"> 2715 <h2>Retrospective observational Clinical Study on Relapsed Malignant Gliomas Treated with Electro-Hyperthermia</h2> 2716 </div> 2717 </header><!-- .entry-header --> 2718 2719 2720<div class="entry-content kl-pub-content"> 2721 <div class="container"> 2722 <div class="acf-fields"> 2723 <div class="acf-row"><span class="publ-label">Indication:</span> Gliomas <hr/> <span class="publ-label">Evidence:</span> </div> 2724 <div class="publ-acf acf-row acf-flex"> 2725 <span class="publ-label">Author: </span> 2726 <div class="szerzok"> 2727 2728 2729 2730 <span class="sz-nev">Giammaria Fiorentini</span> 2731 2732 2733 2734 <span class="sz-nev">Donatella Sarti</span> 2735 2736 2737 2738 <span class="sz-nev">Carlo Milandr</span> 2739 2740 2741 2742 <span class="sz-nev">Patrizia Dentico</span> 2743 2744 2745 2746 <span class="sz-nev">Andrea Mambrini</span> 2747 2748 2749 2750 <span class="sz-nev">Stefano Guadagni</span> 2751 2752 </div> 2753 2754 </div> 2755 <div class="acf-row"><span class="publ-label">No. of patients:</span> 24 <hr/> <span class="publ-label">Therapy:</span> mEHT<hr/> <span class="publ-label">Year:</span> 2017</div> 2756 </div><!-- .acf-fields --> 2757 <p><strong>ABSTRACT</strong></p> 2758<p>Aim: to evaluate the effi cacy and tolerability of electro-hyperthermia (ET) for the treatment of relapsed malignant glioma. Methods: this was a retrospective observational clinical study. Patients were included in the study if they had >18 years, informed consent signed, histological diagnosis of malignant glioma, failure of previous temozolamide-based chemotherapy and radiotherapy, indication for treatment with ET. Hyperthermia was performed with short radiofrequency waves of 13.56 MHz using a capacitive coupling technique keeping the skin surface at 26 C°. The applied power ranged between 40-150 Watts and the calculated average equivalent temperature in the tumors was above 40 C° for more than 90% of the treatment duration (20-60 minutes gradually). Results: 24 consecutive patients were enrolled in the study, 19 (79%) had glioblastoma multiforme (GBM) 13 were of grade 1-3 and 6 of grade 4, 5 (21%) astrocitoma. Tumor response analysis two months after ET showed 2 (8%) complete remission (astrocytomas) and 5 (21%) partial remission (2 astrocitoma, and 3 glioblastomas), with a response rate of 29%. The median duration of response was 16 months (range 6-120). The median survival of whole study population was 19.5 months (range 2-156), 55% survival rate at 1 year, and 15 % at two years. We observed 3 long survivors at 156, 60, 62 months in atrocitomas. Conclusions: ET appears to have promising effi cacy in adults with relapsed malignant glioma. Keywords: Relapsed Malignant Glioma; Electro-Hyperthermia; Survival; Tumor Response</p> 2759 2760 <div id="teljes-cikk" class="btn"> 2761 <a href="https://www.scireslit.com/Neurooncology/IJNBT-ID12.pdf" target="_blank">
2761 View abstract</a> 2762 </div> 2763 2764 </div> <!-- .container --> 2765</div><!-- .entry-content --> 2766 2767 2768 2769</article><!-- #post-3315 --> 2770 2771 2772<article id="post-3316" class="post-3316 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry"> 2773 2774 <header class="pub-entry-header"> 2775 <div class="container"> 2776 <h2>Clinical and economic evaluation of modulated electrohyperthermia concurrent to dose-dense temozolomide 21/28 days regimen in the treatment of recurrent glioblastoma: a retrospective analysis of a 2-centre German cohort trial with systematic comparison</h2> 2777 </div> 2778 </header><!-- .entry-header --> 2779 2780 2781<div class="entry-content kl-pub-content"> 2782 <div class="container"> 2783 <div class="acf-fields"> 2784 <div class="acf-row"><span class="publ-label">Indication:</span> Gliomas (advanced) <hr/> <span class="publ-label">Evidence:</span> Retrospective study</div> 2785 <div class="publ-acf acf-row acf-flex"> 2786 <span class="publ-label">Author: </span> 2787 <div class="szerzok"> 2788 2789 2790 2791 <span class="sz-nev">Roussakow S.</span> 2792 2793 </div> 2794 2795 </div> 2796 <div class="acf-row"><span class="publ-label">No. of patients:</span> 168 <hr/> <span class="publ-label">Therapy:</span> CT+mEHT<hr/> <span class="publ-label">Year:</span> 2017</div> 2797 </div><!-- .acf-fields --> 2798 <p>Abstract</p> 2799<div> 2800<p>OBJECTIVE: To assess the efficacy and cost-effectiveness of modulated electrohyperthermia (mEHT) concurrent to dose-dense temozolomide (ddTMZ) 21/28 days regimen versus ddTMZ 21/28 days alone in patients with recurrent glioblastoma (GBM).</p> 2801<p>DESIGN: A cohort of 54 patients with recurrent GBM treated with ddTMZ+mEHT in 2000-2005 was systematically retrospectively compared with five pooled ddTMZ 21/28 days cohorts (114 patients) enrolled in 2008-2013.</p> 2802<p>RESULTS: The ddTMZ+mEHT cohort had a not significantly improved mean survival time (mST) versus the comparator (p=0.531) after a significantly less mean number of cycles (1.56 vs 3.98, p<0.001). Effect-to-treatment analysis (ETA) suggests that mEHT significantly enhances the efficacy of the ddTMZ 21/28 days regimen (p=0.011), with significantly less toxicity (no grade III-IV toxicity vs 45%-92%, p<0.0001). An estimated maximal attainable median survival time is 10.10 months (9.10-11.10). Cost-effectiveness analysis suggests that, unlike ddTMZ 21/28 days alone, ddTMZ+mEHT is cost-effective versus the applicable cost-effectiveness thresholds â¬US$25 000-50 000/quality-adjusted life year (QALY). Budget impact analysis suggests a significant saving of â¬8 577 947/$11 201 761 with 29.1-38.5 QALY gained per 1000 patients per year. Cost-benefit analysis suggests that mEHT is profitable and will generate revenues between â¬3 124 574 and $6 458 400, with a total economic effect (saving+revenues) of â¬5 700 034 to $8 237 432 per mEHT device over an 8-year period.</p> 2803<p>CONCLUSIONS: Our ETA suggests that mEHT significantly improves survival of patients receiving the ddTMZ 21/28 days regimen. Economic evaluation suggests that ddTMZ+mEHT is cost-effective, budget-saving and profitable. After confirmation of the results, mEHT could be recommended for the treatment of recurrent GBM as a cost-effective enhancer of ddTMZ regimens, and, probably, of the regular 5/28 days regimen. mEHT is applicable also as a single treatment if chemotherapy is impossible, and as a salvage treatment after the failure of chemotherapy.</p> 2804</div> 2805 2806 <div id="teljes-cikk" class="btn"> 2807 <a href="https://www.ncbi.nlm.nih.gov/m/pubmed/29102988/" target="_blank"> View abstract</a> 2808 </div> 2809 2810 </div> <!-- .container --> 2811</div><!-- .entry-content --> 2812 2813 2814 2815</article><!-- #post-3316 --> 2816 2817 2818<article id="post-3317" class="post-3317 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry"> 2819 2820 <header class="pub-entry-header"> 2821 <div class="container"> 2822 <h2>Rescue Therapy in Patient with Glioblastoma Multiforme Combining Chemotherapy, Hyperthermia, Phytotherapy</h2> 2823 </div> 2824 </header><!-- .entry-header --> 2825 2826 2827<div class="entry-content kl-pub-content"> 2828 <div class="container"> 2829 <div class="acf-fields"> 2830 <div class="acf-row"><span class="publ-label">Indication:</span> Glioblastoma <hr/> <span class="publ-label">Evidence:</span> Case report</div> 2831 <div class="publ-acf acf-row acf-flex"> 2832 <span class="publ-label">Author: </span> 2833 <div class="szerzok"> 2834 2835 2836 2837 <span class="sz-nev">Carlo Pastore</span> 2838 2839 2840 2841 <span class="sz-nev">Massimo Fioranelli</span> 2842 2843 2844 2845 <span class="sz-nev">Maria Grazia Roccia</span> 2846 2847 </div> 2848 2849 </div> 2850 <div class="acf-row"><span class="publ-label">No. of patients:</span> <hr/> <span class="publ-label">Therapy:</span> Chemotherapy, Hyperthermia, Phytotherapy<hr/> <span class="publ-label">Year:</span> 2017</div> 2851 </div><!-- .acf-fields --> 2852 <p><strong>Abstract</strong><br /> 2853Glioblastoma multiforme is a pathology that is poorly treatable and tends towards recurrence. If surg
2853ically unresectable, at least without macroscopically visible residue, the prognosis is severe. Here is the case of a 60-yearold woman suffering from recurrent glioblastoma who comes to my observation with no therapeutic options and treated with a combination of antiangiogenic drug, RF capacitive hyperthermia and herbal medicine, earns an acceptable quality of life and survival prolongation of six months.</p> 2854 2855 <div id="teljes-cikk" class="btn"> 2856 <a href="https://www.hilarispublisher.com/open-access/rescue-therapy-in-patient-with-glioblastoma-multiforme-combining-chemotherapy-hyperthermia-phytotherapy-2329-6771-1000199.pdf" target="_blank"> View abstract</a> 2857 </div> 2858 2859 </div> <!-- .container --> 2860</div><!-- .entry-content --> 2861 2862 2863 2864</article><!-- #post-3317 --> 2865 2866 2867<article id="post-3318" class="post-3318 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry"> 2868 2869 <header class="pub-entry-header"> 2870 <div class="container"> 2871 <h2>Newer application of oncothermia to non-malignant diseases such as Dupuytrenâs contracture of the hand and chronic lower back pain lasting more than 4 weeks</h2> 2872 </div> 2873 </header><!-- .entry-header --> 2874 2875 2876<div class="entry-content kl-pub-content"> 2877 <div class="container"> 2878 <div class="acf-fields"> 2879 <div class="acf-row"><span class="publ-label">Indication:</span> Non-oncology <hr/> <span class="publ-label">Evidence:</span> </div> 2880 <div class="publ-acf acf-row acf-flex"> 2881 <span class="publ-label">Author: </span> 2882 <div class="szerzok"> 2883 2884 2885 2886 <span class="sz-nev">Mate A</span> 2887 2888 2889 2890 <span class="sz-nev">Molnar I</span> 2891 2892 2893 2894 <span class="sz-nev">Szoke H</span> 2895 2896 2897 2898 <span class="sz-nev">Hegyi G.</span> 2899 2900 </div> 2901 2902 </div> 2903 <div class="acf-row"><span class="publ-label">No. of patients:</span> 231 <hr/> <span class="publ-label">Therapy:</span> mEHT<hr/> <span class="publ-label">Year:</span> 2017</div> 2904 </div><!-- .acf-fields --> 2905 <h4><strong>ABSTRACT</strong></h4> 2906<p class="text-align-justify">Oncothermia (OTM) is based on electromagnetic interactions with the living matter. Its nano-targeting approach establishes a new paradigm. OTM could be applied not only to treat malignancies but it is feasible to apply for other diseases too. OTH is well proven method from the laboratory level to the clinical applications, promoting the natural processes, re-establishing of the synchronization between the cells. This approach allows therapy of some non-malignant diseases too. Our objective is to use OTM for the irregularities of tissue-growth and for pain syndromes as well. OTM uses precisely tuned radiofrequency (RF) current flowing through the treated part of the body. We made extensive study, proving in details the applicability of the OTM for Dupuytren’s contracture and chronic low back pain, in conjunction with permanent acupuncture method, a modified process of traditional Chinese Medicine (TCM). The synergy of the ancient and the state-of-art medical knowledges is the basic method of the present research. Our results with application of OTM for chronic low back pain and Dupuytren’s contracture shows definite improvements of the patients involved in the study. We measured the success with the Visual Analog Scale (VAS), with anecdotic quality of life (QoL), and the shortening of the of-work period due to the disease. We measured that VAS decreased significantly, the hand contracture became less rigid and less contracted. The QoL of patients improved and their complaints which blocked their regular activity has significantly reduced. OTM method was safe & no adverse effects were observed. Recognition of the distortions in the healthy tissue have some common principles and possibilities in TCM and OTM: both the methods recognize the loss of complexity of the living organization. Data of our recent study verified the relevant end-points of our present study: the safety, the quality of life (QoL), the prolonged painless status of the patient.</p> 2907 2908 <div id="teljes-cikk" class="btn">
2909 <a href="http://www.ingentaconnect.com/content/cog/aetr/2017/00000042/00000002/art00004;jsessionid=1cht8pxx2j3bo.x-ic-live-02" target="_blank"> View abstract</a> 2910 </div> 2911 2912 </div> <!-- .container --> 2913</div><!-- .entry-content --> 2914 2915 2916 2917</article><!-- #post-3318 --> 2918 2919 2920<article id="post-3319" class="post-3319 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry"> 2921 2922 <header class="pub-entry-header"> 2923 <div class="container"> 2924 <h2>Bevacizumab-Based Chemotherapy Combined with Regional Deep Capacitive Hyperthermia in Metastatic Cancer Patients: A Pilot Study</h2> 2925 </div> 2926 </header><!-- .entry-header --> 2927 2928 2929<div class="entry-content kl-pub-content"> 2930 <div class="container"> 2931 <div class="acf-fields"> 2932 <div class="acf-row"><span class="publ-label">Indication:</span> Multiple <hr/> <span class="publ-label">Evidence:</span> </div> 2933 <div class="publ-acf acf-row acf-flex"> 2934 <span class="publ-label">Author: </span> 2935 <div class="szerzok"> 2936 2937 2938 2939 <span class="sz-nev">Ranieri G</span> 2940 2941 2942 2943 <span class="sz-nev">Ferrari C</span> 2944 2945 2946 2947 <span class="sz-nev">Di Palo A</span> 2948 2949 </div> 2950 2951 </div> 2952 <div class="acf-row"><span class="publ-label">No. of patients:</span> 23 <hr/> <span class="publ-label">Therapy:</span> CT+mEHT<hr/> <span class="publ-label">Year:</span> 2017</div> 2953 </div><!-- .acf-fields --> 2954 <h3>Abstract</h3> 2955<div> 2956<p>As an angiogenesis inhibitor, bevacizumab has been investigated in combination with different chemotherapeutic agents, achieving an established role for metastatic <span class="highlight">cancer</span> treatment. However, potential synergic anti-angiogenic effects of hyperthermia have not tested to date in literature. The aim of our study was to analyze efficacy, safety, and survival of anti-angiogenic-based chemotherapy associated to regional deep capacitive hyperthermia (HT) in metastatic <span class="highlight">cancer</span> patients. Twenty-three patients with metastatic colorectal (<i>n</i> = 16), ovarian (<i>n</i> = 5), and breast (<i>n</i> = 2) <span class="highlight">cancer</span> were treated with HT in addition to a standard bevacizumab-based chemotherapy regimen. Treatment response assessment was performed, according to the modified Response Evaluation Criteria for Solid Tumors (mRECIST), at 80 days (timepoint-1) and at 160 days (timepoint-2) after therapy. Disease Response Rate (DRR), considered as the proportion of patients who had the best response rating (complete response (CR), partial response (PR), or stable disease (SD)), was assessed at timepoint-1 and timepoint-2. Chi-squared for linear trend test was performed to evaluated the association between response groups (R/NR) and the number of previous treatment (none, 1, 2, 3), number of chemotherapy cycles (<6, 6, 12, >12), number of hyperthermia sessions (<12, 12, 24, >24), and lines of chemotherapy (I, II). Survival curves were estimated by Kaplan-Meier method. DRR was 85.7% and 72.2% at timepoint-1 and timepoint-2, respectively. HT was well tolerated without additional adverse effects on chemotherapy-related toxicity. Chi-squared for linear trend test demonstrated that the percentage of responders grew in relation to the number of chemotherapy cycles (<i>p</i> = 0.015) and to number of HT sessions (<i>p</i> < 0.001) performed. Both overall survival (OS) and time to progression (TTP) were influenced by the number of chemotherapy cycles (<i>p</i> < 0.001) and HT sessions (<i>p</i> < 0.001) performed. Our preliminary data, that need to be confirmed in larger studies, suggest that the combined treatment of bevacizumab-based chemotherapy with HT has a favorable tumor response, is feasible and well tolerated, and offers a potentially promising option for metastatic <span class="highlight">cancer</span> patients.</p> 2957</div> 2958 2959 <div id="teljes-cikk" class="btn"> 2960 <a href="https://www.ncbi.nlm.nih.gov/pubmed/28684680" target="_blank"> View abstract</a> 2961 </div> 2962 2963 </div> <!-- .container --> 2964</div><!-- .entry-content --> 2965 2966 2967 2968</article><!-- #post-3319 --> 2969 2970 2971<article id="post-3320" class="post-3320 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry"> 2972 2973 <header class="pub-entry-header"> 2974 <div class="container"> 2975 <h2>The safety and pharmacokinetics of high dose intravenous ascorbic acid synergy with modulated electrohyperthermia in Chinese patients with stage III-IV non-small cell lung cancer</h2> 2976 </div> 2977 </header><!-- .entry-header --> 2978 2979 2980<div class="entry-content kl-pub-content"> 2981 <div class="container"> 2982 <div class="acf-fields"> 2983 <div class="acf-row"><span class="publ-label">Indication:</span> Lung <hr/> <span class="publ-label">Evidence:</span> Phase I</div> 2984 <div class="publ-acf acf-row acf-flex"> 2985 <span class="publ-label">Author: </span> 2986 <div class="szerzok"> 2987 2988 2989 2990 <span class="sz-nev">Ou J</span> 2991 2992 2993 2994 <span class="sz-nev">Zhu X</span> 2995 2996 2997 2998 <span class="sz-nev">Lu Y</span> 2999 3000 3001 3002 <span class="sz-nev">Zhao C</span> 3003 3004 3005 3006 <span class="sz-nev">Zhang H</span> 3007 3008 3009 3010 <span class="sz-nev">Wang X</span> 3011 3012 3013 3014 <span class="sz-nev">Gui X</span> 3015 3016 3017 3018 <span class="sz-nev">Wang J</span> 3019 3020 3021 3022 <span class="sz-nev">Zhang X</span> 3023 3024 3025 3026 <span class="sz-nev">Zhang T</span> 3027 3028 3029 3030 <span class="sz-nev">Pang C</span> 3031 3032 </div> 3033 3034 </div> 3035 <div class="acf-row"><span class="publ-label">No. of patients:</span> 35 <hr/> <span class="publ-label">Therapy:</span> mEHT<hr/> <span class="publ-label">Year:</span> 2017</div> 3036 </div><!-- .acf-fields --> 3037 <h2 class="section-title">Abstract</h2> 3038<div id="as0005"> 3039<p id="sp0055">Ascorbic acid (AA) infusion and modulated electrohyperthermia (mEHT) are widely used by integrative cancer practitioners for many years. However, there are no safety and <a title="Learn more about Pharmacokinetics" href="http://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/pharmacokinetics" target="_blank" rel="noopener">pharmacokinetics</a> data in Chinese cancer patients. We carried out a clinical trial to evaluate the safety and pharmacokinetics of those methods in patients with stage III-IV non-small cell lung cancer (NSCLC). Blood ascorbic acid in the fasting state was obtained from 35 NSCLC patients; selecting from them 15 patients with stage III-IV entered the phase I study. They were randomized allocated into 3 groups, and received doses 1.0, 1.2, 1.5 g/kg AA infusions. Participants in the first group received <a title="Learn more about Intravenous therapy" href="http://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/intravenous-therapy" target="_blank" rel="noopener">intravenous</a> AA (IVAA) when mEHT was finished, in the second group IVAA was administered simultaneously with mEHT and in the third group IVAA was applied first, and followed with mEHT. Pharmacokinetic profiles were obtained when they received solely IVAA and when IVAA in combination with mEHT. The process was applied 3 times a week (every other day, weekend days off) for 4 weeks. We found that fasting plasma AA levels were significantly correlated with stage of the disease. Peak concentration of AA was significantly higher in the simultaneous treatments than in other combinations with mEHT or in solely IVAA-managed groups. IVAA synergy with simultaneous mEHT is safe and the concomitant application significantly increases the plasma AA level for NSCLC patients.</p> 3040<h2 class="section-title">Graphical abstract</h2> 3041<div id="as0010"> 3042<p id="sp0060">Pharmacokinetic plots of each treatment in the six groups by increasing dosage. Junwen Ou, Xinyu Zhu, et al.</p> 3043<p><img fetchpriority="high" decoding="async" class="alignnone size-full wp-image-3144" src="https://oncotherm.com/wp-content/uploads/2023/12/1-s20-S0928098717304554-fx1.jpg" alt="" width="429" height="200" srcset="https://oncotherm.com/wp-content/uploads/2023/12/1-s20-S0928098717304554-fx1.jpg 429w, https://oncotherm.com/wp-content/uploads/2023/12/1-s20-S0928098717304554-fx1-300x140.jpg 300w" sizes="(max-width: 429px) 100vw, 429px" /></p> 3044</div> 3045</div> 3046 3047 <div id="teljes-cikk" class="btn"> 3048 <a href="http://www.sciencedirect.com/science/article/pii/S0928098717304554?via%3Dihub=" target="_blank">
3048 View abstract</a> 3049 </div> 3050 3051 </div> <!-- .container --> 3052</div><!-- .entry-content --> 3053 3054 3055 3056</article><!-- #post-3320 --> 3057 3058 3059<article id="post-3321" class="post-3321 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry"> 3060 3061 <header class="pub-entry-header"> 3062 <div class="container"> 3063 <h2>Efficacy of metabolically supported chemotherapy combined with ketogenic diet, hyperthermia, and hyperbaric oxygen therapy for stage IV triple-negative breast cancer</h2> 3064 </div> 3065 </header><!-- .entry-header --> 3066 3067 3068<div class="entry-content kl-pub-content"> 3069 <div class="container"> 3070 <div class="acf-fields"> 3071 <div class="acf-row"><span class="publ-label">Indication:</span> Gynecology <hr/> <span class="publ-label">Evidence:</span> Case report</div> 3072 <div class="publ-acf acf-row acf-flex"> 3073 <span class="publ-label">Author: </span> 3074 <div class="szerzok"> 3075 3076 3077 3078 <span class="sz-nev">Iyikesici MS</span> 3079 3080 3081 3082 <span class="sz-nev">Slocum AK</span> 3083 3084 3085 3086 <span class="sz-nev">Slocum A</span> 3087 3088 </div> 3089 3090 </div> 3091 <div class="acf-row"><span class="publ-label">No. of patients:</span> 1 <hr/> <span class="publ-label">Therapy:</span> CT+mEHT<hr/> <span class="publ-label">Year:</span> 2017</div> 3092 </div><!-- .acf-fields --> 3093 <h2 id="idm140553567017536title" class="head no_bottom_margin ui-helper-clearfix">Abstract</h2> 3094<div> 3095<p id="__p1" class="p p-first-last">Triple-negative breast cancer (TNBC) is more aggressive and metastatic than other breast cancer types. Cytotoxic chemotherapy is presently the predominant systemic therapy for TNBC patients. This case report highlights the influence of metabolically supported chemotherapy (MSCT), ketogenic diet (KD), hyperthermia (HT), and hyperbaric oxygen therapy (HBOT) in an overweight 29-year-old woman with stage IV (T4N3M1) triple-negative invasive ductal carcinoma of the breast. The patient presented with an observable mass in her left breast detected during a physical examination in December 2015. Magnetic resonance imaging revealed a Breast Imaging Reporting and Data System Category 5 tumor and multiple lymphadenomegaly in the left axilla. A Tru-Cut biopsy led to the diagnosis of a triple-negative nuclear grade 2 invasive ductal carcinoma. The patient was admitted to ChemoThermia Oncology Center, Istanbul, Turkey in October 2016, and a whole body (18F)-fluorodeoxyglucose (FDG)-positron emission tomography-computed tomography (PET-CT) scan revealed a 77 mm x 55 mm primary tumor in her left breast, multiple left pectoral and axillary lymph nodes, multiple widespread liver masses, and an upper left nodular abdominal lesion. The patient received a treatment protocol consisting of MSCT, KD, HT, and HBOT. A follow-up whole body 18F-FDG PET-CT scan in February 2017 showed a complete therapeutic response with no evidence of abnormal FDG uptake. The patient continued to receive this treatment protocol and in April 2017 underwent a mastectomy, which revealed a complete pathological response consistent with the response indicated by her PET-CT imaging. This single case study presents evidence of a complete clinical, radiological, and pathological response following a six-month treatment period using a combination of MSCT and a novel metabolic therapy in a patient with stage IV TNBC.</p> 3096</div> 3097<div class="sec"><strong class="kwd-title">Keywords: </strong><span class="kwd-text">metabolically supported chemotherapy, ketogenic diet, hyperthermia, hyperbaric oxygen therapy, pathological complete response, triple negative breast cancer</span></div> 3098 3099 <div id="teljes-cikk" class="btn"> 3100 <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5589510/" target="_blank"> View abstract</a> 3101 </div> 3102 3103 </div> <!-- .container --> 3104</div><!-- .entry-content --> 3105 3106 3107 3108</article><!-- #post-3321 --> 3109 3110 3111<article id="post-3322" class="post-3322 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry"> 3112 3113 <header class="pub-entry-header"> 3114 <div class="container"> 3115 <h2>A new strategy of cancer immunotherapy combining hyperthermia/oncolytic virus pretreatment with specific autologous anti-tumor vaccination – a review</h2> 3116 </div> 3117 </header><!-- .entry-header --> 3118 3119 3120<div class="entry-content kl-pub-content"> 3121 <div class="container"> 3122 <div class="acf-fields"> 3123 <div class="acf-row"><span class="publ-label">Indication:</span> Immuno-oncology <hr/> <span class="publ-label">Evidence:</span> Review</div> 3124 <div class="publ-acf acf-row acf-flex"> 3125 <span class="publ-label">Author: </span> 3126 <div class="szerzok"> 3127 3128 3129 3130 <span class="sz-nev">Schirrmacher V</span> 3131 3132 3133 3134 <span class="sz-nev">Lorenzen D</span> 3135 3136 3137 3138 <span class="sz-nev">Van Gool SW</span> 3139 3140 3141 3142 <span class="sz-nev">Stuecker W</span> 3143 3144 </div> 3145 3146 </div> 3147 <div class="acf-row"><span class="publ-label">No. of patients:</span> 206 <hr/> <span class="publ-label">Therapy:</span> IMT+mEHT<hr/> <span class="publ-label">Year:</span> 2017</div> 3148 </div><!-- .acf-fields --> 3149 <h2>Abstract</h2> 3150<p>This review describes and explains a specific immunotherapy strategy that has been developed at the Immunological and Oncological Center Cologne in Germany. The strategy is based on many years of basic and translational research. It is a highly individualized approach to activate and target the patientâs immune system against the patientâs own tumor. In a first step, the patientâs immune system is conditioned by pretreatment with oncolytic virus in combination with hyperthermia. The second step consists of active-specific autologous anti-tumor vaccination. The vaccine, VOL-DC, consists of autologous Dendritic Cells (DCs) which are loaded with Viral Oncolysate (VOL) from the patientâs tumor cells. VOL transfers to the DCs information about tumor-associated antigens from the patientâs tumor and Pathogen-Associated Molecular Patterns (PAMPs, danger signals) from the virus. The product VOL-DC, which involves Newcastle Disease Virus, has been approved in Germany as an Advanced Therapeutic Medicinal Product for individual treatment by the institution which received this permit. This review includes promising results from case-series studies of glioblastoma patients. It also discusses future strategies for treatment of late-stage disease including combination of this immunotherapy with immune checkpoint blocking antibodies and/or with costimulatory bispecific antibodies.</p> 3151 3152 <div id="teljes-cikk" class="btn"> 3153 <a href="http://www.iozk.de/aktuelles/iozk_austin_oncology_case_reports_2017.pdf" target="_blank">
3153 View abstract</a> 3154 </div> 3155 3156 </div> <!-- .container --> 3157</div><!-- .entry-content --> 3158 3159 3160 3161</article><!-- #post-3322 --> 3162 3163 3164<article id="post-3323" class="post-3323 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry"> 3165 3166 <header class="pub-entry-header"> 3167 <div class="container"> 3168 <h2>Role of HIF-1α in response of tumors to a combination of hyperthermia and radiation in vivo</h2> 3169 </div> 3170 </header><!-- .entry-header --> 3171 3172 3173<div class="entry-content kl-pub-content"> 3174 <div class="container"> 3175 <div class="acf-fields"> 3176 <div class="acf-row"><span class="publ-label">Indication:</span> Immuno-oncology <hr/> <span class="publ-label">Evidence:</span> Review</div> 3177 <div class="publ-acf acf-row acf-flex"> 3178 <span class="publ-label">Author: </span> 3179 <div class="szerzok"> 3180 3181 3182 3183 <span class="sz-nev">Kim W</span> 3184 3185 3186 3187 <span class="sz-nev">Kim MS</span> 3188 3189 3190 3191 <span class="sz-nev">Kim HJ</span> 3192 3193 3194 3195 <span class="sz-nev">Lee E</span> 3196 3197 3198 3199 <span class="sz-nev">Jeong JH</span> 3200 3201 3202 3203 <span class="sz-nev">Park I</span> 3204 3205 3206 3207 <span class="sz-nev">Jeong YK</span> 3208 3209 3210 3211 <span class="sz-nev">Jang WI</span> 3212 3213 </div> 3214 3215 </div> 3216 <div class="acf-row"><span class="publ-label">No. of patients:</span> <hr/> <span class="publ-label">Therapy:</span> RT+mEHT<hr/> <span class="publ-label">Year:</span> 2017</div> 3217 </div><!-- .acf-fields --> 3218 <h3>Abstract</h3> 3219<div> 3220<h4>PURPOSE:</h4> 3221<p>Mild temperature hyperthermia (MTH) increases blood flow and oxygenation in tumours. On the other hand, high-dose-per-fraction irradiation damages blood vessels, decreases blood flow and increases hypoxia in tumours. The radiation-induced hypoxia in tumours activates hypoxia-inducible factor-1α (HIF-1α) and its target genes, such as vascular endothelial growth factor (VEGF), promoting revascularization and recurrence. In the present study, we examined the hypothesis that MTH inhibits radiation-induced upregulation of HIF-1α and its target genes by increasing tumour oxygenation.</p> 3222<h4>MATERIALS AND METHODS:</h4> 3223<p>FSaII fibrosarcoma tumours grown subcutaneously in the legs of C3H mice were used. Tumours were irradiated with 15 Gy using a 60Co irradiator or heated at 41 °C for 30 min using an Oncothermia heating unit. Blood perfusion and hypoxia in tumours were assessed with Hoechst 33342 and pimonidazole staining, respectively. Expression levels of HIF-1α and VEGF were determined using immunohistochemical techniques. Apoptosis of tumour cells was quantitated via TUNEL staining and the effects of treatments on tumour growth rate were assessed by measuring tumour diameters.</p> 3224<h4>RESULTS:</h4> 3225<p>Irradiation of FSaII tumours with a single dose of 15 Gy led to significantly decreased blood perfusion, increased hypoxia and upregulation of HIF-1α and VEGF. On the other hand, MTH at 41 °C for 30 min increased blood perfusion and tumour oxygenation, thereby suppressing radiation-induced HIF-1α and VEGF in tumours, leading to enhanced apoptosis of tumour cells and tumour growth delay.</p> 3226<h4>CONCLUSION:</h4> 3227<p>MTH enhances the anti-tumour effect of high-dose irradiation, at least partly by inhibiting radiation-induced upregulation of HIF-1α.</p> 3228</div> 3229 3230 <div id="teljes-cikk" class="btn"> 3231 <a href="http://www.ncbi.nlm.nih.gov/pubmed/28659004" target="_blank"> View abstract</a> 3232 </div> 3233 3234 </div> <!-- .container --> 3235</div><!-- .entry-content --> 3236 3237 3238 3239</article><!-- #post-3323 --> 3240 3241 3242<article id="post-3324" class="post-3324 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry"> 3243 3244 <header class="pub-entry-header"> 3245 <div class="container"> 3246 <h2>Treatment outcome analysis of chemotherapy combined with modulated electro-hyperthermia compared with chemotherapy alone for recurrent cervical cancer, following irradiation</h2> 3247 </div> 3248 </header><!-- .entry-header --> 3249 3250 3251<div class="entry-content kl-pub-content"> 3252 <div class="container"> 3253 <div class="acf-fields"> 3254 <div class="acf-row"><span class="publ-label">Indication:</span> Gynecology <hr/> <span class="publ-label">Evidence:</span> </div> 3255 <div class="publ-acf acf-row acf-flex"> 3256 <span class="publ-label">Author: </span> 3257 <div class="szerzok"> 3258 3259 3260 3261 <span class="sz-nev">Sun Young Lee</span> 3262 3263 3264 3265 <span class="sz-nev">Na Ri Lee</span> 3266 3267 3268 3269 <span class="sz-nev">Dong Hyu Cho</span> 3270 3271 </div> 3272 3273 </div> 3274 <div class="acf-row"><span class="publ-label">No. of patients:</span> 20 <hr/> <span class="publ-label">Therapy:</span> CT+mEHT<hr/> <span class="publ-label">Year:</span> 2017</div> 3275 </div><!-- .acf-fields --> 3276 <p>The survival of patients with recurrent cervical cancer following irradiation remains poor. Chemotherapy combined with hyperthermia has been demonstrated to improve the response rate. The present study was performed to evaluate the effect of modulated electroâhyperthermia combined with conventional chemotherapy compared with chemotherapy alone on recurrent cervical cancer previously treated with irradiation. A total of 20 patients were treated with chemotherapy alone, and 18 were treated with chemotherapy combined with modulated electroâhyperthermia. A single patient was treated with chemoâradiotherapy as primary treatment and then relapsed; the tumor was inoperable and radioârefractory upon recurrence. Local metastases, including metastasis of the paraâaortic lymph nodes and adjacent pelvic lymph nodes were included, but distant metastases were excluded. Modulated electroâhyperthermia was performed three times per week beginning at chemotherapy initiation, and patients underwent a total of 36 sessions. The overall response
3276(complete remission + partial remission + stable disease/progressive disease) to treatment was significantly greater in the group of patients who underwent chemotherapy combined with modulated electroâhyperthermia (P=0.0461), and at the evaluation conducted at the last followâup visit, the response rate was significantly higher (P=0.0218). Additionally, severe complications were not reported. In the present study, of patients with recurrent cervical cancer previously treated with irradiation, the overall response rate for patients treated with chemotherapy combined with modulated electro-hyperthermia was significantly greater than that for those treated with chemotherapy alone.</p> 3277 3278 <div id="teljes-cikk" class="btn"> 3279 <a href="https://doi.org/10.3892/ol.2017.6117" target="_blank"> View abstract</a> 3280 </div> 3281 3282 </div> <!-- .container --> 3283</div><!-- .entry-content --> 3284 3285 3286 3287</article><!-- #post-3324 --> 3288 3289 3290<article id="post-3325" class="post-3325 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry"> 3291 3292 <header class="pub-entry-header"> 3293 <div class="container"> 3294 <h2>Update on phase III randomized clinical trial investigating the effects of the addition of electro-hyperthermia to chemora-diotherapy for cervical cancer patients in South Africa</h2> 3295 </div> 3296 </header><!-- .entry-header --> 3297 3298 3299<div class="entry-content kl-pub-content"> 3300 <div class="container"> 3301 <div class="acf-fields"> 3302 <div class="acf-row"><span class="publ-label">Indication:</span> Gynecology <hr/> <span class="publ-label">Evidence:</span> Phase III</div> 3303 <div class="publ-acf acf-row acf-flex"> 3304 <span class="publ-label">Author: </span> 3305 <div class="szerzok"> 3306 3307 3308 3309 <span class="sz-nev">C Minnaar</span> 3310 3311 3312 3313 <span class="sz-nev">A Baeyens</span> 3314 3315 3316 3317 <span class="sz-nev">J Kotzen</span> 3318 3319 </div> 3320 3321 </div> 3322 <div class="acf-row"><span class="publ-label">No. of patients:</span> 100 <hr/> <span class="publ-label">Therapy:</span> CT+mEHT<hr/> <span class="publ-label">Year:</span> 2016</div> 3323 </div><!-- .acf-fields --> 3324 <div class="c-rich-text"> 3325<h3>Introduction</h3> 3326<div id="artTabContent"> 3327<div> 3328<div> 3329<section> 3330<div> 3331<p>The Electro-Hyperthermia trial an ongoing phase III randomised clinical trial being conducted at the Charlotte Maxeke Johannesburg Academic Hospital. The general aim is to determine the clinical effects of the addition of modulated electro-hyperthermia (EHT) to the standard treatment protocols for locally advanced cervical cancer patients in state healthcare in South Africa. The objectives are to assess the effects of the addition of EHT on local disease control, quality of life, acute and late toxicity and overall survival.</p> 3332</div> 3333</section> 3334</div> 3335<div> 3336<section> 3337<h3>Materials and methods</h3> 3338<div> 3339<p>The study aims to enrol 236 female participants with FIGO stage IIB distal to IIIB cervical cancer. Participants are being randomised into a âHyperthermiaâ group (EHT plus chemoradiation) and a âControlâ group (chemoradiation alone), randomisation stratums: HIV status; age; stage of disease. All participants are receiving 50 Gy external beam radiation, 3 doses of high dose rate brachytherapy (8 Gy) and cisplatin. The Hyperthermia group is receiving two 55 minute local EHT treatments per week during radiation therapy. Local disease control is being assessed by Positron Emission Tomography (PET) scans. Adverse events, quality of life and overall survival are being recorded and the data is being analysed.</p> 3340</div> 3341</section> 3342</div> 3343<div> 3344<section> 3345<h3>Results</h3> 3346<div> 3347<p>We report preliminary data of the first 100 participants to reach 6 months post treatment. We see a positive trend in survival and local disease control in the group receiving hyperthermia. There are no significant differences in acute adverse events or quality of life between the groups.</p> 3348</div> 3349</section> 3350</div> 3351<div> 3352<section> 3353<h3>Conclusion</h3> 3354<div> 3355<p>The preliminary results on the addition of EHT are positive with no impact on adverse events, however this must be confirmed with more patients on completion of the study.</p> 3356</div> 3357</section> 3358</div> 3359</div> 3360</div> 3361</div> 3362 3363 <div id="teljes-cikk" class="btn"> 3364 <a href="http://www.physicamedica.com/article/S1120-1797(16)30175-2/abstract" target="_blank">
3364 View abstract</a> 3365 </div> 3366 3367 </div> <!-- .container --> 3368</div><!-- .entry-content --> 3369 3370 3371 3372</article><!-- #post-3325 --> 3373 3374 3375<article id="post-3326" class="post-3326 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry"> 3376 3377 <header class="pub-entry-header"> 3378 <div class="container"> 3379 <h2>Stage IV Wilms tumor treated by Korean medicine, hyperthermia and thymosin-α1: A case report</h2> 3380 </div> 3381 </header><!-- .entry-header --> 3382 3383 3384<div class="entry-content kl-pub-content"> 3385 <div class="container"> 3386 <div class="acf-fields"> 3387 <div class="acf-row"><span class="publ-label">Indication:</span> Immuno-oncology <hr/> <span class="publ-label">Evidence:</span> Case report</div> 3388 <div class="publ-acf acf-row acf-flex"> 3389 <span class="publ-label">Author: </span> 3390 <div class="szerzok"> 3391 3392 3393 3394 <span class="sz-nev">Donghyun Lee</span> 3395 3396 3397 3398 <span class="sz-nev">Sung Su Kim</span> 3399 3400 3401 3402 <span class="sz-nev">Shin Seong</span> 3403 3404 3405 3406 <span class="sz-nev">Wonjun Cho</span> 3407 3408 3409 3410 <span class="sz-nev">Hyejin Yu</span> 3411 3412 </div> 3413 3414 </div> 3415 <div class="acf-row"><span class="publ-label">No. of patients:</span> 1 <hr/> <span class="publ-label">Therapy:</span> CT+mEHT<hr/> <span class="publ-label">Year:</span> 2016</div> 3416 </div><!-- .acf-fields --> 3417 <h2 id="__abstractidm139631501530000title">Abstract</h2> 3418<div> 3419<div id="__sec1"> 3420<h3>Introduction</h3> 3421<p id="__p1">Wilms tumor is one of general solid cancers that occur in children, which carries a death rate of 7â8 in a million. The cure rate of Wilms tumor in the recent 30 years has dramatically been improved, but a proper remedy is still not prepared enough in terms of application in tumor therapy upon recurrence after radiotherapy, surgery and chemotherapy. We present an integrative medical remedy â hyperthermia and thymosin-α1 treatment focused on herbal remedy â since there have been cases in which this remedy contributed to remission in the liver-transferred part in the 4th phase of Wilms tumor and stable maintenance of metastatic lung lesion.</p> 3422</div> 3423<div id="__sec2"> 3424<h3>Case Presentation</h3> 3425<p id="__p2">Our patient, a female Korean mongoloid outpatient, was treated from October 25, 2014, to July 22, 2015. The herbal remedy consisted of 8 ml inhalation of Soram nebulizer solution q.d., Soramdan S 8 g p.o., Hangamdan S 1 g p.o., t.i.d., Cheongjangtang 10â30 ml, and Spiam HC 8 g p.o. The integrative medical therapy was done with hyperthermia therapy (oncothermia) and 1.6 mg of thymosin-α1 treatment (Zadaxin) i.m. According to the CT result on July 15th, 2015, the liver metastasis was not seen anymore, while the lung metastasis was maintained stably without tumor progress.</p> 3426</div> 3427<div id="__sec3"> 3428<h3>Conclusions</h3> 3429<p id="__p3">Accompanying integrative medical therapy with herbal remedy in the treatment of Wilms tumor showing progress patterns after surgery and chemotherapy can be meaningful as a new remedy.</p> 3430</div> 3431</div> 3432<div>Key Words: Wilms tumor, Korean medicine therapy, Hangamdan S, Soramdan S, Spiam HC, Hyperthermia, Thymosin-α1</div> 3433 3434 <div id="teljes-cikk" class="btn"> 3435 <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4899649/" target="_blank"> View abstract</a> 3436 </div> 3437 3438 </div> <!-- .container --> 3439</div><!-- .entry-content --> 3440 3441 3442 3443</article><!-- #post-3326 --> 3444 3445 3446<article id="post-3327" class="post-3327 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry"> 3447 3448 <header class="pub-entry-header"> 3449 <div class="container"> 3450 <h2>Positive response of a primary leiomyosarcoma of the breast following salvage hyperthermia and pazopanib</h2> 3451 </div> 3452 </header><!-- .entry-header --> 3453 3454 3455<div class="entry-content kl-pub-content"> 3456 <div class="container"> 3457 <div class="acf-fields"> 3458 <div class="acf-row"><span class="publ-label">Indication:</span> Gynecology <hr/> <span class="publ-label">Evidence:</span> Case report</div> 3459 <div class="publ-acf acf-row acf-flex"> 3460 <span class="publ-label">Author: </span> 3461 <div class="szerzok"> 3462 3463 3464 3465 <span class="sz-nev">Sun Young Lee</span> 3466 3467 3468 3469 <span class="sz-nev">
3469Na-Ri Lee</span> 3470 3471 </div> 3472 3473 </div> 3474 <div class="acf-row"><span class="publ-label">No. of patients:</span> 1 <hr/> <span class="publ-label">Therapy:</span> CT+mEHT<hr/> <span class="publ-label">Year:</span> 2016</div> 3475 </div><!-- .acf-fields --> 3476 <p>Primary sarcomas of the breast are rare tumors, accounting for less than 1% of all breast neoplasms. Leiomyosarcoma is an extremely rare subtype of breast sarcoma [1]. Prognoses for primary breast sarcoma are poor and treatment modalities are limited. Pazopanib is an oral, multitargeted tyrosine kinase inhibitor, with activity against vascular endothelial growth factors (VEGFs) 1, 2, and 3, and platelet-derived growth factors (PDGFs) [2]. Pazopanib has been approved for the treatment of advanced renal cell carcinoma and metastatic soft tissue sarcoma (STS) [2]. Hyperthermia inhibits sub-lethal cellular damage repair and improves oxygenation; thus, making it an attractive therapy for combining with radiation and/or chemotherapy to generate a potentially synergistic response. Hyperthermia has a proven benefit for treating STS [3]. Herein, we report a case of primary breast leiomyosarcoma treated with regional hyperthermia and pazopanib.</p> 3477 3478 <div id="teljes-cikk" class="btn"> 3479 <a href="https://www.ncbi.nlm.nih.gov/pubmed/27079325" target="_blank"> View abstract</a> 3480 </div> 3481 3482 </div> <!-- .container --> 3483</div><!-- .entry-content --> 3484 3485 3486 3487</article><!-- #post-3327 --> 3488 3489 3490<article id="post-3328" class="post-3328 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry"> 3491 3492 <header class="pub-entry-header"> 3493 <div class="container"> 3494 <h2>Complete Response of Locally Advanced (stage III) Rectal Cancer to Metabolically Supported Chemoradiotherapy with Hyperthermia</h2> 3495 </div> 3496 </header><!-- .entry-header --> 3497 3498 3499<div class="entry-content kl-pub-content"> 3500 <div class="container"> 3501 <div class="acf-fields"> 3502 <div class="acf-row"><span class="publ-label">Indication:</span> Rectal Cancer <hr/> <span class="publ-label">Evidence:</span> </div> 3503 <div class="publ-acf acf-row acf-flex"> 3504 <span class="publ-label">Author: </span> 3505 <div class="szerzok"> 3506 3507 3508 3509 <span class="sz-nev">Iyikesici MS.</span> 3510 3511 3512 3513 <span class="sz-nev">Slocum A.</span> 3514 3515 3516 3517 <span class="sz-nev">Turkmen E.</span> 3518 3519 3520 3521 <span class="sz-nev">Akdemir O.</span> 3522 3523 3524 3525 <span class="sz-nev">Slocum AK.</span> 3526 3527 3528 3529 <span class="sz-nev">Berkarda FB.</span> 3530 3531 </div> 3532 3533 </div> 3534 <div class="acf-row"><span class="publ-label">No. of patients:</span> 1 <hr/> <span class="publ-label">Therapy:</span> <hr/> <span class="publ-label">Year:</span> 2016</div> 3535 </div><!-- .acf-fields --> 3536 <p><strong>Abstract<br /> 3537</strong>Background: Locally advanced rectal cancer is defined as a rectal mass that cannot be resected without a high probability of leaving residual disease at the tumor site. While the standard treatment for locally advanced rectal cancer is chemoradiotherapy followed by surgery, this study reports a locally invasive rectal adenocarcinoma patient who achieved complete pathological and clinical remission after receiving a combination of metabolically supported chemotherapy (MSCT), radiotherapy (RT) and hyperthermia (HT). Case presentation: An 81-year-old female underwent a rectosigmoidoscopy at a referring hospital following a complaint of bloody stools for a period of 20 days. The rectosigmoidoscopy revealed an ulcerated tumor beginning at the level of the anal sphincter. A pathological examination of biopsy material revealed moderately differentiated invasive adenocarcinoma and the patient received a diagnosis of stage III (T3N2M0) lowlying rectal cancer. When further follow-up revealed colonic obstruction, the patient was recommended an abdominoperineal resection (APR) and was referred after refusing surgical treatment. The patient received a metabolically supported combination of oxaliplatin, 5-florouracil (5-FU) and calcium folinate (FOLFOX6) concomitant to RT and local HT and, ultimately, never underwent surgery. 27 months since her disease-free PET-CT scan, the patient remains with
3537no sign of disease recurrence. Conclusion: According to the findings of the present study, the non-surgical treatment and achievement of complete clinical and pathological remission of locally advanced rectal adenocarcinoma may be possible by means of a combination of MSCT, RT and HT. Keywords: Pathological complete response; Locally advanced rectal cancer; Metabolically supported chemotherapy; Hyperthermia</p> 3538 3539 3540 </div> <!-- .container --> 3541</div><!-- .entry-content --> 3542 3543 3544 3545</article><!-- #post-3328 --> 3546 3547 3548<article id="post-3329" class="post-3329 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry"> 3549 3550 <header class="pub-entry-header"> 3551 <div class="container"> 3552 <h2>Effect of modulated electrohyperthermia on the pharmacokinetics of oral transmucosal fentanyl citrate in healthy volunteers</h2> 3553 </div> 3554 </header><!-- .entry-header --> 3555 3556 3557<div class="entry-content kl-pub-content"> 3558 <div class="container"> 3559 <div class="acf-fields"> 3560 <div class="acf-row"><span class="publ-label">Indication:</span> Temperature <hr/> <span class="publ-label">Evidence:</span> Open-label study</div> 3561 <div class="publ-acf acf-row acf-flex"> 3562 <span class="publ-label">Author: </span> 3563 <div class="szerzok"> 3564 3565 3566 3567 <span class="sz-nev">Lee SY</span> 3568 3569 3570 3571 <span class="sz-nev">Kim M-G</span> 3572 3573 </div> 3574 3575 </div> 3576 <div class="acf-row"><span class="publ-label">No. of patients:</span> 12 <hr/> <span class="publ-label">Therapy:</span> mEHT<hr/> <span class="publ-label">Year:</span> 2016</div> 3577 </div><!-- .acf-fields --> 3578 <h3>Abstract</h3> 3579<div> 3580<h4>PURPOSE:</h4> 3581<p>This study aimed to determine whether changes occur in fentanyl absorption and disposition when administered in conjunction with modulated electrohyperthermia (mEHT) treatment.</p> 3582<h4>METHODS:</h4> 3583<p>A randomized, single-dose, crossover, open-label study was used to investigate the effect of mEHT on the pharmacokinetic properties of fentanyl in 12 healthy volunteers. The 12 healthy volunteers were each administered a single dose of oral transmucosal fentanyl citrate (OTFC) or a single dose of OTFC with mEHT. mEHT was performed on the abdomen for 1 hour. Blood samples were collected for 24 hours after dosing. The temperature of the abdominal skin surface was assessed before dosing and at 10, 20, and 60 minutes after dosing.</p> 3584<h4>FINDINGS:</h4> 3585<p>Geometric mean ratios (ratio of fentanyl with mEHT to fentanyl alone) for the Cmax and AUC0-last were 1.20 (90% CI, 1.09-1.32) and 1.15 (90% CI, 0.99-1.33), respectively. The mean temperature of the abdominal skin surface increased by approximately 4°C.</p> 3586<h4>IMPLICATIONS:</h4> 3587<p>There was an increase in the overall exposure to the drug without implications of any clinical significance. OTFC can be administered without limitations in combination with mEHT, and it is not necessary to modify the dosing regimen. cris.nih.go,kr Identifier: KCT0001286.</p> 3588</div> 3589 3590 <div id="teljes-cikk" class="btn"> 3591 <a href="https://www.ncbi.nlm.nih.gov/pubmed/27866658" target="_blank"> View abstract</a> 3592 </div> 3593 3594 </div> <!-- .container --> 3595</div><!-- .entry-content --> 3596 3597 3598 3599</article><!-- #post-3329 --> 3600 3601 3602<article id="post-3330" class="post-3330 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry"> 3603 3604 <header class="pub-entry-header"> 3605 <div class="container"> 3606 <h2>Definitive radiotherapy with concurrent oncothermia for stage IIIB nonâsmallâcell lung cancer: A case report</h2> 3607 </div> 3608 </header><!-- .entry-header --> 3609 3610 3611<div class="entry-content kl-pub-content"> 3612 <div class="container"> 3613 <div class="acf-fields"> 3614 <div class="acf-row"><span class="publ-label">Indication:</span> Lung <hr/> <span class="publ-label">Evidence:</span> Case report</div> 3615 <div class="publ-acf acf-row acf-flex"> 3616 <span class="publ-label">Author: </span> 3617 <div class="szerzok"> 3618 3619 3620 3621 <span class="sz-nev">Seung-Gu Yeo</span> 3622 3623 </div> 3624 3625 </div> 3626 <div class="acf-row"><span class="publ-label">No. of patients:</span> 1 <hr/> <span class="publ-label">Therapy:</span> RT+mEHT<hr/> <span class="publ-label">Year:</span> 2015</div> 3627 </div><!-- .acf-fields --> 3628 <h2 id="__abstractidm139703974627696title">Abstract</h2> 3629<p>Hyperthermia enhances the susceptibility of tumors to radiotherapy (RT) and chemotherapy. Oncothermia, also known as electro-hyperthermia, is a new treatment modality developed to overcome the problems of traditional hyperthermia by selectively delivering energy to the malignant tissues. The present study reports the outcome of combined oncothermia and RT in a 75-year-old patient with stage IIIB non-small-cell lung cancer (NSCLC). Due to the advanced age and the performance status of the patient, the combination of systemic chemotherapy and RT was deemed infeasible; therefore, the patient instead decided to undergo oncothermia concurrently with definitive RT. The RT was administered at a dose of 64.8 Gy in 36 fractions using a three-dimensional conformal plan technique. Oncothermia was started concomitantly with RT and was performed for 60 min per session, two sessions per week, for a total of 12 sessions. No severe toxicities developed, with the exception of mild odynophagia, which resolved soon after the treatments. Follow-up computed tomography showed complete tumor response, and the patient was alive with no evidence of the disease 18 months after the completion of the treatment. In conclusion, the present case report suggests that oncothermia combined with RT, with the former possessing radiosensitizing potential and n
3629o additional toxicities, may be a promising alternative for advanced-age and/or frail patients with locally advanced NSCLC.</p> 3630 3631 <div id="teljes-cikk" class="btn"> 3632 <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4509030/" target="_blank"> View abstract</a> 3633 </div> 3634 3635 </div> <!-- .container --> 3636</div><!-- .entry-content --> 3637 3638 3639 3640</article><!-- #post-3330 --> 3641 3642 3643<article id="post-3331" class="post-3331 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry"> 3644 3645 <header class="pub-entry-header"> 3646 <div class="container"> 3647 <h2>The Outcome of the Chemotherapy and Oncothermia for Far Advanced Adenocarcinoma of the Lung: Case reports of four patients</h2> 3648 </div> 3649 </header><!-- .entry-header --> 3650 3651 3652<div class="entry-content kl-pub-content"> 3653 <div class="container"> 3654 <div class="acf-fields"> 3655 <div class="acf-row"><span class="publ-label">Indication:</span> Lung <hr/> <span class="publ-label">Evidence:</span> Case report</div> 3656 <div class="publ-acf acf-row acf-flex"> 3657 <span class="publ-label">Author: </span> 3658 <div class="szerzok"> 3659 3660 3661 3662 <span class="sz-nev">Doo Yun Lee</span> 3663 3664 3665 3666 <span class="sz-nev">Joon Seok Park</span> 3667 3668 3669 3670 <span class="sz-nev">Hae Chul Jung</span> 3671 3672 3673 3674 <span class="sz-nev">Eun Seol Byun</span> 3675 3676 3677 3678 <span class="sz-nev">Seok Jin Haam</span> 3679 3680 3681 3682 <span class="sz-nev">Sung Soo Lee</span> 3683 3684 </div> 3685 3686 </div> 3687 <div class="acf-row"><span class="publ-label">No. of patients:</span> 4 <hr/> <span class="publ-label">Therapy:</span> CT+mEHT<hr/> <span class="publ-label">Year:</span> 2015</div> 3688 </div><!-- .acf-fields --> 3689 <p><strong>ABSTRACT</strong></p> 3690<div> 3691<p>Lung cancer is one of the most aggressive and lethal form of cancers. Patients with far advanced lung cancer are treated by chemotherapy with or without radiotherapy. However, median survival of these patients is less than 6 months. To increase survival and quality of life for these patients, various forms of complementary treatments have been tried in clinical practices, and oncothermia is supposed to be one of the promising candidates. From May 2008 to November 2013, 4 patients with far advanced lung adenocarcinoma (stages IIIB and IV) were treated with oncothermia in addition to conventional chemotherapy at Gangnam Severance Hospital and Bundang CHA Hospital. All these patients have survived for more than 2 years.</p> 3692</div> 3693 3694 <div id="teljes-cikk" class="btn"> 3695 <a href="http://www.scirp.org/journal/PaperInformation.aspx?PaperID=54620" target="_blank"> View abstract</a> 3696 </div> 3697 3698 </div> <!-- .container --> 3699</div><!-- .entry-content --> 3700 3701 3702 3703</article><!-- #post-3331 --> 3704 3705 3706<article id="post-3332" class="post-3332 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry"> 3707 3708 <header class="pub-entry-header"> 3709 <div class="container"> 3710 <h2>Oncolytic Newcastle disease virus as a prospective anti-cancer therapy. A biologic agent with potential to break therapy resistance</h2> 3711 </div> 3712 </header><!-- .entry-header --> 3713 3714 3715<div class="entry-content kl-pub-content"> 3716 <div class="container"> 3717 <div class="acf-fields"> 3718 <div class="acf-row"><span class="publ-label">Indication:</span> Immuno-oncology <hr/> <span class="publ-label">Evidence:</span> </div> 3719 <div class="publ-acf acf-row acf-flex"> 3720 <span class="publ-label">Author: </span> 3721 <div class="szerzok"> 3722 3723 3724 3725 <span class="sz-nev">Schirrmacher V</span> 3726 3727 </div> 3728 3729 </div> 3730 <div class="acf-row"><span class="publ-label">No. of patients:</span> <hr/> <span class="publ-label">Therapy:</span> IMT+mEHT<hr/> <span class="publ-label">Year:</span> 2015</div> 3731 </div><!-- .acf-fields --> 3732 <h3>Abstract</h3> 3733<div> 3734<h4>INTRODUCTION:</h4> 3735<p>Oncolytic viruses (OVs) selectively replicate in tumor cells and cause cancer cell death. Most OVs in clinical studies are genetically engineered. In contrast, the avian Newcastle disease virus (NDV) is a naturally oncolytic RNA virus. While anti-viral immunity is considered a major problem in achieving maximal tumor cell killing by OVs, this review discusses the importance of NDV immunogenic cell death (ICD) and how anti-viral immune responses can be integrated to induce maximal post-oncolytic T-cell-mediated anti-tumor immunity. Since replication of NDV is independent of host cell DNA replication (which is the target of many cytostatic drugs and radiotherapy) and because of other findings, oncolytic NDV is a candidate agent to break therapy resistance of tumor cells.</p> 3736<h4>AREAS COVERED:</h4> 3737<p>Properties of this avian paramyxovirus are summarized with special emphasis to its anti-neoplastic and immune-stimulatory properties. The review then discusses prospective anti-cancer therapies, including treatments with NDV alone, and combinations with an autologous NDV-modified tumor cell vaccine or with a viral oncolysate pulsed dendritic cell vaccine. Various combinatorial approaches between these and with other modalities are also reviewed.</p> 3738<h4>EXPERT OPINION:</h4> 3739<p>Post-oncolytic anti-tumor immunity based on ICD is in the expert’s opinion of greater importance for long-term therapeutic effects than maximal tumor cell killing. Of the various combinatorial approaches discussed, the most promising and feasible for clinical practice appears to be the combination of systemic NDV pre-treatment with anti-tumor vaccination.</p> 3740</div> 3741 3742 <div id="teljes-cikk" class="btn"> 3743 <a href="https://www.ncbi.nlm.nih.gov/pubmed/26436571" target="_blank">
3743 View abstract</a> 3744 </div> 3745 3746 </div> <!-- .container --> 3747</div><!-- .entry-content --> 3748 3749 3750 3751</article><!-- #post-3332 --> 3752 3753 3754<article id="post-3333" class="post-3333 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry"> 3755 3756 <header class="pub-entry-header"> 3757 <div class="container"> 3758 <h2>Results of Oncothermia Combined with Operation, Chemotherapy and Radiation Therapy for Primary, Recurrent and Metastatic Sarcoma</h2> 3759 </div> 3760 </header><!-- .entry-header --> 3761 3762 3763<div class="entry-content kl-pub-content"> 3764 <div class="container"> 3765 <div class="acf-fields"> 3766 <div class="acf-row"><span class="publ-label">Indication:</span> Sarcoma <hr/> <span class="publ-label">Evidence:</span> </div> 3767 <div class="publ-acf acf-row acf-flex"> 3768 <span class="publ-label">Author: </span> 3769 <div class="szerzok"> 3770 3771 3772 3773 <span class="sz-nev">Tae Sig Jeung</span> 3774 3775 3776 3777 <span class="sz-nev">Sun Young Ma</span> 3778 3779 3780 3781 <span class="sz-nev">JiHoon Choi</span> 3782 3783 3784 3785 <span class="sz-nev">Jeasang Yu</span> 3786 3787 3788 3789 <span class="sz-nev">Su Yong Lee</span> 3790 3791 3792 3793 <span class="sz-nev">Sangwook Lim</span> 3794 3795 </div> 3796 3797 </div> 3798 <div class="acf-row"><span class="publ-label">No. of patients:</span> 13 <hr/> <span class="publ-label">Therapy:</span> SRG+CT+mEHT<hr/> <span class="publ-label">Year:</span> 2015</div> 3799 </div><!-- .acf-fields --> 3800 <h4>ABSTRACT</h4> 3801<div> 3802<div>Sarcomas are relatively rare malignancies; however, their huge variety and shortage of the effective therapies make this disease face huge challenge for oncology. It is recently shown that hyperthermia could be successfully applied even in high-risk cases in combination with the available gold-standard regiments. Our aim is to present various advanced cases treated with a new hyperthermia method, oncothermia, showing its advantages and feasibility to successfully treat highly advanced sarcomas with curative intent.</div> 3803</div> 3804 3805 <div id="teljes-cikk" class="btn"> 3806 <a href="http://www.scirp.org/journal/PaperInformation.aspx?PaperID=56280" target="_blank"> View abstract</a> 3807 </div> 3808 3809 </div> <!-- .container --> 3810</div><!-- .entry-content --> 3811 3812 3813 3814</article><!-- #post-3333 --> 3815 3816 3817<article id="post-3334" class="post-3334 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry"> 3818 3819 <header class="pub-entry-header"> 3820 <div class="container"> 3821 <h2>The effect of modulated electro-hyperthermia on the pharmacokinetic properties of nefopam in healthy volunteers: A randomised, single-dose, crossover open-label study</h2> 3822 </div> 3823 </header><!-- .entry-header --> 3824 3825 3826<div class="entry-content kl-pub-content"> 3827 <div class="container"> 3828 <div class="acf-fields"> 3829 <div class="acf-row"><span class="publ-label">Indication:</span> Temperature <hr/> <span class="publ-label">Evidence:</span> Open-label study</div> 3830 <div class="publ-acf acf-row acf-flex"> 3831 <span class="publ-label">Author: </span> 3832 <div class="szerzok"> 3833 3834 3835 3836 <span class="sz-nev">Lee SY</span> 3837 3838 3839 3840 <span class="sz-nev">Kim M-G</span> 3841 3842 </div> 3843 3844 </div> 3845 <div class="acf-row"><span class="publ-label">No. of patients:</span> 12 <hr/> <span class="publ-label">Therapy:</span> mEHT<hr/> <span class="publ-label">Year:</span> 2015</div> 3846 </div><!-- .acf-fields --> 3847 <h3>Abstract</h3> 3848<div> 3849<h4>PURPOSE:</h4> 3850<p>Nefopam is a widely available analgesic for the management of pain. The aim of this study was to reveal the effect of regional hyperthermia of the abdominal area on the pharmacokinetics of nefopam.</p> 3851<h4>MATERIALS AND METHODS:</h4> 3852<p>A randomised, single-dose, crossover, open-label study was conducted to reveal the effect of hyperthermia using modulated electro-hyperthermia on the pharmacokinetics of nefopam. The pharmacokinetics of orally administered nefopam without hyperthermia was studied in 12 healthy volunteers and then 7 days later they were treated with nefopam plus modulated electro-hyperthermia to the abdominal area for 1 h. Blood samples were collected up to 24 h after the drug administration. From the blood concentration-time curve, the maxinum plasma concentration (C(max)), time to C(max) (T(max)) and the area under the curve (AUC) were obtained. The safety and tolerability of these treatments were also assessed.</p> 3853<h4>RESULTS:</h4> 3854<p>The geometric mean ratios (GMRs) ((nefopam + modulated electro-hyperthermia)/nefopam) and the associated 90% confidence intervals (CIs) for C(max), AUC(last) and AUC(inf) were 1.2804 (1.1155â¼1.4696), 1.0512 (0.9555â¼1.1566) and 1.0612 (0.9528â¼1.1819), respectively. The increase in C(max) was statistically significant, and T(max) was significantly shortened.</p> 3855<h4>CONCLUSIONS:</h4> 3856<p>The significant increase in C(max) and decrease in T(max) indicated that modulated electro-hyperthermia increased the absorption of the orally administered nefopam, thereby transitionally increasing the blood concentration of the drug. The AUC is an important parameter that c
3856ontributes to the therapeutic effect of drugs. The lack of significant change in AUC suggests that modulated electro-hyperthermia may increases the absorption of orally administered drugs without increasing the systemic adverse effect of the drugs.</p> 3857</div> 3858 3859 <div id="teljes-cikk" class="btn"> 3860 <a href="http://www.ncbi.nlm.nih.gov/pubmed/26507458" target="_blank"> View abstract</a> 3861 </div> 3862 3863 </div> <!-- .container --> 3864</div><!-- .entry-content --> 3865 3866 3867 3868</article><!-- #post-3334 --> 3869 3870 3871<article id="post-3335" class="post-3335 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry"> 3872 3873 <header class="pub-entry-header"> 3874 <div class="container"> 3875 <h2>Conventional cancer treatment alone or with regional hyperthermia for pain relief in lung cancer: A caseâcontrol study</h2> 3876 </div> 3877 </header><!-- .entry-header --> 3878 3879 3880<div class="entry-content kl-pub-content"> 3881 <div class="container"> 3882 <div class="acf-fields"> 3883 <div class="acf-row"><span class="publ-label">Indication:</span> Lung cancer <hr/> <span class="publ-label">Evidence:</span> Case report</div> 3884 <div class="publ-acf acf-row acf-flex"> 3885 <span class="publ-label">Author: </span> 3886 <div class="szerzok"> 3887 3888 3889 3890 <span class="sz-nev">Yeon-PyoKim</span> 3891 3892 3893 3894 <span class="sz-nev">YuriChoi</span> 3895 3896 3897 3898 <span class="sz-nev">SunKim</span> 3899 3900 3901 3902 <span class="sz-nev">Yoon-SungPark</span> 3903 3904 3905 3906 <span class="sz-nev">In-JaeOh</span> 3907 3908 3909 3910 <span class="sz-nev">Kyu-SikKim</span> 3911 3912 3913 3914 <span class="sz-nev">Young-ChulKim</span> 3915 3916 </div> 3917 3918 </div> 3919 <div class="acf-row"><span class="publ-label">No. of patients:</span> 115 <hr/> <span class="publ-label">Therapy:</span> Conventional treatment, Hyperthermia<hr/> <span class="publ-label">Year:</span> 2015</div> 3920 </div><!-- .acf-fields --> 3921 <p>Objective: To investigate the effect of combining conventional treatment with regional hyperthermia on cancer pain in lung cancer patients.<br /> 3922Design: Caseâcontrol study.<br /> 3923Setting: One Korean university hospital and three complementary cancer clinics.<br /> 3924Main outcomes and measures: Main outcome was effective analgesic score (EAS, PI[1 + (M/10)], 1: anti-inflammatory drug consumption at a regular dosage, M: weekly dose (mg) of oral morphine equivalent and PI: pain intensity) at four time points (baseline (days â30 to 0), time 1 (days 1â60), time 2 (days 61â120), and time 3 (days 121â180)). Propensity score matching between the hyperthermia and control groups was performed using a 1:5 ratio. A linear mixed effects model was employed to measure EAS changes over time in the two groups.<br /> 3925Results: At baseline, there were 83 subjects in the control group and 32 subjects in the hyperthermia group. At time 3, there were 49 subjects in the control group and 16 subjects in the hyperthermia group. Analyses showed rate of change of EAS, treatment Ã time was significant (<em>p</em> = 0.038). This significant difference was mainly observed for time 1 (mean difference: 101.76 points, 95% confidence interval: 10.20â193.32 points, <em>p</em> = 0.030).<br /> 3926Conclusions: Our results indicate an increase in cancer pain in lung cancer patients administered regional hyperthermia, particularly during the early stage of hyperthermia treatment.</p> 3927 3928 <div id="teljes-cikk" class="btn"> 3929 <a href="https://doi.org/10.1016/j.ctim.2015.04.004" target="_blank"> View abstract</a> 3930 </div> 3931 3932 </div> <!-- .container --> 3933</div><!-- .entry-content --> 3934 3935 3936 3937</article><!-- #post-3335 --> 3938 3939 3940<article id="post-3336" class="post-3336 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry"> 3941 3942 <header class="pub-entry-header"> 3943 <div class="container"> 3944 <h2>Second-line chemotherapy with gemcitabine and oxaliplatin in combination with loco-regional hyperthermia (EHY-2000) in patients with refractory metastatic pancreatic cancer – preliminary results of a prospective trial</h2> 3945 </div> 3946 </header><!-- .entry-header --> 3947 3948 3949<div class="entry-content kl-pub-content"> 3950 <div class="container"> 3951 <div class="acf-fields"> 3952 <div class="acf-row"><span class="publ-label">Indication:</span> Pancreas <hr/> <span class="publ-label">Evidence:</span> Clinical study</div> 3953 <div class="publ-acf acf-row acf-flex"> 3954 <span class="publ-label">Author: </span> 3955 <div class="szerzok"> 3956 3957 3958 3959 <span class="sz-nev">Volovat C</span> 3960 3961 3962 3963 <span class="sz-nev">Volovat SR</span> 3964 3965 3966 3967 <span class="sz-nev">Scripcaru V</span> 3968 3969 3970 3971 <span class="sz-nev">Miron L</span> 3972 3973 </div> 3974 3975 </div> 3976 <div class="acf-row"><span class="publ-label">No. of patients:</span> 26 <hr/> <span class="publ-label">Therapy:</span> CT+mEHT<hr/> <span class="publ-label">Year:</span> 2014</div> 3977 </div><!-- .acf-fields --> 3978 <div><strong>Abstract</strong></div> 3979<div></div> 3980<div>There is no standard treatment for second-line in patients with metastatic pancreatic cancer. The treatment with local hyperthermia (41â42°C) in order to enhance the activity gemcitabine-oxaliplatin on liver metastasis and primary advanced tumor was added as standard treatment. The primary objective was the response rate while the secondary objective were the safety of chemotherapy associated with hyperthermia and overall survival. There were 26 patients included, diagnosed with metastatic pancreatic cancer with progressive disease after gemcitabine treatment. The patients were enrolled in the peri
3980od January 2005 â May 2011. The patients received gemcitabine 1000 mg/msq IV and oxaliplatin 100 mg/msq IV day 1(GEMOX) combined with locoregional hyperthermia days1, 3 and 5 all repeated at 14 days. From 26 patients included, 19 patients had an evaluable response at the treatment. The toxicity of chemotherapy for these patients was related with chemotherapy (neutropeniagrade III â 24%; anemia grade III â 8%, thrombopenia grade IIIâ 6%; neurologic toxicity grade III â 22%. Toxicity related to hyperthermia was:discomfort because of bolus pressure (2%), pain related with position (12%), power related pain (2%). Rate of response was stable disease 53%, partial response 18% and progression disease 29%. Progression-free-survival was 3.9 months. Overall survival was 8.9 months.</div> 3981 3982 <div id="teljes-cikk" class="btn"> 3983 <a href="http://www.rrp.infim.ro/2014_66_1/A18.pdf" target="_blank"> View abstract</a> 3984 </div> 3985 3986 </div> <!-- .container --> 3987</div><!-- .entry-content --> 3988 3989 3990 3991</article><!-- #post-3336 --> 3992 3993 3994<article id="post-3337" class="post-3337 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry"> 3995 3996 <header class="pub-entry-header"> 3997 <div class="container"> 3998 <h2>Longâterm remission of prostate cancer with extensive bone metastases upon immunoâ and virotherapy: A case report</h2> 3999 </div> 4000 </header><!-- .entry-header --> 4001 4002 4003<div class="entry-content kl-pub-content"> 4004 <div class="container"> 4005 <div class="acf-fields"> 4006 <div class="acf-row"><span class="publ-label">Indication:</span> Prostate <hr/> <span class="publ-label">Evidence:</span> Case report</div> 4007 <div class="publ-acf acf-row acf-flex"> 4008 <span class="publ-label">Author: </span> 4009 <div class="szerzok"> 4010 4011 4012 4013 <span class="sz-nev">Volker Schirrmacher</span> 4014 4015 4016 4017 <span class="sz-nev">Akos-Sigmund Bihari</span> 4018 4019 4020 4021 <span class="sz-nev">Wilfried Stücker</span> 4022 4023 4024 4025 <span class="sz-nev">Tobias Sprenger</span> 4026 4027 </div> 4028 4029 </div> 4030 <div class="acf-row"><span class="publ-label">No. of patients:</span> 1 <hr/> <span class="publ-label">Therapy:</span> SRG+CT+mEHT<hr/> <span class="publ-label">Year:</span> 2014</div> 4031 </div><!-- .acf-fields --> 4032 <p><strong>Abstract</strong></p> 4033<p>The present study reports the case of a patient with hormone-refractory metastatic prostate cancer who had failed standard therapy, but then achieved complete remission following combined treatment with local hyperthermia (LHT), Newcastle disease virus and dendritic cell (DC) vaccination, which was an unusual combination. In August 2005, the patient underwent a radical prostatectomy. Despite standard treatment, the patient developed progressive bone metastases and stopped conventional therapy in June 2007. Starting in October 2007, the patient was treated with LHT, oncolytic virotherapy and DC vaccination. Prostateâspecific antigen (PSA)-levels, with the highest level of 233.8 ng/ml in January 2008, decreased to 0.8 ng/ml in late February 2008. In March 2008, a reduction in bone metastases could be detected by positron emission tomography/computed tomography. Since then, the PSA levels have remained low and the patient is doing well. The treatment induced a long-lasting antitumor memory T-cell response. This possibly explains the long-term effectiveness of this novel experimental combined treatment approach.</p> 4034 4035 <div id="teljes-cikk" class="btn"> 4036 <a href="https://www.ncbi.nlm.nih.gov/pubmed/25364402" target="_blank"> View abstract</a> 4037 </div> 4038 4039 </div> <!-- .container --> 4040</div><!-- .entry-content --> 4041 4042 4043 4044</article><!-- #post-3337 --> 4045 4046 4047<article id="post-3338" class="post-3338 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry"> 4048 4049 <header class="pub-entry-header"> 4050 <div class="container"> 4051 <h2>Synergy between Oncothermia and Traditional Chinese Medicine</h2> 4052 </div> 4053 </header><!-- .entry-header --> 4054 4055 4056<div class="entry-content kl-pub-content"> 4057 <div class="container"> 4058 <div class="acf-fields"> 4059 <div class="acf-row"><span class="publ-label">Indication:</span> Non-oncology <hr/> <span class="publ-label">Evidence:</span> </div> 4060 <div class="publ-acf acf-row acf-flex"> 4061 <span class="publ-label">Author: </span> 4062 <div class="szerzok"> 4063 4064 4065 4066 <span class="sz-nev">Hegyi G</span> 4067 4068 </div> 4069 4070 </div> 4071 <div class="acf-row"><span class="publ-label">No. of patients:</span> <hr/> <span class="publ-label">Therapy:</span> mEHT+TCM<hr/> <span class="publ-label">Year:</span> 2014</div> 4072 </div><!-- .acf-fields --> 4073 <h4>Abstract</h4> 4074<p>Aim of this article is to show the possibility and great advantage of the synergy of oncothermia with traditional Chinese medicine for treatment of malignant diseases based on the common basis of equilibrium demand. We use the re cognit io n of thedeviat ions fr om the com plex har monyof the org anismor its part for se lectionto actproperly.</p> 4075 4076 <div id="teljes-cikk" class="btn"> 4077 <a href="http://www.maot.hu/wp-content/uploads/2014/09/Heft_SPECIAL_eng.pdf" target="_blank">
4077 View abstract</a> 4078 </div> 4079 4080 </div> <!-- .container --> 4081</div><!-- .entry-content --> 4082 4083 4084 4085</article><!-- #post-3338 --> 4086 4087 4088<article id="post-3339" class="post-3339 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry"> 4089 4090 <header class="pub-entry-header"> 4091 <div class="container"> 4092 <h2>Current Status of Oncothermia Therapy for Lung Cancer</h2> 4093 </div> 4094 </header><!-- .entry-header --> 4095 4096 4097<div class="entry-content kl-pub-content"> 4098 <div class="container"> 4099 <div class="acf-fields"> 4100 <div class="acf-row"><span class="publ-label">Indication:</span> Lung <hr/> <span class="publ-label">Evidence:</span> </div> 4101 <div class="publ-acf acf-row acf-flex"> 4102 <span class="publ-label">Author: </span> 4103 <div class="szerzok"> 4104 4105 4106 4107 <span class="sz-nev">Andras Szasz</span> 4108 4109 4110 4111 <span class="sz-nev"> Ph.D</span> 4112 4113 </div> 4114 4115 </div> 4116 <div class="acf-row"><span class="publ-label">No. of patients:</span> <hr/> <span class="publ-label">Therapy:</span> CT+RT+mEHT<hr/> <span class="publ-label">Year:</span> 2014</div> 4117 </div><!-- .acf-fields --> 4118 <h4 id="__abstractidm140542931376624title">Abstract</h4> 4119<p>Lung cancer is one of the most common malignant tumors, and it has the highest death rate. Oncothermia is a feasible and successful treatment for lung cancer. Results show a remarkable survival benefit for patients, with a good quality of life. The treatment has no, or in some cases mild, side-effects and could decrease the adverse effects of the complementary treatment. Applying oncothermia together with other treatment methods could increase the effects and result in better performance. A comparison of studies demonstrates a good correspondence in the data, which strengthens the reliability of the studies, and clearly shows the feasibility of the application of oncothermia to treating all kinds of pulmonary malignancies including non-small-cell and small-cell primary tumors, and all of the metastatic diseases of the pulmonary system.</p> 4120 4121 <div id="teljes-cikk" class="btn"> 4122 <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4000888/" target="_blank"> View abstract</a> 4123 </div> 4124 4125 </div> <!-- .container --> 4126</div><!-- .entry-content --> 4127 4128 4129 4130</article><!-- #post-3339 --> 4131 4132 4133<article id="post-3340" class="post-3340 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry"> 4134 4135 <header class="pub-entry-header"> 4136 <div class="container"> 4137 <h2>The results of combination of ifosfamid and locoregional hyperthermia (EHY 2000) in patients with advanced abdominal soft-tissue sarcoma after relapse of first line chemotherapy</h2> 4138 </div> 4139 </header><!-- .entry-header --> 4140 4141 4142<div class="entry-content kl-pub-content"> 4143 <div class="container"> 4144 <div class="acf-fields"> 4145 <div class="acf-row"><span class="publ-label">Indication:</span> Sarcoma <hr/> <span class="publ-label">Evidence:</span> </div> 4146 <div class="publ-acf acf-row acf-flex"> 4147 <span class="publ-label">Author: </span> 4148 <div class="szerzok"> 4149 4150 4151 4152 <span class="sz-nev">Volovat C</span> 4153 4154 4155 4156 <span class="sz-nev">Volovat SR</span> 4157 4158 4159 4160 <span class="sz-nev">Scripcaru V</span> 4161 4162 4163 4164 <span class="sz-nev">Miron L</span> 4165 4166 4167 4168 <span class="sz-nev">Lupascu C</span> 4169 4170 </div> 4171 4172 </div> 4173 <div class="acf-row"><span class="publ-label">No. of patients:</span> 24 <hr/> <span class="publ-label">Therapy:</span> CT+mEHT<hr/> <span class="publ-label">Year:</span> 2014</div> 4174 </div><!-- .acf-fields --> 4175 <h4 class="text-align-justify" data-reactid="166">Abstract</h4> 4176<div class="text-align-justify" data-reactid="168">From 2003 to 2011, 24 patients with advanced soft-tissue sarcoma with high-risk pretreated using first line chemotherapy with doxorubicin and recurrence disease were treated with chemotherapy (ifosfamide 3000mg/sqm, day 1â3) and locoregional hyperthermia (1 hour application with temperature between 41.5°C and 42°C, 3 days/week). The purpose was to evaluate the efficacy and safety of chemotherapy combined with locoregional non-invasive hyperthermia for local tumor control in patients with retroperitoneal or visceral advanced soft tissue sarc
4176omas. From 24 patients, 18 patients have had an evaluable response on CT scan using RECIST 1.0 (stable disease 8 patients for 4 months and 1 patients for 1 month, partial response 8 patients for 4 months, progression disease for 1 patient). The response was mainly on local tumor site. The side effects were correlated only with chemotherapy (neutropenia grade III 40%, grade 4 20%, trombocytopenia 2%, anemia grade III 10%, neurologic toxicity 9%). No toxicity was correlated with hyperthermia treatment.</div> 4177 4178 <div id="teljes-cikk" class="btn"> 4179 <a href="https://www.researchgate.net/publication/273968670_The_results_of_combination_of_ifosfamid_and_locoregional_hyperthermia_EHY_2000_in_patients_with_advanced_abdominal_soft-tissue_sarcoma_after_relapse_of_first_line_chemotherapyh" target="_blank"> View abstract</a> 4180 </div> 4181 4182 </div> <!-- .container --> 4183</div><!-- .entry-content --> 4184 4185 4186 4187</article><!-- #post-3340 --> 4188 4189 4190<article id="post-3341" class="post-3341 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry"> 4191 4192 <header class="pub-entry-header"> 4193 <div class="container"> 4194 <h2>Sorafenib and locoregional deep electroâhyperthermia in advanced hepatocellular carcinoma: A phase II study</h2> 4195 </div> 4196 </header><!-- .entry-header --> 4197 4198 4199<div class="entry-content kl-pub-content"> 4200 <div class="container"> 4201 <div class="acf-fields"> 4202 <div class="acf-row"><span class="publ-label">Indication:</span> Gastrointestinal <hr/> <span class="publ-label">Evidence:</span> Phase II</div> 4203 <div class="publ-acf acf-row acf-flex"> 4204 <span class="publ-label">Author: </span> 4205 <div class="szerzok"> 4206 4207 4208 4209 <span class="sz-nev">Gennaro Gadaleta-Caldarola</span> 4210 4211 4212 4213 <span class="sz-nev">Stefania Infusino</span> 4214 4215 4216 4217 <span class="sz-nev">Ida Galise</span> 4218 4219 4220 4221 <span class="sz-nev">Girolamo Ranier</span> 4222 4223 4224 4225 <span class="sz-nev">Gianluca Vinciarelli</span> 4226 4227 4228 4229 <span class="sz-nev">Vito Fazio</span> 4230 4231 4232 4233 <span class="sz-nev">Rosa Divella</span> 4234 4235 4236 4237 <span class="sz-nev">Antonella Daniele</span> 4238 4239 4240 4241 <span class="sz-nev">Gianfranco Filippelli</span> 4242 4243 </div> 4244 4245 </div> 4246 <div class="acf-row"><span class="publ-label">No. of patients:</span> 21 <hr/> <span class="publ-label">Therapy:</span> CT+mEHT<hr/> <span class="publ-label">Year:</span> 2014</div> 4247 </div><!-- .acf-fields --> 4248 <p>Abstract.</p> 4249<p>The standard treatment for advanced hepatocellular carcinoma (HCC) is sorafenib, a multikinase inhibitor of tumor cell proliferation and angiogenesis. Hyperthermia inhibits angiogenesis and promotes apoptosis. Potential synergic antiangiogenic and proapoptotic effects represent the rationale for combining sorafenib with electro-hyperthermia (EHY) in HCC. A total of 21 patients (median age, 64 years; range, 55-73 years) with advanced HCC were enrolled in the current study between February 2009 and September 2010. EHY was achieved by arranging capacitive electrodes with a deep hypothermia radiofrequency field of 13.56 Mhz at 80 W for 60 min, three times per week for six weeks, followed by two weeks without treatment, in combination with sorafenib at a dose of 800 mg every other day. According to the modified Response Evaluation Criteria in Solid Tumors criteria, 50% achieved stable disease, 5% achieved partial response and 45% achieved progressive disease. No complete response was observed. The progression-free survival (PFS) rate at six months was 38%, while the median PFS and overall survival times were 5.2 [95% confidence interval (CI), 4.2-6.2) and 10.4 (95% CI, 10-11) months, respectively. The overall incidence of treatment-related adverse events was 80%, predominantly of grade 1 or 2. Grade 3 toxicity included fatigue, diarrhea, hand-foot skin reaction and hypertension. In the present study, the sorafenib plus EHY combination was feasible and well tolerated, and no major complications were observed. The initial findings indicated that this combination offers a promising option for advanced HCC.</p> 4250 4251 <div id="teljes-cikk" class="btn"> 4252 <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4156230/" target="_blank">
4252 View abstract</a> 4253 </div> 4254 4255 </div> <!-- .container --> 4256</div><!-- .entry-content --> 4257 4258 4259 4260</article><!-- #post-3341 --> 4261 4262 4263<article id="post-3342" class="post-3342 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry"> 4264 4265 <header class="pub-entry-header"> 4266 <div class="container"> 4267 <h2>Long-term remission of prostate cancer with extensive bone metastases upon immuno- and virotherapy: A case report</h2> 4268 </div> 4269 </header><!-- .entry-header --> 4270 4271 4272<div class="entry-content kl-pub-content"> 4273 <div class="container"> 4274 <div class="acf-fields"> 4275 <div class="acf-row"><span class="publ-label">Indication:</span> Prostate <hr/> <span class="publ-label">Evidence:</span> Case report</div> 4276 <div class="publ-acf acf-row acf-flex"> 4277 <span class="publ-label">Author: </span> 4278 <div class="szerzok"> 4279 4280 4281 4282 <span class="sz-nev">Schirrmacher V</span> 4283 4284 4285 4286 <span class="sz-nev">Bihari A-S</span> 4287 4288 4289 4290 <span class="sz-nev">Stücker W</span> 4291 4292 </div> 4293 4294 </div> 4295 <div class="acf-row"><span class="publ-label">No. of patients:</span> 1 <hr/> <span class="publ-label">Therapy:</span> mEHT+OV therapy+DC<hr/> <span class="publ-label">Year:</span> 2014</div> 4296 </div><!-- .acf-fields --> 4297 <h3>Abstract</h3> 4298<p>The present study reports the case of a patient with hormone-refractory metastatic prostate cancer who had failed standard therapy, but then achieved complete remission following combined treatment with local hyperthermia (LHT), Newcastle disease virus and dendritic cell (DC) vaccination, which was an unusual combination. In August 2005, the patient underwent a radical prostatectomy. Despite standard treatment, the patient developed progressive bone metastases and stopped conventional therapy in June 2007. Starting in October 2007, the patient was treated with LHT, oncolytic virotherapy and DC vaccination. Prostate-specific antigen (PSA)-levels, with the highest level of 233.8 ng/ml in January 2008, decreased to 0.8 ng/ml in late February 2008. In March 2008, a reduction in bone metastases could be detected by positron emission tomography/computed tomography. Since then, the PSA levels have remained low and the patient is doing well. The treatment induced a long-lasting antitumor memory T-cell response. This possibly explains the long-term effectiveness of this novel experimental combined treatment approach.</p> 4299 4300 <div id="teljes-cikk" class="btn"> 4301 <a href="http://www.ncbi.nlm.nih.gov/pubmed/25364402" target="_blank"> View abstract</a> 4302 </div> 4303 4304 </div> <!-- .container --> 4305</div><!-- .entry-content --> 4306 4307 4308 4309</article><!-- #post-3342 --> 4310 4311 4312<article id="post-3343" class="post-3343 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry"> 4313 4314 <header class="pub-entry-header"> 4315 <div class="container"> 4316 <h2>Electrochemical Therapy of Tumors</h2> 4317 </div> 4318 </header><!-- .entry-header --> 4319 4320 4321<div class="entry-content kl-pub-content"> 4322 <div class="container"> 4323 <div class="acf-fields"> 4324 <div class="acf-row"><span class="publ-label">Indication:</span> Hemangioma <hr/> <span class="publ-label">Evidence:</span> </div> 4325 <div class="publ-acf acf-row acf-flex"> 4326 <span class="publ-label">Author: </span> 4327 <div class="szerzok"> 4328 4329 4330 4331 <span class="sz-nev">Li Jing-Hong</span> 4332 4333 4334 4335 <span class="sz-nev">Xin Yu Ling</span> 4336 4337 </div> 4338 4339 </div> 4340 <div class="acf-row"><span class="publ-label">No. of patients:</span> <hr/> <span class="publ-label">Therapy:</span> ECT<hr/> <span class="publ-label">Year:</span> 2013</div> 4341 </div><!-- .acf-fields --> 4342 <h4>ABSTRACT</h4> 4343<p>Application of electric current for the tumor destruction has a long time history. The theory of the direct galvanic current (galvanotherapy, GT) is worked out by B. Nordenstrom in the frame of biologically closed electric circuits (BCECs). Later, GT was extended by chemical considerations (EChT), and, starting with pioneering work of Professor Xin Yu Ling, a wide, intensive application had been developed in China. My objective is showing the principles and practice of the EChT treatment modality for multiple advanced lesions.<
4343/p> 4344 4345 <div id="teljes-cikk" class="btn"> 4346 <a href="http://www.hindawi.com/archive/2013/858319/" target="_blank"> View abstract</a> 4347 </div> 4348 4349 </div> <!-- .container --> 4350</div><!-- .entry-content --> 4351 4352 4353 4354</article><!-- #post-3343 --> 4355 4356 4357<article id="post-3344" class="post-3344 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry"> 4358 4359 <header class="pub-entry-header"> 4360 <div class="container"> 4361 <h2>Androtherm application for the Peyronie’s Disease</h2> 4362 </div> 4363 </header><!-- .entry-header --> 4364 4365 4366<div class="entry-content kl-pub-content"> 4367 <div class="container"> 4368 <div class="acf-fields"> 4369 <div class="acf-row"><span class="publ-label">Indication:</span> Prostate <hr/> <span class="publ-label">Evidence:</span> </div> 4370 <div class="publ-acf acf-row acf-flex"> 4371 <span class="publ-label">Author: </span> 4372 <div class="szerzok"> 4373 4374 4375 4376 <span class="sz-nev">Ballerini M</span> 4377 4378 4379 4380 <span class="sz-nev">Baronzio G F</span> 4381 4382 4383 4384 <span class="sz-nev">Capito G</span> 4385 4386 4387 4388 <span class="sz-nev">Szasz O</span> 4389 4390 4391 4392 <span class="sz-nev">Cassutti V</span> 4393 4394 </div> 4395 4396 </div> 4397 <div class="acf-row"><span class="publ-label">No. of patients:</span> 30 <hr/> <span class="publ-label">Therapy:</span> mEHT<hr/> <span class="publ-label">Year:</span> 2013</div> 4398 </div><!-- .acf-fields --> 4399 <p><strong>Abstract</strong></p> 4400<p>Peyronie’s disease is characterized by a scarring fibrosis within the tunica albuginea of the penis that could lead to penile length loss, narrowing, curvature, erectile dysfunction, or pain with erection. This problem has recently no appropriate treatment. Our objective is to treat this kind of disease by a new kind of hyperthermia method.</p> 4401 4402 <div id="teljes-cikk" class="btn"> 4403 <a href="http://www.hindawi.com/archive/2013/962349/" target="_blank"> View abstract</a> 4404 </div> 4405 4406 </div> <!-- .container --> 4407</div><!-- .entry-content --> 4408 4409 4410 4411</article><!-- #post-3344 --> 4412 4413 4414<article id="post-3345" class="post-3345 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry"> 4415 4416 <header class="pub-entry-header"> 4417 <div class="container"> 4418 <h2>Low back pain â complex approach of treatment by different CAM modalities (Acupuncture and other type of dry-needling, âTargeted RF non invasive physiotherapyâ for low back pain).</h2> 4419 </div> 4420 </header><!-- .entry-header --> 4421 4422 4423<div class="entry-content kl-pub-content"> 4424 <div class="container"> 4425 <div class="acf-fields"> 4426 <div class="acf-row"><span class="publ-label">Indication:</span> Non-oncology <hr/> <span class="publ-label">Evidence:</span> Phase I/II</div> 4427 <div class="publ-acf acf-row acf-flex"> 4428 <span class="publ-label">Author: </span> 4429 <div class="szerzok"> 4430 4431 4432 4433 <span class="sz-nev">Hegyi G</span> 4434 4435 4436 4437 <span class="sz-nev">Jian Li</span> 4438 4439 </div> 4440 4441 </div> 4442 <div class="acf-row"><span class="publ-label">No. of patients:</span> 2861 <hr/> <span class="publ-label">Therapy:</span> mEHT<hr/> <span class="publ-label">Year:</span> 2013</div> 4443 </div><!-- .acf-fields --> 4444 <h3><strong>Abstract</strong></h3> 4445<p>For at least 2,500 years, acupuncture has been an integral part of the traditional Chinese medicine. Recently, more people are diagnosed with chronic disease, and many of them are poorly treated with conventional therapies. Those frequently prefer other forms of complementary medical treatments. Based on the theory of homeostatic equilibrium being the basis of health, acupuncture focuses on restoring the homeostasis by manipulation of the complementary and opposing elements of yin and yang. It is possible that by affecting afferent nerve signaling, acupuncture may influence the release of endogenous opioids to promote pain relief. Our objective is giving western trained physicians clinical applications together with acupuncture and modern physiotherapeutic equipment (booster) to accommodate accelerating interests in acupuncture and related techniques in modern complex treatment of chronic low back pain. In recent prospective phase I/II study, statistical data verified the relevant end points of the study: the safety, the quality of life (QoL), the rest time, duration of painless state, and cost/benefit ratio.</p> 4446 4447 <div id="teljes-cikk" class="btn"> 4448 <a href="http://www.hindawi.com/archive/2013/326595/" target="_blank">
4448 View abstract</a> 4449 </div> 4450 4451 </div> <!-- .container --> 4452</div><!-- .entry-content --> 4453 4454 4455 4456</article><!-- #post-3345 --> 4457 4458 4459<article id="post-3346" class="post-3346 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry"> 4460 4461 <header class="pub-entry-header"> 4462 <div class="container"> 4463 <h2>Oncothermia with chemotherapy in the patients with Small Cell Lung Cancer</h2> 4464 </div> 4465 </header><!-- .entry-header --> 4466 4467 4468<div class="entry-content kl-pub-content"> 4469 <div class="container"> 4470 <div class="acf-fields"> 4471 <div class="acf-row"><span class="publ-label">Indication:</span> Lung <hr/> <span class="publ-label">Evidence:</span> Phase I</div> 4472 <div class="publ-acf acf-row acf-flex"> 4473 <span class="publ-label">Author: </span> 4474 <div class="szerzok"> 4475 4476 4477 4478 <span class="sz-nev">Doo Yun Lee</span> 4479 4480 4481 4482 <span class="sz-nev">Seok Jin Haam</span> 4483 4484 4485 4486 <span class="sz-nev">Tae Hoon Kim</span> 4487 4488 4489 4490 <span class="sz-nev">Jae Yoon Lim</span> 4491 4492 4493 4494 <span class="sz-nev">Eun Jung Kim</span> 4495 4496 4497 4498 <span class="sz-nev">Na Young Kim</span> 4499 4500 </div> 4501 4502 </div> 4503 <div class="acf-row"><span class="publ-label">No. of patients:</span> 31 <hr/> <span class="publ-label">Therapy:</span> CT+mEHT<hr/> <span class="publ-label">Year:</span> 2013</div> 4504 </div><!-- .acf-fields --> 4505 <p><strong>Abstract</strong></p> 4506<p>Small-cell lung cancer (SCLC) is one of the most aggressive and lethal forms of lung cancers. Chemotherapy and radiotherapy would be standard modality for SCLC with median survival being less than 4 months only. Complementary treatment to chemotherapy is desired. Oncothermia will be one of the candidates to this addition. We have made a study of 31 SCLC patients from April 2006 to March 2012. 23 cases were treated with combined chemotherapy and oncothermia, and 8 cases were treated with chemotherapy alone. Three patients from 14 patients (14/31) died in the study period; there were equal numbers in the two arms, including one long survival case of 28 months and one of 26 months, in the combination and chemo-group, respectively .16 patients (16/31) are alive: 4 patients with chemotherapy only, including one long survival case of 28.7 months, and 11 cases with combined therapy including three long survival cases of more than 3 years. We conclude that the combined use of chemotherapy and oncothermia has significantly enhanced the survival rate in comparison with the use of chemotherapy alone (log-rank test: P value < 0.02).</p> 4507 4508 <div id="teljes-cikk" class="btn"> 4509 <a href="https://www.hindawi.com/archive/2013/910363/" target="_blank"> View abstract</a> 4510 </div> 4511 4512 </div> <!-- .container --> 4513</div><!-- .entry-content --> 4514 4515 4516 4517</article><!-- #post-3346 --> 4518 4519 4520<article id="post-3347" class="post-3347 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry"> 4521 4522 <header class="pub-entry-header"> 4523 <div class="container"> 4524 <h2>Hypoxia Immunity, Metabolism and Hyperthermia</h2> 4525 </div> 4526 </header><!-- .entry-header --> 4527 4528 4529<div class="entry-content kl-pub-content"> 4530 <div class="container"> 4531 <div class="acf-fields"> 4532 <div class="acf-row"><span class="publ-label">Indication:</span> Immuno-oncology <hr/> <span class="publ-label">Evidence:</span> Review</div> 4533 <div class="publ-acf acf-row acf-flex"> 4534 <span class="publ-label">Author: </span> 4535 <div class="szerzok"> 4536 4537 4538 4539 <span class="sz-nev">Baronzio G</span> 4540 4541 4542 4543 <span class="sz-nev">Kiselevsky M</span> 4544 4545 4546 4547 <span class="sz-nev">Ballerini M</span> 4548 4549 4550 4551 <span class="sz-nev">Cassuti V</span> 4552 4553 </div> 4554 4555 </div> 4556 <div class="acf-row"><span class="publ-label">No. of patients:</span> <hr/> <span class="publ-label">Therapy:</span> mEHT<hr/> <span class="publ-label">Year:</span> 2013</div> 4557 </div><!-- .acf-fields --> 4558 <p><strong>Abstract</strong></p> 4559<p>Hypoxia is common in solid tumors and in many other disease states such as myocardial infarction, stroke, bone fracture, and pneumonitis. Once hypoxia has developed, the undernourished and hypoxic cells trigger signals in order to obtain new blood vessels to satisfy their increasing demands and to resolve hypoxia. The principal signal activated is an ancestral oxygen sensor, the hypoxia inducible factor (HIF). After its nuclear translocation, HIF triggers a series of mediators that recruit, into the hypoxic milieu, several immature myeloid, mesenchymal, and endothelial progenitors cells. Resident and recruited cells participate in the processes of neoangiogenesis, for resolving the hypoxia, while at the same time trigger an inflammatory reaction. The inflammatory reaction has as primary end point, the repair of the damaged area, but if an insufficient production of resolvins is produced, the inflammatory reaction becomes chronic and is unable to repair the damaged t
4559issue. In this brief overview, we will show the differences and the similar events present in cancer, myocardial infarction, and stroke. Furthermore, the metabolic alterations produced in the tumor by hypoxia/HIF axis and the consequences on hyperthermic treatment are also discussed.</p> 4560 4561 <div id="teljes-cikk" class="btn"> 4562 <a href="https://www.hindawi.com/archive/2013/528909/" target="_blank"> View abstract</a> 4563 </div> 4564 4565 </div> <!-- .container --> 4566</div><!-- .entry-content --> 4567 4568 4569 4570</article><!-- #post-3347 --> 4571 4572 4573<article id="post-3348" class="post-3348 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry"> 4574 4575 <header class="pub-entry-header"> 4576 <div class="container"> 4577 <h2>Lyme Disease and Oncothermia</h2> 4578 </div> 4579 </header><!-- .entry-header --> 4580 4581 4582<div class="entry-content kl-pub-content"> 4583 <div class="container"> 4584 <div class="acf-fields"> 4585 <div class="acf-row"><span class="publ-label">Indication:</span> Lyme-disease <hr/> <span class="publ-label">Evidence:</span> Phase III</div> 4586 <div class="publ-acf acf-row acf-flex"> 4587 <span class="publ-label">Author: </span> 4588 <div class="szerzok"> 4589 4590 4591 4592 <span class="sz-nev">Zais O</span> 4593 4594 </div> 4595 4596 </div> 4597 <div class="acf-row"><span class="publ-label">No. of patients:</span> 12 <hr/> <span class="publ-label">Therapy:</span> mEHT+Vitamins<hr/> <span class="publ-label">Year:</span> 2013</div> 4598 </div><!-- .acf-fields --> 4599 <h4>Abstract</h4> 4600<p>Lyme disease is a tick-borne disease with multiple organ failures, and systemic disorders. Dramatic change becomes apparent in the chronic phase of the disease. Chronic fatigue syndrome, lapse of concentration, depression, joint pain, and muscle pain are a few, but major clinical symptoms characterizing the disease. The human immune system is defenseless. Borrelia uses various mechanisms to escape from immunoattacks or antibiotic therapies. This âstealth phenomenonâ needs new therapeutic principles to be interrupted. Our objective in this paper is to study the effect of oncothermia, which is a well-established oncological therapy, on Lyme disease. First, in our present work, we definitely concentrate on the quality of life of the patients.</p> 4601 4602 <div id="teljes-cikk" class="btn"> 4603 <a href="http://www.hindawi.com/archive/2013/275013/" target="_blank"> View abstract</a> 4604 </div> 4605 4606 </div> <!-- .container --> 4607</div><!-- .entry-content --> 4608 4609 4610 4611</article><!-- #post-3348 --> 4612 4613 4614<article id="post-3349" class="post-3349 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry"> 4615 4616 <header class="pub-entry-header"> 4617 <div class="container"> 4618 <h2>Oncothermia Application for Various Malignant Diseases</h2> 4619 </div> 4620 </header><!-- .entry-header --> 4621 4622 4623<div class="entry-content kl-pub-content"> 4624 <div class="container"> 4625 <div class="acf-fields"> 4626 <div class="acf-row"><span class="publ-label">Indication:</span> Multiple <hr/> <span class="publ-label">Evidence:</span> Retrospective study</div> 4627 <div class="publ-acf acf-row acf-flex"> 4628 <span class="publ-label">Author: </span> 4629 <div class="szerzok"> 4630 4631 4632 4633 <span class="sz-nev">Youngsuk Lee</span> 4634 4635 </div> 4636 4637 </div> 4638 <div class="acf-row"><span class="publ-label">No. of patients:</span> 277 <hr/> <span class="publ-label">Therapy:</span> CT+RT+mEHT<hr/> <span class="publ-label">Year:</span> 2013</div> 4639 </div><!-- .acf-fields --> 4640 <h5>ABSTRACT</h5> 4641<p>Oncothermia was introduced to our hospital in 2010. Our objective is to report results of 277 patients treated by oncothermia during 20 months. We present some characteristic cases and statistical study of the overall results. We concluded by stating the feasibility of oncothermia to treat high variety of malignant diseases also in their very advanced (T4N3M1) stages.</p> 4642 4643 <div id="teljes-cikk" class="btn"> 4644 <a href="http://www.hindawi.com/archive/2013/245156/" target="_blank"> View abstract</a> 4645 </div> 4646 4647 </div> <!-- .container --> 4648</div><!-- .entry-content --> 4649 4650 4651 4652</article><!-- #post-3349 --> 4653 4654 4655<article id="post-3350" class="post-3350 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry"> 4656 4657 <header class="pub-entry-header"> 4658 <div class="container"> 4659 <h2>Oncothermia in HIV positive and negative locally advanced cervical cancer patients in South Africa</h2> 4660 </div> 4661 </header><!-- .entry-header --> 4662 4663 4664<div class="entry-content kl-pub-content"> 4665 <div class="container"> 4666 <div class="acf-fields"> 4667 <div class="acf-row"><span class="publ-label">Indication:</span> Gynecology <hr/> <span class="publ-label">Evidence:</span> Phase III</div> 4668 <div class="publ-acf acf-row acf-flex"> 4669 <span class="publ-label">Author: </span> 4670 <div class="szerzok"> 4671 4672 4673 4674 <span class="sz-nev">Carrie Strauss</span> 4675 4676 4677 4678 <span class="sz-nev">Jeffrey Kotzen</span> 4679 4680 4681 4682 <span class="sz-nev">
4682Ans Baeyens</span> 4683 4684 4685 4686 <span class="sz-nev">Irma Maré</span> 4687 4688 </div> 4689 4690 </div> 4691 <div class="acf-row"><span class="publ-label">No. of patients:</span> 236 <hr/> <span class="publ-label">Therapy:</span> CT+RT+mEHT<hr/> <span class="publ-label">Year:</span> 2013</div> 4692 </div><!-- .acf-fields --> 4693 <p><strong>Abstract</strong></p> 4694<p>Aim. Investigate the clinical, economic, and cellular effects of the addition of oncothermia to standard treatment for HIV-positive and -negative locally advanced cervical cancer patients in public healthcare in South Africa. Objectives. Evaluate the effect that the addition of oncothermia has on local disease control, progression-free survival, overall survival at 2 years, treatment toxicity, quality of life, economic impact, and HIV status of participants. Radiobiology investigations will evaluate thermoradiosensitivity and the molecular markers for thermoradiosensitivity. Methodology. Phase III randomised clinical trial involving 236 HIV-negative and -positive stage IIb-III locally advanced cervical cancer patients. Treatment includes cisplatin, external beam radiation, and brachytherapy. The study group will receive oncothermia treatments. Participants will be monitored for two years after completion of treatment. Hypothesis. The addition of oncothermia to standard treatment protocols will result in improved clinical response without increasing treatment toxicity in HIV-positive patients or raising healthcare costs.</p> 4695 4696 <div id="teljes-cikk" class="btn"> 4697 <a href="https://www.hindawi.com/archive/2013/293968/" target="_blank"> View abstract</a> 4698 </div> 4699 4700 </div> <!-- .container --> 4701</div><!-- .entry-content --> 4702 4703 4704 4705</article><!-- #post-3350 --> 4706 4707 4708<article id="post-3351" class="post-3351 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry"> 4709 4710 <header class="pub-entry-header"> 4711 <div class="container"> 4712 <h2>Treatment of advanced cervical cancer with complex chemoradio â hyperthermia</h2> 4713 </div> 4714 </header><!-- .entry-header --> 4715 4716 4717<div class="entry-content kl-pub-content"> 4718 <div class="container"> 4719 <div class="acf-fields"> 4720 <div class="acf-row"><span class="publ-label">Indication:</span> Gynecology <hr/> <span class="publ-label">Evidence:</span> Retrospective study</div> 4721 <div class="publ-acf acf-row acf-flex"> 4722 <span class="publ-label">Author: </span> 4723 <div class="szerzok"> 4724 4725 4726 4727 <span class="sz-nev">Lajos Pesti</span> 4728 4729 4730 4731 <span class="sz-nev">Zsófia Dankovics</span> 4732 4733 4734 4735 <span class="sz-nev">Péter Lorencz</span> 4736 4737 4738 4739 <span class="sz-nev">András Csejtei</span> 4740 4741 </div> 4742 4743 </div> 4744 <div class="acf-row"><span class="publ-label">No. of patients:</span> 72 <hr/> <span class="publ-label">Therapy:</span> CT+mEHT<hr/> <span class="publ-label">Year:</span> 2013</div> 4745 </div><!-- .acf-fields --> 4746 <p><strong>Abstract</strong></p> 4747<p>This single arm, retrospective, single institution study investigated intention to treat patients (n=72) with advanced cancer of cervix of uterus. The study was performed in 2001â2010, providing 331 sessions. All patients had radiotherapies as fractional radiotherapy and intracavital brachytherapy. Some patients (n=34) received chemotherapy (Cisplatin 40 mg/m2/week; concomitantly with tele-radiotherapy) as well. Complementary to the teleradiotherapy, oncothermia was used two times a week, targeting the pelvis. Applied energy dose was 45 W, 60 min. Oncothermia was applied immediately after the infusion, when chemotherapy was also administered. Complete and partial remission were achieved in trimodal therapies for 73.5% of the patients, while we could stabilize the disease for 14.7% of the patients.</p> 4748 4749 <div id="teljes-cikk" class="btn"> 4750 <a href="https://www.hindawi.com/archive/2013/192435/" target="_blank"> View abstract</a> 4751 </div> 4752 4753 </div> <!-- .container --> 4754</div><!-- .entry-content --> 4755 4756 4757 4758</article><!-- #post-3351 --> 4759 4760 4761<article id="post-3352" class="post-3352 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry"> 4762 4763 <header class="pub-entry-header"> 4764 <div class="container"> 4765 <h2>Successful Treatment of Advanced Ovarian Cancer with Thermochemotherapy and Adjuvant Immune Therapy</h2> 4766 </div> 4767 </header><!-- .entry-header --> 4768 4769 4770<div class="entry-content kl-pub-content"> 4771 <div class="container"> 4772 <div class="acf-fields"> 4773 <div class="acf-row"><span class="publ-label">Indication:</span> Gynecology <hr/> <span class="publ-label">Evidence:</span> Case report</div> 4774 <div class="publ-acf acf-row acf-flex"> 4775 <span class="publ-label">Author: </span> 4776 <div class="szerzok"> 4777 4778 4779 4780 <span class="sz-nev">R. Kleef</span> 4781 4782 4783 4784 <span class="sz-nev">S. Kekic</span> 4785 4786 4787 4788 <span class="sz-nev">N. Ludwig</span> 4789 4790 </div> 4791 4792 </div> 4793 <div class="acf-row"><span class="publ-label">No. of patients:</span> 1 <hr/> <span class="publ-label">Therapy:</span> CT+mEHT<hr/> <span class="publ-label">Year:</span> 2012</div> 4794 </div><!-- .acf-fields --> 4795 <p><strong>Abstract</strong><br /> 4796We report on a 4-year progression-free survival of a 54-year-old female first diagnosed in December 2007 with advanced bilateral ovarian cancer FIGO IIIc, disseminated peritoneal carcinosis and malignant diaphragm invasion. Treatment started in January 2008 with 6 cycles of Taxol 175 mg/m2/carboplatin AUC 5 in 3-week intervals. Twenty-four hours following each chemotherapy session, fever-range long-duration whole-body hyperthermia (WBH) was performed at the temperature plateau of 40°C body core temperature for 6 h. Three months after completion of chemotherapy, 4 more long-duration WBH procedures were performed in monthly intervals. Importantly, long-duration WBH was paralleled with intradermal vaccination of autologous dendritic cells. No other treatment was given to the patient. Four years following the first diagnosis, the patient is still in complete remission with no evidence of disease.</p> 4797 4798 <div id="teljes-cikk" class="btn"> 4799 <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=Successful%20Treatment%20of%20Advanced%20Ovarian%20Cancer%20with%20Thermochemotherapy%20and%20Adjuvant%20Immune%20Therapy" target="_blank">
4799 View abstract</a> 4800 </div> 4801 4802 </div> <!-- .container --> 4803</div><!-- .entry-content --> 4804 4805 4806 4807</article><!-- #post-3352 --> 4808 4809 4810<article id="post-3353" class="post-3353 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry"> 4811 4812 <header class="pub-entry-header"> 4813 <div class="container"> 4814 <h2>Für und Wider des Prostata-Karzinom-Screenings</h2> 4815 </div> 4816 </header><!-- .entry-header --> 4817 4818 4819<div class="entry-content kl-pub-content"> 4820 <div class="container"> 4821 <div class="acf-fields"> 4822 <div class="acf-row"><span class="publ-label">Indication:</span> Prostate <hr/> <span class="publ-label">Evidence:</span> </div> 4823 <div class="publ-acf acf-row acf-flex"> 4824 <span class="publ-label">Author: </span> 4825 <div class="szerzok"> 4826 4827 4828 4829 <span class="sz-nev">Douwes FR</span> 4830 4831 </div> 4832 4833 </div> 4834 <div class="acf-row"><span class="publ-label">No. of patients:</span> <hr/> <span class="publ-label">Therapy:</span> <hr/> <span class="publ-label">Year:</span> 2011</div> 4835 </div><!-- .acf-fields --> 4836 4837 4838 </div> <!-- .container --> 4839</div><!-- .entry-content --> 4840 4841 4842 4843</article><!-- #post-3353 --> 4844 4845 4846<article id="post-3354" class="post-3354 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry"> 4847 4848 <header class="pub-entry-header"> 4849 <div class="container"> 4850 <h2>Adjuvante Radiotherapie: Welcher Patient mit Prostatakarzinom profitiert?</h2> 4851 </div> 4852 </header><!-- .entry-header --> 4853 4854 4855<div class="entry-content kl-pub-content"> 4856 <div class="container"> 4857 <div class="acf-fields"> 4858 <div class="acf-row"><span class="publ-label">Indication:</span> Prostate <hr/> <span class="publ-label">Evidence:</span> </div> 4859 <div class="publ-acf acf-row acf-flex"> 4860 <span class="publ-label">Author: </span> 4861 <div class="szerzok"> 4862 4863 4864 4865 <span class="sz-nev">Douwes FR</span> 4866 4867 </div> 4868 4869 </div> 4870 <div class="acf-row"><span class="publ-label">No. of patients:</span> <hr/> <span class="publ-label">Therapy:</span> <hr/> <span class="publ-label">Year:</span> 2011</div> 4871 </div><!-- .acf-fields --> 4872 4873 4874 </div> <!-- .container --> 4875</div><!-- .entry-content --> 4876 4877 4878 4879</article><!-- #post-3354 --> 4880 4881 4882<article id="post-3355" class="post-3355 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry"> 4883 4884 <header class="pub-entry-header"> 4885 <div class="container"> 4886 <h2>Successful Treatment of Solitary Bone Metastasis of Non-Small Cell Lung Cancer with Bevacizumab and Hyperthermia</h2> 4887 </div> 4888 </header><!-- .entry-header --> 4889 4890 4891<div class="entry-content kl-pub-content"> 4892 <div class="container"> 4893 <div class="acf-fields"> 4894 <div class="acf-row"><span class="publ-label">Indication:</span> Bone <hr/> <span class="publ-label">Evidence:</span> Case report</div> 4895 <div class="publ-acf acf-row acf-flex"> 4896 <span class="publ-label">Author: </span> 4897 <div class="szerzok"> 4898 4899 4900 4901 <span class="sz-nev">Gábor Rubovszky</span> 4902 4903 4904 4905 <span class="sz-nev">Tünde Nagy</span> 4906 4907 4908 4909 <span class="sz-nev">Mária GÅdény</span> 4910 4911 4912 4913 <span class="sz-nev">András Szász</span> 4914 4915 4916 4917 <span class="sz-nev">István Láng</span> 4918 4919 </div> 4920 4921 </div> 4922 <div class="acf-row"><span class="publ-label">No. of patients:</span> 1 <hr/> <span class="publ-label">Therapy:</span> CT+mEHT<hr/> <span class="publ-label">Year:</span> 2011</div> 4923 </div><!-- .acf-fields --> 4924 <p><strong>Abstract</strong></p> 4925<p>Non-small cell lung cancer (NSCLC) represents 85 % of all malignant lung cancers. In metastatic disease the principle goal of palliative therapy is to prolong survival with least toxicity and best patientsâ quality of life. Bevacizumab (BEV) has been approved as first line treatment in combination with platinum based chemotherapy and maintenance therapy in NSCLC. BEV can be added safely to several chemotherapeutic agents, however there is no data on coadministration with thermotherapy. Even in localized disease no robust evidence exists about the beneficial effect of loco-regional thermotherapy on overall survival, but it might be used successfully in symptom palliation. In this article a successful co-administration of BEV and hyperthermia is reported in a patient with monolocalized bone metastasis from previously operated NSCLC. This case suggests that electrohyperthermia can probably be incorporated in palliative therapy added not only to radiotherapy or chemotherapy but also to anti-angiogenic BEV treatment.</p> 4926 4927 <div id="teljes-cikk" class="btn"> 4928 <a href="https://www.ncbi.nlm.nih.gov/pubmed/22752712" target="_blank">
4928 View abstract</a> 4929 </div> 4930 4931 </div> <!-- .container --> 4932</div><!-- .entry-content --> 4933 4934 4935 4936</article><!-- #post-3355 --> 4937 4938 4939<article id="post-3356" class="post-3356 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry"> 4940 4941 <header class="pub-entry-header"> 4942 <div class="container"> 4943 <h2>Neue Studie heizt Diskussion über den Wert von PSA-Tests an</h2> 4944 </div> 4945 </header><!-- .entry-header --> 4946 4947 4948<div class="entry-content kl-pub-content"> 4949 <div class="container"> 4950 <div class="acf-fields"> 4951 <div class="acf-row"><span class="publ-label">Indication:</span> Prostate <hr/> <span class="publ-label">Evidence:</span> </div> 4952 <div class="publ-acf acf-row acf-flex"> 4953 <span class="publ-label">Author: </span> 4954 <div class="szerzok"> 4955 4956 4957 4958 <span class="sz-nev">Douwes FR</span> 4959 4960 </div> 4961 4962 </div> 4963 <div class="acf-row"><span class="publ-label">No. of patients:</span> <hr/> <span class="publ-label">Therapy:</span> <hr/> <span class="publ-label">Year:</span> 2011</div> 4964 </div><!-- .acf-fields --> 4965 4966 4967 </div> <!-- .container --> 4968</div><!-- .entry-content --> 4969 4970 4971 4972</article><!-- #post-3356 --> 4973 4974
4975<article id="post-3357" class="post-3357 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry"> 4976 4977 <header class="pub-entry-header"> 4978 <div class="container"> 4979 <h2>Oncothermia: Emerging Therapy in Oncology</h2> 4980 </div> 4981 </header><!-- .entry-header --> 4982 4983 4984<div class="entry-content kl-pub-content"> 4985 <div class="container"> 4986 <div class="acf-fields"> 4987 <div class="acf-row"><span class="publ-label">Indication:</span> Multiple <hr/> <span class="publ-label">Evidence:</span> Review</div> 4988 <div class="publ-acf acf-row acf-flex"> 4989 <span class="publ-label">Author: </span> 4990 <div class="szerzok"> 4991 4992 4993 4994 <span class="sz-nev">Marwan Akasheh</span> 4995 4996 </div> 4997 4998 </div> 4999 <div class="acf-row"><span class="publ-label">No. of patients:</span> <hr/> <span class="publ-label">Therapy:</span> <hr/> <span class="publ-label">Year:</span> 2010</div> 5000 </div><!-- .acf-fields --> 5001 <h4>Abstract</h4> 5002<p class="text-align-justify">The healing effect of heat was already mentioned in the advanced cultures of the old Egypt (2400 B.C.), but only the medical professionals of the Greek Antique used this therapeutic approach consistently, acknowledged it and called it over-warming (in Greek: Hyperthermia). Oncothermia is a new paradigm which entails the generation of temperature gradient by self-selection absorption of electric field energy based on the bio-impedance selection and modulated radiofrequency electric current to produce lethal heat flow between the extra- and intracellular matrix of the tumor cell membrane. It provides synergies with other traditional treatment modalities. The spread of this technology worldwide is a strong evidence to support it, based on palliative pain control and prolongation of survival in many solid tumors e.g. liver, pancreas, brain, prostate and lung when other therapies fail.</p> 5003<p><strong>Keywords:</strong><br /> 5004Oncothermia, Cancer, Deep Electro-Hyperthermia, Conductive Hyperthermia, Modulated Radiofrequency Electric Field.</p> 5005 5006 <div id="teljes-cikk" class="btn"> 5007 <a href="http://journals.ju.edu.jo/JMJ/article/view/2088" target="_blank"> View abstract</a> 5008 </div> 5009 5010 </div> <!-- .container --> 5011</div><!-- .entry-content --> 5012 5013 5014 5015</article><!-- #post-3357 --> 5016 5017 5018<article id="post-3358" class="post-3358 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry"> 5019 5020 <header class="pub-entry-header"> 5021 <div class="container"> 5022 <h2>Transcranial electro-hyperthermia combined with alkylating chemotherapy in patients with relapsed high-grade gliomas: phase I clinical results</h2> 5023 </div> 5024 </header><!-- .entry-header --> 5025 5026 5027<div class="entry-content kl-pub-content"> 5028 <div class="container"> 5029 <div class="acf-fields"> 5030 <div class="acf-row"><span class="publ-label">Indication:</span> Gliomas (advanced) <hr/> <span class="publ-label">Evidence:</span> Phase I</div> 5031 <div class="publ-acf acf-row acf-flex"> 5032 <span class="publ-label">Author: </span> 5033 <div class="szerzok"> 5034 5035 5036 5037 <span class="sz-nev">Wismeth C</span> 5038 5039 5040 5041 <span class="sz-nev">Dudel C</span> 5042 5043 5044 5045 <span class="sz-nev">Pascher C</span> 5046 5047 5048 5049 <span class="sz-nev">
5049Ramm P</span> 5050 5051 5052 5053 <span class="sz-nev">Pietsch T</span> 5054 5055 5056 5057 <span class="sz-nev">Hirschmann</span> 5058 5059 5060 5061 <span class="sz-nev">Reinert C</span> 5062 5063 5064 5065 <span class="sz-nev">Proescholdt M</span> 5066 5067 5068 5069 <span class="sz-nev">Rümmele P</span> 5070 5071 5072 5073 <span class="sz-nev">Schuierer G</span> 5074 5075 5076 5077 <span class="sz-nev">Bogdahn U</span> 5078 5079 5080 5081 <span class="sz-nev">Hau P</span> 5082 5083 </div> 5084 5085 </div> 5086 <div class="acf-row"><span class="publ-label">No. of patients:</span> 15 <hr/> <span class="publ-label">Therapy:</span> CT+mEHT<hr/> <span class="publ-label">Year:</span> 2009</div> 5087 </div><!-- .acf-fields --> 5088 <h3>Abstract</h3> 5089<p>Non-invasive loco-regional electro-hyperthermia (EHT) plus alkylating chemotherapy is occasionally used as salvage treatment in the relapse of patients with high-grade gliomas. Experimental data and retrospective studies suggest potential effects. However, no prospective clinical results are available. We performed a single-center prospective non-controlled single-arm Phase I trial. Main inclusion criteria were recurrent high-grade glioma WHO Grade III or IV, age 18-70, and Karnofsky performance score > or = 70. Primary endpoints were dose-limiting toxicities (DLT) and maximum tolerated dose (MTD) with the combined regimen. Groups of 3 or 4 patients were treated 2-5 times a week in a dose-escalation scheme with EHT. Alkylating chemotherapy (ACNU, nimustin) was administered at a dose of 90 mg/m(2) on day 1 of 42 days for up to six cycles or until tumor progression (PD) or DLT occurred. Fifteen patients with high-grade gliomas were included. Relevant toxicities were local pain and increased focal neurological signs or intracranial pressure. No DLT occurred. In some patients, the administration of mannitol during EHT or long-term use of corticosteroids was necessary to resolve symptoms. Although some patients showed responses in their primarily treated sites, the pattern of response was not well defined. EHT plus alkylating chemotherapy is tolerable in patients with relapse of high-grade gliomas. Episodes of intracranial pressure were, at least, possibly attributed to EHT but did not cause DLTs. A Phase II trial targeting treatment effects is warranted on the basis of the results raised in this trial.</p> 5090 5091 <div id="teljes-cikk" class="btn"> 5092 <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=Transcranial%20electro-hyperthermia%20combined%20with%20alkylating%20chemotherapy%20in%20patients%20with%20relapsed%20high-grade%20gliomas%20%E2%80%93%20Phase%20I%20clinical%20results" target="_blank"> View abstract</a> 5093 </div> 5094 5095 </div> <!-- .container --> 5096</div><!-- .entry-content --> 5097 5098 5099 5100</article><!-- #post-3358 --> 5101 5102 5103<article id="post-3359" class="post-3359 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry"> 5104 5105 <header class="pub-entry-header"> 5106 <div class="container"> 5107 <h2>Clinical study for advanced non-small-cell lung-cancer treated by oncothermia</h2> 5108 </div> 5109 </header><!-- .entry-header --> 5110 5111 5112<div class="entry-content kl-pub-content"> 5113 <div class="container"> 5114 <div class="acf-fields"> 5115 <div class="acf-row"><span class="publ-label">Indication:</span> Lung <hr/> <span class="publ-label">Evidence:</span> Open-label study</div> 5116 <div class="publ-acf acf-row acf-flex"> 5117 <span class="publ-label">Author: </span> 5118 <div class="szerzok"> 5119 5120 5121 5122 <span class="sz-nev">Dani A</span> 5123 5124 5125 5126 <span class="sz-nev">Varkonyi A</span> 5127 5128 5129 5130 <span class="sz-nev">Magyar T</span> 5131 5132 5133 5134 <span class="sz-nev">Szasz A</span> 5135 5136 </div> 5137 5138 </div> 5139 <div class="acf-row"><span class="publ-label">No. of patients:</span> 258 <hr/> <span class="publ-label">Therapy:</span> CT+RT+mEHT<hr/> <span class="publ-label">Year:</span> 2009</div> 5140 </div><!-- .acf-fields --> 5141 <p><strong>Abstract</strong></p> 5142<p>The non-small-cell-lung-cancer (NSCLC) is a common malignant tumor, and generally not best candidates for hyperthermia due to the cooling effect of the breathing. We present two retrospective clinical studies for NSCLC done by two medical centers (HTT-MED Day-clinic and Peterfy Hospital) made by special modulated field electro-hyperthermia, called oncothermia. Both of the centers made the treatments by oncothermia in combination with the conventional tumor-therapies. We present the data from both of the centers and make a metaanalysis as well. Results show a remarkable survival benefit for the patients compared to the historical data. The comparison of the studies demonstrates a good correspondence in the data, which strengthens the reliability of the studies, and greatly points out the feasibility of the oncothermia application on the NSCLC.</p> 5143 5144 <div id="teljes-cikk" class="btn"> 5145 <a href="http://www.oncotherm.com/sites/oncotherm/files/2017-07/Clinical_study_for_advanced_non-small-cell_lung_cancer_treated.pdf?_gl=1*1ydmeok*_ga*OTcyNjI1MTIwLjE3MDI2MzM4MDM.*_ga_MD8BX5Q6D8*MTcwMjk4NDg5Ny4xLjEuMTcwMjk4NTE1Mi4wLjAuMA.." target="_blank">
5145 View abstract</a> 5146 </div> 5147 5148 </div> <!-- .container --> 5149</div><!-- .entry-content --> 5150 5151 5152 5153</article><!-- #post-3359 --> 5154 5155 5156<article id="post-3360" class="post-3360 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry"> 5157 5158 <header class="pub-entry-header"> 5159 <div class="container"> 5160 <h2>Clinical study for advanced pancreas cancer treated by oncothermia</h2> 5161 </div> 5162 </header><!-- .entry-header --> 5163 5164 5165<div class="entry-content kl-pub-content"> 5166 <div class="container"> 5167 <div class="acf-fields"> 5168 <div class="acf-row"><span class="publ-label">Indication:</span> Pancreas <hr/> <span class="publ-label">Evidence:</span> Clinical study</div> 5169 <div class="publ-acf acf-row acf-flex"> 5170 <span class="publ-label">Author: </span> 5171 <div class="szerzok"> 5172 5173 5174 5175 <span class="sz-nev">Dani A</span> 5176 5177 5178 5179 <span class="sz-nev">Varkonyi A</span> 5180 5181 5182 5183 <span class="sz-nev">Magyar T</span> 5184 5185 5186 5187 <span class="sz-nev">Szasz A</span> 5188 5189 </div> 5190 5191 </div> 5192 <div class="acf-row"><span class="publ-label">No. of patients:</span> 99 <hr/> <span class="publ-label">Therapy:</span> CT+RT+mEHT<hr/> <span class="publ-label">Year:</span> 2008</div> 5193 </div><!-- .acf-fields --> 5194 <p><strong>Abstract</strong></p> 5195<p>Pancreas cancer (PCA) is an aggressive, common malignant tumor. We present two retrospective clinical studies of PCA done in two medical centers (HTT-MED Day-clinic and Peterfy Hospital). Both of the centers made the treatments by oncothermia in combination with the conventional tumor-therapies. We present the data from both centers and make a metaanalysis of the data as well. Results show a remarkable survival benefit for the patients compared to the historical data. The comparison of the studies shows a good correspondence in the data, which strengthens the reliability of the studies, and points out the feasibility of the oncothermia application on PCA.</p> 5196 5197 <div id="teljes-cikk" class="btn"> 5198 <a href="http://www.pyatthealth.com/wp-content/uploads/2015/03/Hyperthermia-Pancreatic-Cancer.pdf" target="_blank"> View abstract</a> 5199 </div> 5200 5201 </div> <!-- .container --> 5202</div><!-- .entry-content --> 5203 5204 5205 5206</article><!-- #post-3360 --> 5207 5208 5209<article id="post-3361" class="post-3361 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry"> 5210 5211 <header class="pub-entry-header"> 5212 <div class="container"> 5213 <h2>Prostatakarzinom: Neue Aspekte für Diagnostik und Therapie</h2> 5214 </div> 5215 </header><!-- .entry-header --> 5216 5217 5218<div class="entry-content kl-pub-content"> 5219 <div class="container"> 5220 <div class="acf-fields"> 5221 <div class="acf-row"><span class="publ-label">Indication:</span> Prostate <hr/> <span class="publ-label">Evidence:</span> </div> 5222 <div class="publ-acf acf-row acf-flex"> 5223 <span class="publ-label">Author: </span> 5224 <div class="szerzok"> 5225 5226 5227 5228 <span class="sz-nev">Douwes FR</span> 5229 5230 </div> 5231 5232 </div> 5233 <div class="acf-row"><span class="publ-label">No. of patients:</span> <hr/> <span class="publ-label">Therapy:</span> <hr/> <span class="publ-label">Year:</span> 2008</div> 5234 </div><!-- .acf-fields --> 5235 5236 5237 </div> <!-- .container --> 5238</div><!-- .entry-content --> 5239 5240 5241 5242</article><!-- #post-3361 --> 5243 5244 5245<article id="post-3362" class="post-3362 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry"> 5246 5247 <header class="pub-entry-header"> 5248 <div class="container"> 5249 <h2>Prospective phase II trial for recurrent high-grade malignant gliomas with capacitive coupled low radiofrequency (LRF) deep hyperthermia</h2> 5250 </div> 5251 </header><!-- .entry-header --> 5252 5253 5254<div class="entry-content kl-pub-content"> 5255 <div class="container"> 5256 <div class="acf-fields"> 5257 <div class="acf-row"><span class="publ-label">Indication:</span> Gliomas (advanced) <hr/> <span class="publ-label">Evidence:</span> Phase II</div> 5258 <div class="publ-acf acf-row acf-flex"> 5259 <span class="publ-label">Author: </span> 5260 <div class="szerzok"> 5261 5262 5263 5264 <span class="sz-nev">Hager ED</span> 5265 5266 5267 5268 <span class="sz-nev">Sahinbas H</span> 5269 5270 5271 5272 <span class="sz-nev">Groenemeyer DH</span> 5273 5274 5275 5276 <span class="sz-nev">Migeod F</span> 5277 5278 </div> 5279 5280 </div> 5281 <div class="acf-row"><span class="publ-label">No. of patients:</span> 179 <hr/> <span class="publ-label">Therapy:</span> CT+RT+mEHT<hr/> <span class="publ-label">Year:</span> 2008</div> 5282 </div><!-- .acf-fields --> 5283 <p><strong>Abstract</strong></p> 5284<p>Treatment of malignant gliomas is in spite of many new approaches still disappointing. Median survival time (MST) of pts. with glioblastoma multiforme (GM) after diagnosis is 6 to 12 months. Surgery is treatment of first choice, but in most cases healing is not possible. The aims of surgery are tumor debulking or decompression of the brain. Radiation will double MST after surgery but high grade gliomas are not very radiosensitivesurvival. Concomitant radiation with temozollamide
5284could increase median survival time of pts with GM from 12.1 to 14.6 months.</p> 5285 5286 <div id="teljes-cikk" class="btn"> 5287 <a href="http://www.portmoodyhealth.com/resource/prospective-phase-ii-trial-for-recurrent-high-grade-malignant-gliomas-with-capacitive-coupled-low-radiofrequency-lrf-deep-hyperthermia/" target="_blank"> View abstract</a> 5288 </div> 5289 5290 </div> <!-- .container --> 5291</div><!-- .entry-content --> 5292 5293 5294 5295</article><!-- #post-3362 --> 5296 5297 5298<article id="post-3363" class="post-3363 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry"> 5299 5300 <header class="pub-entry-header"> 5301 <div class="container"> 5302 <h2>Sanfte Hilfen für die Prostata</h2> 5303 </div> 5304 </header><!-- .entry-header --> 5305 5306 5307<div class="entry-content kl-pub-content"> 5308 <div class="container"> 5309 <div class="acf-fields"> 5310 <div class="acf-row"><span class="publ-label">Indication:</span> Prostate <hr/> <span class="publ-label">Evidence:</span> </div> 5311 <div class="publ-acf acf-row acf-flex"> 5312 <span class="publ-label">Author: </span> 5313 <div class="szerzok"> 5314 5315 5316 5317 <span class="sz-nev">Douwes FR</span> 5318 5319 </div> 5320 5321 </div> 5322 <div class="acf-row"><span class="publ-label">No. of patients:</span> <hr/> <span class="publ-label">Therapy:</span> <hr/> <span class="publ-label">Year:</span> 2008</div> 5323 </div><!-- .acf-fields --> 5324 5325 5326 </div> <!-- .container --> 5327</div><!-- .entry-content --> 5328 5329 5330 5331</article><!-- #post-3363 --> 5332 5333 5334<article id="post-3364" class="post-3364 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry"> 5335 5336 <header class="pub-entry-header"> 5337 <div class="container"> 5338 <h2>Deep electro-hyperthermia (EHY) with or without thermo-active agents in patients with advanced hepatic cell carcinoma: phase II study</h2> 5339 </div> 5340 </header><!-- .entry-header --> 5341 5342 5343<div class="entry-content kl-pub-content"> 5344 <div class="container"> 5345 <div class="acf-fields"> 5346 <div class="acf-row"><span class="publ-label">Indication:</span> Liver <hr/> <span class="publ-label">Evidence:</span> Phase II</div> 5347 <div class="publ-acf acf-row acf-flex"> 5348 <span class="publ-label">Author: </span> 5349 <div class="szerzok"> 5350 5351 5352 5353 <span class="sz-nev">Ferrari VD</span> 5354 5355 5356 5357 <span class="sz-nev">De Ponti S</span> 5358 5359 5360 5361 <span class="sz-nev">Valcamonico F</span> 5362 5363 5364 5365 <span class="sz-nev">Amoroso V</span> 5366 5367 5368 5369 <span class="sz-nev">Grisanti S</span> 5370 5371 5372 5373 <span class="sz-nev">Rangoni G</span> 5374 5375 5376 5377 <span class="sz-nev">Marpicati P</span> 5378 5379 5380 5381 <span class="sz-nev">Vassalli L</span> 5382 5383 5384 5385 <span class="sz-nev">Simoncini E</span> 5386 5387 5388 5389 <span class="sz-nev">Marini G</span> 5390 5391 </div> 5392 5393 </div> 5394 <div class="acf-row"><span class="publ-label">No. of patients:</span> 22 <hr/> <span class="publ-label">Therapy:</span> SRG+CT+mEHT<hr/> <span class="publ-label">Year:</span> 2007</div> 5395 </div><!-- .acf-fields --> 5396 <p><strong>Background</strong>: Advanced HCC has no standard chemotherapy , all pts would be valuabled in clinical trials. We evaluated effectiveness and toxicity of capacitatively coupled low-frequency 13.56 MHz deep hyperthermia (Oncotherm-EHY 2000) treatment on chemo- refractory malignant primary liver cancer which underwent all other possible treatment. <strong>Methods</strong>: From February 2005 to July 2006, we enrolled 22 pts with advanced HCC. ECOG PS was 1 or O. Viral hepatic infection status was 7 HBV+, 8 HCV+, 1 HCV/HBV+. Median age was 67,5 y (range 63 -78), male/female 20/2 . 15 pts were uneligible for liver surgery, 3 pts received TACE, 1 PEI, 1 a lot of therapy. 7 pts were pre-treated with surgery, 2 also received TACE, 1 PEI and 1 a lot of therapy. 75% of pts were in stage C of BCLC classification. 2 pts had also distant metastases, 70% of pts had portal vein thromboses. 8 pts underwent only to EHY without CT. Schedule: EHY was achieved by arrangements of capacitative electrodes with a radiofrequency field of 13.56 Mhz (RF-DHT) at 80- 130 W equivalent to 41 °- 47° C for 60 minutes, 2 times/w for 5 weeks in combination with thermo-active agents . EHY was applied over 2 time a week over 1 hour as mono – combined therapy . Concomitant chemotherapy was oxaliplatin 50 mgr at fixed dose on D 1and D 15. One
5396cycle is 10 treatments of EHY ; 4 pts underwent 2 cycles and 2 pts to 3 cycles and 1 pt to 4 cycles . Median number of cycles was 1,5 (range 1â4), total EHY applications were 365. <strong>Results</strong>: EHY plus thermo-active drug is beneficial on clinical conditions off treated pts with an excellent compliance on out- patients. We observed 1 CR ( pt has only one bone metastases after 6 months without liver relapse), no PR, 25% of SD. Median survival time was 20â5 weeks (5 – 81+) We noted that 11 pts (50%) presented evidence of increasing well-being. Toxicity : 4 pts had skin reaction after application of EHY. In 3 pts we observed cutaneous hyperemia on the area of treatment and mild burn on the skin ; all symptoms disappeared after local steroid therapy , treatment was interrupted until resolution. <strong>Conclusions</strong>: Low toxicity and clinical benefit will be confirmed in further clinical studies. Capacitively coupled low-frequency 13.56 deep-hyperthermia is feasible for chemo-refractory HCC.</p> 5397 5398 <div id="teljes-cikk" class="btn"> 5399 <a href="http://ascopubs.org/doi/abs/10.1200/jco.2007.25.18_suppl.15168" target="_blank"> View abstract</a> 5400 </div> 5401 5402 </div> <!-- .container --> 5403</div><!-- .entry-content --> 5404 5405 5406 5407</article><!-- #post-3364 --> 5408 5409 5410<article id="post-3365" class="post-3365 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry"> 5411 5412 <header class="pub-entry-header"> 5413 <div class="container"> 5414 <h2>Retrospective clinical study of adjuvant electro-hyperthermia treatment for advanced brain-gliomas</h2> 5415 </div> 5416 </header><!-- .entry-header --> 5417 5418 5419<div class="entry-content kl-pub-content"> 5420 <div class="container"> 5421 <div class="acf-fields"> 5422 <div class="acf-row"><span class="publ-label">Indication:</span> Gliomas (advanced) <hr/> <span class="publ-label">Evidence:</span> Retrospective study</div> 5423 <div class="publ-acf acf-row acf-flex"> 5424 <span class="publ-label">Author: </span> 5425 <div class="szerzok"> 5426 5427 5428 5429 <span class="sz-nev">Sahinbas H</span> 5430 5431 5432 5433 <span class="sz-nev">Groenemeyer DHW</span> 5434 5435 5436 5437 <span class="sz-nev">Boecher E</span> 5438 5439 5440 5441 <span class="sz-nev">Szasz A</span> 5442 5443 </div> 5444 5445 </div> 5446 <div class="acf-row"><span class="publ-label">No. of patients:</span> 140 <hr/> <span class="publ-label">Therapy:</span> mEHT<hr/> <span class="publ-label">Year:</span> 2007</div> 5447 </div><!-- .acf-fields --> 5448 <h3>Summary</h3> 5449<p>Malignant gliomas represent about 70 % of all brain tumors. Despite advances in standard therapy consisting of surgery, radiation therapy and chemotherapy, gliomas remain an essentially fatal disease, with a median survival time of 10 to 12 months and a 2-year survival rate of 8 % to 12 %. Electro-hyperthermia applied either alone or in combination with chemo- and/or radio-therapy is an advanced hyperthermia technique that has been used as adjuvant treatment for patients with malignant glioma. We present the results of a retrospective study of 140 patients with different stages of malignant glioma, which were treated/followed from January 2000 to February 2005. The endpoint was the overall survival and the survival from the 1st electro-hyperthermia treatment. The overall median survival time for patients with mostly advanced malignant glioma who received adjuvant electro-hyperthermia in this study was 20.4 months. The median survival time from the first electro-hyperthermia treatment was 6.6 months. Electro-hyperthermia was safe and well tolerated. The presented results show the feasibility of the treatment and suggest a benefit of the electro-hyperthermia treatment for patients with advanced malignant glioma.</p> 5450 5451 <div id="teljes-cikk" class="btn"> 5452 <a href="https://www.thieme-connect.com/products/ejournals/abstract/10.1055/s-2007-986020" target="_blank"> View abstract</a> 5453 </div> 5454 5455 </div> <!-- .container --> 5456</div><!-- .entry-content --> 5457 5458 5459 5460</article><!-- #post-3365 --> 5461 5462 5463<article id="post-3366" class="post-3366 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry"> 5464 5465 <header class="pub-entry-header"> 5466 <div class="container"> 5467 <h2>A Phase II Clinical Study on Relapsed Malignant Gliomas Treated with Electro-hyperthermia</h2> 5468 </div> 5469 </header><!-- .entry-header --> 5470 5471 5472<div class="entry-content kl-pub-content"> 5473 <div class="container"> 5474 <div class="acf-fields"> 5475 <div class="acf-row"><span class="publ-label">Indication:</span> Gliomas (advanced) <hr/> <span class="publ-label">Evidence:</span> Phase II</div> 5476 <div class="publ-acf acf-row acf-flex"> 5477 <span class="publ-label">Author: </span> 5478 <div class="szerzok"> 5479 5480 5481 5482 <span class="sz-nev">Giammaria Fiorentini</span> 5483 5484 5485 5486 <span class="sz-nev">Petros Giovanis</span> 5487 5488 5489 5490 <span class="sz-nev">Susanna Rossi</span> 5491 5492 5493 5494 <span class="sz-nev">Patrizia Dentico</span> 5495 5496 5497 5498 <span class="sz-nev">Raffaele Paola</span> 5499 5500 5501 5502 <span class="sz-nev">Gina Turrisi</span> 5503 5504 5505 5506 <span class="sz-nev">Paolo Bernardeschi</span> 5507 5508 </div> 5509 5510 </div> 5511 <div class="acf-row"><span class="publ-label">No. of patients:</span> 12 <hr/> <span class="publ-label">Therapy:</span> CT+RT+mEHT<hr/> <span class="publ-label">Year:</span> 2006</div> 5512 </div><!-- .acf-fields --> 5513 <p><strong>Abstract</strong></p> 5514<p>The purpose of this study was to evaluate the activity and toxicity of electro-hyperthermia (ET) on relapsed malignant glioma patients. Twelve patients with histologically diagnosed malignant glioma entered the study. Eight patients had glioblastoma multiforme, two had anaplastic astrocytoma grade III and two had anaplastic oligodendroglioma. All patients were pre-treated with temozolamide-based chemotherapy and radiotherapy. Hyperthermia with short radiofrequency waves of 13.56 MHz was applied using a capacitive coupling technique keeping the skin surface at 20°C. The applied power ranged between 40-150 Watts and the calculated average equivalent temperature in the tumours was above 40°C for more than 90% of the treatment duration. One complete remission and 2 partial remission were achieved, with a response rate of 25%. The median duration of response was 10 months (range 4-32). The median survival of the entire patient population was 9 months, with 25% survival rate at 1 year. ET appears to have some effectiveness in adults with relapsed malignant glioma.</p> 5515 5516 <div id="teljes-cikk" class="btn"> 5517 <a href="http://iv.iiarjournals.org/content/20/6A/721.abstract?sid=f49bdb28-d1ae-45fe-ab24-f8344195a4ae" target="_blank">
5517 View abstract</a> 5518 </div> 5519 5520 </div> <!-- .container --> 5521</div><!-- .entry-content --> 5522 5523 5524 5525</article><!-- #post-3366 --> 5526 5527 5528<article id="post-3367" class="post-3367 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry"> 5529 5530 <header class="pub-entry-header"> 5531 <div class="container"> 5532 <h2>Glioblastoma multiforme Grad IV: Regionale Tiefenhyperthermie, Antiangiogenese mit Thalidomid, Hochdosis-Ascorbinsäureinfusionen und komplementäre Therapie</h2> 5533 </div> 5534 </header><!-- .entry-header --> 5535 5536 5537<div class="entry-content kl-pub-content"> 5538 <div class="container"> 5539 <div class="acf-fields"> 5540 <div class="acf-row"><span class="publ-label">Indication:</span> Gliomas (advanced) <hr/> <span class="publ-label">Evidence:</span> </div> 5541 <div class="publ-acf acf-row acf-flex"> 5542 <span class="publ-label">Author: </span> 5543 <div class="szerzok"> 5544 5545 5546 5547 <span class="sz-nev">Hager ED</span> 5548 5549 5550 5551 <span class="sz-nev">Birkenmeier J</span> 5552 5553 </div> 5554 5555 </div> 5556 <div class="acf-row"><span class="publ-label">No. of patients:</span> <hr/> <span class="publ-label">Therapy:</span> <hr/> <span class="publ-label">Year:</span> 2006</div> 5557 </div><!-- .acf-fields --> 5558 <p><strong>Einleitung</strong></p> 5559<p>Epidemiologisch werden primäre Hirntumoren in Deutschland mit einer Inzidenz von etwa 10/100 000 Einwohner und Jahr beobachtet. Im Erwachsenenalter sind hierbei bis zu 50 % aller Gehirntumoren den Gliomen zuzuordnen mit deutlichem Anstieg ab dem 65. Lebensjahr auf ca. 18/100 000 Einwohner [<b><a href="https://www.thieme-connect.com/products/ejournals/abstract/10.1055/s-2006-952050#R006-01" target="_blank" rel="noopener">1</a></b>], [<b><a href="https://www.thieme-connect.com/products/ejournals/abstract/10.1055/s-2006-952050#R006-02" target="_blank" rel="noopener">2</a></b>]. Männer erkranken statistisch gesehen häufiger als Frauen (m/w: 1,2-1,9/1).</p> 5560<p>Die histologische Klassifikation, die nach dem überwiegendem Zelltyp vorgenommen wird, stellt eine wesentliche Grundlage für die Behandlung von malignen Gliomen dar, da die verschiedenen, feingeweblichen Entitäten ein unterschiedliches biologisches Verhalten und somit auch eine unterschiedliche Malignität aufweisen [<b><a href="https://www.thieme-connect.com/products/ejournals/abstract/10.1055/s-2006-952050#R006-15" target="_blank" rel="noopener">15</a></b>].</p> 5561<p>Nach <em class="ITALIC">Kernohan (1949)</em> und <em class="ITALIC">Russel (1977)</em> werden die einzelnen Tumoren in bis zu 4 Malignitätsgraden, entsprechend dem histologischen Grad der Entdifferenzierung und des Wachstumsverhaltens, unterteilt. Für Grad-I- und -II-Tumoren wird eine mittlere Ãberlebensdauer von 3 bis 5 Jahren angegeben. Bereits Gehirntumore vom Grad III mit malignem, infiltrativem Tumorwachstum verzeichnen eine Ãberlebensdauer von 2 bis 3 Jahren, während die Prognose für Patienten mit einem hochmalignem Glioblastoma multiforme Grad IV mit einer mittleren Ãberlebenszeit von 10 bis 12 Monaten als ganz schlecht anzusehen ist [<b><a href="https://www.thieme-connect.com/products/ejournals/abstract/10.1055/s-2006-952050#R006-01" target="_blank" rel="noopener">1</a></b>], [<b><a href="https://www.thieme-connect.com/products/ejournals/abstract/10.1055/s-2006-952050#R006-05" target="_blank" rel="noopener">5</a></b>].</p> 5562<p>Je nach histologischer Klassifikation kommen als leitlinienorientierte BehandlungsmaÃnahmen von Hirntumoren die operative Entfernung [<b><a href="https://www.thieme-connect.com/products/ejournals/abstract/10.1055/s-2006-952050#R006-01" target="_blank" rel="noopener">1</a></b>], [<b><a href="https://www.thieme-connect.com/products/ejournals/abstract/10.1055/s-2006-952050#R006-02" target="_blank" rel="noopener">2</a></b>], [<b><a href="https://www.thieme-connect.com/products/ejournals/abstract/10.1055/s-2006-952050#R006-14" target="_blank" rel="noopener">14</a></b>] – zumindest eines GroÃteils des Tumors – und eine postoperative Bestrahlung mit einer empfohlenen Dosis von 60 Gy [<b><a href="https://www.thieme-connect.com/products/ejournals/abstract/10.1055/s-2006-952050#R006-01" target="_blank" rel="noopener">1</a></b>], [<b><a href="https://www.thieme-connect.com/products/ejournals/abstract/10.1055/s-2006-952050#R006-02" target="_blank" rel="noopener">2</a></b>
5562], [<b><a href="https://www.thieme-connect.com/products/ejournals/abstract/10.1055/s-2006-952050#R006-13" target="_blank" rel="noopener">13</a></b>], [<b><a href="https://www.thieme-connect.com/products/ejournals/abstract/10.1055/s-2006-952050#R006-14" target="_blank" rel="noopener">14</a></b>] sowie ggf. die Chemotherapie (z.B. Temozolomid) in Frage [<b><a href="https://www.thieme-connect.com/products/ejournals/abstract/10.1055/s-2006-952050#R006-03" target="_blank" rel="noopener">3</a></b>], [<b><a href="https://www.thieme-connect.com/products/ejournals/abstract/10.1055/s-2006-952050#R006-09" target="_blank" rel="noopener">9</a></b>].</p> 5563<p>Die Radiatio erfuhr in den letzten Jahren einen stärkergradigen positiven Effekt mit Verlängerung der Ãberlebenszeit um etwa 4 bis 5 Monate, bedingt dadurch, dass eine höhere Strahlendosis hierbei exakter auf den Tumor gerichtet werden kann [<b><a href="https://www.thieme-connect.com/products/ejournals/abstract/10.1055/s-2006-952050#R006-08" target="_blank" rel="noopener">8</a></b>].</p> 5564<p>Der Nutzen einer Chemotherapie ist allerdings nach wie vor äuÃerst umstritten und wird unter Experten kontrovers diskutiert, so insbesondere beim Grad-IV-Glioblastom, wo kein wesentlicher Effekt evaluierbar ist [<b><a href="https://www.thieme-connect.com/products/ejournals/abstract/10.1055/s-2006-952050#R006-01" target="_blank" rel="noopener">1</a></b>]. Nach einer aktuellen randomisierten EORTC-Studie [<b><a href="https://www.thieme-connect.com/products/ejournals/abstract/10.1055/s-2006-952050#R006-12" target="_blank" rel="noopener">12</a></b>] bei Glioblastomen aus dem Jahr 2005 konnte die mediane Ãberlebenszeit von Patienten in gutem AZ durch eine Radiochemotherapie mit Temozolomid von 12 auf 15 Monate gesteigert werden, während bei Patienten in schlechtem AZ die adjuvante Chemotherapie nicht sicher wirksam war [<b><a href="https://www.thieme-connect.com/products/ejournals/abstract/10.1055/s-2006-952050#R006-05" target="_blank" rel="noopener">5</a></b>], [<b><a href="https://www.thieme-connect.com/products/ejournals/abstract/10.1055/s-2006-952050#R006-13" target="_blank" rel="noopener">13</a></b>]. Literaturangaben zufolge lassen weder eine Polychemotherapie inkl. des PCV-Schemas [<b><a href="https://www.thieme-connect.com/products/ejournals/abstract/10.1055/s-2006-952050#R006-01" target="_blank" rel="noopener">1</a></b>], [<b><a href="https://www.thieme-connect.com/products/ejournals/abstract/10.1055/s-2006-952050#R006-02" target="_blank" rel="noopener">2</a></b>], [<b><a href="https://www.thieme-connect.com/products/ejournals/abstract/10.1055/s-2006-952050#R006-07" target="_blank" rel="noopener">7</a></b>] noch eine Monotherapie mit BCNU oder ACNU nennenswert wirksame und lebensverlängernde Ansprechraten erkennen, wobei die individuelle Lebensqualität der Patienten unter dem Therapieregime entsprechende Berücksichtigung finden sollte [<b><a href="https://www.thieme-connect.com/products/ejournals/abstract/10.1055/s-2006-952050#R006-05" target="_blank" rel="noopener">5</a></b>], [<b><a href="https://www.thieme-connect.com/products/ejournals/abstract/10.1055/s-2006-952050#R006-11" target="_blank" rel="noopener">11</a></b>].</p> 5565 5566 <div id="teljes-cikk" class="btn"> 5567 <a href="https://www.thieme-connect.com/products/ejournals/abstract/10.1055/s-2006-952050" target="_blank"> View abstract</a> 5568 </div> 5569 5570 </div> <!-- .container --> 5571</div><!-- .entry-content --> 5572 5573 5574 5575</article><!-- #post-3367 --> 5576 5577 5578<article id="post-3368" class="post-3368 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry"> 5579 5580 <header class="pub-entry-header"> 5581 <div class="container"> 5582 <h2>Behandlung des fortgeschrittenen Pankreaskarzinoms mit regionaler Hyperthermie und einer Zytostase mit Mitomycin- C und 5-Fluorouracil/ Folinsäure</h2> 5583 </div> 5584 </header><!-- .entry-header --> 5585 5586 5587<div class="entry-content kl-pub-content"> 5588 <div class="container"> 5589 <div class="acf-fields"> 5590 <div class="acf-row"><span class="publ-label">Indication:</span> Pancreas <hr/> <span class="publ-label">Evidence:</span> </div> 5591 <div class="publ-acf acf-row acf-flex"> 5592 <span class="publ-label">Author: </span> 5593 <div class="szerzok"> 5594 5595 5596 5597 <span class="sz-nev">Douwes F</span> 5598 5599 5600 5601 <span class="sz-nev">Migeod F</span> 5602 5603 5604 5605 <span class="sz-nev">Grote C</span> 5606 5607 </div> 5608 5609 </div> 5610 <div class="acf-row"><span class="publ-label">No. of patients:</span> 30 <hr/> <span class="publ-label">Therapy:</span> CT+mEHT<hr/> <span class="publ-label">Year:</span> 2006</div> 5611 </div><!-- .acf-fields --> 5612 <p><strong>Zusammenfassung</strong></p> 5613<p><strong>Hintergrund</strong></p> 5614<p>Das Pankreaskarzinom stellt für die onkologische Therapie nach wie vor eine groÃe Herausforderung dar. Bisher lässt sich der fortsc
5614hreitende Verlauf der Erkrankung kaum aufhalten, so dass die 5- Jahres- Ãberlebensrate unter 1% liegt. Aufgrund der niedrigen Ansprechraten einer zytostatischen Therapie soll die Wirksamkeit einer Chemotherapie mit Mitomycin C/ 5-Fluorouracil/ Folinsäure durch den Einsatz der regionalen Hyperthermie verstärkt werden.</p> 5615<p><strong>Methoden</strong></p> 5616<p>Die Behandlungsergebnisse von 30 Patienten mit einem fortgeschrittenen Pankreaskarzinom wurden ausgewertet. Die Therapie bestand in einer Zytostase mit Mitomycin C (8 mg/m2), Tag 1 sowie 5-Fluorouracil (500 mg/m2) und Folinsäure (200 mg/m2) am Tag 1-5 und einer regionalen kapazitiven Hyperthermie (13,56 MHz), welche am Tag 1, 3, 5 und 10 für jeweils 60 min. angewendet wurde. Während der Hyperthermie wurden dabei im Tumorgewebe Temperaturen von 420C bis 440C erreicht. Der Behandlungszyklus wurde alle 4 Wochen, bis zum Auftreten einer Progression, wiederholt.</p> 5617<p><strong>Ergebnisse</strong></p> 5618<p>Die 30 Patienten erhielten insgesamt 94 Behandlungszyklen. Als Resultat der Kombinationstherapie kam es bei einem Patienten zu einer kompletten Remission, 10 (33,3%) weitere zeigte eine partielle Remission. Bei 12 (40%) konnte eine Stabilisierung der Erkrankung erreicht werden, 7 Patienten (23,3%) sprachen nicht auf die Therapie an. Die mediane Ãberlebenszeit betrug 8 Monate (2-53), die mediane Zeit bis zur Progression (1-40 Monate). Schluss Die Kombination von regionaler Hyperthermie und Chemotherapie stellt eine sinnvolle Erweiterung in der palliativen Behandlung von Pankreaskarzinomen dar. Die in unserer Klinik gemachten Erfahrungen zeigen eine erhöhte Effektivität der eingesetzten Zytostatika bei guter Verträglichkeit.</p> 5619 5620 <div id="teljes-cikk" class="btn"> 5621 <a href="https://www.researchgate.net/publication/237633519_Behandlung_des_fortgeschrittenen_Pankreaskarzinoms_mit_regionaler_Hyperthermie_und_einer_Zytostase_mit_Mitomycin_C_und_5FluorouracilFolinsaure" target="_blank"> View abstract</a> 5622 </div> 5623 5624 </div> <!-- .container --> 5625</div><!-- .entry-content --> 5626 5627 5628 5629</article><!-- #post-3368 --> 5630 5631 5632<article id="post-3369" class="post-3369 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry"> 5633 5634 <header class="pub-entry-header"> 5635 <div class="container"> 5636 <h2>Thermo-chemotherapy of the advanced pancreas carcinoma</h2> 5637 </div> 5638 </header><!-- .entry-header --> 5639 5640 5641<div class="entry-content kl-pub-content"> 5642 <div class="container"> 5643 <div class="acf-fields"> 5644 <div class="acf-row"><span class="publ-label">Indication:</span> Pancreas <hr/> <span class="publ-label">Evidence:</span> </div> 5645 <div class="publ-acf acf-row acf-flex"> 5646 <span class="publ-label">Author: </span> 5647 <div class="szerzok"> 5648 5649 5650 5651 <span class="sz-nev">Douwes FR</span> 5652 5653 </div> 5654 5655 </div> 5656 <div class="acf-row"><span class="publ-label">No. of patients:</span> 18 <hr/> <span class="publ-label">Therapy:</span> CT+mEHT<hr/> <span class="publ-label">Year:</span> 2006</div> 5657 </div><!-- .acf-fields --> 5658 <div data-reactid="57"><strong>Abstract</strong></div> 5659<div data-reactid="59">The results of chemotherapy of pancreas carcinoma are still disappointing. In nearly all cases the disease progresses, response rates to cytotoxic therapy are low and the 5-year survival rate amounts to 1%. The purpose of the present study was to evaluate whether response rate, time to progression and survival time can be improved by the combination of cytostatic treatment and loco-regional hyperthermia (thermo-chemotherapy). Results: According to the standard criteria, 1 patient had a complete remission, 10 patients had a partial remission; 7 patients did not respond to the therapy and showed progressive disease. Thermo-chemotherapy as applied in this clinical study shows a remarkable clinical outcome in advanced pancreas cancer and is well tolerated. The results suggest further evaluation in randomized trials.</div> 5660 5661 <div id="teljes-cikk" class="btn"> 5662 <a href="https://www.researchgate.net/publication/287861898_Thermo-chemotherapy_of_the_advanced_pancreas_carcinoma" target="_blank"> View abstract</a> 5663 </div> 5664 5665 </div> <!-- .container --> 5666</div><!-- .entry-content --> 5667 5668 5669 5670</article><!-- #post-3369 --> 5671 5672 5673<article id="post-3370" class="post-3370 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry"> 5674 5675 <header class="pub-entry-header"> 5676 <div class="container"> 5677 <h2>Malignes Melanom Stadium IV: Anwendung von regionaler Tiefenhyperthermie, Tamoxifen, Interferon-α und komplementären Therapien</h2> 5678 </div> 5679 </header><!-- .entry-header --> 5680 5681 5682<div class="entry-content kl-pub-content"> 5683 <div class="container"> 5684 <div class="acf-fields"> 5685 <div class="acf-row"><span class="publ-label">Indication:</span> Melanoma <hr/> <span class="publ-label">Evidence:</span> </div> 5686 <div class="publ-acf acf-row acf-flex"> 5687 <span class="publ-label">Author: </span> 5688 <div class="szerzok"> 5689 5690 5691 5692 <span class="sz-nev">Hager ED</span> 5693 5694 5695 5696 <span class="sz-nev">Birkenmeier J</span> 5697 5698 </div> 5699 5700 </div> 5701 <div class="acf-row"><span class="publ-label">No. of patients:</span> <hr/> <span class="publ-label">Therapy:</span> <hr/> <span class="publ-label">Year:</span> 2006</div> 5702 </div><!-- .acf-fields --> 5703 <article> 5704<div id="sections"> 5705<section id="abstract"> 5706<h3>Einleitung</h3> 5707<p>Die Prognose von Patienten mit metastasiertem Melanom ist schlecht. Alle bisherigen Behandlungskonzepte sind unbefriedigend. Die mediane Ãberlebenszeit liegt in den meisten Studien zwischen 6 und 9 Monaten und das 5-Jahresüberleben bei nur 1 bis 2 %.</p> 5708<p>
5708Zytostatika ermöglichen Ansprechraten zwischen 10 und 20 % mit einem Anteil von kompletten Ansprechraten von bis zu 5 %. Am besten sprechen Haut-, Lymphknoten- und Lungenmetastasen an. Obwohl ein Viertel der kompletten Remissionen länger anhalten, überleben weniger als 2 % der Patienten 5-6 Jahre. Dacarbazin ist das einzige für diese Indikation zugelassene Zytostatikum, aber es gibt keine Phase-III-Studien, die einen Ãberlebensvorteil im Vergleich zu anderen Behandlungen oder selbst Nicht-Behandlungen zeigen. Temozolomid, als aktiver Metabolit von Dacarbazin, kann ebenfalls angewendet werden. Platinderivate weisen eine mäÃige Aktivität bei Melanomen auf; ebenso Vinblastin und Taxane. Nach Phase-II-Untersuchungen scheint die Kombination mit Tamoxifen die antineoplastische Wirkung von Zytostatika zu verstärken (von 10 % auf über 40 % mit Å CR); aber in Phase-III-Studien wurden diese Resultate bisher nicht bestätigt.</p> 5709<p>Obwohl die Immuntherapie nur bei einem kleinen Prozentsatz der Patienten effektiv ist, können die Resultate in Einzelfällen dramatisch sein. Die bisher am meisten untersuchten Substanzen sind Interferon-α (IFN-α) und Interleukin-2 (IL-2), weshalb sie in die Therapie einbezogen werden. Das Tumoransprechen liegt bei 15 %, ist aber meist auf kleinvolumige kutane oder Weichteiltumore beschränkt. Allerdings kann die progressionsfreie Zeit von Patienten mit einer kompletten Remission (ca. 5 %) nach einer Immuntherapie sehr lang sein. Monoklonale Antikörper gegen Ganglioside, meist GD2 und GD3, zeigten antitumorale Aktivitäten in Phase-I/II-Studien. Durch Konjugation mit Antikörpern und Fusion mit Proteinen kann die Wirkung noch gesteigert werden. Die adoptive Immuntherapie mit âIL-2-aktivierten peripheren Blut-Lymphozytenâ (LAK-Zellen) führte zu keinem therapeutischen Vorteil. Dagegen konnte mit âTumor-infiltrierenden Lymphozytenâ (TILs) in Phase-I/II-Studien ein Ansprechen in bis zu 34 % erreicht werden. Vakzinationsstrategien mit verschiedenen Melanom-Zellpräparationen erwiesen sich potenziell effektiv, aber die optimalen Bedingungen für diese Therapien müssen noch gefunden werden. Dies gilt auch für die Therapie mit dendritischen Zellen. Das Hauptproblem der Immuntherapie liegt wohl in der Ãberwindung der tumorassoziierten Immunsuppressionen.</p> 5710</section> 5711</div> 5712</article> 5713 5714 <div id="teljes-cikk" class="btn"> 5715 <a href="https://www.thieme-connect.com/products/ejournals/abstract/10.1055/s-2006-932313" target="_blank"> View abstract</a> 5716 </div> 5717 5718 </div> <!-- .container --> 5719</div><!-- .entry-content --> 5720 5721 5722 5723</article><!-- #post-3370 --> 5724 5725 5726<article id="post-3371" class="post-3371 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry"> 5727 5728 <header class="pub-entry-header"> 5729 <div class="container"> 5730 <h2>Hyperthermia in combination with ACNU chemotherapy in the treatment of recurrent glioblastoma</h2> 5731 </div> 5732 </header><!-- .entry-header --> 5733 5734 5735<div class="entry-content kl-pub-content"> 5736 <div class="container"> 5737 <div class="acf-fields"> 5738 <div class="acf-row"><span class="publ-label">Indication:</span> Gliomas (advanced) <hr/> <span class="publ-label">Evidence:</span> </div> 5739 <div class="publ-acf acf-row acf-flex"> 5740 <span class="publ-label">Author: </span> 5741 <div class="szerzok"> 5742 5743 5744 5745 <span class="sz-nev">Douwes F</span> 5746 5747 5748 5749 <span class="sz-nev">Douwes O</span> 5750 5751 5752 5753 <span class="sz-nev">Migeod F</span> 5754 5755 5756 5757 <span class="sz-nev">Grote C</span> 5758 5759 5760 5761 <span class="sz-nev">Bogovic J</span> 5762 5763 </div> 5764 5765 </div> 5766 <div class="acf-row"><span class="publ-label">No. of patients:</span> 19 <hr/> <span class="publ-label">Therapy:</span> SRG+CT+RT+mEHT<hr/> <span class="publ-label">Year:</span> 2006</div> 5767 </div><!-- .acf-fields --> 5768 5769 5770 </div> <!-- .container --> 5771</div><!-- .entry-content --> 5772 5773 5774 5775</article><!-- #post-3371 --> 5776 5777 5778<article id="post-3372" class="post-3372 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry"> 5779 5780 <header class="pub-entry-header"> 5781 <div class="container"> 5782 <h2>Bestrahlung der Prostata erhöht Rektum-Ca-Risiko</h2> 5783 </div> 5784 </header><!-- .entry-header --> 5785 5786 5787<div class="entry-content kl-pub-content"> 5788 <div class="container"> 5789 <div class="acf-fields"> 5790 <div class="acf-row"><span class="publ-label">Indication:</span> Prostate <hr/> <span class="publ-label">Evidence:</span> </div> 5791 <div class="publ-acf acf-row acf-flex"> 5792 <span class="publ-label">Author: </span> 5793 <div class="szerzok"> 5794 5795 5796 5797 <span class="sz-nev">Douwes FR</span> 5798 5799 </div> 5800 5801 </div> 5802 <div class="acf-row"><span class="publ-label">No. of patients:</span> <hr/> <span class="publ-label">Therapy:</span> <hr/> <span class="publ-label">Year:</span> 2005</div> 5803 </div><!-- .acf-fields --> 5804 5805 5806 </div> <!-- .container --> 5807</div><!-- .entry-content --> 5808 5809 5810 5811</article><!-- #post-3372 --> 5812 5813 5814<article id="post-3373" class="post-3373 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry"> 5815 5816 <header class="pub-entry-header"> 5817 <div class="container"> 5818 <h2>Whole body hyperthermia combined with carboplatin/paclitaxel in patients with ovarian carcinoma â Phase-II-study</h2> 5819 </div> 5820 </header><!-- .entry-header --> 5821 5822 5823<div class="entry-content kl-pub-content"> 5824 <div class="container"> 5825 <div class="acf-fields"> 5826 <div class="acf-row"><span class="publ-label">Indication:</span> Gynecology <hr/> <span class="publ-label">Evidence:</span> Phase II</div> 5827 <div class="publ-acf acf-row acf-flex"> 5828 <span class="publ-label">Author: </span> 5829 <div class="szerzok"> 5830 5831 5832 5833 <span class="sz-nev">Strobl B</span> 5834 5835 5836 5837 <span class="sz-nev">Rjosk D</span> 5838 5839 5840 5841 <span class="sz-nev">Janni W</span> 5842 5843 5844 5845 <span class="sz-nev">et al.</span> 5846 5847 </div> 5848 5849 </div> 5850 <div class="acf-row"><span class="publ-label">No. of patients:</span> 9 <hr/> <span class="publ-label">Therapy:</span> CT+WBH<hr/> <span class="publ-label">Year:</span> 2004</div> 5851 </div><!-- .acf-fields --> 5852 5853 <div id="teljes-cikk" class="btn"> 5854 <a href="http://ascopubs.org/doi/abs/10.1200/jco.2004.22.14_suppl.5128" target="_blank">
5854 View abstract</a> 5855 </div> 5856 5857 </div> <!-- .container --> 5858</div><!-- .entry-content --> 5859 5860 5861 5862</article><!-- #post-3373 --> 5863 5864 5865<article id="post-3374" class="post-3374 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry"> 5866 5867 <header class="pub-entry-header"> 5868 <div class="container"> 5869 <h2>Rebell gegen den Krebs. Biologische Intersivtherapie â Neue Hoffnung für Patienten?</h2> 5870 </div> 5871 </header><!-- .entry-header --> 5872 5873 5874<div class="entry-content kl-pub-content"> 5875 <div class="container"> 5876 <div class="acf-fields"> 5877 <div class="acf-row"><span class="publ-label">Indication:</span> Prostate <hr/> <span class="publ-label">Evidence:</span> </div> 5878 <div class="publ-acf acf-row acf-flex"> 5879 <span class="publ-label">Author: </span> 5880 <div class="szerzok"> 5881 5882 5883 5884 <span class="sz-nev">Maar K</span> 5885 5886 </div> 5887 5888 </div> 5889 <div class="acf-row"><span class="publ-label">No. of patients:</span> <hr/> <span class="publ-label">Therapy:</span> <hr/> <span class="publ-label">Year:</span> 2004</div> 5890 </div><!-- .acf-fields --> 5891 5892 5893 </div> <!-- .container --> 5894</div><!-- .entry-content --> 5895 5896 5897 5898</article><!-- #post-3374 --> 5899 5900 5901<article id="post-3375" class="post-3375 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry"> 5902 5903 <header class="pub-entry-header"> 5904 <div class="container"> 5905 <h2>Whole-body hyperthermia in combination with platinum containing drugs in patients with recurrent ovarian cancer</h2> 5906 </div> 5907 </header><!-- .entry-header --> 5908 5909 5910<div class="entry-content kl-pub-content"> 5911 <div class="container"> 5912 <div class="acf-fields"> 5913 <div class="acf-row"><span class="publ-label">Indication:</span> Gynecology <hr/> <span class="publ-label">Evidence:</span> </div> 5914 <div class="publ-acf acf-row acf-flex"> 5915 <span class="publ-label">Author: </span> 5916 <div class="szerzok"> 5917 5918 5919 5920 <span class="sz-nev">Douwes F</span> 5921 5922 5923 5924 <span class="sz-nev">BogoviC J</span> 5925 5926 5927 5928 <span class="sz-nev">Douwes O et al.</span> 5929 5930 </div> 5931 5932 </div> 5933 <div class="acf-row"><span class="publ-label">No. of patients:</span> 21 <hr/> <span class="publ-label">Therapy:</span> CT+WBH<hr/> <span class="publ-label">Year:</span> 2004</div> 5934 </div><!-- .acf-fields --> 5935 <h3>Abstract</h3> 5936<div> 5937<h5>BACKGROUND:</h5> 5938<p class="text-align-justify">Patients with advanced ovarian cancer have an enormous risk of relapse after primary therapy, and the prognosis for these patients remains bleak. Primary and acquired resistance of tumor cells to antineoplastic drugs is a major cause of the limited effectiveness of chemotherapy. The effect of whole-body hyperthermia (WBH) combined with platinum-containing chemotherapy in the treatment of recurrent ovarian cancer was examined in this study.</p> 5939</div> 5940 5941 <div id="teljes-cikk" class="btn"> 5942 <a href="http://www.ncbi.nlm.nih.gov/pubmed/15108039" target="_blank"> View abstract</a> 5943 </div> 5944 5945 </div> <!-- .container --> 5946</div><!-- .entry-content --> 5947 5948 5949 5950</article><!-- #post-3375 --> 5951 5952 5953<article id="post-3376" class="post-3376 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry"> 5954 5955 <header class="pub-entry-header"> 5956 <div class="container"> 5957 <h2>Lebermetastasen bei kolorektalen Karzinomen</h2> 5958 </div> 5959 </header><!-- .entry-header --> 5960 5961 5962<div class="entry-content kl-pub-content"> 5963 <div class="container"> 5964 <div class="acf-fields"> 5965 <div class="acf-row"><span class="publ-label">Indication:</span> Liver <hr/> <span class="publ-label">Evidence:</span> </div> 5966 <div class="publ-acf acf-row acf-flex"> 5967 <span class="publ-label">Author: </span> 5968 <div class="szerzok"> 5969 5970 5971 5972 <span class="sz-nev">Hager ED</span> 5973 5974 </div> 5975 5976 </div> 5977 <div class="acf-row"><span class="publ-label">No. of patients:</span> <hr/> <span class="publ-label">Therapy:</span> <hr/> <span class="publ-label">Year:</span> 2004</div> 5978 </div><!-- .acf-fields --> 5979 5980 5981 </div> <!-- .container --> 5982</div><!-- .entry-content --> 5983 5984 5985 5986</article><!-- #post-3376 --> 5987 5988 5989<article id="post-3377" class="post-3377 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry"> 5990 5991 <header class="pub-entry-header"> 5992 <div class="container"> 5993 <h2>Thermo-Chemotherapie des fortgeschrittenen Pankreaskarzinoms. Ergebnisseeiner klinischen Anwendungsstudie</h2> 5994 </div> 5995 </header><!-- .entry-header --> 5996 5997 5998<div class="entry-content kl-pub-content"> 5999 <div class="container"> 6000 <div class="acf-fields"> 6001 <div class="acf-row"><span class="publ-label">Indication:</span> Pancreas <hr/> <span class="publ-label">Evidence:</span> Clinical study</div> 6002 <div class="publ-acf acf-row acf-flex"> 6003 <span class="publ-label">Author: </span> 6004 <div class="szerzok"> 6005 6006 6007 6008 <span class="sz-nev">Douwes FR</span> 6009 6010 </div> 6011 6012 </div> 6013 <div class="acf-row"><span class="publ-label">No. of patients:</span> 30 <hr/> <span class="publ-label">Therapy:</span> CT+mEHT<hr/> <span class="publ-label">Year:</span> 2004</div> 6014 </div><!-- .acf-fields --> 6015 <div class="c-rich-text"> 6016<p><strong>ABSTRACT</strong>: Oncothermia is a method of hyperthermia in oncology, controlling the locally applied deep heat by selectively targeting the cellular membrane of the malignant cells. The selection of the method is based on various biophysical and biochemical achievements. There are various differences between the malignant and healthy cells, which could be used for their selection by heat targeting. The primary selection factor is a different metabolic activity which creates distinguishable environments of the malignant cells. The other factor is the clear difference of dielectric properties of the membrane and near-membrane extracellular electrolytes, marking off the malignancies. There is also a structural factor, which is clear in the different pathological patterns of the malignancy from their healthy counterparts. This last is described by fractal pattern evaluation technique, in which dynamic time-fractal transformation is used for further discernment of the malignancy. My objective is to show a new heating method, which makes oncological hyperthermia controllable and effective. 1. Introduction Oncological hyperthermia is the overheating of the malignant tissues locally or systemically. The method is deduced from the ancient medical practices, where the heat therapies had a central role in medicine. The local hyperthermia by the radiation of red-hot iron was the first known oncological treatment applied by Hy
6016pocrites, who described the method [1]. The main idea was originated from sacral considerations formulating the overall force of the âfire.â However, physiological consideration was also behind that together with beliefs: the local heat accelerates the metabolic activity without extra supply of this action from the unheated neighboring volumes. This physiological mechanism is accompanied by severe hypoxia, and it finally kills the target by acidosis. The working idea has recently been shown, proving the impoverishment of ATP and enrichment of lactate in the locally heated tumor tissue [2]. Due to the primitive heating techniques, the ancient radiative heat is only rarely applied in real cases. The central point of the locally applied oncological hyperthermia is the selective heat delivery into the deep-seated tumors. The discovery of the electromagnetic heating gave new perspectives for deep heating, and hyperthermia started its first âgolden eraâ in oncology. It was among the first modern curative applications of modern techniques in oncology [3] and was followed by a controlled clinical study involving 100 patients as early as 1912. It showed remarkable.</p> 6017</div> 6018 6019 6020 </div> <!-- .container --> 6021</div><!-- .entry-content --> 6022 6023 6024 6025</article><!-- #post-3377 --> 6026 6027 6028<article id="post-3378" class="post-3378 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry"> 6029 6030 <header class="pub-entry-header"> 6031 <div class="container"> 6032 <h2>Malignus és benignus prosztatadaganatok hyperthermiája</h2> 6033 </div> 6034 </header><!-- .entry-header --> 6035 6036 6037<div class="entry-content kl-pub-content"> 6038 <div class="container"> 6039 <div class="acf-fields"> 6040 <div class="acf-row"><span class="publ-label">Indication:</span> Prostate <hr/> <span class="publ-label">Evidence:</span> </div> 6041 <div class="publ-acf acf-row acf-flex"> 6042 <span class="publ-label">Author: </span> 6043 <div class="szerzok"> 6044 6045 6046 6047 <span class="sz-nev">Szasz A</span> 6048 6049 </div> 6050 6051 </div> 6052 <div class="acf-row"><span class="publ-label">No. of patients:</span> 252 <hr/> <span class="publ-label">Therapy:</span> mEHT<hr/> <span class="publ-label">Year:</span> 2003</div> 6053 </div><!-- .acf-fields --> 6054 6055 6056 </div> <!-- .container --> 6057</div><!-- .entry-content --> 6058 6059 6060 6061</article><!-- #post-3378 --> 6062 6063 6064<article id="post-3379" class="post-3379 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry"> 6065 6066 <header class="pub-entry-header"> 6067 <div class="container"> 6068 <h2>The treatment of patients with high-grade malignant gliomas with RF-hyperthermia</h2> 6069 </div> 6070 </header><!-- .entry-header --> 6071 6072 6073<div class="entry-content kl-pub-content"> 6074 <div class="container"> 6075 <div class="acf-fields"> 6076 <div class="acf-row"><span class="publ-label">Indication:</span> <hr/> <span class="publ-label">Evidence:</span> </div> 6077 <div class="publ-acf acf-row acf-flex"> 6078 <span class="publ-label">Author: </span> 6079 <div class="szerzok"> 6080 6081 6082 6083 <span class="sz-nev">Hager ED</span> 6084 6085 6086 6087 <span class="sz-nev">Dziambor H</span> 6088 6089 6090 6091 <span class="sz-nev">App EM</span> 6092 6093 6094 6095 <span class="sz-nev">Popa C</span> 6096 6097 6098 6099 <span class="sz-nev">Popa O</span> 6100 6101 6102 6103 <span class="sz-nev">Hertlein M</span> 6104 6105 </div> 6106 6107 </div> 6108 <div class="acf-row"><span class="publ-label">No. of patients:</span> 36 <hr/> <span class="publ-label">Therapy:</span> CT+RT+mEHT<hr/> <span class="publ-label">Year:</span> 2003</div> 6109 </div><!-- .acf-fields --> 6110 6111 6112 </div> <!-- .container --> 6113</div><!-- .entry-content --> 6114 6115 6116 6117</article><!-- #post-3379 --> 6118 6119 6120<article id="post-3380" class="post-3380 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry"> 6121 6122 <header class="pub-entry-header"> 6123 <div class="container"> 6124 <h2>Tolerability of external electro-hyperthermia in the treatment of solid tumors</h2> 6125 </div> 6126 </header><!-- .entry-header --> 6127 6128 6129<div class="entry-content kl-pub-content"> 6130 <div class="container"> 6131 <div class="acf-fields"> 6132 <div class="acf-row"><span class="publ-label">Indication:</span> Toxicity <hr/> <span class="publ-label">Evidence:</span> </div> 6133 <div class="publ-acf acf-row acf-flex"> 6134 <span class="publ-label">Author: </span> 6135 <div class="szerzok"> 6136 6137 6138 6139 <span class="sz-nev">Cremona F</span> 6140 6141 6142 6143 <span class="sz-nev">Pignata A</span> 6144 6145 6146 6147 <span class="sz-nev">Izzo F</span> 6148 6149 6150 6151 <span class="sz-nev">Ruffolo F</span> 6152 6153 6154 6155 <span class="sz-nev">Delrio P</span> 6156 6157 </div> 6158 6159 </div> 6160 <div class="acf-row"><span class="publ-label">No. of patients:</span> <hr/> <span class="publ-label">Therapy:</span> <hr/> <span class="publ-label">Year:</span> 2003</div> 6161 </div><!-- .acf-fields --> 6162 6163 <div id="teljes-cikk" class="btn"> 6164 <a href="http://www.ncbi.nlm.nih.gov/pubmed/12903605" target="_blank">
6164 View abstract</a> 6165 </div> 6166 6167 </div> <!-- .container --> 6168</div><!-- .entry-content --> 6169 6170 6171 6172</article><!-- #post-3380 --> 6173 6174 6175<article id="post-3381" class="post-3381 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry"> 6176 6177 <header class="pub-entry-header"> 6178 <div class="container"> 6179 <h2>Whole-body hyperthermia in combination with platinum-containing drugs in patients with recurrent ovarian cancer</h2> 6180 </div> 6181 </header><!-- .entry-header --> 6182 6183 6184<div class="entry-content kl-pub-content"> 6185 <div class="container"> 6186 <div class="acf-fields"> 6187 <div class="acf-row"><span class="publ-label">Indication:</span> <hr/> <span class="publ-label">Evidence:</span> </div> 6188 <div class="publ-acf acf-row acf-flex"> 6189 <span class="publ-label">Author: </span> 6190 <div class="szerzok"> 6191 6192 6193 6194 <span class="sz-nev">Friedrich Douwes</span> 6195 6196 6197 6198 <span class="sz-nev">Juri Bogovic</span> 6199 6200 6201 6202 <span class="sz-nev">Ortrun Douwes</span> 6203 6204 6205 6206 <span class="sz-nev">Friedrich Migeod</span> 6207 6208 6209 6210 <span class="sz-nev">Christoph Grote</span> 6211 6212 </div> 6213 6214 </div> 6215 <div class="acf-row"><span class="publ-label">No. of patients:</span> 21 <hr/> <span class="publ-label">Therapy:</span> CT+mEHT<hr/> <span class="publ-label">Year:</span> 2003</div> 6216 </div><!-- .acf-fields --> 6217 <p><strong>Abstract</strong></p> 6218<p>Background. Patients with advanced ovarian cancer have an enormous risk of relapse after primary therapy, and the prognosis for these patients remains bleak. Primary and acquired resistance of tumor cells to antineoplastic drugs is a major cause of the limited effectiveness of chemotherapy. The effect of whole-body hyperthermia (WBH) combined with platinum-containing chemotherapy in the treatment of recurrent ovarian cancer was examined in this study. Methods. Patients studied were those with pathologically veriï¬ed epithelial ovarian cancer after operation who had had ï¬rst-line chemotherapy with cisplatin or carboplatin, and relapsed. All 21 patients were treated with WBH and platinum-based chemotherapy. During the WBH, a core temperature of 41.5°Câ42°C was attained in the rectum. We combined the WBH with 300â400mg/dl artiï¬cial hyperglycemia. The plateau temperature was held over a period of, on average, 90 30min, and the artiï¬cial hyperglycemia, on average, 240 30min. WBH was repeated at the beginning of each new chemotherapy cycle. Results. One patient (4.8%) had a complete remission, 7 patients (33.3%) had a partial remission, stable disease was noted in 10 patients (47.6%), and 3 (14.3%) patients did not respond and had progressive disease. Median time to progression was 6.5 months, and median survival time, 16.5 months. Conclusion. Our results validate the efï¬cacy of WBH in the treatment of patients with recurrent platinum-resistant ovarian cancer. The overall tolerance of this treatment was good. The priority for all patients was an improvement in life quality; this was seen 3â4 days after WBH. The encouraging results should be conï¬rmed in randomized studies.</p> 6219 6220 <div id="teljes-cikk" class="btn"> 6221 <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=Whole-body%20hyperthermia%20in%20combination%20with%20platinum-containing%20drugs%20in%20patients%20with%20recurrent%20ovarian%20cancer" target="_blank"> View abstract</a> 6222 </div> 6223 6224 </div> <!-- .container --> 6225</div><!-- .entry-content --> 6226 6227 6228 6229</article><!-- #post-3381 --> 6230 6231 6232<article id="post-3382" class="post-3382 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry"> 6233 6234 <header class="pub-entry-header"> 6235 <div class="container"> 6236 <h2>Radiofrequency Transurethral Hyperthermia and complete Androgen Blockade. A Nonsurgical Approach to Treating Prostate Cancer</h2> 6237 </div> 6238 </header><!-- .entry-header --> 6239 6240 6241<div class="entry-content kl-pub-content"> 6242 <div class="container"> 6243 <div class="acf-fields"> 6244 <div class="acf-row"><span class="publ-label">Indication:</span> Prostate <hr/> <span class="publ-label">Evidence:</span> </div> 6245 <div class="publ-acf acf-row acf-flex"> 6246 <span class="publ-label">Author: </span> 6247 <div class="szerzok"> 6248 6249 6250 6251 <span class="sz-nev">Douwes FR</span> 6252 6253 6254 6255 <span class="sz-nev">Lieberman S</span> 6256 6257 </div> 6258 6259 </div> 6260 <div class="acf-row"><span class="publ-label">No. of patients:</span> 184 <hr/> <span class="publ-label">Therapy:</span> mEHT<hr/> <span class="publ-label">Year:</span> 2002</div> 6261 </div><!-- .acf-fields --> 6262 6263 <div id="teljes-cikk" class="btn"> 6264 <a href="http://connection.ebscohost.com/c/articles/83564104/radiofrequency-transurethral-hyperthermia-complete-androgen-blockade-nonsurgical-approach-treating-prostate-cancer" target="_blank">
6264 View abstract</a> 6265 </div> 6266 6267 </div> <!-- .container --> 6268</div><!-- .entry-content --> 6269 6270 6271 6272</article><!-- #post-3382 --> 6273 6274 6275<article id="post-3383" class="post-3383 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry"> 6276 6277 <header class="pub-entry-header"> 6278 <div class="container"> 6279 <h2>Transurethral hyperthermia in early stage prostate cancer</h2> 6280 </div> 6281 </header><!-- .entry-header --> 6282 6283 6284<div class="entry-content kl-pub-content"> 6285 <div class="container"> 6286 <div class="acf-fields"> 6287 <div class="acf-row"><span class="publ-label">Indication:</span> Prostate <hr/> <span class="publ-label">Evidence:</span> </div> 6288 <div class="publ-acf acf-row acf-flex"> 6289 <span class="publ-label">Author: </span> 6290 <div class="szerzok"> 6291 6292 6293 6294 <span class="sz-nev">Douwes FR</span> 6295 6296 </div> 6297 6298 </div> 6299 <div class="acf-row"><span class="publ-label">No. of patients:</span> 34 <hr/> <span class="publ-label">Therapy:</span> mEHT<hr/> <span class="publ-label">Year:</span> 2001</div> 6300 </div><!-- .acf-fields --> 6301 <p><strong>Objective</strong></p> 6302<p>A treatment only has value if it can be demonstrated to be more effective than doing nothing. The major treatment for early prostate cancer (PC) is surgery or radiation. Unfortunately, none of these has been clearly shown to have a positive effect on long-term survival. In a study published in JAMA in 1997 a prospective, population-based study in Sweden showed that 223 patients that did not have a radical prostatectomy had the same long-term survival rate (81%) as those that did. Several statistics show that prostatectomy in early-stage cancer cannot affect the natural course of the disease. Several investigations have shown the efficiency of hyperthermia in different malignant tumours. We now have more than 10 years of experience with hyperthermia for the treatment of PC and the results are promising. The strategy of modern anticancer therapy is directed towards the control of local tumour growth with the maximum possible elimination of the neoplastic cell load. Hyperthermia offers support for both direct cell killing and sensitising neoplastic cells to hormone-, radio- and chemo-therapy.</p> 6303 6304 6305 </div> <!-- .container --> 6306</div><!-- .entry-content --> 6307 6308 6309 6310</article><!-- #post-3383 --> 6311 6312 6313<article id="post-3384" class="post-3384 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry"> 6314 6315 <header class="pub-entry-header"> 6316 <div class="container"> 6317 <h2>Posttreatment Histology and Microcirculation Status of Osteogenic Sarcoma after a Neoadjuvant Chemo- and Radiotherapy in Combination with Local Electromagnetic Hyperthermia</h2> 6318 </div> 6319 </header><!-- .entry-header --> 6320 6321 6322<div class="entry-content kl-pub-content"> 6323 <div class="container"> 6324 <div class="acf-fields"> 6325 <div class="acf-row"><span class="publ-label">Indication:</span> Bone <hr/> <span class="publ-label">Evidence:</span> Retrospective study</div> 6326 <div class="publ-acf acf-row acf-flex"> 6327 <span class="publ-label">Author: </span> 6328 <div class="szerzok"> 6329 6330 6331 6332 <span class="sz-nev">Bogovic J</span> 6333 6334 6335 6336 <span class="sz-nev">Douwes F</span> 6337 6338 6339 6340 <span class="sz-nev">Muravjov G</span> 6341 6342 6343 6344 <span class="sz-nev">Istomin J</span> 6345 6346 </div> 6347 6348 </div> 6349 <div class="acf-row"><span class="publ-label">No. of patients:</span> 62 <hr/> <span class="publ-label">Therapy:</span> CT+RT+mEHT<hr/> <span class="publ-label">Year:</span> 2001</div> 6350 </div><!-- .acf-fields --> 6351 <div class="c-rich-text"> 6352<h3>Abstract</h3> 6353<h4>BACKGROUND:</h4> 6354<p>Many biological attributes of tumors (including regional blood flow and microcirculation) can deteriorate the homogeneity of heat distribution and temperature elevation during hyperthermia. We analyzed the connection between the microcirculation status of osteogenic sarcomas and the posttreatment histology after neoadjuvant chemotherapy, irradiation and local hyperthermia.</p> 6355<h4>PATIENTS AND METHODS:</h4> 6356<p>62 patients with histologically verified osteosarcoma (35 men, 27 women, age 9-53, average 21 years) were enrolled in the retrospective pathohistological study. 61 patients were evaluable. In 72.6% of cases the tumor was localized in bones forming knee joints. All patients received neoadjuvant treatment [6 hyperthermias (60 min, 42-45 degrees C), daunorubicin 30-50 mg/m(2), 6 infusions, adriamycin or cisplatin 30 mg/m(2) for 3 days or once 90 mg/m(2) monochemotherapy before the hyperthermic procedure; subsequently gamma-therapy, 20-36 Gy] followed by surgery. From archives, a control group was formed of 20 therapy-naive tumors. Resected tumors were histologically examined for assessment of spontaneous and therapeutically induced alterations. For analysis of the functionality status of microcirculation on histological cuts, 40 tumors (without selection) were investigated: 10 controls and 10 cases each with minimal, subtotal and total posttreatment alterations.</p> 6357<h4>RESULTS:</h4> 6358<p>Chemotherapy and radiotherapy in combination with local hyperthermia induced a distinct damage to osteosarcoma. In 39.3 and 35.7% of cases there was subtotal and total devitalization of tumor parenchyma, respectively. Thrombosis of magistral and middle vessels, stasis in the microcirculation tree (collapse), damage to intimal vessels and endothelial cells, and necrotic alterations of the vessel walls appeared predominantly in central areas of tumors. Tumors with minimal devitalization of the parenchyma had a share of nonfunctional vessels ranging from 10.6 to 61.7%, mean 29.7%. In tumors with subtotal necrosis, between 34.5 and 72.0% (mean 49.46%) of vessels were nonfunctional (stasis, thrombosis). In 10 cases with 100% necrosis of the osteosarcoma parenchyma, a mean of 56.05% of nonfunctional vessels was registered (12.3-83.0%). In the control group, between 2.85 and 73.4% (mean 21.69%) of vessels showed damage to the microcirculation.</p> 6359<h4>CONCLUSION:</h4> 6360<p>There is a direct correlation between deterioration of the microcirculation in osteosarcoma and thermo-radiochemotherapy- induced tissue alteration; the devitalization grade is directly proportional to the number of nonfunctional vessels in the tumor.</p> 6361</div> 6362 6363 <div id="teljes-cikk" class="btn"> 6364 <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=Posttreatment%20Histology%20and%20Microcirculation%20Status%20of%20Osteogenic%20Sarcoma%20after%20a%20Neoadjuvant%20Chemo-%20and%20Radiotherapy%20in%20Combination%20with%20Local%20Electromagnetic%20Hyperthermia" target="_blank">
6364 View abstract</a> 6365 </div> 6366 6367 </div> <!-- .container --> 6368</div><!-- .entry-content --> 6369 6370 6371 6372</article><!-- #post-3384 --> 6373 6374 6375<article id="post-3385" class="post-3385 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry"> 6376 6377 <header class="pub-entry-header"> 6378 <div class="container"> 6379 <h2>Deep hyperthermia with radiofrequencies in patients with liver metastases from colorectal cancer</h2> 6380 </div> 6381 </header><!-- .entry-header --> 6382 6383 6384<div class="entry-content kl-pub-content"> 6385 <div class="container"> 6386 <div class="acf-fields"> 6387 <div class="acf-row"><span class="publ-label">Indication:</span> Gastrointestinal <hr/> <span class="publ-label">Evidence:</span> Clinical study</div> 6388 <div class="publ-acf acf-row acf-flex"> 6389 <span class="publ-label">Author: </span> 6390 <div class="szerzok"> 6391 6392 6393 6394 <span class="sz-nev">Hager ED </span> 6395 6396 6397 6398 <span class="sz-nev">Dziambor H</span> 6399 6400 6401 6402 <span class="sz-nev">Höhmann D</span> 6403 6404 6405 6406 <span class="sz-nev">Gallenbeck D</span> 6407 6408 6409 6410 <span class="sz-nev">Stephan M</span> 6411 6412 6413 6414 <span class="sz-nev">Popa C.</span> 6415 6416 </div> 6417 6418 </div> 6419 <div class="acf-row"><span class="publ-label">No. of patients:</span> 80 <hr/> <span class="publ-label">Therapy:</span> CT+mEHT<hr/> <span class="publ-label">Year:</span> 1999</div> 6420 </div><!-- .acf-fields --> 6421 <p><strong>Abstract</strong></p> 6422<p>Patients at advanced stage of colorectal cancer with liver metastases have been treated with deep hyperthermia alone or in combination with chemotherapy (5-FU + FA + MMC). Hyperthermia was achieved by arrangements of capacitive electrodes with a radiofrequency field of 13.56 MHz (RF-DHT). This prospective open single-arm clinical study with 80 patients suffering from liver metastases from colorectal cancer gives some first hints, that deep RF-hyperthermia alone may have a substantial beneficial effect on overall survival time of patients with liver metastases from colorectal cancer. Long lasting no-change, partial and even some complete remissions could be observed. The overall median survival time from progression of metastases or relapse was 24.5 months and survival rates at 1, 2 or 3 years from first diagnosis of metastases or progression were twice as high as expected from patients treated with chemotherapy. The combination of hyperthermia with delayed chemotherapy did not change overall survival time. These encouraging results deserve to be confirmed in randomized clinical studies.</p> 6423 6424 <div id="teljes-cikk" class="btn"> 6425 <a href="https://www.ncbi.nlm.nih.gov/pubmed/10629627" target="_blank"> View abstract</a> 6426 </div> 6427 6428 </div> <!-- .container --> 6429</div><!-- .entry-content --> 6430 6431 6432 6433</article><!-- #post-3385 --> 6434 6435 6436<article id="post-3386" class="post-3386 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry"> 6437 6438 <header class="pub-entry-header"> 6439 <div class="container"> 6440 <h2>Hoffnung bei Prostata-Beschwerden. Die neue Therapie ohne Messer</h2> 6441 </div> 6442 </header><!-- .entry-header --> 6443 6444 6445<div class="entry-content kl-pub-content"> 6446 <div class="container"> 6447 <div class="acf-fields"> 6448 <div class="acf-row"><span class="publ-label">Indication:</span> Prostate <hr/> <span class="publ-label">Evidence:</span> </div> 6449 <div class="publ-acf acf-row acf-flex"> 6450 <span class="publ-label">Author: </span> 6451 <div class="szerzok"> 6452 6453 6454 6455 <span class="sz-nev">Douwes F</span> 6456 6457 6458 6459 <span class="sz-nev">Sillner L</span> 6460 6461 6462 6463 <span class="sz-nev">Köhnlechner M</span> 6464 6465 </div> 6466 6467 </div> 6468 <div class="acf-row"><span class="publ-label">No. of patients:</span> <hr/> <span class="publ-label">Therapy:</span> <hr/> <span class="publ-label">Year:</span> 1999</div> 6469 </div><!-- .acf-fields --> 6470 6471 <div id="teljes-cikk" class="btn"> 6472 <a href="http://www.zvab.com/9783776620863/Hoffnung-Prostata-Beschwerden-neue-Therapie-Messer-3776620862/plp" target="_blank"> View abstract</a> 6473 </div> 6474 6475 </div> <!-- .container --> 6476</div><!-- .entry-content --> 6477 6478 6479 6480</article><!-- #post-3386 --> 6481 6482 6483<article id="post-3387" class="post-3387 klinikai-publikaciok type-klinikai-publikaciok status-publish hentry"> 6484 6485 <header class="pub-entry-header"> 6486 <div class="container"> 6487 <h2>Complex therapy of the not in sano respectable carcinoma of the pancreas â a pilot study</h2> 6488 </div> 6489 </header><!-- .entry-header --> 6490 6491 6492<div class="entry-content kl-pub-content"> 6493 <div class="container"> 6494 <div class="acf-fields"> 6495 <div class="acf-row"><span class="publ-label">Indication:</span> Pancreas <hr/> <span class="publ-label">Evidence:</span> </div> 6496 <div class="publ-acf acf-row acf-flex"> 6497 <span class="publ-label">Author: </span> 6498 <div class="szerzok"> 6499 6500 6501 6502 <span class="sz-nev">Hager ED</span> 6503 6504 6505 6506 <span class="sz-nev">Süsse B</span> 6507 6508 6509 6510 <span class="sz-nev">Popa C</span> 6511 6512 6513 6514 <span class="sz-nev">Schritttwieser G</span> 6515 6516 6517 6518 <span class="sz-nev">Heise A</span> 6519 6520 6521 6522 <span class="sz-nev">Kleef R</span> 6523 6524 </div> 6525 6526 </div> 6527 <div class="acf-row"><span class="publ-label">No. of patients:</span> <hr/> <span class="publ-label">Therapy:</span> <hr/> <span class="publ-label">Year:</span> 1994</div> 6528 </div><!-- .acf-fields --> 6529 6530 6531 </div> <!-- .container --> 6532</div><!-- .entry-content --> 6533 6534 6535 6536</article><!-- #post-3387 --> 6537 6538 6539 </div> 6540 </main><!-- #main --> 6541 6542 6543 <footer id="colophon" class="site-footer"> 6544 <div class="container"> 6545 6546 <section id="siteorigin-panels-builder-5" class="widget widget_siteorigin-panels-builder"><div id="pl-w6603f2bb2643b" class="panel-layout" ><div id="pg-w6603f2bb2643b-0" class="panel-grid panel-no-style" ><div id="pgc-w6603f2bb2643b-0-0" class="panel-grid-cell" ><div id="panel-w6603f2bb2643b-0-0-0" class="so-panel widget widget_sow-image panel-first-child panel-last-child" data-index="0" ><div 6547 6548 class="so-widget-sow-image so-widget-sow-image-default-c67d20f9f743" 6549 6550 > 6551<div class="sow-image-container"> 6552 <img 6553 src="https://oncotherm.com/wp-content/uploads/2022/11/logo_ar-01.svg" width="220" height="50" alt="" decoding="async" loading="lazy" class="so-widget-image"/> 6554 </div> 6555 6556</div></div></div></div><div id="pg-w6603f2bb2643b-1" class="panel-grid panel-has-style" ><div id="foo-mid" class="panel-row-style panel-row-style-for-w6603f2bb2643b-1" ><div id="pgc-w6603f2bb2643b-1-0" class="panel-grid-cell" ><div id="panel-w6603f2bb2643b-1-0-0" class="so-panel widget widget_sow-editor panel-first-child panel-last-child" data-index="1" ><div class="footer-text left-foo panel-widget-style panel-widget-style-for-w6603f2bb2643b-1-0-0" ><div 6557 6558 class="so-widget-sow-editor so-widget-sow-editor-base" 6559 6560 > 6561<div class="siteorigin-widget-tinymce textwidget"> 6562 <p><strong>ONCOTHERM KFT.</strong></p> 6563<p>Gyár u. 2.<br /> 65642040 Budaörs, Hungary</p> 6565</div> 6566</div></div></div></div><div id="pgc-w6603f2bb2643b-1-1" class="panel-grid-cell" ><div id="panel-w6603f2bb2643b-1-1-0" class="so-panel widget widget_sow-editor panel-first-child panel-last-child" data-index="2" ><div class="footer-text panel-widget-style panel-widget-style-for-w6603f2bb2643b-1-1-0" ><div 6567 6568 class="so-widget-sow-editor so-widget-sow-editor-base" 6569 6570 > 6571<div class="siteorigin-widget-tinymce textwidget"> 6572 <p style="text-align: center;"><a href="tel:+3623555510">+36 23 555 510</a><br /> 6573<a href="mailto:info@oncotherm.org">info@oncotherm.org</a></p> 6574</div> 6575</div></div></div></div><div id="pgc-w6603f2bb2643b-1-2" class="panel-grid-cell" ><div id="panel-w6603f2bb2643b-1-2-0" class="so-panel widget widget_sow-editor panel-first-child panel-last-child" data-index="3" ><div class="footer-text panel-widget-style panel-widget-style-for-w6603f2bb2643b-1-2-0" ><div 6576 6577 class="so-widget-sow-editor so-widget-sow-editor-base" 6578 6579 > 6580<div class="siteorigin-widget-tinymce textwidget"> 6581 <p style="text-align: right;"><a href="https://oncotherm.com/privacy-policy/">Privacy Policy</a><br /> 6582<a href="https://oncotherm.com/impressum/">Impressum</a></p> 6583</div> 6584</div></div></div></div></div></div><div id="pg-w6603f2bb2643b-2" class="panel-grid panel-no-style" ><div id="pgc-w6603f2bb2643b-2-0" class="panel-grid-cell" ><div id="panel-w6603f2bb2643b-2-0-0" class="so-panel widget widget_sow-social-media-buttons panel-first-child panel-last-child" data-index="4" ><div id="social-footer" class="panel-widget-style panel-widget-style-for-w6603f2bb2643b-2-0-0" ><div 6585 6586 class="so-widget-sow-social-media-buttons so-widget-sow-social-media-buttons-flat-8f436be6ec16" 6587 6588 > 6589 6590<div class="social-media-button-container"> 6591 6592 <a 6593 class="sow-social-media-button-facebook-0 sow-social-media-button" title="Oncotherm Kft. on Facebook" aria-label="Oncotherm Kft. on Facebook" target="_blank" rel="noopener noreferrer" href="https://www.facebook.com/oncotherm" > 6594 <span> 6595 <span class="sow-icon-fontawesome sow-fab" data-sow-icon="" 6596 6597 aria-hidden="true"></span> </span> 6598 </a> 6599 6600 <a 6601 class="sow-social-media-button-linkedin-0 sow-social-media-button" title="Oncotherm Kft. on Linkedin" aria-label="Oncotherm Kft. on Linkedin" target="_blank" rel="noopener noreferrer" href="https://www.linkedin.com/company/17896963/" > 6602 <span> 6603 <span class="sow-icon-fontawesome sow-fab" data-sow-icon="" 6604 6605 aria-hidden="true"></span> </span> 6606 </a> 6607 6608 <a 6609 class="sow-social-media-button-youtube-0 sow-social-media-button" title="Oncotherm Kft. on Youtube" aria-label="Oncotherm Kft. on Youtube" target="_blank" rel="noopener noreferrer" href="https://www.youtube.com/channel/UCpXgKlXcuZFIsVCOmx85pLg" > 6610 <span> 6611 <span class="sow-icon-fontawesome sow-fab" data-sow-icon="" 6612 6613 aria-hidden="true"></span> </span> 6614 </a> 6615 </div> 6616</div></div></div></div></div><div id="pg-w6603f2bb2643b-3" class="panel-grid panel-has-style" ><div id="bottom-footer" class="panel-row-style panel-row-style-for-w6603f2bb2643b-3" ><div id="pgc-w6603f2bb2643b-3-0" class="panel-grid-cell" ><div id="panel-w6603f2bb2643b-3-0-0" class="so-panel widget widget_execphp panel-first-child panel-last-child" data-index="5" > <div class="execphpwidget"><p style="text-align: right;">Copyright © 2026 Oncotherm. All rights reserved.</p></div> 6617 </div></div></div></div></div></section> </div><!-- .site-info --> 6618 </footer><!-- #colophon --> 6619 <div id="to-top"> 6620 <a href="#page" class="totop"><img src="https://oncotherm.com/wp-content/themes/oncotherm/js/rightarrow-01.svg" /></a> 6621 </div> 6622</div><!-- #page -->
6623<script src="https://cdnjs.cloudflare.com/ajax/libs/gsap/3.9.1/gsap.min.js"></script>
vendor: 1 bytes, line 6623
6623
6624<script src="https://cdnjs.cloudflare.com/ajax/libs/gsap/3.9.1/ScrollToPlugin.min.js"></script>
vendor: 1 bytes, line 6624
6624
6625<script src="https://cdnjs.cloudflare.com/ajax/libs/gsap/3.9.1/ScrollTrigger.min.js"></script>
vendor: 1 bytes, line 6625
6625
6626<script> 6627 gsap.registerPlugin(ScrollToPlugin, ScrollTrigger); 6628 6629</script>
vendor: 1 bytes, line 6629
6629
6630<script src="https://cdn.jsdelivr.net/npm/[email protected]/dist/hc-sticky.min.js"></script>
vendor: 1 bytes, line 6630
6630
6631<script type="speculationrules"> 6632{"prefetch":[{"source":"document","where":{"and":[{"href_matches":"/*"},{"not":{"href_matches":["/wp-*.php","/wp-admin/*","/wp-content/uploads/*","/wp-content/*","/wp-content/plugins/*","/wp-content/themes/oncotherm/*","/*\\?(.+)"]}},{"not":{"selector_matches":"a[rel~=\"nofollow\"]"}},{"not":{"selector_matches":".no-prefetch, .no-prefetch a"}}]},"eagerness":"conservative"}]} 6633</script>
vendor: 1 bytes, line 6633
6633
6634<script id="lbwps-photoswipe5-js-module" src="https://oncotherm.com/wp-content/plugins/lightbox-photoswipe/assets/ps5/frontend.min.js?ver=5.13.0" type="module"></script>
6634 6635<div class="wpc-filters-overlay"></div> 6636<style media="all" id="siteorigin-panels-layouts-footer">/* Layout w6489d1a75c44d */ #pgc-w6489d1a75c44d-0-0 , #pgc-w6489d1a75c44d-1-0 { width:100%;width:calc(100% - ( 0 * 30px ) ) } #pg-w6489d1a75c44d-0 , #pl-w6489d1a75c44d .so-panel:last-of-type { margin-bottom:0px } #pl-w6489d1a75c44d .so-panel { margin-bottom:30px } #pg-w6489d1a75c44d-0.panel-has-style > .panel-row-style, #pg-w6489d1a75c44d-0.panel-no-style , #pg-w6489d1a75c44d-1.panel-has-style > .panel-row-style, #pg-w6489d1a75c44d-1.panel-no-style { -webkit-align-items:flex-start;align-items:flex-start } @media (max-width:780px){ #pg-w6489d1a75c44d-0.panel-no-style, #pg-w6489d1a75c44d-0.panel-has-style > .panel-row-style, #pg-w6489d1a75c44d-0 , #pg-w6489d1a75c44d-1.panel-no-style, #pg-w6489d1a75c44d-1.panel-has-style > .panel-row-style, #pg-w6489d1a75c44d-1 { -webkit-flex-direction:column;-ms-flex-direction:column;flex-direction:column } #pg-w6489d1a75c44d-0 > .panel-grid-cell , #pg-w6489d1a75c44d-0 > .panel-row-style > .panel-grid-cell , #pg-w6489d1a75c44d-1 > .panel-grid-cell , #pg-w6489d1a75c44d-1 > .panel-row-style > .panel-grid-cell { width:100%;margin-right:0 } #pl-w6489d1a75c44d .panel-grid-cell { padding:0 } #pg-w6489d1a75c44d-0 .panel-grid-cell-empty , #pg-w6489d1a75c44d-1 .panel-grid-cell-empty { display:none } #pl-w6489d1a75c44d .panel-grid .panel-grid-cell-mobile-last { margin-bottom:0px } } /* Layout w6603f2bb2643b */ #pgc-w6603f2bb2643b-0-0 , #pgc-w6603f2bb2643b-2-0 , #pgc-w6603f2bb2643b-3-0 { width:100%;width:calc(100% - ( 0 * 30px ) ) } #pg-w6603f2bb2643b-0 { margin-bottom:40px } #pgc-w6603f2bb2643b-1-0 , #pgc-w6603f2bb2643b-1-1 , #pgc-w6603f2bb2643b-1-2 { width:33.3333%;width:calc(33.3333% - ( 0.66666666666667 * 30px ) ) } #pg-w6603f2bb2643b-1 { margin-bottom:8px } #pg-w6603f2bb2643b-2 { margin-bottom:20px } #pg-w6603f2bb2643b-3 , #pl-w6603f2bb2643b .so-panel:last-of-type { margin-bottom:0px } #pl-w6603f2bb2643b .so-panel { margin-bottom:30px } #pg-w6603f2bb2643b-0.panel-has-style > .panel-row-style, #pg-w6603f2bb2643b-0.panel-no-style , #pg-w6603f2bb2643b-3.panel-has-style > .panel-row-style, #pg-w6603f2bb2643b-3.panel-no-style { -webkit-align-items:flex-start;align-items:flex-start } #pg-w6603f2bb2643b-1.panel-has-style > .panel-row-style, #pg-w6603f2bb2643b-1.panel-no-style , #pg-w6603f2bb2643b-2.panel-has-style > .panel-row-style, #pg-w6603f2bb2643b-2.panel-no-style { -webkit-align-items:flex-end;align-items:flex-end } @media (max-width:780px){ #pg-w6603f2bb2643b-0.panel-no-style, #pg-w6603f2bb2643b-0.panel-has-style > .panel-row-style, #pg-w6603f2bb2643b-0 , #pg-w6603f2bb2643b-1.panel-no-style, #pg-w6603f2bb2643b-1.panel-has-style > .panel-row-style, #pg-w6603f2bb2643b-1 , #pg-w6603f2bb2643b-3.panel-no-style, #pg-w6603f2bb2643b-3.panel-has-style > .panel-row-style, #pg-w6603f2bb2643b-3 { -webkit-flex-direction:column;-ms-flex-direction:column;flex-direction:column } #pg-w6603f2bb2643b-0 > .panel-grid-cell , #pg-w6603f2bb2643b-0 > .panel-row-style > .panel-grid-cell , #pg-w6603f2bb2643b-1 > .panel-grid-cell , #pg-w6603f2bb2643b-1 > .panel-row-style > .panel-grid-cell , #pg-w6603f2bb2643b-3 > .panel-grid-cell , #pg-w6603f2bb2643b-3 > .panel-row-style > .panel-grid-cell { width:100%;margin-right:0 } #pgc-w6603f2bb2643b-1-0 , #pgc-w6603f2bb2643b-1-1 { margin-bottom:30px } #pl-w6603f2bb2643b .panel-grid-cell { padding:0 } #pg-w6603f2bb2643b-0 .panel-grid-cell-empty , #pg-w6603f2bb2643b-1 .panel-grid-cell-empty , #pg-w6603f2bb2643b-2 .panel-grid-cell-empty , #pg-w6603f2bb2643b-3 .panel-grid-cell-empty { display:none } #pl-w6603f2bb2643b .panel-grid .panel-grid-cell-mobile-last { margin-bottom:0px } } </style>
6636<script data-cfasync="false"> 6637 window.dFlipLocation = 'https://oncotherm.com/wp-content/plugins/3d-flipbook-dflip-lite/assets/'; 6638 window.dFlipWPGlobal = {"text":{"toggleSound":"Turn on\/off Sound","toggleThumbnails":"Toggle Thumbnails","toggleOutline":"Toggle Outline\/Bookmark","previousPage":"Previous Page","nextPage":"Next Page","toggleFullscreen":"Toggle Fullscreen","zoomIn":"Zoom In","zoomOut":"Zoom Out","toggleHelp":"Toggle Help","singlePageMode":"Single Page Mode","doublePageMode":"Double Page Mode","downloadPDFFile":"Download PDF File","gotoFirstPage":"Go to First Page","gotoLastPage":"Go to Last Page","share":"Share","mailSubject":"I wanted you to see this FlipBook","mailBody":"Check out this site {{url}}","loading":"DearFlip: Loading "},"viewerType":"flipbook","moreControls":"download,pageMode,startPage,endPage,sound","hideControls":"","scrollWheel":"false","backgroundColor":"#777","backgroundImage":"","height":"auto","paddingLeft":"20","paddingRight":"20","controlsPosition":"bottom","duration":800,"soundEnable":"true","enableDownload":"true","showSearchControl":"false","showPrintControl":"false","enableAnnotation":false,"enableAnalytics":"false","webgl":"true","hard":"none","maxTextureSize":"1600","rangeChunkSize":"524288","zoomRatio":1.5,"stiffness":3,"pageMode":"0","singlePageMode":"0","pageSize":"0","autoPlay":"false","autoPlayDuration":5000,"autoPlayStart":"false","linkTarget":"2","sharePrefix":"flipbook-"}; 6639 </script>
6639 6640
6640<script id="wp-hooks-js" src="https://oncotherm.com/wp-includes/js/dist/hooks.min.js?ver=f0f188028580e8dc1255"></script>
vendor: 1 bytes, line 6640
6640
6641<script id="wp-i18n-js" src="https://oncotherm.com/wp-includes/js/dist/i18n.min.js?ver=1dfe7db3940c23ea9216"></script>
vendor: 1 bytes, line 6641
6641
6642<script id="wp-i18n-js-after"> 6643wp.i18n.setLocaleData( { 'text direction\u0004ltr': [ 'ltr' ] } ); 6644//# sourceURL=wp-i18n-js-after 6645</script>
vendor: 1 bytes, line 6645
6645
6646<script id="swv-js" src="https://oncotherm.com/wp-content/plugins/contact-form-7/includes/swv/js/index.js?ver=6.1.7"></script>
vendor: 1 bytes, line 6646
6646
6647<script id="contact-form-7-js-translations"> 6648( function( domain, translations ) { 6649 var localeData = translations.locale_data[ domain ] || translations.locale_data.messages; 6650 localeData[""].domain = domain; 6651 wp.i18n.setLocaleData( localeData, domain ); 6652} )( "contact-form-7", {"translation-revision-date":"2026-05-05 18:32:38+0000","generator":"GlotPress\/4.0.3","domain":"messages","locale_data":{"messages":{"":{"domain":"messages","plural-forms":"nplurals=2; plural=n != 1;","lang":"en_GB"},"This contact form is placed in the wrong place.":["This contact form is placed in the wrong place."],"Error:":["Error:"]}},"comment":{"reference":"includes\/js\/index.js"}} ); 6653//# sourceURL=contact-form-7-js-translations 6654</script>
vendor: 1 bytes, line 6654
6654
6655<script id="contact-form-7-js-before"> 6656var wpcf7 = { 6657 "api": { 6658 "root": "https:\/\/oncotherm.com\/wp-json\/", 6659 "namespace": "contact-form-7\/v1" 6660 } 6661}; 6662//# sourceURL=contact-form-7-js-before 6663</script>
vendor: 1 bytes, line 6663
6663
6664<script id="contact-form-7-js" src="https://oncotherm.com/wp-content/plugins/contact-form-7/includes/js/index.js?ver=6.1.7"></script>
vendor: 1 bytes, line 6664
6664
6665<script id="cf7apps-honeypot-refill-js-extra"> 6666var cf7appsHoneypotRefill = {"forceRefillOnInit":""}; 6667//# sourceURL=cf7apps-honeypot-refill-js-extra 6668</script>
vendor: 1 bytes, line 6668
6668
6669<script id="cf7apps-honeypot-refill-js" src="https://oncotherm.com/wp-content/plugins/contact-form-7-honeypot/legacy-honeypot/includes/js/honeypot-refill.js?ver=3.7.1"></script>
vendor: 1 bytes, line 6669
6669
6670<script id="fitvids-js" src="https://oncotherm.com/wp-content/plugins/fitvids-for-wordpress/jquery.fitvids.js?ver=1.1"></script>
vendor: 1 bytes, line 6670
6670
6671<script id="rmp_menu_scripts-js-extra"> 6672var rmp_menu = {"ajaxURL":"https://oncotherm.com/wp-admin/admin-ajax.php","wp_nonce":"2534aa4b82","menu":[{"menu_theme":"Default","theme_type":"default","theme_location_menu":"0","submenu_submenu_arrow_width":"40","submenu_submenu_arrow_width_unit":"px","submenu_submenu_arrow_height":"39","submenu_submenu_arrow_height_unit":"px","submenu_arrow_position":"right","submenu_sub_arrow_background_colour":"","submenu_sub_arrow_background_hover_colour":"","submenu_sub_arrow_background_colour_active":"","submenu_sub_arrow_background_hover_colour_active":"","submenu_sub_arrow_border_width":"","submenu_sub_arrow_border_width_unit":"px","submenu_sub_arrow_border_colour":"#1d4354","submenu_sub_arrow_border_hover_colour":"#3f3f3f","submenu_sub_arrow_border_colour_active":"#1d4354","submenu_sub_arrow_border_hover_colour_active":"#3f3f3f","submenu_sub_arrow_shape_colour":"#fff","submenu_sub_arrow_shape_hover_colour":"#fff","submenu_sub_arrow_shape_colour_active":"#fff","submenu_sub_arrow_shape_hover_colour_active":"#fff","use_header_bar":"off","header_bar_items_order":{"logo":"off","title":"on","additional content":"off","menu":"on","search":"off"},"header_bar_title":"Responsive Menu","header_bar_html_content":"","header_bar_logo":"","header_bar_logo_link":"","header_bar_logo_width":"","header_bar_logo_width_unit":"%","header_bar_logo_height":"","header_bar_logo_height_unit":"px","header_bar_height":"80","header_bar_height_unit":"px","header_bar_padding":{"top":"0px","right":"5%","bottom":"0px","left":"5%"},"header_bar_font":"","header_bar_font_size":"14","header_bar_font_size_unit":"px","header_bar_text_color":"#ffffff","header_bar_background_color":"#1d4354","header_bar_breakpoint":"8000","header_bar_position_type":"fixed","header_bar_adjust_page":"on","header_bar_scroll_enable":"off","header_bar_scroll_background_color":"#36bdf6","mobile_breakpoint":"600","tablet_breakpoint":"1024","transition_speed":"0.5","sub_menu_speed":"0.2","show_menu_on_page_load":"off","menu_disable_scrolling":"off","menu_overlay":"off","menu_overlay_colour":"rgba(0,0,0,0.7)","desktop_menu_width":"","desktop_menu_width_unit":"%","desktop_menu_positioning":"absolute","desktop_menu_side":"left","desktop_menu_to_hide":"","use_current_theme_location":"off","mega_menu":{"225":"off","227":"off","229":"off","228":"off","226":"off"},"desktop_submenu_open_animation":"none","desktop_submenu_open_animation_speed":"100ms","desktop_submenu_open_on_click":"off","desktop_menu_hide_and_show":"off","menu_name":"Mobil main menu","menu_to_use":"2","different_menu_for_mobile":"off","menu_to_use_in_mobile":"main-menu","use_mobile_menu":"on","use_tablet_menu":"on","use_desktop_menu":"off","menu_display_on":"all-pages","menu_to_hide":"","submenu_descriptions_on":"off","custom_walker":"","menu_background_colour":"#162c4d","menu_depth":"5","smooth_scroll_on":"off","smooth_scroll_speed":"500","menu_font_icons":{"id":["225"],"icon":[""]},"menu_links_height":"40","menu_links_height_unit":"px","menu_links_line_height":"40","menu_links_line_height_unit":"px","menu_depth_0":"5","menu_depth_0_unit":"%","menu_font_size":"15","menu_font_size_unit":"px","menu_font":"","menu_font_weight":"normal","menu_text_alignment":"left","menu_text_letter_spacing":"","menu_word_wrap":"off","menu_link_colour":"#9e8053","menu_link_hover_colour":"#9e8053","menu_current_link_colour":"#9e8053","menu_current_link_hover_colour":"#9e8053","menu_item_background_colour":"","menu_item_background_hover_colour":"","menu_current_item_background_colour":"","menu_current_item_background_hover_colour":"","menu_border_width":"","menu_border_width_unit":"px","menu_item_border_colour":"#1d4354","menu_item_border_colour_hover":"#1d4354","menu_current_item_border_colour":"#1d4354","menu_current_item_border_hover_colour":"#3f3f3f","submenu_links_height":"40","submenu_links_height_unit":"px","submenu_links_line_height":"40","submenu_links_line_height_unit":"px","menu_depth_side":"left","menu_depth_1":"10","menu_depth_1_unit":"%","menu_depth_2":"15","menu_depth_2_unit":"%","menu_depth_3":"20","menu_depth_3_unit":"%","menu_depth_4":"25","menu_depth_4_unit":"%","submenu_item_background_colour":"","submenu_item_background_hover_colour":"","submenu_current_item_background_colour":"","submenu_current_item_background_hover_colour":"","submenu_border_width":"","submenu_border_width_unit":"px","submenu_item_border_colour":"#1d4354","submenu_item_border_colour_hover":"#1d4354","submenu_current_item_border_colour":"#1d4354","submenu_current_item_border_hover_colour":"#3f3f3f","submenu_font_size":"13","submenu_font_size_unit":"px","submenu_font":"","submenu_font_weight":"normal","submenu_text_letter_spacing":"","submenu_text_alignment":"left","submenu_link_colour":"#9e8053","submenu_link_hover_colour":"#9e8053","submenu_current_link_colour":"#9e8053","submenu_current_link_hover_colour":"#9e8053","inactive_arrow_shape":"+","active_arrow_shape":"-","inactive_arrow_font_icon":"","active_arrow_font_icon":"","
6672inactive_arrow_image":"","active_arrow_image":"","submenu_arrow_width":"40","submenu_arrow_width_unit":"px","submenu_arrow_height":"40","submenu_arrow_height_unit":"px","arrow_position":"right","menu_sub_arrow_shape_colour":"#9e8053","menu_sub_arrow_shape_hover_colour":"#9e8053","menu_sub_arrow_shape_colour_active":"#9e8053","menu_sub_arrow_shape_hover_colour_active":"#9e8053","menu_sub_arrow_border_width":"","menu_sub_arrow_border_width_unit":"px","menu_sub_arrow_border_colour":"#1d4354","menu_sub_arrow_border_hover_colour":"#3f3f3f","menu_sub_arrow_border_colour_active":"#1d4354","menu_sub_arrow_border_hover_colour_active":"#3f3f3f","menu_sub_arrow_background_colour":"","menu_sub_arrow_background_hover_colour":"","menu_sub_arrow_background_colour_active":"rgba(33,33,33,0.01)","menu_sub_arrow_background_hover_colour_active":"","fade_submenus":"off","fade_submenus_side":"left","fade_submenus_delay":"100","fade_submenus_speed":"500","use_slide_effect":"off","slide_effect_back_to_text":"Back","accordion_animation":"on","auto_expand_all_submenus":"off","auto_expand_current_submenus":"off","menu_item_click_to_trigger_submenu":"off","button_width":"55","button_width_unit":"px","button_height":"55","button_height_unit":"px","button_background_colour":"#193156","button_background_colour_hover":"#193156","button_background_colour_active":"#193156","toggle_button_border_radius":"5","button_transparent_background":"on","button_left_or_right":"right","button_position_type":"fixed","button_distance_from_side":"5","button_distance_from_side_unit":"%","button_top":"15","button_top_unit":"px","button_push_with_animation":"off","button_click_animation":"boring","button_line_margin":"9","button_line_margin_unit":"px","button_line_width":"32","button_line_width_unit":"px","button_line_height":"2","button_line_height_unit":"px","button_line_colour":"#9e8053","button_line_colour_hover":"#9e8053","button_line_colour_active":"#9e8053","button_font_icon":"","button_font_icon_when_clicked":"","button_image":"","button_image_when_clicked":"","button_title":"","button_title_open":"","button_title_position":"left","menu_container_columns":"","button_font":"","button_font_size":"14","button_font_size_unit":"px","button_title_line_height":"13","button_title_line_height_unit":"px","button_text_colour":"#fff","button_trigger_type_click":"on","button_trigger_type_hover":"off","button_click_trigger":"","items_order":{"title":"","additional content":"on","menu":"on","search":"on","social-icons":""},"menu_title":"Responsive Menu","menu_title_link":"","menu_title_link_location":"_self","menu_title_image":"","menu_title_font_icon":"","menu_title_section_padding":{"top":"10%","right":"5%","bottom":"0%","left":"5%"},"menu_title_background_colour":"","menu_title_background_hover_colour":"","menu_title_font_size":"25","menu_title_font_size_unit":"px","menu_title_alignment":"center","menu_title_font_weight":"400","menu_title_font_family":"","menu_title_colour":"#ffffff","menu_title_hover_colour":"#fff","menu_title_image_width":"","menu_title_image_width_unit":"%","menu_title_image_height":"","menu_title_image_height_unit":"px","menu_additional_content":"Add more content here...","menu_additional_section_padding":{"top":"0%","right":"5%","bottom":"10%","left":"5%"},"menu_additional_content_font_size":"16","menu_additional_content_font_size_unit":"px","menu_additional_content_alignment":"center","menu_additional_content_colour":"#6fda44","menu_social_icons":[],"menu_social_icons_size":"24","menu_social_icons_size_unit":"px","menu_social_icons_layout":"horizontal","menu_social_icons_alignment":"center","menu_social_icons_gap":"10","menu_social_icons_gap_unit":"px","menu_social_icons_section_padding":{"top":"0%","right":"0%","bottom":"0%","left":"0%"},"menu_search_box_text":"Search","menu_search_box_code":"","menu_search_section_padding":{"top":"5%","right":"5%","bottom":"5%","left":"5%"},"menu_search_box_height":"45","menu_search_box_height_unit":"px","menu_search_box_border_radius":"30","menu_search_box_text_colour":"#14253f","menu_search_box_background_colour":"#ffffff","menu_search_box_placeholder_colour":"#14253f","menu_search_box_border_colour":"","menu_section_padding":{"top":"0px","right":"0px","bottom":"0px","left":"0px"},"menu_width":"75","menu_width_unit":"%","menu_maximum_width":"350","menu_maximum_width_unit":"px","menu_minimum_width":"320","menu_minimum_width_unit":"px","menu_auto_height":"off","menu_container_padding":{"top":"0px","right":"0px","bottom":"0px","left":"0px"},"menu_container_background_colour":"#1d4354","menu_background_image":"","animation_type":"slide","menu_appear_from":"left","animation_speed":"0.5","page_wrapper":"body","menu_close_on_body_click":"off","menu_close_on_scroll":"off","menu_close_on_link_click":"off","enable_touch_gestures":"off","hamburger_position_selector":"","menu_id":2025,"active_toggle_contents":"-","inactive_toggle_contents":"+"}]}; 6673//# sourceURL=rmp_menu_scripts-js-extra 6674</script>
vendor: 1 bytes, line 6674
6674
6675<script id="rmp_menu_scripts-js" src="https://oncotherm.com/wp-content/plugins/responsive-menu/v4.0.0/assets/js/rmp-menu.min.js?ver=4.7.3"></script>
vendor: 1 bytes, line 6675
6675
6676<script id="pojo-a11y-js-extra"> 6677var PojoA11yOptions = {"focusable":"","remove_link_target":"","add_role_links":"1","enable_save":"1","save_expiration":"6"}; 6678//# sourceURL=pojo-a11y-js-extra 6679</script>
vendor: 1 bytes, line 6679
6679
6680<script id="pojo-a11y-js" src="https://oncotherm.com/wp-content/plugins/pojo-accessibility/modules/legacy/assets/js/app.min.js?ver=1.0.0"></script>
vendor: 1 bytes, line 6680
6680
6681<script id="oncotherm-navigation-js" src="https://oncotherm.com/wp-content/themes/oncotherm/js/navigation.js?ver=1.0.0"></script>
vendor: 1 bytes, line 6681
6681
6682<script id="google-api-js" async defer src="https://maps.googleapis.com/maps/api/js?key=AIzaSyB_iiSjX5r5NhuYo76slnO94iS0slyXWL4&callback=initMap&loading=async"></script>
vendor: 1 bytes, line 6682
6682
6683<script id="google-map-js" src="https://oncotherm.com/wp-content/themes/oncotherm/js/gmap.js?ver=1.0.0"></script>
vendor: 1 bytes, line 6683
6683
6684<script id="dflip-script-js" src="https://oncotherm.com/wp-content/plugins/3d-flipbook-dflip-lite/assets/js/dflip.min.js?ver=2.4.37"></script>
vendor: 86 bytes, lines 6684-6685
6684 6685<script id="google-recaptcha-js" src="https://www.google.com/recaptcha/api.js?render=
66856LdoVqYpAAAAAI2la0roHGhvvbDMgeGifOyPAJRr
vendor: 25 bytes, line 6685
6685&ver=3.0"></script>
6686<script id="wp-polyfill-js" src="https://oncotherm.com/wp-includes/js/dist/vendor/wp-polyfill.min.js?ver=3.15.0"></script>
vendor: 1 bytes, line 6686
6686
6687<script id="wpcf7-recaptcha-js-before"> 6688var wpcf7_recaptcha = { 6689 "sitekey": "6LdoVqYpAAAAAI2la0roHGhvvbDMgeGifOyPAJRr", 6690 "actions": { 6691 "homepage": "homepage", 6692 "contactform": "contactform" 6693 } 6694}; 6695//# sourceURL=wpcf7-recaptcha-js-before 6696</script>
vendor: 1 bytes, line 6696
6696
6697<script id="wpcf7-recaptcha-js" src="https://oncotherm.com/wp-content/plugins/contact-form-7/modules/recaptcha/index.js?ver=6.1.7"></script>
vendor: 1 bytes, line 6697
6697
6698<script id="jquery-ui-core-js-before"> 6699jQuery.uiBackCompat = true; 6700//# sourceURL=jquery-ui-core-js-before 6701</script>
vendor: 1 bytes, line 6701
6701
6702<script id="jquery-ui-core-js" src="https://oncotherm.com/wp-includes/js/jquery/ui/core.min.js?ver=1.14.2"></script>
vendor: 1 bytes, line 6702
6702
6703<script id="jquery-ui-mouse-js" src="https://oncotherm.com/wp-includes/js/jquery/ui/mouse.min.js?ver=1.14.2"></script>
vendor: 1 bytes, line 6703
6703
6704<script id="jquery-ui-slider-js" src="https://oncotherm.com/wp-includes/js/jquery/ui/slider.min.js?ver=1.14.2"></script>
vendor: 1 bytes, line 6704
6704
6705<script id="wc-jquery-ui-touchpunch-js" src="https://oncotherm.com/wp-content/plugins/filter-everything/assets/js/jquery-ui-touch-punch/jquery-ui-touch-punch.min.js?ver=1.9.6"></script>
vendor: 1 bytes, line 6705
6705
6706<script id="wpc-filter-everything-js-extra"> 6707var wpcFilterFront = {"ajaxUrl":"https://oncotherm.com/wp-admin/admin-ajax.php","wpcAjaxEnabled":"","wpcStatusCookieName":"wpcContainersStatus","wpcMoreLessCookieName":"wpcMoreLessStatus","wpcHierarchyListCookieName":"wpcHierarchyListStatus","wpcWidgetStatusCookieName":"wpcWidgetStatus","wpcMobileWidth":"768","showBottomWidget":"no","_nonce":"9a06b8db7d","wpcPostContainers":{"default":".buttons"},"wpcAutoScroll":"","wpcAutoScrollOffset":"150","wpcWaitCursor":"1","wpcPostsPerPage":{"3389":16},"wpcUseSelect2":"","wpcDateFilters":"","wpcPopupCompatMode":"","wpcApplyButtonSets":[3389],"wpcQueryOnThePageSets":[3389],"wpcNoPostsContainerMsg":"It appears that this page does not contain the container specified in the \u00abResults container\u00bb option. Try to specify the correct one in the Filter Set settings or the common plugin Settings.","wpcIsPro":"","permalinksEnabled":"","wpcMoreLessCount":"5","wpcSearchChipsText":"search: %s","chipsTitle":"Remove %s from results","chipsReset":"Reset all"}; 6708//# sourceURL=wpc-filter-everything-js-extra 6709</script>
vendor: 1 bytes, line 6709
6709
6710<script id="wpc-filter-everything-js" src="https://oncotherm.com/wp-content/plugins/filter-everything/assets/js/filter-everything.min.js?ver=1.9.6"></script>
6710 6711
6711<script type="text/javascript"> 6712 jQuery(document).ready(function () { 6713 jQuery('body').fitVids(); 6714 }); 6715 </script>
6715 <a id="pojo-a11y-skip-content" class="pojo-skip-link pojo-skip-content" tabindex="1" accesskey="s" href="#content">Skip to content</a> 6716 <nav id="pojo-a11y-toolbar" class="pojo-a11y-toolbar-right" aria-label="Accessibility Toolbar"> 6717 <div class="pojo-a11y-toolbar-toggle"> 6718 <a class="pojo-a11y-toolbar-link pojo-a11y-toolbar-toggle-link" href="javascript:void(0);" title="Accessibility" role="button"> 6719 <span class="pojo-sr-only sr-only">Open toolbar</span> 6720 <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" fill="currentColor" width="1em"> 6721 <title>Accessibility</title> 6722 <path d="M50 .8c5.7 0 10.4 4.7 10.4 10.4S55.7 21.6 50 21.6s-10.4-4.7-10.4-10.4S44.3.8 50 .8zM92.2 32l-21.9 2.3c-2.6.3-4.6 2.5-4.6 5.2V94c0 2.9-2.3 5.2-5.2 5.2H60c-2.7 0-4.9-2.1-5.2-4.7l-2.2-24.7c-.1-1.5-1.4-2.5-2.8-2.4-1.3.1-2.2 1.1-2.4 2.4l-2.2 24.7c-.2 2.7-2.5 4.7-5.2 4.7h-.5c-2.9 0-5.2-2.3-5.2-5.2V39.4c0-2.7-2-4.9-4.6-5.2L7.8 32c-2.6-.3-4.6-2.5-4.6-5.2v-.5c0-2.6 2.1-4.7 4.7-4.7h.5c19.3 1.8 33.2 2.8 41.7 2.8s22.4-.9 41.7-2.8c2.6-.2 4.9 1.6 5.2 4.3v1c-.1 2.6-2.1 4.8-4.8 5.1z"/> </svg> 6723 </a> 6724 </div> 6725 <div class="pojo-a11y-toolbar-overlay"> 6726 <div class="pojo-a11y-toolbar-inner"> 6727 <p class="pojo-a11y-toolbar-title">Accessibility</p> 6728 6729 <ul class="pojo-a11y-toolbar-items pojo-a11y-tools"> 6730 <li class="pojo-a11y-toolbar-item"> 6731 <a href="#" class="pojo-a11y-toolbar-link pojo-a11y-btn-resize-font pojo-a11y-btn-resize-plus" data-action="resize-plus" data-action-group="resize" tabindex="-1" role="button"> 6732 <span class="pojo-a11y-toolbar-icon"><svg version="1.1" xmlns="http://www.w3.org/2000/svg" width="1em" viewBox="0 0 448 448"><title>Increase font size</title><path fill="currentColor" d="M256 200v16c0 4.25-3.75 8-8 8h-56v56c0 4.25-3.75 8-8 8h-16c-4.25 0-8-3.75-8-8v-56h-56c-4.25 0-8-3.75-8-8v-16c0-4.25 3.75-8 8-8h56v-56c0-4.25 3.75-8 8-8h16c4.25 0 8 3.75 8 8v56h56c4.25 0 8 3.75 8 8zM288 208c0-61.75-50.25-112-112-112s-112 50.25-112 112 50.25 112 112 112 112-50.25 112-112zM416 416c0 17.75-14.25 32-32 32-8.5 0-16.75-3.5-22.5-9.5l-85.75-85.5c-29.25 20.25-64.25 31-99.75 31-97.25 0-176-78.75-176-176s78.75-176 176-176 176 78.75 176 176c0 35.5-10.75 70.5-31 99.75l85.75 85.75c5.75 5.75 9.25 14 9.25 22.5z"></path></svg></span><span class="pojo-a11y-toolbar-text">Increase font size</span> </a> 6733 </li> 6734 6735 <li class="pojo-a11y-toolbar-item"> 6736 <a href="#" class="pojo-a11y-toolbar-link pojo-a11y-btn-resize-font pojo-a11y-btn-resize-minus" data-action="resize-minus" data-action-group="resize" tabindex="-1" role="button"> 6737 <span class="pojo-a11y-toolbar-icon"><svg version="1.1" xmlns="http://www.w3.org/2000/svg" width="1em" viewBox="0 0 448 448"><title>Reduce font size</title><path fill="currentColor" d="M256 200v16c0 4.25-3.75 8-8 8h-144c-4.25 0-8-3.75-8-8v-16c0-4.25 3.75-8 8-8h144c4.25 0 8 3.75 8 8zM288 208c0-61.75-50.25-112-112-112s-112 50.25-112 112 50.25 112 112 112 112-50.25 112-112zM416 416c0 17.75-14.25 32-32 32-8.5 0-16.75-3.5-22.5-9.5l-85.75-85.5c-29.25 20.25-64.25 31-99.75 31-97.25 0-176-78.75-176-176s78.75-176 176-176 176 78.75 176 176c0 35.5-10.75 70.5-31 99.75l85.75 85.75c5.75 5.75 9.25 14 9.25 22.5z"></path></svg></span><span class="pojo-a11y-toolbar-text">Reduce font size</span> </a> 6738 </li> 6739 6740 <li class="pojo-a11y-toolbar-item"> 6741 <a href="#" class="pojo-a11y-toolbar-link pojo-a11y-btn-background-group pojo-a11y-btn-grayscale" data-action="grayscale" data-action-group="schema" tabindex="-1" role="button"> 6742 <span class="pojo-a11y-toolbar-icon"><svg version="1.1" xmlns="http://www.w3.org/2000/svg" width="1em" viewBox="0 0 448 448"><title>Greyscale</title><path fill="currentColor" d="M15.75 384h-15.75v-352h15.75v352zM31.5 383.75h-8v-351.75h8v351.75zM55 383.75h-7.75v-351.75h7.75v351.75zM94.25 383.75h-7.75v-351.75h7.75v351.75zM133.5 383.75h-15.5v-351.75h15.5v351.75zM165 383.75h-7.75v-351.75h7.75v351.75zM180.75 383.75h-7.75v-351.75h7.75v351.75zM196.5 383.75h-7.75v-351.75h7.75v351.75zM235.75 383.75h-15.75v-351.75h15.75v351.75zM275 383.75h-15.75v-351.75h15.75v351.75zM306.5 383.75h-15.75v-351.75h15.75v351.75zM338 383.75h-15.75v-351.75h15.75v351.75zM361.5 383.75h-15.75v-351.75h15.75v351.75zM408.75 383.75h-23.5v-351.75h23.5v351.75zM424.5 383.75h-8v-351.75h8v351.75zM448 384h-15.75v-352h15.75v352z"></path></svg></span><span class="pojo-a11y-toolbar-text">Greyscale</span> </a> 6743 </li> 6744 6745 <li class="pojo-a11y-toolbar-item"> 6746 <a href="#" class="pojo-a11y-toolbar-link pojo-a11y-btn-background-group pojo-a11y-btn-high-contrast" data-action="high-contrast" data-action-group="schema" tabindex="-1" role="button"> 6747 <span class="pojo-a11y-toolbar-icon"><svg version="1.1" xmlns="http://www.w3.org/2000/svg" width="1em" viewBox="0 0 448 448"><title>High contrast</title>
6747<path fill="currentColor" d="M192 360v-272c-75 0-136 61-136 136s61 136 136 136zM384 224c0 106-86 192-192 192s-192-86-192-192 86-192 192-192 192 86 192 192z"></path></svg></span><span class="pojo-a11y-toolbar-text">High contrast</span> </a> 6748 </li> 6749 6750 <li class="pojo-a11y-toolbar-item"> 6751 <a href="#" class="pojo-a11y-toolbar-link pojo-a11y-btn-background-group pojo-a11y-btn-negative-contrast" data-action="negative-contrast" data-action-group="schema" tabindex="-1" role="button"> 6752 6753 <span class="pojo-a11y-toolbar-icon"><svg version="1.1" xmlns="http://www.w3.org/2000/svg" width="1em" viewBox="0 0 448 448"><title>Negative contrast</title><path fill="currentColor" d="M416 240c-23.75-36.75-56.25-68.25-95.25-88.25 10 17 15.25 36.5 15.25 56.25 0 61.75-50.25 112-112 112s-112-50.25-112-112c0-19.75 5.25-39.25 15.25-56.25-39 20-71.5 51.5-95.25 88.25 42.75 66 111.75 112 192 112s149.25-46 192-112zM236 144c0-6.5-5.5-12-12-12-41.75 0-76 34.25-76 76 0 6.5 5.5 12 12 12s12-5.5 12-12c0-28.5 23.5-52 52-52 6.5 0 12-5.5 12-12zM448 240c0 6.25-2 12-5 17.25-46 75.75-130.25 126.75-219 126.75s-173-51.25-219-126.75c-3-5.25-5-11-5-17.25s2-12 5-17.25c46-75.5 130.25-126.75 219-126.75s173 51.25 219 126.75c3 5.25 5 11 5 17.25z"></path></svg></span><span class="pojo-a11y-toolbar-text">Negative contrast</span> </a> 6754 </li> 6755 6756 <li class="pojo-a11y-toolbar-item"> 6757 <a href="#" class="pojo-a11y-toolbar-link pojo-a11y-btn-background-group pojo-a11y-btn-light-background" data-action="light-background" data-action-group="schema" tabindex="-1" role="button"> 6758 <span class="pojo-a11y-toolbar-icon"><svg version="1.1" xmlns="http://www.w3.org/2000/svg" width="1em" viewBox="0 0 448 448"><title>Light background</title><path fill="currentColor" d="M184 144c0 4.25-3.75 8-8 8s-8-3.75-8-8c0-17.25-26.75-24-40-24-4.25 0-8-3.75-8-8s3.75-8 8-8c23.25 0 56 12.25 56 40zM224 144c0-50-50.75-80-96-80s-96 30-96 80c0 16 6.5 32.75 17 45 4.75 5.5 10.25 10.75 15.25 16.5 17.75 21.25 32.75 46.25 35.25 74.5h57c2.5-28.25 17.5-53.25 35.25-74.5 5-5.75 10.5-11 15.25-16.5 10.5-12.25 17-29 17-45zM256 144c0 25.75-8.5 48-25.75 67s-40 45.75-42 72.5c7.25 4.25 11.75 12.25 11.75 20.5 0 6-2.25 11.75-6.25 16 4 4.25 6.25 10 6.25 16 0 8.25-4.25 15.75-11.25 20.25 2 3.5 3.25 7.75 3.25 11.75 0 16.25-12.75 24-27.25 24-6.5 14.5-21 24-36.75 24s-30.25-9.5-36.75-24c-14.5 0-27.25-7.75-27.25-24 0-4 1.25-8.25 3.25-11.75-7-4.5-11.25-12-11.25-20.25 0-6 2.25-11.75 6.25-16-4-4.25-6.25-10-6.25-16 0-8.25 4.5-16.25 11.75-20.5-2-26.75-24.75-53.5-42-72.5s-25.75-41.25-25.75-67c0-68 64.75-112 128-112s128 44 128 112z"></path></svg></span><span class="pojo-a11y-toolbar-text">Light background</span> </a> 6759 </li> 6760 6761 <li class="pojo-a11y-toolbar-item"> 6762 <a href="#" class="pojo-a11y-toolbar-link pojo-a11y-btn-links-underline" data-action="links-underline" data-action-group="toggle" tabindex="-1" role="button"> 6763 <span class="pojo-a11y-toolbar-icon"><svg version="1.1" xmlns="http://www.w3.org/2000/svg" width="1em" viewBox="0 0 448 448"><title>Underline links</title><path fill="currentColor" d="M364 304c0-6.5-2.5-12.5-7-17l-52-52c-4.5-4.5-10.75-7-17-7-7.25 0-13 2.75-18 8 8.25 8.25 18 15.25 18 28 0 13.25-10.75 24-24 24-12.75 0-19.75-9.75-28-18-5.25 5-8.25 10.75-8.25 18.25 0 6.25 2.5 12.5 7 17l51.5 51.75c4.5 4.5 10.75 6.75 17 6.75s12.5-2.25 17-6.5l36.75-36.5c4.5-4.5 7-10.5 7-16.75zM188.25 127.75c0-6.25-2.5-12.5-7-17l-51.5-51.75c-4.5-4.5-10.75-7-17-7s-12.5 2.5-17 6.75l-36.75 36.5c-4.5 4.5-7 10.5-7 16.75 0 6.5 2.5 12.5 7 17l52 52c4.5 4.5 10.75 6.75 17 6.75 7.25 0 13-2.5 18-7.75-8.25-8.25-18-15.25-18-28 0-13.25 10.75-24 24-24 12.75 0 19.75 9.75 28 18 5.25-5 8.25-10.75 8.25-18.25zM412 304c0 19-7.75 37.5-21.25 50.75l-36.75 36.5c-13.5 13.5-31.75 20.75-50.75 20.75-19.25 0-37.5-7.5-51-21.25l-51.5-51.75c-13.5-13.5-20.75-31.75-20.75-50.75 0-19.75 8-38.5 22-52.25l-22-22c-13.75 14-32.25 22-52 22-19 0-37.5-7.5-51-21l-52-52c-13.75-13.75-21-31.75-21-51 0-19 7.75-37.5 21.25-50.75l36.75-36.5c13.5-13.5 31.75-20.75 50.75-20.75 19.25 0 37.5 7.5 51 21.25l51.5 51.75c13.5 13.5 20.75 31.75 20.75 50.75 0 19.75-8 38.5-22 52.25l22 22c13.7
67635-14 32.25-22 52-22 19 0 37.5 7.5 51 21l52 52c13.75 13.75 21 31.75 21 51z"></path></svg></span><span class="pojo-a11y-toolbar-text">Underline links</span> </a> 6764 </li> 6765 6766 <li class="pojo-a11y-toolbar-item"> 6767 <a href="#" class="pojo-a11y-toolbar-link pojo-a11y-btn-readable-font" data-action="readable-font" data-action-group="toggle" tabindex="-1" role="button"> 6768 <span class="pojo-a11y-toolbar-icon"><svg version="1.1" xmlns="http://www.w3.org/2000/svg" width="1em" viewBox="0 0 448 448"><title>Readable font</title><path fill="currentColor" d="M181.25 139.75l-42.5 112.5c24.75 0.25 49.5 1 74.25 1 4.75 0 9.5-0.25 14.25-0.5-13-38-28.25-76.75-46-113zM0 416l0.5-19.75c23.5-7.25 49-2.25 59.5-29.25l59.25-154 70-181h32c1 1.75 2 3.5 2.75 5.25l51.25 120c18.75 44.25 36 89 55 133 11.25 26 20 52.75 32.5 78.25 1.75 4 5.25 11.5 8.75 14.25 8.25 6.5 31.25 8 43 12.5 0.75 4.75 1.5 9.5 1.5 14.25 0 2.25-0.25 4.25-0.25 6.5-31.75 0-63.5-4-95.25-4-32.75 0-65.5 2.75-98.25 3.75 0-6.5 0.25-13 1-19.5l32.75-7c6.75-1.5 20-3.25 20-12.5 0-9-32.25-83.25-36.25-93.5l-112.5-0.5c-6.5 14.5-31.75 80-31.75 89.5 0 19.25 36.75 20 51 22 0.25 4.75 0.25 9.5 0.25 14.5 0 2.25-0.25 4.5-0.5 6.75-29 0-58.25-5-87.25-5-3.5 0-8.5 1.5-12 2-15.75 2.75-31.25 3.5-47 3.5z"></path></svg></span><span class="pojo-a11y-toolbar-text">Readable font</span> </a> 6769 </li> 6770 <li class="pojo-a11y-toolbar-item"> 6771 <a href="#" class="pojo-a11y-toolbar-link pojo-a11y-btn-reset" data-action="reset" tabindex="-1" role="button"> 6772 <span class="pojo-a11y-toolbar-icon"><svg version="1.1" xmlns="http://www.w3.org/2000/svg" width="1em" viewBox="0 0 448 448"><title>Reset</title><path fill="currentColor" d="M384 224c0 105.75-86.25 192-192 192-57.25 0-111.25-25.25-147.75-69.25-2.5-3.25-2.25-8 0.5-10.75l34.25-34.5c1.75-1.5 4-2.25 6.25-2.25 2.25 0.25 4.5 1.25 5.75 3 24.5 31.75 61.25 49.75 101 49.75 70.5 0 128-57.5 128-128s-57.5-128-128-128c-32.75 0-63.75 12.5-87 34.25l34.25 34.5c4.75 4.5 6 11.5 3.5 17.25-2.5 6-8.25 10-14.75 10h-112c-8.75 0-16-7.25-16-16v-112c0-6.5 4-12.25 10-14.75 5.75-2.5 12.75-1.25 17.25 3.5l32.5 32.25c35.25-33.25 83-53 132.25-53 105.75 0 192 86.25 192 192z"></path></svg></span> 6773 <span class="pojo-a11y-toolbar-text">Reset</span> 6774 </a> 6775 </li> 6776 </ul> 6777 </div> 6778 </div> 6779 </nav> 6780 6781 <!-- Cookie Compliance for WordPress (formerly Compliance by Hu-manity.co) plugin v3.1.9 https://cookie-compliance.co/ --> 6782 <div id="cookie-notice" role="dialog" class="cookie-notice-hidden cookie-revoke-hidden cn-position-bottom" aria-label="Cookie Compliance" style="background-color: rgba(20,37,63,1);"><div class="cookie-notice-container" style="color: #9e8053"><span id="cn-notice-text" class="cn-text-container">We use cookies on this site to enhance your user experience. By clicking on the Accept button, you agree to our use of cookies.</span><span id="cn-notice-buttons" class="cn-buttons-container"><button id="cn-accept-cookie" data-cookie-set="accept" class="cn-set-cookie cn-button cn-button-custom btn" aria-label="Accept">Accept</button><button id="cn-refuse-cookie" data-cookie-set="refuse" class="cn-set-cookie cn-button cn-button-custom btn" aria-label="Deny">Deny</button><button data-link-url="https://oncotherm.com/privacy-policy/" data-link-target="_blank" id="cn-more-info" class="cn-more-info cn-button cn-button-custom btn" aria-label="Privacy Policy">Privacy Policy</button></span><button type="button" id="cn-close-notice" data-cookie-set="accept" class="cn-close-icon" aria-label="Deny" tabindex="0"></button></div> 6783 6784 </div> 6785 <!-- / Cookie Compliance for WordPress plugin --> 6786
6787<script> 6788 //kereso 6789jQuery('#keres-ikon').on('click', function(){ 6790 jQuery('#kereso').fadeToggle(); 6791 jQuery(this).toggleClass('open'); 6792 jQuery(".main-navigation").toggleClass('fade'); 6793}) 6794 6795//elemek sticky 6796var Sticky = new hcSticky('#sticker', { 6797 top: 0, 6798 bottom:90, 6799 stickTo: '.st-wrap', 6800 wrapperClassName: 'sticker', 6801 6802}); 6803 6804 6805//fejlec tapadas 6806let header = jQuery("#masthead,#palyazat"); 6807 6808jQuery(window).scroll(function() { 6809 6810 var scroll = jQuery(window).scrollTop(); 6811 6812 if (scroll >= 1) { 6813 header.addClass('styk'); 6814 } else { 6815 header.removeClass('styk'); 6816 } 6817 6818 }); 6819</script>
6819 6820</body> 6821</html>
Line numbers count LF bytes from the start of the resource, as the search results do. Vendor segments are library code the classifier recognised; they are stored but not indexed. Bytes are shown as Latin1 characters, one per byte.